Science 37 (SNCE) S-1/A27 Dec 21IPO registration (amended)Financial data

Company Profile

Document and Entity Information

Document and Entity Information (Imported)	9 Months Ended
Document and Entity Information (Imported)	Sep. 30, 2021
Document and Entity Information [Abstract]
Document Type	S-1/A
Entity Registrant Name	Science 37 Holdings, Inc.
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Central Index Key	0001819113
Amendment Flag	true
Amendment Description	Amendment No.1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 17, 2019	Dec. 31, 2018
Current assets
Cash	$ 7,996,362			$ 32,478,948				$ 27,787,314
Prepaid expenses				543,148				551,689
Total Current Assets	19,221,149			46,047,504				32,985,653
TOTAL ASSETS	39,746,218			57,031,226				40,327,720
Current liabilities
Total Liabilities	28,869,555			20,080,293				8,029,973
Common stock subject to possible redemption, 8,009,041 and shares at $10.00 per share as of September 30, 2021 and June 30, 2021	143,086,271			143,086,271	$ 93,929,920	$ 86,394,680	$ 80,397,819	106,884,111
Stockholders' (Deficit) Equity
Common stock, $0.0001 par value; 30,000,000 shares authorized; 2,002,260 shares issued and outstanding at September 30, 2021 and June 30, 2021, excluding 8,009,041 shares of common stock subject to possible redemption	1,039			856				839
Additional paid-in capital	998,110			1,611,049				1,374,319
Accumulated deficit	(136,979,761)			(107,747,243)				(75,961,522)
Total Stockholders' (Deficit) Equity	(106,135,338)	$ (122,287,890)	$ (114,572,770)	(106,135,338)		(106,135,338)		(74,586,364)		$ (56,550,017)
LIABILITIES, COMMON STOCK SUBJECT TO REDEMPTION AND STOCKHOLDERS' (DEFICIT) EQUITY	39,746,218			$ 57,031,226				$ 40,327,720
LifeSci Acquisition II Corp
Current assets
Cash	200,897	416,111				25,000
Prepaid expenses	88,500	121,157
Total Current Assets	289,397	537,268				25,000
Deferred offering costs						28,000
Cash held in Trust Account	80,121,806	80,120,809
TOTAL ASSETS	80,411,203	80,658,077				53,000
Current liabilities
Accounts payable and accrued expenses	714,561	131,805				1,000
Total Liabilities	714,561	131,805				29,000
Commitments and Contingencies
Common stock subject to possible redemption, 8,009,041 and shares at $10.00 per share as of September 30, 2021 and June 30, 2021	80,090,410	80,090,410
Stockholders' (Deficit) Equity
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value; 30,000,000 shares authorized; 2,002,260 shares issued and outstanding at September 30, 2021 and June 30, 2021, excluding 8,009,041 shares of common stock subject to possible redemption	201	201				216
Additional paid-in capital	998,110	998,110				24,784
Accumulated deficit	(1,392,079)	(562,449)				(1,000)
Total Stockholders' (Deficit) Equity	(393,768)	435,862			$ 23,920	24,000			$ 0
LIABILITIES, COMMON STOCK SUBJECT TO REDEMPTION AND STOCKHOLDERS' (DEFICIT) EQUITY	$ 80,411,203	$ 80,658,077				$ 53,000

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, shares outstanding	41,587,368
Common shares, par value, (per share)	$ 0.0001			$ 0.0001	$ 0.0001			$ 0.0001
Common shares, shares authorized	74,666,115			74,666,115				61,057,864
Common shares, shares issued	4,595,168			2,765,097				8,396,425
Common shares, shares outstanding	4,595,168		4,488,416	2,765,097	8,544,436		8,468,742	8,396,425	8,273,865
Temporary equity, shares issued	41,587,368			41,587,368				32,653,742
Temporary equity, shares outstanding	41,587,368			41,587,368	41,692,230			32,653,742
LifeSci Acquisition II Corp
Preferred stock, par value, (per share)	$ 0.0001	$ 0.0001				$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000				1,000,000
Preferred stock, shares issued	0	0				0
Preferred stock, shares outstanding	0	0				0
Common shares, par value, (per share)	$ 0.0001	$ 0.0001				$ 0.0001
Common shares, shares authorized	30,000,000	30,000,000				30,000,000
Common shares, shares issued	2,002,260	2,002,260				2,156,250
Common shares, shares outstanding	2,002,260	2,002,260				2,156,250
Temporary equity, shares outstanding	8,009,041	8,009,041
Common stock subject to redemption \| LifeSci Acquisition II Corp
Temporary equity, shares issued		8,009,041				0
Temporary equity, shares outstanding	8,009,041	8,009,041				0
Purchase price, per unit		$ 10				$ 10

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended						6 Months Ended			9 Months Ended		12 Months Ended
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Formation and operating costs													$ 56,167,682	$ 33,208,354
Loss from operations	$ (14,929,954)			$ (7,910,997)						$ (29,690,049)	$ (20,120,360)		(32,463,463)	(19,127,356)
Other income:
Interest earned on marketable securities held in Trust Account	151			1,554						1,424	76,019		77,229	625,608
Other income, net	238,083			227,167						457,531	770,412		789,379	658,580
Loss before income taxes													(31,674,084)	(18,468,776)
Net loss	$ (14,691,871)	$ (7,715,120)	$ (6,825,527)	$ (7,683,830)	$ (5,916,947)	$ (5,749,171)		$ (1,000)		$ (29,232,518)	$ (19,349,948)		$ (31,674,084)	$ (18,468,776)
Weighted Average Number of Shares Outstanding, Basic	4,551,755			8,522,923				1,875,000		3,818,717	8,458,434		8,197,409	8,310,333
Weighted Average Number of Shares Outstanding, Diluted	4,551,755	3,956,455		8,522,923	8,442,703		3,446,123		8,425,655	3,818,717	8,458,434		8,197,409	8,310,604
Basic net loss per common share	$ (3.23)			$ (0.90)						$ (7.66)	$ (2.29)		$ (3.86)	$ (2.22)
Diluted net loss per common share	$ (3.23)	$ (1.95)		$ (0.90)	$ (0.70)		$ (4.22)		$ (1.38)	$ (7.66)	$ (2.29)		$ (3.86)	$ (2.22)
LifeSci Acquisition II Corp
Formation and operating costs	$ 830,627			$ 80				$ 1,000				$ 591,846
Loss from operations	(830,627)			(80)				(1,000)				(591,846)
Other income:
Interest earned on marketable securities held in Trust Account	997											30,397
Other income, net												30,397
Net loss	$ (829,630)			$ (80)				$ (1,000)				$ (561,449)
Weighted Average Number of Shares Outstanding, Basic	10,011,301			1,875,000								6,734,489
Weighted Average Number of Shares Outstanding, Diluted	10,011,301			1,875,000				1,875,000				6,734,489
Basic net loss per common share	$ (0.08)			$ 0				$ 0				$ (0.08)
Diluted net loss per common share	$ (0.08)			$ 0								$ (0.08)
Common Stock \| LifeSci Acquisition II Corp
Other income:
Weighted Average Number of Shares Outstanding, Basic								1,875,000				6,734,489
Weighted Average Number of Shares Outstanding, Diluted								1,875,000				6,734,489
Basic net loss per common share								$ 0				$ (0.08)
Diluted net loss per common share								$ 0				$ (0.08)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)	Common StockLifeSci Acquisition II Corp	Common Stock	Additional Paid-in CapitalLifeSci Acquisition II Corp	Additional Paid-in Capital	Accumulated DeficitLifeSci Acquisition II Corp	Accumulated Deficit	LifeSci Acquisition II Corp	Total
Balance at the beginning at Dec. 31, 2018		$ 827		$ 941,902		$ (57,492,746)		$ (56,550,017)
Balance at the beginning (in shares) at Dec. 31, 2018		8,273,865
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss						(18,468,776)		(18,468,776)
Balance at the end at Dec. 31, 2019		$ 839		1,374,319		(75,961,522)		(74,586,364)
Balance at the end (in shares) at Dec. 31, 2019		8,396,425
Balance at the beginning at Dec. 17, 2019	$ 0		$ 0		$ 0		$ 0
Balance at the beginning (in shares) at Dec. 17, 2019	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss					(1,000)		(1,000)	(1,000)
Balance at the end at Jun. 30, 2020	$ 216	$ 856	24,784	1,611,049	(1,000)	(106,135,338)	24,000	(106,135,338)
Balance at the end (in shares) at Jun. 30, 2020	2,156,250	2,765,097
Balance at the beginning at Dec. 31, 2019		$ 839		1,374,319		(75,961,522)		(74,586,364)
Balance at the beginning (in shares) at Dec. 31, 2019		8,396,425
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss						(5,749,171)		(5,749,171)
Balance at the beginning at Dec. 31, 2019		$ 839		1,374,319		(75,961,522)		(74,586,364)
Balance at the beginning (in shares) at Dec. 31, 2019		8,396,425
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss								(19,349,948)
Balance at the end at Sep. 30, 2020	$ 216		24,784		(1,080)		23,920
Balance at the end (in shares) at Sep. 30, 2020	2,156,250
Balance at the beginning at Dec. 31, 2019		$ 839		1,374,319		(75,961,522)		(74,586,364)
Balance at the beginning (in shares) at Dec. 31, 2019		8,396,425
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss						(31,674,084)		(31,674,084)
Balance at the end at Dec. 31, 2020								(106,135,338)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss						(5,916,947)		(5,916,947)
Balance at the end at Jun. 30, 2020	$ 216	$ 856	24,784	1,611,049	(1,000)	(106,135,338)	24,000	(106,135,338)
Balance at the end (in shares) at Jun. 30, 2020	2,156,250	2,765,097
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss					(80)	(7,683,830)	(80)	(7,683,830)
Balance at the end at Sep. 30, 2020	$ 216		24,784		(1,080)		23,920
Balance at the end (in shares) at Sep. 30, 2020	2,156,250
Balance at the beginning at Jun. 30, 2020	$ 216	$ 856	24,784	1,611,049	(1,000)	(106,135,338)	24,000	(106,135,338)
Balance at the beginning (in shares) at Jun. 30, 2020	2,156,250	2,765,097
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of 3,146,454 Private Placement Warrants			2,831,809				2,831,809
Net loss					(561,449)		(561,449)
Balance at the end at Jun. 30, 2021	$ 201	$ 1,028	998,110	3,663,679	(562,449)	(118,623,183)	435,862	(122,287,890)
Balance at the end (in shares) at Jun. 30, 2021	2,002,260	4,488,416
Balance at the beginning at Dec. 31, 2020								(106,135,338)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss						(6,825,527)		(6,825,527)
Balance at the end at Mar. 31, 2021		$ 907		2,168,412		(112,403,451)		(114,572,770)
Balance at the end (in shares) at Mar. 31, 2021		3,271,804
Balance at the beginning at Dec. 31, 2020								(106,135,338)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss								(29,232,518)
Balance at the end at Sep. 30, 2021	$ 201	$ 1,039	998,110	4,769,114	(1,392,079)	(132,209,608)	(393,768)	(106,135,338)
Balance at the end (in shares) at Sep. 30, 2021	2,002,260	4,595,168
Balance at the beginning at Mar. 31, 2021		$ 907		2,168,412		(112,403,451)		(114,572,770)
Balance at the beginning (in shares) at Mar. 31, 2021		3,271,804
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss						(7,715,120)		(7,715,120)
Balance at the end at Jun. 30, 2021	$ 201	$ 1,028	998,110	3,663,679	(562,449)	(118,623,183)	435,862	(122,287,890)
Balance at the end (in shares) at Jun. 30, 2021	2,002,260	4,488,416
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss					(829,630)	(14,691,871)	(829,630)	(14,691,871)
Balance at the end at Sep. 30, 2021	$ 201	$ 1,039	$ 998,110	$ 4,769,114	$ (1,392,079)	$ (132,209,608)	$ (393,768)	$ (106,135,338)
Balance at the end (in shares) at Sep. 30, 2021	2,002,260	4,595,168

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS	3 Months Ended
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS	Sep. 30, 2020USD ($)
Adjustments to reconcile net loss to net cash used in operating activities:
Interest earned on marketable securities held in Trust Account	$ (1,554)
Cash Flows from Financing Activities:
Cash - Ending	47,800,690
LifeSci Acquisition II Corp
Cash Flows from Operating Activities:
Net loss	(80)
Changes in operating assets and liabilities:
Prepaid expenses	(25,000)
Net cash used in operating activities	(25,080)
Cash Flows from Financing Activities:
Proceeds from promissory note	175,000
Payments of offering costs	(66,195)
Net cash provided by financing activities	(108,805)
Net Change in Cash	83,725
Cash - Beginning	25,000
Cash - Ending	108,725
Non-Cash Investing and Financing Activities:
Offering costs included in accrued offering costs	$ 19,450

DESCRIPTION OF ORGANIZATION AND

DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS	3 Months Ended	12 Months Ended
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS	Sep. 30, 2021	Jun. 30, 2021
LifeSci Acquisition II Corp
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS	NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Science 37 Holdings, Inc. (formerly LifeSci Acquisition II Corp.) (the “Company”) was incorporated in Delaware on December 18, 2019. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business transaction with one or more businesses or entities (a “Business Combination”). The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of September 30, 2021, the Company had not commenced any operations. All activity through September 30, 2021 relates to the Company’s formation and the initial public offering (“Initial Public Offering”), which is described below, and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The registration statement for the Company’s Initial Public Offering was declared effective on November 20, 2020. On November 24, 2020 the Company consummated the Initial Public Offering of 8,009,041 shares of common stock (the “Public Shares”), which includes the partial exercise by the underwriter of its over-allotment option in the amount of 509,041 Public Shares, at $10.00 per Public Share, generating gross proceeds of $80,090,410 which is described in Note 4. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 3,146,454 warrants (the “Private Warrants”) at a price of $0.90 per Private Warrant in a private placement to LifeSci Holdings, LLC (the “Sponsor”), an entity affiliated LifeSci Capital LLC, generating gross proceeds of $2,831,809, which is described in Note 5. Transaction costs amounted to $1,858,498, consisting of $1,601,808 in cash underwriting fees and $256,690 of other offering costs. Following the closing of the Initial Public Offering on November 24, 2020, an amount of $ 80,090,410 On May 6, 2021, LSAQ entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among LSAQ, LifeSci Acquisition II Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of LSAQ (“Merger Sub”), and Science 37, Inc., a Delaware corporation (“Legacy Science 37”). Pursuant to the Merger Agreement, Merger Sub was merged with and into Legacy Science 37, with Legacy Science 37 surviving the merger as a wholly owned subsidiary of LSAQ (the “Business Combination” and, together with the other transactions contemplated by the Merger Agreement, the “Transactions”). On October 4, 2021, LSAQ held a special meeting of stockholders (the “Special Meeting”), at which the LSAQ stockholders considered and adopted, among other matters, a proposal to approve the Business Combination, including (a) adopting the Merger Agreement and (b) approving the other transactions and matters contemplated by the Merger Agreement and related agreements as described in the Proxy Statement/Prospectus. Pursuant to the terms and subject to the conditions set forth in the Merger Agreement, following the Special Meeting, on October 6, 2021, the Transactions were consummated. In connection with the Closing, the Company changed its name from LifeSci Acquisition II Corp. to Science 37 Holdings, Inc. Holders of 2,299,493 shares of LSAQ’s common stock sold in its initial public offering properly exercised their right to have such shares redeemed for a full pro rata portion of the trust account holding the proceeds from LSAQ’s initial public offering, calculated as of two business days prior to the consummation of the Business Combination, which was approximately $10.00 per share, or $23,003,944 in the aggregate. An aggregate of $23,003,944 was paid from the Company’s trust account to holders that properly exercised their right to have public shares redeemed, and the remaining balance immediately prior to the Closing of approximately $57.1 million remained in the trust account. The remaining amount in the trust account was used to fund the Business Combination. Preferred Stock . Immediately prior to the effective time of the Merger (the “Effective Time”), each issued and outstanding share of Legacy Science 37’s Series A, Series B, Series C, Series D and Series D-1 redeemable convertible preferred stock, par value $0.0001 per share (collectively, the “Science 37 Preferred Stock”), was converted into shares of the common stock, par value $0.0001 per share, of Science 37 (the “Science 37 common stock”) at the then-applicable conversion rate (the “Science 37 Preferred Stock Conversion”). Common Stock . At the Effective Time, following the Science 37 Preferred Stock Conversion, each share of Science 37 Common Stock (including shares of Science 37 Common Stock outstanding as a result of the Science 37 Preferred Stock Conversion, but excluding shares the holders of which perfect rights of appraisal under Delaware law) converted into the right to receive such number of shares of our common stock (“Common Stock”) equal to the Exchange Ratio (subject to rounding mechanisms as described in the Merger Agreement) and a number of Earn-Out Shares (as defined below). The Exchange Ratio is defined in the Merger Agreement to be the quotient of (i) 100,000,000 divided by (ii) the number of shares of Science 37’s Fully Diluted Capital Stock (as defined in the Merger Agreement). The Exchange Ratio was equal to approximately 1.815. Stock Options . At the Effective Time, each outstanding option to purchase shares of Science 37 Common Stock granted under the Science 37, Inc. 2015 Stock Plan (each, a “Science 37 Option”), whether or not then vested and exercisable, was converted automatically (and without any required action on the part of such holder of outstanding Science 37 Option) into an option to purchase a number of shares of Common Stock equal to the number of shares subject to such Science 37 Option immediately prior to the Effective Time multiplied by the Exchange Ratio (rounded down to the nearest whole share), with a per share exercise price equal to the exercise price per share of Science 37 Common Stock of such Science 37 Option immediately prior to the Effective Time divided by the Exchange Ratio (rounded up to the nearest whole cent). Earn-Out Shares . Following the Closing, former holders of shares of Science 37 Common Stock (including shares received as a result of the Science 37 Preferred Stock Conversion) and former holders of Science 37 Options are entitled to receive their respective pro rata shares of up to 12,500,000 additional shares of Common Stock (the “Earn-Out Shares”) if, within the three-year period beginning on the Closing Date, the closing share price of the Common Stock equals or exceeds either of two share price thresholds as set forth in the Merger Agreement over a period of at least 20 trading days within a 30-day trading period (each, a “Triggering Event”) and, in respect of a former holder of Science 37 Options, the holder continues to provide services to the Company or one of its subsidiaries at the time of such Triggering Event. If there is a change of control of the Company or its successor within such three-year period following the Closing that will result in the holders of Common Stock receiving a per share price equal to or in excess of any Triggering Event threshold(s), then immediately prior to such change of control, any Triggering Event that has not previously occurred shall be deemed to have occurred and the Company shall issue the Earn-Out Shares to the former holders of shares of Science 37 Common Stock and former holders of Science 37 Options in accordance with their respective pro rata shares. Pursuant to subscription agreements entered into in connection with the Merger Agreement (collectively, the “Subscription Agreements”), certain investors agreed to subscribe for an aggregate of 20,000,000 newly-issued shares of Common Stock at a purchase price of $10.00 per share for an aggregate purchase price of $200,000,000 (the “PIPE Investment”). At the Closing, the Company consummated the PIPE Investment. After giving effect to the Transactions, the redemption of public shares as described above, and the consummation of the PIPE Investment on October 6 th , 2021, there were 114,707,150 shares of Common Stock issued and outstanding . Liquidity and Capital Resources As of September 30, 2021, the Company had cash of $200,897 not held in the Trust Account and available for working capital purposes. The Company does not believe it will need to raise additional funds in order to meet the expenditures required for operating our business through the consummation of the business combination. Additionally, the Company notes that the consummation of the business combination on October 6 th , 2021, as mentioned above, brought in additional funds in the amount of $200,000,000 through the consummated PIPE Investment. As such, the Company notes that sufficient cash and capital is available to cover any expected costs or expenses incurred by the Company through the business combination date and through twelve months of the issuance of this report.	NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Science 37 Holdings, Inc. (Formerly LifeSci Acquisition II Corp.) (the “Company”) was incorporated in Delaware on December 18, 2019. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business transaction with one or more businesses or entities (a “Business Combination”). Although the Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends to focus on businesses operating in North America in the healthcare industry. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of June 30, 2021, the Company had not commenced any operations. All activity through June 30, 2021 relates to the Company’s formation and the initial public offering (“Initial Public Offering”), which is described below, and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The registration statement for the Company’s Initial Public Offering was declared effective on November 20, 2020. On November 24, 2020 the Company consummated the Initial Public Offering of 8,009,041 shares of common stock (the “Public Shares”), which includes the partial exercise by the underwriter of its over-allotment option in the amount of 509,041 Public Shares, at $10.00 per Public Share, generating gross proceeds of $80,090,412 which is described in Note 4. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 3,146,454 warrants (the “Private Warrants”) at a price of $0.90 per Private Warrant in a private placement to LifeSci Holdings, LLC (the “Sponsor”), an entity affiliated LifeSci Capital LLC, generating gross proceeds of $2,831,809, which is described in Note 5. Transaction costs amounted to $1,858,498, consisting of $1,601,808 in cash underwriting fees and $256,690 of other offering costs. Following the closing of the Initial Public Offering on November 24, 2020, an amount of $80,090,412 ($10.00 per Public Share) from the net proceeds of the sale of the Public Shares in the Initial Public Offering and the sale of the Private Warrants was placed in a trust account (the “Trust Account”), and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended, or the Investment Company Act, with a maturity of 183 days or less or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the funds in the Trust Account as described below. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Warrants, although substantially all of the net proceeds are intended to be applied toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the balance in the Trust Account (net of amounts previously released to the Company to pay its tax obligations and for working capital purposes, subject to an annual limit of $250,000) at the time of the signing an agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination. The Company will provide its stockholders with the opportunity to redeem all or a portion of their Public Shares sold in the Initial Public Offering upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then on deposit in the Trust Account (initially $10.00 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations or for working capital purposes). The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor and other initial stockholders (collectively, the “Initial Stockholders”) have agreed to (a) vote their Founder Shares (as defined in Note 6), and any Public Shares held by them in favor of a Business Combination and (b) not to convert any shares (including Founder Shares) in connection with a stockholder vote to approve a Business Combination or sell any such shares to the Company in a tender offer in connection with a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming their shares with respect to more than an aggregate of 20% of the Public Shares. The Company will have until November 24, 2022 to consummate a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than five business days thereafter, redeem 100% of the outstanding Public Shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (net of taxes payable), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Company’s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirements of applicable law. The proceeds deposited in the Trust Account could, however, become subject to claims of creditors. The Sponsor and Chardan Healthcare Investments LLC have agreed to (i) waive their redemption rights with respect to Founder Shares and any Public Shares they may acquire during or after the Initial Public Offering in connection with the consummation of a Business Combination, (ii) to waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if the Company fails to consummate a Business Combination within the Combination Period and (iii) not to propose an amendment to the Company’s Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the public stockholders an opportunity to redeem their Public Shares in conjunction with any such amendment. However, the Sponsor will be entitled to liquidating distributions with respect to any Public Shares acquired if the Company fails to consummate a Business Combination or liquidates within the Combination Period. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below $10.00 per share, except as to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Liquidity and Capital Resources As of June 30, 2021, the Company had cash of $416,111 not held in the Trust Account and available for working capital purposes. The Company does not believe it will need to raise additional funds in order to meet the expenditures required for operating our business. However, if the estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to our Business Combination. Moreover, the Company may need to obtain additional financing or draw on the Working Capital Loans (as defined below) either to complete a Business Combination or because it becomes obligated to redeem a significant number of the public shares upon consummation of our Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities laws, the Company would only complete such financing simultaneously with the completion of our Business Combination. If the Company is unable to complete the Business Combination because it does not have sufficient funds available, the Company will be forced to cease operations and liquidate the Trust Account. In addition, following the Business Combination, if cash on hand is insufficient, the Company may need to obtain additional financing in order to meet our obligations.

REVISION OF PREVIOUSLY ISSUED F

REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	3 Months Ended	12 Months Ended
REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	Sep. 30, 2021	Jun. 30, 2021
LifeSci Acquisition II Corp
REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	NOTE 2. REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS In connection with the preparation of the Company’s financial statements as of September 30, 2021, the Company concluded it should revise its financial statements to classify all Public Shares in temporary equity. In accordance with the SEC and its staff’s guidance on redeemable equity instruments, ASC 480, paragraph 10-S99, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. The Company previously determined the common stock subject to possible redemption to be equal to the redemption value of $10.00 per common stock while also taking into consideration a redemption cannot result in net tangible assets being less than $5,000,001. Previously, the Company did not consider redeemable shares classified as temporary equity as part of net tangible assets. Effective with these financial statements, the Company revised this interpretation to include temporary equity in net tangible assets. Accordingly, effective with this filing, the Company presents all redeemable common stock as temporary equity and recognizes accretion from the initial book value to redemption value at the time of its Initial Public Offering and in accordance with ASC 480. As a result, management has noted a reclassification adjustment related to temporary equity and permanent equity. This resulted in an adjustment to the initial carrying value of the common stock subject to possible redemption with the offset recorded to additional paid-in capital (to the extent available), accumulated deficit and common stock. The Company will present this revision in a prospective manner in all future filings. Under this approach, the previously issued Initial Public Offering Balance Sheet and Form 10-Q’s will not be amended, but historical amounts presented in the current and future filings will be recast to be consistent with the current presentation. In connection with the change in presentation for the common stock subject to redemption, the Company also revised its income (loss) per common share calculation to allocate net income (loss) pro rata to common stock. This presentation contemplates a Business Combination as the most likely outcome, in which case, both classes of common stock share pro rata in the income (loss) of the Company. There has been no change in the Company’s total assets, liabilities or operating results. The impact of the revision on the Company’s financial statements is reflected in the following table. As Previously Balance Sheet as of June 30, 2021 (audited) Reported Adjustment As Revised Common stock subject to possible redemption $ 75,526,270 $ 4,564,140 $ 80,090,410 Common stock $ 246 $ (45) $ 201 Additional paid-in capital $ 5,562,205 $ (4,564,095) $ 998,110 Accumulated deficit $ (562,449) $ — $ (562,449) Total Stockholders’ Equity (Deficit) $ 5,000,002 $ (4,564,140) $ 435,862	NOTE 2. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS In connection with the preparation of the Company’s financial statements, management identified errors made in its historical financial statements where, at the closing of the Company’s Initial Public Offering, the Company improperly classified its common stock subject to possible redemption. The Company previously determined the common stock subject to possible redemption to be equal to the redemption value, while also taking into consideration a redemption cannot result in net tangible assets being less than $5,000,001. Management determined that the Public Shares underlying the Units issued during the Initial Public Offering can be redeemed or become redeemable subject to the occurrence of future events considered outside the Company’s control. Therefore, management concluded that temporary equity should include all shares of common stock subject to possible redemption, resulting in the common stock subject to possible redemption being equal to their redemption value. As a result, management has noted a reclassification error related to temporary equity and permanent equity. This resulted in an adjustment to the initial carrying value of the common stock subject to possible redemption with the offset recorded to additional paid-in capital (to the extent available), accumulated deficit and common stock. In connection with the change in presentation for the common stock subject to possible redemption, the Company also restated its income (loss) per common share calculation to allocate net income (loss) evenly to all common stock. This presentation contemplates a Business Combination as the most likely outcome, in which case, all shares of common stock share pro rata in the income (loss) of the Company. There has been no change in the Company’s total assets, liabilities or operating results. As Previously Reported Adjustment As Restated Balance Sheet as of November 24, 2020 Common stock subject to possible redemption $ 76,087,640 $ 4,002,770 $ 80,090,410 Common stock $ 256 $ (40) $ 216 Additional paid-in capital $ 5,000,825 $ (4,002,730) $ 998,095 Accumulated deficit $ (1,080) $ — $ (1,080) Total Stockholders’ Equity $ 5,000,001 $ (4,002,770) $ 997,231 Number of shares of common stock subject to possible redemption 7,608,764 400,277 8,009,041 Balance Sheet as of December 31, 2020 (Unaudited) Common stock subject to possible redemption $ 76,007,090 $ 4,083,320 $ 80,090,410 Common stock $ 256 $ (40) $ 216 Additional paid-in capital $ 5,081,375 $ (4,083,280) $ 998,095 Accumulated deficit $ (81,623) $ — $ (81,623) Total Stockholders’ Equity $ 5,000,008 $ (4,083,320) $ 916,688 Number of shares of common stock subject to possible redemption 7,600,709 408,332 8,009,041 Balance Sheet as of March 31, 2021 (Unaudited) Common stock subject to possible redemption $ 75,901,950 $ 4,188,460 $ 80,090,410 Common stock $ 242 $ (41) $ 201 Additional paid-in capital $ 5,186,529 $ (4,188,419) $ 998,110 Accumulated deficit $ (186,762) $ — $ (186,762) Total Stockholders’ Equity $ 5,000,009 $ (4,188,460) $ 811,549 Number of shares of common stock subject to possible redemption 7,590,195 418,846 8,009,041 Balance Sheet as of June 30, 2021 Common stock subject to possible redemption $ 75,526,270 $ 4,564,140 $ 80,090,410 Common stock $ 246 $ (45) $ 201 Additional paid-in capital $ 5,562,205 $ (4,564,095) $ 998,110 Accumulated deficit $ (562,449) $ — $ (562,449) Total Stockholders’ Equity $ 5,000,002 $ (4,564,140) $ 435,862 Number of shares of common stock subject to possible redemption 7,552,627 456,414 8,009,041 Statement of Cash Flows for the six months ended December 31, 2020 (Unaudited) Initial classification of common stock subject to possible redemption $ 76,087,640 (76,087,640) $ — Change in value of Common Stock subject to possible redemption $ (80,550) $ 80,550 $ — Statement of Cash Flows for the nine months ended March 31, 2021 (Unaudited) Initial classification of common stock subject to possible redemption $ 76,087,640 (76,087,640) $ — Change in value of Common Stock subject to possible redemption $ (105,140) $ 105,140 $ — Statement of Cash Flows for the period ended June 30, 2021 (Unaudited) Initial classification of common stock subject to possible redemption $ 76,087,640 (76,087,640) $ — Change in value of Common Stock subject to possible redemption $ (375,680) $ 375,680 $ — Condensed Statement of Changes in Stockholders’ Equity for three months ended December 31, 2020 (Unaudited) Sale of 8,009,041 Units, net of underwriter discounts and offering expenses $ 78,231,912 $ (78,231,912) $ — Initial value of Common Stock subject to redemption $ 76,007,090 $ (76,007,090) $ — Accretion for Common Stock to redemption amount $ — $ (1,858,498) $ (1,858,498) Total Stockholders’ Equity $ 5,000,008 $ (4,083,320) $ 916,688 Condensed Statement of Changes in Stockholders’ Equity for three months ended March 31, 2021 (Unaudited) Change in value of Common Stock subject to redemption $ 105,140 $ (105,140) $ — Total Stockholders’ Equity $ 5,000,009 $ (4,188,460) $ 811,549 Condensed Statement of Changes in Stockholders’ Equity for three months ended June 30, 2021 (Unaudited) Change in value of Common Stock subject to redemption $ 375,680 $ (375,680) $ — Total Stockholders’ Equity $ 5,000,002 $ (4,564,140) $ 435,862 Statement of Operations for the three months ended December 31, 2020 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,875,000 (1,875,000) — Basic and diluted net loss per common stock $ (0.04) $ 0.04 $ — Basic and diluted weighted average shares outstanding, common stock — 5,112,023 5,112,023 Basic and diluted net loss (income) per share, common stock $ — $ (0.02) $ (0.02) Statement of Operations for the six months ended December 31, 2020 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,875,000 (1,875,000) — Basic and diluted net loss per common stock $ (0.04) $ 0.04 $ — Basic and diluted weighted average shares outstanding, common stock — 3,502,260 3,502,260 Basic and diluted net loss (income) per share, common stock $ — $ (0.02) $ (0.02) Statement of Operations for the three months ended March 31, 2021 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,990,948 (1,990,948) — Basic and diluted net loss per common stock $ (0.05) $ 0.05 $ — Basic and diluted weighted average shares outstanding, common stock — 10,011,301 10,011,301 Basic and diluted net loss (income) per share, common stock $ — $ (0.01) $ (0.01) Statement of Operations for the nine months ended March 31, 2021 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,913,085 (1,913,085) — Basic and diluted net loss per common stock $ (0.10) $ 0.10 $ — Basic and diluted weighted average shares outstanding, common stock — 5,646,205 5,646,205 Basic and diluted net loss (income) per share, common stock $ — $ (0.03) $ (0.03) Statement of Operations for the year ended June 30, 2021 Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,951,216 (1,951,216) — Basic and diluted net loss per common stock $ (0.29) $ 0.29 $ — Basic and diluted weighted average shares outstanding, common stock — 6,734,489 6,734,489 Basic and diluted net loss (income) per share, common stock $ — $ (0.08) $ (0.08)

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2021	Jun. 30, 2021
LifeSci Acquisition II Corp
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s prospectus for its Initial Public Offering as filed with the SEC on November 23, 2020, the Company’s Current Reports on Form 8-K, as filed with the SEC on November 25, 2020, and December 1, 2020, as well as the Company’s Annual Report on Form 10-K, as amended and filed with the SEC on December 20, 2021. The interim results for the three months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending June 30, 2022 or for any future periods. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its majority owned subsidiary where the Company has the ability to exercise control. All significant intercompany balances and transactions have been eliminated in consolidation. Activities in relation to the noncontrolling interest are not considered to be significant and are, therefore, not presented in the accompanying unaudited condensed consolidated financial statements. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2021 and June 30, 2021. Common Stock Subject to Possible Redemption The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at September 30, 2021 and June 30, 2021, common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ equity (deficit) section of the Company’s unaudited condensed consolidated balance sheets. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable common stock resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit. At September 30, 2021 and June 30, 2021, the common stock reflected in the condensed consolidated balance sheets are reconciled in the following table: Gross proceeds $ 80,090,410 Less: Common stock issuance costs $ (1,858,498) Plus: Accretion of carrying value to redemption value $ 1,858,498 Common stock subject to possible redemption $ 80,090,410 Offering Costs Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs amounting to $1,858,498 were charged to temporary equity upon the completion of the Initial Public Offering. Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740 “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2021 and June 30, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may subject to potential examination by federal, state and city taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal, state and city tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company is subject to income tax examinations by major taxing authorities since inception. Net Loss Per Common Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Accretion associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 3,146,454 common stock in the aggregate. As of September 30, 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net loss per common stock is the same as basic net loss per common stock for the periods presented. Three Months Ended September 30, 2021 Basic and diluted net income (loss) per common stock Numerator: Allocation of net income (loss), as adjusted $ (829,630) Denominator: Basic and diluted 10,011,301 Basic and diluted $ (0.08) Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying unaudited condensed consolidated balance sheets, primarily due to their short-term nature. Warrant Classification The Company accounts for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815-40-15-7D under which the warrants do meet the criteria for equity treatment and must be recorded as equity. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. We are currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated financial statements.	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”). Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2021 and 2020. Common Stock Subject to Possible Redemption (Restated — see Note 2) The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2021, common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ equity section of the Company’s consolidated balance sheets. Under ASC 480-10-S99, the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid-in capital and accumulated deficit. At June 30, 2021, the common stock subject to possible redemption reflected in the balance sheet is reconciled in the following table: Gross proceeds $ 80,090,410 Less: Common stock issuance costs (1,858,498) Plus: Accretion of carrying value to redemption value 1,858,498 Common stock subject to possible redemption $ 80,090,410 Offering Costs Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs amounting to $1,858,498 were charged to stockholders’ equity upon the completion of the Initial Public Offering. Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740 “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the consolidated financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the consolidated financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2021 and 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may be subject to potential examination by federal, state and city taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal, state and city tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company is subject to income tax examinations by major taxing authorities since inception. Net Loss Per Common Share (Restated, see Note 2) The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. The Company applies the two-class method in calculating earnings per share. Accretion associated with the redeemable shares of Common Stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, as described in Note 4, since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 3,146,454 Common Stock in the aggregate. As of June 30, 2021, the Company did not have any other dilutive securities or other contracts that could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. As a result, diluted net loss per common share is the same as basic net loss per common share for the periods presented. The following table reflects the calculation of basic and diluted net loss per common share (in dollars, except per share amounts): For the Period from December 18, 2019 (Inception) Year Ended through June 30, June 30, 2021 2020 Basic and diluted net income (loss) per common stock Numerator: Allocation of net income (loss), as adjusted $ (561,449) $ (1,000) Denominator: Basic and diluted weighted average shares outstanding 6,734,489 1,875,000 Basic and diluted net income (loss) per common stock $ (0.08) $ (0.00) Note: As of June 30, 2021 and 2020, basic and diluted shares are the same as there are no non-redeemable securities that are dilutive to the Company’s stockholders. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximate the carrying amounts represented in the accompanying consolidated balance sheets, primarily due to their short-term nature. Warrant Classification The Company accounts for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815-40-15-7D under which the warrants do meet the criteria for equity treatment and must be recorded as equity. Recent Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, “Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”), to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. We are currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

INITIAL PUBLIC OFFERING

INITIAL PUBLIC OFFERING	3 Months Ended	12 Months Ended
INITIAL PUBLIC OFFERING	Sep. 30, 2021	Jun. 30, 2021
LifeSci Acquisition II Corp
INITIAL PUBLIC OFFERING	NOTE 4. INITIAL PUBLIC OFFERING Pursuant to the Initial Public Offering, the Company sold 8,009,041 Public Shares, which includes the partial exercise by the underwriters of their over-allotment option in the amount of 509,041 Public Shares, at a purchase price of $10.00 per Public Share.	NOTE 4. INITIAL PUBLIC OFFERING Pursuant to the Initial Public Offering, the Company sold 8,009,041 Public Shares, which includes the partial exercise by the underwriters of their over-allotment option in the amount of 509,041 Public Shares, at a purchase price of $10.00 per Public Share.

PRIVATE PLACEMENT

PRIVATE PLACEMENT	3 Months Ended	12 Months Ended
PRIVATE PLACEMENT	Sep. 30, 2021	Jun. 30, 2021
LifeSci Acquisition II Corp
PRIVATE PLACEMENT	NOTE 5. PRIVATE PLACEMENT Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 3,146,454 Private Warrants at a price of $0.90 per Private Warrant for an aggregate purchase price of $2,831,809. Each Private Warrant is exercisable to purchase one share of common stock at an exercise price of $11.50 per warrant. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Warrants.	NOTE 5. PRIVATE PLACEMENT Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 3,146,454 Private Warrants at a price of $0.90 per Private Warrant for an aggregate purchase price of $2,831,809. Each Private Warrant is exercisable to purchase one share of common stock at an exercise price of $11.50 per warrant. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Warrants.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended	9 Months Ended	12 Months Ended
RELATED PARTY TRANSACTIONS	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
RELATED PARTY TRANSACTIONS		8. Related-Party Transactions In 2020, the Company subleased office space in Torrance, California to Good Dermatology, a professional medical corporation owned by the Founder and former CEO. Under the terms of the sublease, lease expenses incurred by the Company were 100% passed through to Good Dermatology. Total sublease income was $29,174 and $87,523 for the three and nine months ended September 30, 2020. The sublease was terminated as of November 30, 2020. 8. Related-Party Transactions (continued) For the three months ended September 30, 2021 and 2020, the Company had revenue of $2,756,011 and $3,146,148 , respectively, and for the nine months ended September 30, 2021 and 2020, the Company had revenue of $10,803,604 and $3,243,667 , respectively, and expenses of $128,084 and $0 , respectively, and as of September 30, 2021 and December 31, 2020, receivables of $2,244,157 and $6,927,470 , respectively, from Pharmaceutical Products Development, LLC, a shareholder who holds a minority interest in the Company and a seat on the Company’s Board of Directors. Pharmaceutical Products Development, LLC became a minority shareholder of the Company during the first quarter of 2019. For the three months ended September 30, 2021 and 2020, the Company had revenue of $269,547 and $108,280 , respectively, and for the nine months ended September 30, 2021 and 2020, the Company had revenue of $565,092 and $226,843 , respectively, and as of September 30, 2021 and December 31, 2020, receivables of $166,474 and $129,857 , respectively, from Novartis, who has a 50% ownership in dRX Capital AG, a shareholder who, until July 2021, had a minority interest in the Company and a seat on the Company’s Board of Directors. In July 2021, dRX Capital AG was dissolved and their interest in the Company was distributed to their owners. This dissolution and distribution did not cause any other shareholder of the Company to obtain a minority interest in the Company. For the three months ended September 30, 2021 and 2020, the Company had revenue of $9,875 and $0 , respectively, and for the nine months ended September 30, 2021 and 2020, the Company had revenue of $350,585 and $0 , respectively, and as of September 30, 2021 and December 31, 2020, receivables of $2,185 and $0 , respectively, from Allovir, who is an investee of a minority shareholder and Board of Directors seat holder of the Company. The minority shareholder became a shareholder of the Company in the third quarter of 2016.		13. Related-Party Transactions In 2020 and 2019, the Company subleased office space in Torrance, California to Good Dermatology, a professional medical corporation owned by the Founder and former CEO. Under the terms of the sublease, lease expenses incurred by the Company were 100% passed through to Good Dermatology. Total sublease income was $106,972 and $116,697 for the years ended December 31, 2020 and 2019, respectively. The sublease was terminated as of November 30, 2020. During the year ended December 31, 2019, the Company purchased clinical trial investigator services in an arm’s length transaction totaling $273,787 from Good Dermatology, a professional medical corporation owned by the Founder and former CEO. No services were purchased from Good Dermatology during the year ended December 31, 2020. During the year ended December 31, 2019, the Founder and former CEO had a personal loan from the Company in the amount of $300,000 which was paid off in its entirety, including accrued interest of $15,682 on June 26, 2019. There was a zero balance on the loan at December 31, 2019. For the years ended December 31, 2020 and 2019, the Company had revenue of $9,106,645 and $0, respectively, and as of December 31, 2020 and 2019, receivables of $6,927,470 and $0, respectively, from Pharmaceutical Products Development, LLC, a shareholder who holds a minority interest in the Company. Pharmaceutical Products Development, LLC became a minority shareholder of the Company during the first quarter of 2019. For the years ended December 31, 2020 and 2019, the Company had revenue of $351,034 and $451,558, respectively, and as of December 31, 2020 and 2019, receivables of $129,857 and $9,825, respectively, from Novartis, who has a 50% ownership in dRX Capital AG, a shareholder who has a minority interest in the Company. dRX Capital AG became a minority shareholder of the Company in the third quarter of 2015.
LifeSci Acquisition II Corp
RELATED PARTY TRANSACTIONS	NOTE 6. RELATED PARTY TRANSACTIONS Founder Shares On January 1, 2020, the Company issued an aggregate of 2,156,250 shares of common stock (the “Founder Shares”) to the Sponsor for an aggregate purchase price of $25,000. On September 30, 2020, LifeSci Holdings LLC transferred 215,625 Founder Shares to Chardan Healthcare Investments LLC, an investor in the Sponsor. The Founder Shares included an aggregate of up to 153,990 shares of common stock that remained subject to forfeiture by the Sponsor, following the underwriters’ election to partially exercise their over-allotment option so that the number of Founder Shares would collectively represent 20% of the Company’s issued and outstanding shares upon the completion of the Initial Public Offering. On January 8, 2021, the underwriters’ election to exercise their remaining over-allotment option expired unexercised, resulting in 127,260 shares no longer subject to forfeiture and the forfeiture of 153,990 shares. Accordingly, as of January 8, 2021, there were 2,002,260 Founder Shares issued and outstanding . The Sponsor and Chardan Healthcare Investments LLC have agreed that, subject to certain limited exceptions, 50% of the Founder Shares will not be transferred, assigned, sold or released from escrow until the earlier of (i) six months after the date of the consummation of a Business Combination or (ii) the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30- trading day period commencing after a Business Combination and the remaining 50% of the Founder Shares will not be transferred, assigned, sold or released from escrow until six months after the date of the consummation of a Business Combination, or earlier, in either case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the stockholders having the right to exchange their shares of common stock for cash, securities or other property. Administrative Support Agreement The Company entered into an agreement, commencing on November 20, 2020 through the earlier of the Company’s consummation of a Business Combination and its liquidation, to pay an affiliate of the Sponsor a total of $10,000 per month for office space, utilities and secretarial support. For the three months ended September 30, 2021 and 2020, the Company incurred $30,000 and $0, respectively, in fees for these services, of which $100,000 and $70,000 is included in accrued expenses in the accompanying unaudited condensed consolidated balance sheets at September 30, 2021 and June 30, 2021, respectively. Promissory Note — Related Party On June 19, 2020, the Company issued an unsecured promissory note to the Sponsor (the “Promissory Note”), pursuant to which the Company could borrow up to an aggregate principal amount of $175,000. The Promissory Note was non-interest bearing and payable within 15 days of the Sponsor providing the Company with written notice of demand. The outstanding balance under the Promissory Note of $175,000 was repaid at the closing of the Initial Public Offering on November 24, 2020. No future borrowings are permitted under this note. Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds from time to time or at any time, as may be required (“Working Capital Loans”). Each Working Capital Loan would be evidenced by a promissory note. The Working Capital Loans would be paid upon consummation of a Business Combination, without interest or, at the lender’s discretion, up to $500,000 of such Working Capital Loans may be converted into warrants of the post Business Combination entity at a price of $0.90 per warrant. In the event that a Business Combination does not close, the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The warrants would be identical to the Private Warrants. As of September 30, 2021 and June 30, 2020, the Company had no outstanding borrowings under the Working Capital Loans.		NOTE 6. RELATED PARTY TRANSACTIONS Founder Shares On January 1, 2020, the Company issued an aggregate of 2,156,250 shares of common stock (the "Founder Shares") to the Sponsor for an aggregate purchase price of $25,000. On September 30, 2020, LifeSci Holdings LLC transferred 215,625 Founder Shares to Chardan Healthcare Investments LLC, an investor in the Sponsor. The Founder Shares included an aggregate of up to 153,990 shares of common stock that remained subject to forfeiture by the Sponsor, following the underwriters’ election to partially exercise their over-allotment option so that the number of Founder Shares would collectively represent 20% of the Company’s issued and outstanding shares upon the completion of the Initial Public Offering. On January 8, 2021, the underwriters’ election to exercise their remaining over-allotment option expired unexercised, resulting in 127,260 shares no longer subject to forfeiture and the forfeiture of 153,990 shares. Accordingly, as of January 8, 2021 and June 30, 2021, there were 2,002,260 Founder Shares issued and outstanding. The Sponsor and Chardan Healthcare Investments LLC have agreed that, subject to certain limited exceptions, 50% of the Founder Shares will not be transferred, assigned, sold or released from escrow until the earlier of (i) six months after the date of the consummation of a Business Combination or (ii) the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30- trading day period commencing after a Business Combination and the remaining 50% of the Founder Shares will not be transferred, assigned, sold or released from escrow until six months after the date of the consummation of a Business Combination, or earlier, in either case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the stockholders having the right to exchange their shares of common stock for cash, securities or other property. Administrative Support Agreement The Company entered into an agreement, commencing on November 20, 2020 through the earlier of the Company’s consummation of a Business Combination and its liquidation, to pay an affiliate of the Sponsor a total of $10,000 per month for office space, utilities and secretarial support. For the year ended June 30, 2021, the Company incurred $70,000 in fees for these services, of which is included in accounts payable and accrued expenses in the accompanying consolidated balance sheets. For the year ended June 30, 2020 the Company did not incur any fees for these services. Promissory Note — Related Party On June 19, 2020, the Company issued an unsecured promissory note to the Sponsor (the “Promissory Note”), pursuant to which the Company could borrow up to an aggregate principal amount of $175,000. On July 9, 2020 the Company borrowed $175,000 from the Sponsor. The Promissory Note was non-interest bearing and payable within 15 days of the Sponsor providing the Company with written notice of demand. The outstanding balance under the Promissory Note of $175,000 was repaid at the closing of the Initial Public Offering on November 24, 2020. No future borrowings are permitted under this note. Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds from time to time or at any time, as may be required (“Working Capital Loans”). Each Working Capital Loan would be evidenced by a promissory note. The Working Capital Loans would be paid upon consummation of a Business Combination, without interest or, at the lender’s discretion, up to $500,000 of such Working Capital Loans may be converted into warrants of the post Business Combination entity at a price of $0.90 per warrant. In the event that a Business Combination does not close, the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The warrants would be identical to the Private Warrants. As of June 30, 2021 and 2020, the Company had no outstanding borrowings under the Working Capital Loans.

COMMITMENTS

COMMITMENTS	3 Months Ended	9 Months Ended	12 Months Ended
COMMITMENTS	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
COMMITMENTS		9. Commitments and Contingencies Legal Proceedings During 2019 and 2020, the Company was in state court litigation in California. Noah Craft and Belinda Tan, former co-founders and former Chief Executive Officer and Chief Medical Officer, respectively, asserted derivative claims purportedly on behalf of the Company alleging that several of its current and former directors and investors committed various breaches of duty in connection with the termination of Craft and Tan’s employment. Craft and Tan also asserted direct tort claims arising from the same facts against the non-Company defendants. Moreover, Tan asserted a direct claim against the Company and certain current and former directors for gender discrimination. The Company disputed that it was liable, and that none of Craft and Tan’s claims had merit. Notwithstanding the Company’s stance, the litigation was settled in court in November 2020. As of September 30, 2021, all elements and payments associated with the settlement have been completed which included the following: 1) In June 2020, the Director Defendants paid $100,000 to the Company, which was used to offset the legal settlement in 3) below. 2) As part of the settlement, the Company paid $3,675,000 to Plaintiffs (“First Payment”) in December 2020. In return, the Plaintiffs conveyed all the Company shares and any other securities or interest in the Company shares. The Plaintiffs held the equivalent on an as converted basis of 5,901,076 common shares. 3) In December 2020, the Company accrued $1,225,000 for the legal settlement which was paid in June 2021 (“Second Payment”). 9. Commitments and Contingencies (continued) New Office Lease In March 2021, the Company entered into an operating lease agreement to lease office space in Culver City, CA commencing in July 2021 through October 2024 totaling $1,578,821 . Future minimum lease payments under non-cancellable leases as of September 30, 2021 were as follows: Operating Leases 2021 (remaining three months) $ 188,943 2022 1,286,301 2023 629,369 2024 599,327 2025 137,888 2026 11,517 Thereafter — Total future minimum lease payments $ 2,853,345 Less imputed interest (264,774) Total $ 2,588,571 Reported as of September 30, 2021: Other current liabilities $ 1,103,283 Operating lease liabilities 1,485,288 Total $ 2,588,571		14. Commitments and Contingencies Legal Proceedings During 2019 and 2020, the Company was in state court litigation in California. Noah Craft and Belinda Tan, former co-founders and former Chief Executive Officer and Chief Medical Officer, respectively, asserted derivative claims purportedly on behalf of the Company alleging that several of its current and former directors and investors committed various breaches of duty in connection with the termination of Craft and Tan’s employment. Craft and Tan also asserted direct tort claims arising from the same facts against the non-Company defendants. Moreover, Tan asserted a direct claim against the Company and certain current and former directors for gender discrimination. The Company disputed that it was liable, and that none of Craft and Tan’s claims had merit. On September 30, 2019, the Los Angeles County Superior Court stayed this litigation indefinitely after ruling that a contractual forum selection clause required Craft’s and Tan’s claims to be brought in Delaware. Craft and Tan have partially appealed that ruling to the California Court of Appeal. On February 26, 2020 agreement was reached on the terms of the pending litigation described above, and on June 30, 2020, the long form agreement was executed by all parties, and was settled in court in November 2020. The settlement agreement included the following elements: 1) Within five business days after a Final Dismissal occurred: a. The Director Defendants caused their insurers to pay $100,000 to Science 37. b. Science 37 paid $3,675,000 to Plaintiffs (“First Payment”). 2) Within five business days of the Plaintiffs’ receipt of the First Payment, the Plaintiffs conveyed all Science 37 shares and any other securities or interest in Science 37 shares. The Plaintiffs held the equivalent on an as converted basis of 5,901,076 common shares. 3) Good Dermatology, a company wholly owned by the Plaintiffs, was focused on providing dermatology care. Historically, Good Dermatology had sub-contracted employees from Science 37, and had allowed Science 37 the use of their medical offices to conduct clinical trials. In addition, Science 37 had advanced funds for rental payments and employee payroll, for the benefit of Good Dermatology. Good Dermatology delivered $600,000 to Science 37 to cover all outstanding obligations as of February 26, 2020: a. Within five business days after the Effective Date (June 30, 2020), Plaintiffs instructed Good Dermatology to pay Science 37 $400,000 for part of the payables due to Science 37 for rent, employee costs, etc. This amount was received in early July 2020. b. It was contemplated that Good Dermatology would dissolve or be wound down. Within five business days of such action, Science 37 is to pay the Plaintiffs either $1,225,000 or $ 1,025,000 (“Second Payment”). The amount paid was determined by whether Plaintiffs i) elected to pay $200,000 directly to Science 37 to satisfy the $600,000 outlined in 3) above and in which case, Science 37 would pay to the Plaintiffs $1,225,000 or ii) elected to pay $0 directly to Science 37 in which the Second Payment to the Plaintiffs would be $1,025,000 . Plaintiffs elected to pay $200,000 , resulting in Science 37 owing $1,225,000 . As of December 31, 2020, this payment is pending upon Good Dermatology’s dissolution. c. Additionally, prior to dissolution, Good Dermatology agreed to pay Science 37 all sums which accrued, arose or were incurred on Good Dermatology’s behalf by Science 37 from the time of February 26, 2020 through dissolution. 14. Commitments and Contingencies (continued) As of December 31, 2020, all payments were made by both parties with the exception of $1,225,000 owed by Science 37 to Plaintiffs in 3b above, the amount of which is recorded in accrued expenses on the balance sheet. The $1,225,000 was paid by Science 37 in June 2021.
LifeSci Acquisition II Corp
COMMITMENTS	NOTE 7. COMMITMENTS Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position and/or search for a target company, the specific impact is not readily determinable as of the date of the condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Registration and Stockholder Rights Pursuant to a registration rights agreement entered into on November 20, 2020, the holders of the Founder Shares and the Private Warrants and any shares that may be issued upon conversion of Working Capital Loans (and all underlying securities) will be entitled to registration and stockholder rights. The holders of a majority of these securities are entitled to make up to two demands that the Company register such securities. The holders of the majority of the Founders Warrants can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the Private Warrants can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. The Sponsor and its related persons may not, with respect to the Private Warrants purchased by it, (i) have more than one demand registration right at the Company’s expense, (ii) exercise their demand registration rights more than five (5) years from the effective date of the registration statement of the Initial Public Offering, and (iii) exercise their “piggy-back” registration rights more than seven (7) years from the effective date of the Initial Public Offering, as long as the Sponsor or any of its related persons are beneficial owners of Private Warrants. Underwriting Agreement The Company granted the underwriters a 45-day option from the date of the Initial Public Offering to purchase up to 1,125,000 additional Public Shares to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. As a result of the underwriter’s election to partially exercise the over-allotment option to purchase an additional 509,041 Public Shares, a total of 615,959 Public Shares remained available for purchase at a price of $10.00 per Public Share. On January 8, 2021, the underwriters’ election to exercise their remaining over-allotment option expired unexercised. The underwriters were paid cash underwriting discount of $0.20 per Public Share, or $1,601,808 in the aggregate. Business Combination Marketing Agreement The Company has engaged LifeSci Capital LLC and Ladenburg Thalmann & Co. Inc. (“Ladenburg Thalmann “) as advisors in connection with a Business Combination to assist the Company in holding meetings with its stockholders to discuss the potential Business Combination and the target business’ attributes, introduce the Company to potential investors that are interested in purchasing the Company’s securities in connection with a Business Combination, assist the Company in obtaining stockholder approval for the Business Combination and assist the Company with its press releases and public filings in connection with the Business Combination. The Company will pay LifeSci Capital LLC and Ladenburg Thalmann a cash fee for such services upon the consummation of a Business Combination in an amount equal to 3.5% of the gross proceeds of the Initial Public Offering, or $2,803,164, (exclusive of any applicable finders’ fees which might become payable) with 75% of such fee payable to LifeSci Capital LLC and 25% to Ladenburg Thalmann; provided that up to 33% of the fee may be allocated in the Company’s sole discretion to other third parties who are investment banks or financial advisory firms not participating in Initial Public Offering that assist the Company in identifying and consummating a Business Combination.		NOTE 7. COMMITMENTS Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position and/or search for a target company, the specific impact is not readily determinable as of the date of the consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Registration and Stockholder Rights Pursuant to a registration rights agreement entered into on November 20, 2020, the holders of the Founder Shares and the Private Warrants and any shares that may be issued upon conversion of Working Capital Loans (and all underlying securities) will be entitled to registration and stockholder rights. The holders of a majority of these securities are entitled to make up to two demands that the Company register such securities. The holders of the majority of the Founders Warrants can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the Private Warrants can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. The Sponsor and its related persons may not, with respect to the Private Warrants purchased by it, (i) have more than one demand registration right at the Company’s expense, (ii) exercise their demand registration rights more than five (5) years from the effective date of the registration statement of the Initial Public Offering, and (iii) exercise their “piggy-back” registration rights more than seven (7) years from the effective date of the Initial Public Offering, as long as the Sponsor or any of its related persons are beneficial owners of Private Warrants. Underwriting Agreement The Company granted the underwriters a 45-day option from the date of the Initial Public Offering to purchase up to 1,125,000 additional Public Shares to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. As a result of the underwriter’s election to partially exercise the over-allotment option to purchase an additional 509,041 Public Shares, a total of 615,959 Public Shares remained available for purchase at a price of $10.00 per Public Share. On January 8, 2021, the underwriters’ election to exercise their remaining over-allotment option expired unexercised. The underwriters were paid a cash underwriting discount of $0.20 per Public Share, or $1,601,808 in the aggregate. Business Combination Marketing Agreement The Company has engaged LifeSci Capital LLC and Ladenburg Thalmann & Co. Inc. (“Ladenburg Thalmann “) as advisors in connection with a Business Combination to assist the Company in holding meetings with its stockholders to discuss the potential Business Combination and the target business’ attributes, introduce the Company to potential investors that are interested in purchasing the Company’s securities in connection with a Business Combination, assist the Company in obtaining stockholder approval for the Business Combination and assist the Company with its press releases and public filings in connection with the Business Combination. The Company will pay LifeSci Capital LLC and Ladenburg Thalmann a cash fee for such services upon the consummation of a Business Combination in an amount equal to 3.5% of the gross proceeds of the Initial Public Offering, or $2,803,164, with 75% of such fee payable to LifeSci Capital LLC and 25% to Ladenburg Thalmann; provided that up to 33% of the fee may be allocated in the Company’s sole discretion to other third parties who are investment banks or financial advisory firms not participating in Initial Public Offering that assist the Company in identifying and consummating a Business Combination. Business Combination Agreement On May 6, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with LifeSci Acquisition II Merger Sub, Inc. (“Merger Sub”), and Science 37, Inc. (“Science 37”), pursuant to which the Merger Sub will merge with and into Science 37, with Science 37 surviving the merger as the Company’s wholly-owned subsidiary (the “Merger”). The Company’s board of directors has unanimously (i) approved and declared advisable the Merger Agreement, the Merger and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Merger Agreement and related matters by our stockholders. Immediately prior to the effective time of the Merger (the “Effective Time”) and subject to the consent of the holders of a majority of the then outstanding shares of Science 37’s Series A, Series, B, Series C, Series D and Series D-1 preferred stock, par value $0.0001 per share (collectively, the “Science 37 Preferred Stock”), voting together as a single class on an as-converted basis, each issued and outstanding share of Science 37 Preferred Stock will be converted into shares of the common stock, par value $0.0001 per share, of Science 37 (the “Science 37 Common Stock”) at the then-applicable conversion rates (the “Science 37 Preferred Stock Conversion”). At the Effective Time, each outstanding and unexercised warrant to purchase shares of Science 37 capital stock (“Science 37 Warrant”) that is outstanding and unexercised immediately prior to the Effective Time will be converted into a warrant exercisable to receive the Company’s common stock, in accordance with its terms. From and after the Effective Time: (i) each Science 37 Warrant assumed by the Company may be exercised solely for shares of the Company’s common stock; (ii) the number of shares of the Company’s common stock subject to each Science 37 Warrant assumed by the Company will be determined by multiplying (A) the number of shares of Science 37 Common Stock, or the number of shares of Science 37 Common Stock issuable upon exercise of the Science 37 Warrant that were subject to such Science 37 Warrant immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number up to the nearest whole number of shares of the Company’s common stock; (iii) the per share exercise price for the Company’s common stock issuable upon exercise of each Science 37 Warrant assumed by the Company will be determined by dividing the per share exercise price of Science 37 Common Stock subject to the Science 37 Warrant, as in effect immediately prior to the Effective Time, by the Exchange Ratio and rounding the resulting exercise price up to the nearest whole cent; and (iv) any restriction on any Science 37 Warrant assumed by the Company will continue in full force and effect and the terms and other provisions of such Science 37 Warrant will otherwise remain unchanged. The Exchange Ratio is defined in the Merger Agreement to be the quotient of (i) 100,000,000 divided by (ii) the number of shares of Science 37’s Fully Diluted Capital Stock (as defined in the Merger Agreement). At the Effective Time, following the Science 37 Preferred Stock Conversion, each share of Science 37 Common Stock (including shares of Science 37 Common Stock outstanding as a result of the Science 37 Preferred Stock Conversion, but excluding shares the holders of which perfect rights of appraisal under Delaware law) will be converted into the right to receive such number of shares of the Company’s common stock equal to the Exchange Ratio (subject to rounding mechanisms as described in the Merger Agreement) and a number of Earn-Out Shares (as defined below). At the Effective Time, each outstanding option to purchase shares of Science 37 Common Stock, whether or not then vested and exercisable, will be converted automatically (and without any required action on the part of such holder of outstanding option) into an option to purchase shares of the Company’s common stock equal to the number of shares subject to such option prior to the Effective Time multiplied by the Exchange Ratio, with the per share exercise price equal to the exercise price prior to the Effective Time divided by the Exchange Ratio. Following the closing of the Merger, former holders of shares of Science 37 Common Stock (including shares received as a result of the Science 37 Preferred Stock Conversion) and former holders of Science 37 stock options will be entitled to receive their pro rata share of up to 12,500,000 additional shares of the Company’s common stock (the “Earn-Out Shares”) if, within a three-year period following May 6, 2021, the signing date of the Merger Agreement, the closing share price of the Company’s common stock equals or exceeds any of two thresholds over any 20 trading days within a 30-day trading period (each, a “Triggering Event”) and, in respect of a former holder of Science 37 stock options, the holder continues to provide services to the Company or one of the subsidiaries at the time of such Triggering Event. In connection with the execution of the Merger Agreement, LSAQ entered into subscription agreements (collectively, the “Subscription Agreements”) with certain parties subscribing for shares of LSAQ Common Stock (the “Subscribers”) pursuant to which the Subscribers have agreed to purchase, and LSAQ has agreed to sell to the Subscribers, an aggregate of 20,000,000 shares of LSAQ Common Stock, for a purchase price of $10.00 per share and an aggregate purchase price of $200,000,000. The obligations to consummate the transactions contemplated by the Subscription Agreements are conditioned upon, among other things, customary closing conditions and the consummation of the transactions contemplated by the Merger Agreement. The Merger Agreement contains customary representations, warranties and covenants of the parties thereto. The consummation of the proposed Merger is subject to certain conditions as further described in the Merger Agreement.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended	9 Months Ended	12 Months Ended
STOCKHOLDERS' EQUITY	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
STOCKHOLDERS' EQUITY		6. Stockholders’ Deficit Par value for common shares is $0.0001 . The following is a summary of common share activity for the nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Common shares, beginning balance 4,488,416 8,468,742 2,765,097 8,396,425 Issuance of common shares 106,752 75,694 1,830,071 148,011 Common shares, ending balance 4,595,168 8,544,436 4,595,168 8,544,436 The Company has one common stock warrant outstanding with available shares to be issued of 6,439 and an exercise price of $1.61 per share as of September 30, 2021. This warrant was exercised on October 4, 2021.		11. Shareholders’ Deficit Science 37 was formed under Delaware law and is treated as a “C” corporation for U.S. tax purposes. Par value for common shares is $0.0001. The following is a summary of common share activity for the years ended December 31, 2020 and 2019: 2020 2019 Common stock shares, beginning balance 8,396,425 8,273,865 Issuance of common stock 164,886 122,560 Repurchase of common stock (5,796,214) — Common stock shares, ending balance 2,765,097 8,396,425 The Company has one common stock warrant outstanding with available shares to be issued of 6,439 and an exercise price of $1.61 per share as of December 31, 2020.
LifeSci Acquisition II Corp
STOCKHOLDERS' EQUITY	NOTE 8. STOCKHOLDERS’ EQUITY Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. At September 30, 2021 and June 30, 2021, there were no shares of preferred stock issued or outstanding. Common Stock — The Company is authorized to issue 30,000,000 shares of common stock with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share. At September 30, 2021 and June 30, 2021, there were 2,002,260 shares of non-redeemable common stock, excluding 8,009,041 shares of common stock subject to possible redemption which are presented as temporary equity. Warrants — The Private Warrants will become exercisable at any time commencing on the later of (1) one year after the closing of the Initial Public Offering or (2) the consummation of a Business Combination; provided that the Company has an effective and current registration statement covering the shares of common stock issuable upon the exercise of the Public Warrants and a current prospectus relating to such shares of common stock. The Private Warrants purchased by the Sponsor will be exercisable on a cashless basis and not be exercisable more than five years from the commencement of sales of the Initial Public Offering, in accordance with FINRA Rule 5110(g)(8)(A), as long as the Sponsor or any of its related persons beneficially own these Private Warrants.		NOTE 8. STOCKHOLDERS’ EQUITY Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. At June 30, 2021 and 2020, there were no shares of preferred stock issued or outstanding. Common Stock — The Company is authorized to issue 30,000,000 shares of common stock with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share. At June 30, 2021 and 2020, there were 2,002,260 and 2,156,250 shares of common stock issued and outstanding , excluding 8,009,041 and no shares of common stock subject to possible redemption, respectively. Warrants — The Private Warrants will become exercisable at any time commencing on the later of (1) one year after the closing of the Initial Public Offering or (2) the consummation of a Business Combination; provided that the Company has an effective and current registration statement covering the shares of common stock issuable upon the exercise of the Public Warrants and a current prospectus relating to such shares of common stock. The Private Warrants purchased by the Sponsor will be exercisable on a cashless basis and not be exercisable more than five years from the commencement of sales of the Initial Public Offering, in accordance with FINRA Rule 5110(g)(8)(A), as long as the Sponsor or any of its related persons beneficially own these Private Warrants.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended	9 Months Ended	12 Months Ended
FAIR VALUE MEASUREMENTS	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021
FAIR VALUE MEASUREMENTS		3. Fair Value Measurements Fair value is the price that would be received to sell an asset or paid to transfer a liability between market participants in the principal market or the most advantageous market when no principal market exists. Market participants are assumed to be independent, knowledgeable, able, and willing to transact an exchange and not under duress. Considerable judgment may be required in interpreting market data used to develop the estimates of fair value. Accordingly, estimates of fair value are not necessarily indicative of the amounts that could be realized in a current or future market exchange. Fair values for substantially all the Company’s financial and non-financial instruments were measured using market, income, or cost approaches. The three levels of input are as follows: Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial instruments, including cash and cash equivalents, are recorded at cost, which approximates fair value. The Company does not have any assets or liabilities measured at Level 2 or Level 3.
LifeSci Acquisition II Corp
FAIR VALUE MEASUREMENTS	NOTE 9. FAIR VALUE MEASUREMENTS The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. The Company classifies its U.S. Treasury and equivalent securities as held-to-maturity in accordance with ASC Topic 320 “Investments — Debt and Equity Securities.” Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost on the accompanying balance sheets and adjusted for the amortization or accretion of premiums or discounts. The Company classifies its securities in the Trust Account that are invested in funds, such as Mutual Funds or Money Market Funds, that primarily invest in U.S. Treasury and equivalent securities as Trading Securities in accordance with ASC Topic 320 “Investments — Debt and Equity Securities. Trading Securities are recorded at fair market value on the accompanying consolidated balance sheets. At September 30, 2021, assets held in the Trust Account were comprised of $80,131,806 in cash. During the three months ended September 30, 2021, the Company did not withdraw any interest income from the Trust Account. At June 30, 2021, assets held in the Trust Account were comprised of $80,120,809 in a mutual fund that is invested primarily in U.S. Treasury Securities. Through June 30, 2021, the Company did not withdraw any of the interest earned on the Trust Account. The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at September 30, 2021 and June 30, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Trading Securities Level Fair Value June 30, 2021 Mutual Fund 1 80,120,809		NOTE 10. FAIR VALUE MEASUREMENTS The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on an assessment of the assumptions that market participants would use in pricing the asset or liability. The Company classifies its U.S. Treasury and equivalent securities as held-to-maturity in accordance with ASC Topic 320, “Investments — Debt and Equity Securities.” Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost on the accompanying consolidated balance sheets and adjusted for the amortization or accretion of premiums or discounts. The Company classifies its securities in the Trust Account that are invested in funds, such as Mutual Funds or Money Market Funds, that primarily invest in U.S. Treasury and equivalent securities as Trading Securities in accordance with ASC Topic 320, “Investments — Debt and Equity Securities.” Trading Securities are recorded at fair market value on the accompanying consolidated balance sheets. At June 30, 2021, assets held in the Trust Account were comprised of $0 in cash and $80,120,809 in a mutual fund that is invested primarily in U.S. Treasury Securities. Through June 30, 2021, the Company has not withdrawn any of the interest earned on the Trust Account. The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at June 30, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Trading Securities Level Fair Value June 30, 2021 Mutual Fund 1 $ 80,120,809

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended	9 Months Ended	12 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
SUBSEQUENT EVENTS		12. Subsequent Events Merger with LSAQ On May 7, 2021, the Company announced a planned merger with LSAQ under a definitive business combination agreement. On October 6, 2021, the agreement was consummated, with the Company surviving the merger as Science 37 Holdings, Inc, now a public company. All outstanding common and preferred shares of legacy Science 37, Inc. converted into common shares of the surviving Science 37 Holdings, Inc. through application of an exchange ratio of approximately 1.815. In addition, awards under the Company's existing 2015 stock incentive plan continue under the same terms and conditions as were previously applicable to such awards, subject to the same exchange ratio for exercise price and number of options outstanding. Common shares and warrants held by former LSAQ shareholders were converted to 10,858,261 common shares of Science 37 Holdings, Inc. Science 37 Holdings, Inc. began trading on the Nasdaq stock exchange as SNCE effective October 7, 2021. The financial statements as of September 30, 2021, including share and per share amounts, do not include the effects of the merger. The table below shows, on a pro forma basis, the impact of the merger on certain condensed balance sheet items as of September 30, 2021: Balance Sheet Data: Actual Pro Forma Cash and cash equivalents $ 7,996,362 $ 242,991,191 Working capital (5,566,182) 228,647,166 Total assets 39,746,217 273,843,757 Redeemable convertible preferred stock 143,086,271 — Accumulated deficit (136,979,761) (136,979,761) Total stockholders’ equity (deficit) $ (132,209,608) $ 163,290,011 Share Data: Actual Pro Forma Redeemable convertible preferred stock outstanding 41,587,368 — Common stock outstanding 4,595,168 114,707,150 Going Concern From August 2021, the Company began to accelerate investments in hiring and in other critical areas, such as the technology platform, to facilitate the delivery of anticipated revenues, resulting from an increase in net bookings. Also, as several meaningful conditions of the contemplated transaction were met, the Company increased spend related to the requirements of being a publicly-traded company. The Company’s increased costs adversely affected the Company’s results of operations and liquidity and there was substantial doubt as to the Company’s ability to continue as a going concern at that time. On October 6, 2021, the definitive business combination agreement was consummated, with Science 37, Inc. surviving the merger as Science 37 Holdings, Inc., a now public company. All outstanding common and preferred shares of legacy Science 37, Inc. converted into common shares of the surviving Science 37 Holdings, Inc. through application of an exchange ratio of approximately 1.815. In addition, awards under the Company’s existing 2015 stock incentive plan continue under the same terms and conditions as were previously applicable to such awards, subject to the same exchange ratio for exercise price and number of options outstanding. Science 37 Holdings, Inc. began trading on the Nasdaq stock exchange as SNCE effective October 7, 2021. 12. Subsequent Events (continued) In conjunction with this merger, Science 37, Inc. received funds held in LSAQ's working capital and trust accounts together with $ 200 million in PIPE financing from institutional and strategic investors to further fund Science 37, Inc.’s decentralized trial technology platform and extend into new adjacencies. As a result of the Merger and inclusive of the PIPE financing, Science 37, Inc. received $ 234.2 million, net of fees and expenses paid in connection with the closing of the business combination. The transaction will be accounted for as a reverse capitalization in accordance with GAAP. Under the reverse capitalization model, the merger will be treated as Science 37, Inc. is issuing equity for the net assets of LSAQ, with no goodwill or intangible assets recorded, and LSAQ will be treated as the acquiree for financial reporting purposes. This is primarily because, subsequent to the merger, Science 37, Inc. shareholders have a majority of the voting power of the combined company. In addition, Science 37, Inc. comprises all of the ongoing operations, senior management, and a majority of the governing body of the combined company. As a result of the merger and related PIPE financing, the substantial doubt about the Company's ability to continue as a going concern has been alleviated. The Company has evaluated subsequent events through November 15, 2021, the date on which the accompanying condensed consolidated financial statements were issued, noting no additional items requiring disclosure.		18. Subsequent Events On March 25, 2021, the Company entered into an operating lease agreement for office space which will commence on July 1, 2021. The Company’s financial commitment for the office space is disclosed under Leases. On May 7, 2021, the Company announced a planned merger with LifeSci Acquisition II Corp (LSAQ) under a definitive business combination agreement. Going Concern From August 2021, the Company began to accelerate investments in hiring and in other critical areas, such as the technology platform, to facilitate the delivery of anticipated revenues, resulting from an increase in net bookings. Also, as several meaningful conditions of the contemplated transaction were met, the Company increased spend related to the requirements of being a publicly-traded company. The Company’s increased costs adversely affected the Company’s results of operations and liquidity and there was substantial doubt as to the Company’s ability to continue as a going concern at that time. On October 6, 2021, the definitive business combination agreement was consummated, with Science 37, Inc. surviving the merger as Science 37 Holdings, Inc., a now public company. All outstanding common and preferred shares of legacy Science 37, Inc. converted into common shares of the surviving Science 37 Holdings, Inc. through application of an exchange ratio of approximately 1.815. In addition, awards under the Company’s existing 2015 stock incentive plan continue under the same terms and conditions as were previously applicable to such awards, subject to the same exchange ratio for exercise price and number of options outstanding. Science 37 Holdings, Inc. began trading on the Nasdaq stock exchange as SNCE effective October 7, 2021. In conjunction with this merger, Science 37, Inc. received funds held in LSAQ’s working capital and trust accounts together with $200 million in PIPE financing from institutional and strategic investors to further fund Science 37, Inc.’s decentralized trial technology platform and extend into new adjacencies. As a result of the Merger and inclusive of the PIPE financing, Science 37, Inc. received $234.2 million, net of fees and expenses paid in connection with the closing of the business combination. The transaction will be accounted for as a reverse capitalization in accordance with GAAP. Under the reverse capitalization model, the merger will be treated as Science 37, Inc. is issuing equity for the net assets of LSAQ, with no goodwill or intangible assets recorded, and LSAQ will be treated as the acquiree for financial reporting purposes. This is primarily because, subsequent to the merger, Science 37, Inc. shareholders have a majority of the voting power of the combined company. In addition, Science 37, Inc. comprises all of the ongoing operations, senior management, and a majority of the governing body of the combined company. As a result of the merger and related PIPE financing, the substantial doubt about the Company’s ability to continue as a going concern has been alleviated. The Company has evaluated subsequent events through November 5, 2021, the date on which the accompanying consolidated financial statements were issued, noting no additional items requiring disclosure.
LifeSci Acquisition II Corp
SUBSEQUENT EVENTS	NOTE 10. SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed consolidated financial statements were issued. Based upon this review, except as disclosed below , the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements. On October 4, 2021, LSAQ held a special meeting of stockholders (the “Special Meeting”), at which the LSAQ stockholders considered and adopted, among other matters, a proposal to approve the Business Combination, including (a) adopting the Merger Agreement and (b) approving the other transactions and matters contemplated by the Merger Agreement and related agreements as described in the Proxy Statement/Prospectus. Pursuant to the terms and subject to the conditions set forth in the Merger Agreement, following the Special Meeting, on October 6, 2021, the Transactions were consummated. In connection with the Closing, the Company changed its name from LifeSci Acquisition II Corp. to Science 37 Holdings, Inc. Holders of 2,299,493 shares of LSAQ’s common stock sold in its initial public offering (the “public shares”) exercised their right to have such shares redeemed for a full pro rata portion of the trust account holding the proceeds from LSAQ’s initial public offering, calculated as of two business days prior to the consummation of the Business Combination, which was approximately $10.00 per share, or $23,003,944 in the aggregate. As noted above, an aggregate of $23,003,944 was paid from the Company’s trust account to holders that properly exercised their right to have public shares redeemed, and the remaining balance immediately prior to the Closing of approximately $57.1 million remained in the trust account. The remaining amount in the trust account was used to fund the Business Combination (See Note 1).		NOTE 11. SUBSEQUENT EVENTS On October 4, 2021, the Company held a special meeting of stockholders (the “Special Meeting”), at which stockholders considered and adopted, among other matters, a proposal to approve the Business Combination, including (a) adopting the Merger Agreement and (b) approving the other transactions and matters contemplated by the Merger Agreement and related agreements as described in the Proxy Statement/Prospectus. Pursuant to the terms and subject to the conditions set forth in the Merger Agreement, following the Special Meeting, on October 6, 2021, the Transactions were consummated. In connection with the Closing, the Company changed its name from LifeSci Acquisition II Corp. to Science 37 Holdings, Inc. Holders of 2,299,493 shares of LSAQ’s common stock sold in its initial public offering exercised their right to have such shares redeemed for a full pro rata portion of the trust account holding the proceeds from LSAQ’s initial public offering, calculated as of two business days prior to the consummation of the Business Combination, which was approximately $10.00 per share, or $23,003,944 in the aggregate. An aggregate of $23,003,944 was paid from the Company’s trust account to holders that properly exercised their right to have public shares redeemed, and the remaining balance immediately prior to the Closing of approximately $57.1 million remained in the trust account. The remaining amount in the trust account was used to fund the Business Combination.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended	9 Months Ended	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Basis of Presentation		Description of Business The Company is a leading provider of technology-based solutions that enable decentralized clinical trials on behalf of biopharmaceutical sponsors. The Company pioneered the decentralized clinical trial model and developed the industry’s first Decentralized Clinical Trial Operating System (DCT OS), combining its technology platform, which orchestrates workflows, supports evidence generation, and harmonizes data seamlessly, with its Specialized Network of patient communities, on-demand telemedicine investigators, flexible mobile nurses, scalable remote coordinators and robust connected technologies. By bringing research to patients and providers more directly, the Company’s operating system increases access and patient diversity, which can help speed the development of potentially life-saving drug treatments. On May 7, 2021, the Company announced a planned merger with LifeSci Acquisition II Corp (“LSAQ”) under a definitive business combination agreement. The merger was consummated on October 6, 2021, whereby LSAQ acquired 100% of the Company's issued and outstanding securities through a reverse merger of the Company with and into a wholly owned subsidiary of LSAQ, with the Company surviving the merger as Science 37 Holdings, Inc, now a public company. In conjunction with this merger, the Company received $200 million through a private investment in public entity (PIPE) offering from leading institutional and strategic investors to further fund the Company’s decentralized trial technology platform and extend into new adjacencies.
Use of Estimates				Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. These estimates are based on historical experience and various other assumptions believed reasonable under the circumstances. The Company evaluates its estimates on an ongoing basis and makes changes to the estimates and related disclosures as experience develops or new information becomes known, including facts and circumstances related to the novel coronavirus disease pandemic. Actual results may differ from those estimated. The Company’s most significant estimates and assumptions used in the preparation of the accompanying consolidated financial statements relate to contract cost estimates in revenue recognition, capitalized software costs, and the valuation of the Company’s common stock.
Cash and Cash Equivalents				Cash and Cash Equivalents The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents, which consist of cash on deposit with banks are stated at cost, which approximates fair value.
Income Taxes				Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records valuation allowances to reduce deferred tax assets to the amount the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not upheld on examination by the taxing authorities based solely upon the technical merits of the positions. The Company recognizes interest and penalties, if any, related to unrecognized income tax uncertainties in income tax expense.
Deferred Offering Costs				Deferred Rent Under prior GAAP (ASC 840), rent expense on facility leases, including free rent and scheduled rent increases, is recorded on a straight-line basis over the term of the lease for the year ending December 31, 2019. The difference between the straight-line rent expense and the amount payable under the lease is included in deferred rent on the accompanying 2019 balance sheet. Lease incentives were recorded and amortized as a reduction of rent expense on a straight-line basis over the term of the lease.
Net Loss Per Common Share		Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.		Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.
Concentration of Credit Risk		Concentration Risks Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, deposits of up to $250,000 at Federal Deposit Insurance Corporation (FDIC) insured institutions are covered by FDIC insurance. At times, deposits at the Company’s financial institution may exceed federally insured limits. Management periodically assesses the financial condition of the institution and believes that any possible credit risk is minimal. The Company has not experienced any loss from such risk.
Recent Accounting Pronouncements				Accounting Pronouncements Adopted as of December 31, 2020 In February 2016, the FASB issued new accounting guidance that requires lessees to recognize leases greater than 12 months in duration on their balance sheet as a right-of-use asset and a lease liability, as well as the disclosure of key information about leasing arrangements. The income statement will reflect lease expense for operating leases, and amortization and interest expense for financing leases. The Company adopted this new accounting guidance on January 1, 2020 and elected the practical expedients that retained the lease classification, initial direct costs, and determination of whether contracts are or contain a lease, for any leases that existed prior to adoption of the new guidance. The Company also elected the transition method which allows for disclosures to be updated prospectively and prior periods to be presented in accordance with previous GAAP. The adoption of this standard had a material impact on the Company’s balance sheet but did not have a material impact on the Company’s results of operations or cash flows.
LifeSci Acquisition II Corp
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s prospectus for its Initial Public Offering as filed with the SEC on November 23, 2020, the Company’s Current Reports on Form 8-K, as filed with the SEC on November 25, 2020, and December 1, 2020, as well as the Company’s Annual Report on Form 10-K, as amended and filed with the SEC on December 20, 2021. The interim results for the three months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending June 30, 2022 or for any future periods.		Basis of Presentation The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”).
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its majority owned subsidiary where the Company has the ability to exercise control. All significant intercompany balances and transactions have been eliminated in consolidation. Activities in relation to the noncontrolling interest are not considered to be significant and are, therefore, not presented in the accompanying unaudited condensed consolidated financial statements.
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.		Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.		Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2021 and June 30, 2021.		Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2021 and 2020.
Common Stock Subject to Possible Redemption	Common Stock Subject to Possible Redemption The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at September 30, 2021 and June 30, 2021, common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ equity (deficit) section of the Company’s unaudited condensed consolidated balance sheets. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable common stock resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit. At September 30, 2021 and June 30, 2021, the common stock reflected in the condensed consolidated balance sheets are reconciled in the following table: Gross proceeds $ 80,090,410 Less: Common stock issuance costs $ (1,858,498) Plus: Accretion of carrying value to redemption value $ 1,858,498 Common stock subject to possible redemption $ 80,090,410		Common Stock Subject to Possible Redemption (Restated — see Note 2) The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2021, common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ equity section of the Company’s consolidated balance sheets. Under ASC 480-10-S99, the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid-in capital and accumulated deficit. At June 30, 2021, the common stock subject to possible redemption reflected in the balance sheet is reconciled in the following table: Gross proceeds $ 80,090,410 Less: Common stock issuance costs (1,858,498) Plus: Accretion of carrying value to redemption value 1,858,498 Common stock subject to possible redemption $ 80,090,410
Offering Costs	Offering Costs Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs amounting to $1,858,498 were charged to temporary equity upon the completion of the Initial Public Offering.		Offering Costs Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs amounting to $1,858,498 were charged to stockholders’ equity upon the completion of the Initial Public Offering.
Income Taxes	Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740 “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2021 and June 30, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may subject to potential examination by federal, state and city taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal, state and city tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company is subject to income tax examinations by major taxing authorities since inception.		Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740 “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the consolidated financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the consolidated financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2021 and 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may be subject to potential examination by federal, state and city taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal, state and city tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company is subject to income tax examinations by major taxing authorities since inception.
Net Loss Per Common Share	Net Loss Per Common Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Accretion associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 3,146,454 common stock in the aggregate. As of September 30, 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net loss per common stock is the same as basic net loss per common stock for the periods presented. Three Months Ended September 30, 2021 Basic and diluted net income (loss) per common stock Numerator: Allocation of net income (loss), as adjusted $ (829,630) Denominator: Basic and diluted 10,011,301 Basic and diluted $ (0.08)		Net Loss Per Common Share (Restated, see Note 2) The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. The Company applies the two-class method in calculating earnings per share. Accretion associated with the redeemable shares of Common Stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, as described in Note 4, since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 3,146,454 Common Stock in the aggregate. As of June 30, 2021, the Company did not have any other dilutive securities or other contracts that could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. As a result, diluted net loss per common share is the same as basic net loss per common share for the periods presented. The following table reflects the calculation of basic and diluted net loss per common share (in dollars, except per share amounts): For the Period from December 18, 2019 (Inception) Year Ended through June 30, June 30, 2021 2020 Basic and diluted net income (loss) per common stock Numerator: Allocation of net income (loss), as adjusted $ (561,449) $ (1,000) Denominator: Basic and diluted weighted average shares outstanding 6,734,489 1,875,000 Basic and diluted net income (loss) per common stock $ (0.08) $ (0.00) Note: As of June 30, 2021 and 2020, basic and diluted shares are the same as there are no non-redeemable securities that are dilutive to the Company’s stockholders.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.		Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying unaudited condensed consolidated balance sheets, primarily due to their short-term nature.		Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximate the carrying amounts represented in the accompanying consolidated balance sheets, primarily due to their short-term nature.
Warrant Classification	Warrant Classification The Company accounts for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815-40-15-7D under which the warrants do meet the criteria for equity treatment and must be recorded as equity.		Warrant Classification The Company accounts for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815-40-15-7D under which the warrants do meet the criteria for equity treatment and must be recorded as equity.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. We are currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated financial statements.		Recent Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, “Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”), to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. We are currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

REVISION OF PREVIOUSLY ISSUED_2

REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)	3 Months Ended	9 Months Ended	12 Months Ended
REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021
Summary of the impact of the revision on the financial statements		The financial statements as of September 30, 2021, including share and per share amounts, do not include the effects of the merger. The table below shows, on a pro forma basis, the impact of the merger on certain condensed balance sheet items as of September 30, 2021: Balance Sheet Data: Actual Pro Forma Cash and cash equivalents $ 7,996,362 $ 242,991,191 Working capital (5,566,182) 228,647,166 Total assets 39,746,217 273,843,757 Redeemable convertible preferred stock 143,086,271 — Accumulated deficit (136,979,761) (136,979,761) Total stockholders’ equity (deficit) $ (132,209,608) $ 163,290,011 Share Data: Actual Pro Forma Redeemable convertible preferred stock outstanding 41,587,368 — Common stock outstanding 4,595,168 114,707,150
LifeSci Acquisition II Corp
Summary of the impact of the revision on the financial statements	The impact of the revision on the Company’s financial statements is reflected in the following table. As Previously Balance Sheet as of June 30, 2021 (audited) Reported Adjustment As Revised Common stock subject to possible redemption $ 75,526,270 $ 4,564,140 $ 80,090,410 Common stock $ 246 $ (45) $ 201 Additional paid-in capital $ 5,562,205 $ (4,564,095) $ 998,110 Accumulated deficit $ (562,449) $ — $ (562,449) Total Stockholders’ Equity (Deficit) $ 5,000,002 $ (4,564,140) $ 435,862		As Previously Reported Adjustment As Restated Balance Sheet as of November 24, 2020 Common stock subject to possible redemption $ 76,087,640 $ 4,002,770 $ 80,090,410 Common stock $ 256 $ (40) $ 216 Additional paid-in capital $ 5,000,825 $ (4,002,730) $ 998,095 Accumulated deficit $ (1,080) $ — $ (1,080) Total Stockholders’ Equity $ 5,000,001 $ (4,002,770) $ 997,231 Number of shares of common stock subject to possible redemption 7,608,764 400,277 8,009,041 Balance Sheet as of December 31, 2020 (Unaudited) Common stock subject to possible redemption $ 76,007,090 $ 4,083,320 $ 80,090,410 Common stock $ 256 $ (40) $ 216 Additional paid-in capital $ 5,081,375 $ (4,083,280) $ 998,095 Accumulated deficit $ (81,623) $ — $ (81,623) Total Stockholders’ Equity $ 5,000,008 $ (4,083,320) $ 916,688 Number of shares of common stock subject to possible redemption 7,600,709 408,332 8,009,041 Balance Sheet as of March 31, 2021 (Unaudited) Common stock subject to possible redemption $ 75,901,950 $ 4,188,460 $ 80,090,410 Common stock $ 242 $ (41) $ 201 Additional paid-in capital $ 5,186,529 $ (4,188,419) $ 998,110 Accumulated deficit $ (186,762) $ — $ (186,762) Total Stockholders’ Equity $ 5,000,009 $ (4,188,460) $ 811,549 Number of shares of common stock subject to possible redemption 7,590,195 418,846 8,009,041 Balance Sheet as of June 30, 2021 Common stock subject to possible redemption $ 75,526,270 $ 4,564,140 $ 80,090,410 Common stock $ 246 $ (45) $ 201 Additional paid-in capital $ 5,562,205 $ (4,564,095) $ 998,110 Accumulated deficit $ (562,449) $ — $ (562,449) Total Stockholders’ Equity $ 5,000,002 $ (4,564,140) $ 435,862 Number of shares of common stock subject to possible redemption 7,552,627 456,414 8,009,041 Statement of Cash Flows for the six months ended December 31, 2020 (Unaudited) Initial classification of common stock subject to possible redemption $ 76,087,640 (76,087,640) $ — Change in value of Common Stock subject to possible redemption $ (80,550) $ 80,550 $ — Statement of Cash Flows for the nine months ended March 31, 2021 (Unaudited) Initial classification of common stock subject to possible redemption $ 76,087,640 (76,087,640) $ — Change in value of Common Stock subject to possible redemption $ (105,140) $ 105,140 $ — Statement of Cash Flows for the period ended June 30, 2021 (Unaudited) Initial classification of common stock subject to possible redemption $ 76,087,640 (76,087,640) $ — Change in value of Common Stock subject to possible redemption $ (375,680) $ 375,680 $ — Condensed Statement of Changes in Stockholders’ Equity for three months ended December 31, 2020 (Unaudited) Sale of 8,009,041 Units, net of underwriter discounts and offering expenses $ 78,231,912 $ (78,231,912) $ — Initial value of Common Stock subject to redemption $ 76,007,090 $ (76,007,090) $ — Accretion for Common Stock to redemption amount $ — $ (1,858,498) $ (1,858,498) Total Stockholders’ Equity $ 5,000,008 $ (4,083,320) $ 916,688 Condensed Statement of Changes in Stockholders’ Equity for three months ended March 31, 2021 (Unaudited) Change in value of Common Stock subject to redemption $ 105,140 $ (105,140) $ — Total Stockholders’ Equity $ 5,000,009 $ (4,188,460) $ 811,549 Condensed Statement of Changes in Stockholders’ Equity for three months ended June 30, 2021 (Unaudited) Change in value of Common Stock subject to redemption $ 375,680 $ (375,680) $ — Total Stockholders’ Equity $ 5,000,002 $ (4,564,140) $ 435,862 Statement of Operations for the three months ended December 31, 2020 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,875,000 (1,875,000) — Basic and diluted net loss per common stock $ (0.04) $ 0.04 $ — Basic and diluted weighted average shares outstanding, common stock — 5,112,023 5,112,023 Basic and diluted net loss (income) per share, common stock $ — $ (0.02) $ (0.02) Statement of Operations for the six months ended December 31, 2020 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,875,000 (1,875,000) — Basic and diluted net loss per common stock $ (0.04) $ 0.04 $ — Basic and diluted weighted average shares outstanding, common stock — 3,502,260 3,502,260 Basic and diluted net loss (income) per share, common stock $ — $ (0.02) $ (0.02) Statement of Operations for the three months ended March 31, 2021 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,990,948 (1,990,948) — Basic and diluted net loss per common stock $ (0.05) $ 0.05 $ — Basic and diluted weighted average shares outstanding, common stock — 10,011,301 10,011,301 Basic and diluted net loss (income) per share, common stock $ — $ (0.01) $ (0.01) Statement of Operations for the nine months ended March 31, 2021 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,913,085 (1,913,085) — Basic and diluted net loss per common stock $ (0.10) $ 0.10 $ — Basic and diluted weighted average shares outstanding, common stock — 5,646,205 5,646,205 Basic and diluted net loss (income) per share, common stock $ — $ (0.03) $ (0.03) Statement of Operations for the year ended June 30, 2021 Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,951,216 (1,951,216) — Basic and diluted net loss per common stock $ (0.29) $ 0.29 $ — Basic and diluted weighted average shares outstanding, common stock — 6,734,489 6,734,489 Basic and diluted net loss (income) per share, common stock $ — $ (0.08) $ (0.08)

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended	9 Months Ended	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Schedule of reconciliation of common stocks reflected in the condensed balance sheets				2020 2019 Preferred shares authorized Series A preferred 6,746,233 6,746,233 Series B preferred 7,588,369 7,588,369 Series C preferred 6,001,269 6,001,269 Series D preferred 12,317,871 17,596,960 Series D1 preferred 9,038,488 — Total preferred shares authorized 41,692,230 37,932,831 2020 2019 Preferred shares issued and outstanding Series A preferred 6,641,371 6,746,233 Series B preferred 7,588,369 7,588,369 Series C preferred 6,001,269 6,001,269 Series D preferred 12,317,871 12,317,871 Series D1 preferred 9,038,488 — Total preferred shares issued and outstanding 41,587,368 32,653,742
Schedule of basic and diluted net income (loss) per common stock		Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net Loss $ (14,691,871) $ (7,683,830) $ (29,232,518) $ (19,349,948) Denominator: Basic weighted average common shares outstanding 4,551,755 8,522,923 3,818,717 8,458,434 Earnings (loss) per share: Basic and diluted $ (3.23) $ (0.90) $ (7.66) $ (2.29)		2020 2019 Numerator: Net Loss $ (31,674,084) $ (18,468,776) Denominator: Basic weighted average common shares outstanding 8,197,409 8,310,333 Earnings (loss) per share: Basic and diluted $ (3.86) $ (2.22)
LifeSci Acquisition II Corp
Schedule of reconciliation of common stocks reflected in the condensed balance sheets	At September 30, 2021 and June 30, 2021, the common stock reflected in the condensed consolidated balance sheets are reconciled in the following table: Gross proceeds $ 80,090,410 Less: Common stock issuance costs $ (1,858,498) Plus: Accretion of carrying value to redemption value $ 1,858,498 Common stock subject to possible redemption $ 80,090,410		At June 30, 2021, the common stock subject to possible redemption reflected in the balance sheet is reconciled in the following table: Gross proceeds $ 80,090,410 Less: Common stock issuance costs (1,858,498) Plus: Accretion of carrying value to redemption value 1,858,498 Common stock subject to possible redemption $ 80,090,410
Schedule of basic and diluted net income (loss) per common stock	Three Months Ended September 30, 2021 Basic and diluted net income (loss) per common stock Numerator: Allocation of net income (loss), as adjusted $ (829,630) Denominator: Basic and diluted 10,011,301 Basic and diluted $ (0.08)		For the Period from December 18, 2019 (Inception) Year Ended through June 30, June 30, 2021 2020 Basic and diluted net income (loss) per common stock Numerator: Allocation of net income (loss), as adjusted $ (561,449) $ (1,000) Denominator: Basic and diluted weighted average shares outstanding 6,734,489 1,875,000 Basic and diluted net income (loss) per common stock $ (0.08) $ (0.00)

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended	12 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Sep. 30, 2021	Jun. 30, 2021
LifeSci Acquisition II Corp
Schedule of company's assets that are measured at fair value on a recurring basis	Trading Securities Level Fair Value June 30, 2021 Mutual Fund 1 80,120,809	Trading Securities Level Fair Value June 30, 2021 Mutual Fund 1 $ 80,120,809

DESCRIPTION OF ORGANIZATION A_2

DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)	Oct. 06, 2021USD ($)D$ / sharesshares	Nov. 24, 2020USD ($)$ / sharesshares	Dec. 18, 2019	Sep. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020$ / sharesshares	Sep. 30, 2020$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020$ / sharesshares	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019$ / sharesshares	Mar. 31, 2021shares	Mar. 31, 2020shares	Dec. 31, 2018shares
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares) \| shares				6,439	6,439			6,439			6,439
Cash of not held in the trust account and available for working capital purposes								$ (5,566,182)
Number of shares redeemed \| shares								9,038,488
Aggregate amount of redeemed shares								$ 39,999,919
Amount paid from Trust account											$ 3,675,000
Common shares, par value, (per share) \| $ / shares				$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001
Number of shares issued \| shares				106,752		75,694		1,830,071	148,011		164,886	122,560
Common shares, shares issued \| shares				4,595,168	2,765,097			4,595,168			2,765,097	8,396,425
Common shares, shares outstanding \| shares				4,595,168	2,765,097	8,544,436		4,595,168	8,544,436		2,765,097	8,396,425	4,488,416	8,468,742	8,273,865
LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Sale of Units, net of underwriting discounts and offering expenses (in shares) \| shares					8,009,041
Proceeds from sale of Private Placement Warrants										$ 2,831,809
Transaction Costs		$ 1,858,498
Underwriting fees		1,601,808
Other offering costs		$ 256,690
Threshold minimum aggregate fair market value as a percentage of the assets held in the Trust Account										80.00%
Threshold percentage of outstanding voting securities of the target to be acquired by post-transaction company to complete business combination										50.00%
Cash of not held in the trust account and available for working capital purposes				$ 200,897						$ 416,111
Aggregate purchase price							$ 25,000
Condition for future business combination number of businesses minimum			1
Payments for investment of cash in Trust Account										80,090,412
Working capital subject to annual limit										250,000
Condition for future business combination threshold Net Tangible Assets										$ 5,000,001
Threshold percentage of Public Shares subject to redemption without the Company's prior written consent										20.00%
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)										100.00%
Threshold business days for redemption of public shares										5 days
Amount of remaining balance in Trust account				$ 80,121,806				$ 80,121,806		$ 80,120,809
Preferred stock, par value, (per share) \| $ / shares				$ 0.0001			$ 0.0001	$ 0.0001		$ 0.0001
Common shares, par value, (per share) \| $ / shares				$ 0.0001			$ 0.0001	$ 0.0001		$ 0.0001
Proceeds from Issuance of Common Stock							$ 25,000
Common shares, shares issued \| shares				2,002,260			2,156,250	2,002,260		2,002,260
Common shares, shares outstanding \| shares				2,002,260			2,156,250	2,002,260		2,002,260
Initial Public Offering \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Sale of Units, net of underwriting discounts and offering expenses (in shares) \| shares		8,009,041
Purchase price, per unit \| $ / shares		$ 10
Payments for investment of cash in Trust Account		$ 80,090,412
Number of shares issued \| shares		8,009,041		1,125,000
Purchase price, per share \| $ / shares		$ 10
Private Placement \| Private Placement Warrants \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares) \| shares		3,146,454		3,146,454				3,146,454		3,146,454
Price of warrant \| $ / shares		$ 0.90		$ 0.90				$ 0.90		$ 0.90
Proceeds from sale of Private Placement Warrants		$ 2,831,809		$ 2,831,809						$ 2,831,809
Over-allotment option \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Sale of Units, net of underwriting discounts and offering expenses (in shares) \| shares		509,041
Purchase price, per unit \| $ / shares		$ 10		$ 10				10		$ 10
Proceeds from issuance initial public offering		$ 80,090,410
Number of shares issued \| shares		509,041		509,041						509,041
Purchase price, per share \| $ / shares		$ 10		$ 10				$ 10		$ 10
Subsequent events \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Purchase price, per unit \| $ / shares	$ 10
Aggregate purchase price	$ 23,003,944
Payments for investment of cash in Trust Account	$ 57,100,000
Redemption of shares calculated based on business days prior to consummation of business combination (in days)	2 days
Number of shares issued \| shares	2,299,493
Purchase price, per share \| $ / shares	$ 10
Common shares, shares issued \| shares	114,707,150
Common shares, shares outstanding \| shares	114,707,150
Merger agreement \| Subsequent events
Subsidiary, Sale of Stock [Line Items]
Number of shares redeemed \| shares	2,299,493
Price per share \| $ / shares	$ 10
Aggregate amount of redeemed shares	$ 23,003,944
Amount paid from Trust account	$ 23,003,944
Preferred stock, par value, (per share) \| $ / shares	$ 0.0001
Common shares, par value, (per share) \| $ / shares	$ 0.0001
Numerator for calculation for conversion of shares	$ 100,000,000
Exchange ratio	1.815
Number of Earn-Out Shares \| shares	12,500,000
Merger agreement \| Subsequent events \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Number of shares redeemed \| shares	2,299,493
Price per share \| $ / shares	$ 10
Aggregate amount of redeemed shares	$ 23,003,944
Amount paid from Trust account	23,003,944
Amount of remaining balance in Trust account	$ 57,100,000
Threshold period for issue of Earn-Out Shares	3 years
Trading days for issuance of Earn-Out Shares \| D	20
Consecutive trading days for Earn-Out of shares \| D	30
Subscription agreement \| Subsequent events
Subsidiary, Sale of Stock [Line Items]
Purchase price, per unit \| $ / shares	$ 10
Purchase price, per share \| $ / shares	$ 10
Subscription agreement \| Subsequent events \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Number of shares issued \| shares	20,000,000
Proceeds from Issuance of Common Stock	$ 200,000,000

REVISION OF PREVIOUSLY ISSUED_3

REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Details) - USD ($)	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Nov. 24, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 17, 2019	Dec. 31, 2018
Balance Sheet
Common stock subject to possible redemption	$ 143,086,271			$ 143,086,271		$ 93,929,920	$ 86,394,680	$ 80,397,819	$ 106,884,111
Common stock	1,039			856					839
Additional paid-in capital	998,110			1,611,049					1,374,319
Accumulated deficit	(136,979,761)			(107,747,243)					(75,961,522)
Total Stockholders' Equity (Deficit)	(106,135,338)	$ (122,287,890)	$ (114,572,770)	(106,135,338)			(106,135,338)		$ (74,586,364)		$ (56,550,017)
LifeSci Acquisition II Corp
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Minimum net tangible assets		5,000,001
Balance Sheet
Common stock subject to possible redemption	80,090,410	80,090,410
Common stock	201	201					216
Additional paid-in capital	998,110	998,110					24,784
Accumulated deficit	(1,392,079)	(562,449)					(1,000)
Total Stockholders' Equity (Deficit)	$ (393,768)	435,862				$ 23,920	$ 24,000			$ 0
Restatement of redeemable common stock as temporary equity \| LifeSci Acquisition II Corp
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Redemption value per share						$ 10
Minimum net tangible assets						$ 5,000,001
Balance Sheet
Common stock subject to possible redemption		80,090,410	80,090,410	80,090,410	$ 80,090,410
Common stock		201	201	216	216
Additional paid-in capital		998,110	998,110	998,095	998,095
Accumulated deficit		(562,449)	(186,762)	(81,623)	(1,080)
Total Stockholders' Equity (Deficit)		435,862	811,549	916,688	997,231
As Previously Reported \| LifeSci Acquisition II Corp
Balance Sheet
Common stock subject to possible redemption		75,526,270
Common stock		246
Additional paid-in capital		5,562,205
Accumulated deficit		(562,449)
Total Stockholders' Equity (Deficit)		5,000,002
As Previously Reported \| Restatement of redeemable common stock as temporary equity \| LifeSci Acquisition II Corp
Balance Sheet
Common stock subject to possible redemption		75,526,270	75,901,950	76,007,090	76,087,640
Common stock		246	242	256	256
Additional paid-in capital		5,562,205	5,186,529	5,081,375	5,000,825
Accumulated deficit		(562,449)	(186,762)	(81,623)	(1,080)
Total Stockholders' Equity (Deficit)		5,000,002	5,000,009	5,000,008	5,000,001
Adjustment \| LifeSci Acquisition II Corp
Balance Sheet
Common stock subject to possible redemption		4,564,140
Common stock		(45)
Additional paid-in capital		(4,564,095)
Total Stockholders' Equity (Deficit)		(4,564,140)
Adjustment \| Restatement of redeemable common stock as temporary equity \| LifeSci Acquisition II Corp
Balance Sheet
Common stock subject to possible redemption		4,564,140	4,188,460	4,083,320	4,002,770
Common stock		(45)	(41)	(40)	(40)
Additional paid-in capital		(4,564,095)	(4,188,419)	(4,083,280)	(4,002,730)
Total Stockholders' Equity (Deficit)		$ (4,564,140)	$ (4,188,460)	$ (4,083,320)	$ (4,002,770)

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020
Unrecognized tax benefits		$ 239,927					$ 239,927	$ 239,927
Anti-dilutive securities attributable to warrants (in shares)	50,445,978		40,345,124	50,195,421	48,113,121		43,058,865	35,919,104
Exercise price of warrants	$ 1.61	$ 1.61		$ 1.61			$ 1.61
Sale of Private Placement Warrants (in shares)	6,439	6,439		6,439			6,439
LifeSci Acquisition II Corp
Unrecognized tax benefits	$ 0			$ 0		$ 0			$ 0
Unrecognized tax benefits accrued for interest and penalties	$ 0			0		$ 0			$ 0
Anti-dilutive securities attributable to warrants (in shares)	50,445,978					3,146,454
Federal depository insurance coverage	$ 250,000			$ 250,000		$ 250,000
Units Issued During Period, Shares, New Issues		8,009,041
Offering Costs	$ 1,858,498					$ 1,858,498

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Common stocks reflected in the condensed balance sheets (Details) - USD ($)	12 Months Ended	15 Months Ended
	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Common stock subject to possible redemption		$ 143,086,271	$ 143,086,271	$ 93,929,920	$ 86,394,680	$ 80,397,819	$ 106,884,111
LifeSci Acquisition II Corp
Gross proceeds	$ 80,090,410	80,090,410
Common stock issuance costs	1,858,498	(1,858,498)
Accretion of carrying value to redemption value	1,858,498	1,858,498
Common stock subject to possible redemption	$ 80,090,410	$ 80,090,410

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of income (loss) per share (Details) - USD ($)	3 Months Ended				6 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Allocation of net income (loss), as adjusted	$ (14,691,871)		$ (7,683,830)					$ (29,232,518)	$ (19,349,948)		$ (31,674,084)	$ (18,468,776)
Denominator:
Basic weighted average shares outstanding	4,551,755		8,522,923			1,875,000		3,818,717	8,458,434		8,197,409	8,310,333
Diluted weighted average shares outstanding	4,551,755	3,956,455	8,522,923	8,442,703	3,446,123		8,425,655	3,818,717	8,458,434		8,197,409	8,310,604
Basic net loss per common share	$ (3.23)		$ (0.90)					$ (7.66)	$ (2.29)		$ (3.86)	$ (2.22)
Diluted net loss per common share	$ (3.23)	$ (1.95)	$ (0.90)	$ (0.70)	$ (4.22)		$ (1.38)	$ (7.66)	$ (2.29)		$ (3.86)	$ (2.22)
LifeSci Acquisition II Corp
Numerator:
Allocation of net income (loss), as adjusted	$ (829,630)
Denominator:
Basic weighted average shares outstanding	10,011,301		1,875,000							6,734,489
Diluted weighted average shares outstanding	10,011,301		1,875,000			1,875,000				6,734,489
Basic net loss per common share	$ (0.08)		$ 0			$ 0				$ (0.08)
Diluted net loss per common share	$ (0.08)		$ 0							$ (0.08)

INITIAL PUBLIC OFFERING (Detail

INITIAL PUBLIC OFFERING (Details) - $ / shares	Nov. 24, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)		106,752	75,694	1,830,071	148,011		164,886	122,560
Initial Public Offering \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)	8,009,041	1,125,000
Purchase price, per share	$ 10
Over-allotment option \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)	509,041	509,041				509,041
Purchase price, per share	$ 10	$ 10		$ 10		$ 10

PRIVATE PLACEMENT (Details)

PRIVATE PLACEMENT (Details) - USD ($)	Nov. 24, 2020	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued		6,439		6,439
Exercise price of warrant		$ 1.61		$ 1.61
LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Aggregate purchase price			$ 2,831,809
Private Placement \| Private Placement Warrants \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued	3,146,454	3,146,454	3,146,454
Price of warrants	$ 0.90	$ 0.90	$ 0.90
Aggregate purchase price	$ 2,831,809	$ 2,831,809	$ 2,831,809
Number of shares per warrant		1	1
Exercise price of warrant		$ 11.50	$ 11.50

RELATED PARTY TRANSACTIONS - Fo

RELATED PARTY TRANSACTIONS - Founder Shares (Details)	Jan. 08, 2021shares	Jan. 08, 2020shares	Jan. 01, 2020USD ($)D$ / sharesshares	Sep. 30, 2021shares	Sep. 30, 2020shares	Jun. 30, 2020USD ($)shares	Sep. 30, 2021shares	Sep. 30, 2020shares	Dec. 31, 2020shares	Dec. 31, 2019shares	Jun. 30, 2021shares	Mar. 31, 2021shares	Mar. 31, 2020shares	Dec. 31, 2018shares
Related Party Transaction [Line Items]
Number of shares issued				106,752	75,694		1,830,071	148,011	164,886	122,560
Common shares, shares issued				4,595,168			4,595,168		2,765,097	8,396,425
Common shares, shares outstanding				4,595,168	8,544,436		4,595,168	8,544,436	2,765,097	8,396,425		4,488,416	8,468,742	8,273,865
LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Aggregate purchase price \| $						$ 25,000
Common shares, shares issued				2,002,260		2,156,250	2,002,260				2,002,260
Common shares, shares outstanding				2,002,260		2,156,250	2,002,260				2,002,260
Founder shares \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders			20.00%
Common shares, shares issued	2,002,260	2,002,260									2,002,260
Common shares, shares outstanding	2,002,260	2,002,260									2,002,260
Founder shares \| Sponsor \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Number of shares issued			2,156,250
Aggregate purchase price \| $			$ 25,000
Aggregate number of shares owned					215,625			215,625
Shares subject to forfeiture	153,990	153,990
Number of shares not subject to forfeiture	127,260	127,260
Maximum shares subject to forfeiture (in shares)			153,990
First Fifty Percent Of Shares \| Founder shares \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) \| $ / shares			$ 12.50
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination \| D			20
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination \| D			30
Threshold Period For Not To Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination			6 months
Threshold Period For Not To Transfer Assign Or Sell Any Shares Or Warrants Based On Date Of Consummation Of Business Combination Or Closing Price Of Shares Exceed Threshold Stock Price			50.00%
Remaining Fifty Percent Of Shares \| Founder shares \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Percentage of shares or warrants agreed not be transferred, assigned, sold or released from escrow			50.00%

RELATED PARTY TRANSACTIONS - Ad

RELATED PARTY TRANSACTIONS - Additional Information (Details) - USD ($)	Nov. 24, 2020	Nov. 20, 2020	Jun. 19, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Jul. 09, 2020	Jun. 30, 2020
Related Party Transaction [Line Items]
Expenses incurred						$ 128,084	$ 0
LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Repayment of promissory note - related party								$ 175,000
Sponsor \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Maximum borrowing capacity of related party promissory note									$ 175,000
Administrative Support Agreement \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Expenses per month		$ 10,000
Expenses incurred				$ 30,000	$ 0			70,000
Amount included in accrued expenses				100,000		100,000		70,000
Promissory Note with Related Party \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Maximum borrowing capacity of related party promissory note			$ 175,000
Instrument term			15 days
Repayment of promissory note - related party	$ 175,000
Related Party Loans \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Outstanding balance of related party note				0		0		0		$ 0
Loan conversion agreement warrant				$ 500,000		$ 500,000		$ 500,000
Price of warrant				$ 0.90		$ 0.90		$ 0.90

COMMITMENTS (Details)

COMMITMENTS (Details)	Nov. 24, 2020$ / sharesshares	Sep. 30, 2021USD ($)item$ / sharesshares	Sep. 30, 2020shares	Sep. 30, 2021item$ / sharesshares	Sep. 30, 2020shares	Dec. 31, 2021item	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020shares	Dec. 31, 2019shares
Other Commitments [Line Items]
Number of shares issued \| shares		106,752	75,694	1,830,071	148,011			164,886	122,560
LifeSci Acquisition II Corp
Other Commitments [Line Items]
Maximum number of demands for registration of securities \| item		2		2		2
Threshold period to exercise registration rights		3 months				3 months
Maximum demand registration right at entity's expense \| item		1				1
Threshold period to exercise registration rights from the effective date of registration statement of Initial Public Offering		5 years				5 years
Threshold period to exercise "piggy-back" registration rights from the effective date of registration statement of Initial Public Offering		7 years				7 years
Underwriting cash discount per unit \| $ / shares		$ 0.20					$ 0.20
Underwriter Cash Discount \| $		$ 1,601,808					$ 1,601,808
Initial Public Offering \| LifeSci Acquisition II Corp
Other Commitments [Line Items]
Deferred Fee Per Unit \| $ / shares							$ 1,125,000
Number of shares issued \| shares	8,009,041	1,125,000
Purchase price, per share \| $ / shares	$ 10
Over-allotment option \| LifeSci Acquisition II Corp
Other Commitments [Line Items]
Number of shares issued \| shares	509,041	509,041					509,041
Shares available for issue \| shares		615,959		615,959			615,959
Purchase price, per share \| $ / shares	$ 10	$ 10		$ 10			$ 10

COMMITMENTS - Business Combinat

COMMITMENTS - Business Combination Marketing Agreement (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021
LifeSci Capital LLC and Ladenburg Thalmann
Other Commitments [Line Items]
Cash fee for services as percentage of gross proceeds of IPO	3.50%
LifeSci Acquisition II Corp
Other Commitments [Line Items]
Cash fee for services on gross proceeds of IPO	$ 2,803,164
Percentage of fees payable to service provider	75.00%
Percentage of fees that can be allocated to third party service provider	33.00%
Subscription agreement \| LifeSci Acquisition II Corp \| Common Stock
Other Commitments [Line Items]
Number of shares agreed to be issued		20,000,000
Aggregate purchase price		$ 200,000,000
Science 37 Inc [Member] \| LifeSci Acquisition II Corp
Other Commitments [Line Items]
Quotient for determining exchange ratio		100,000,000
Percentage of fees payable to service provider	25.00%
Science 37 Inc [Member] \| Merger agreement \| LifeSci Acquisition II Corp \| Common Stock
Other Commitments [Line Items]
Authorized earnout shares (in shares)		12,500,000
Earnout period (in months)		3 years
Earnout shares, threshold trading days		20 days
Earnout shares, threshold trading period		30 days

STOCKHOLDERS' EQUITY - Preferre

STOCKHOLDERS' EQUITY - Preferred Stock Shares (Details) - $ / shares	Sep. 30, 2021	Jun. 30, 2021	Jun. 30, 2020
Preferred shares, shares outstanding	41,587,368
LifeSci Acquisition II Corp
Preferred shares, shares authorized	1,000,000	1,000,000	1,000,000
Preferred stock, par value, (per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred shares, shares issued	0	0	0
Preferred shares, shares outstanding	0	0	0

STOCKHOLDERS' EQUITY - Common S

STOCKHOLDERS' EQUITY - Common Stock Shares (Details)	Sep. 30, 2021Vote$ / sharesshares	Jun. 30, 2021Vote$ / sharesshares	Mar. 31, 2021shares	Dec. 31, 2020$ / sharesshares	Sep. 30, 2020$ / sharesshares	Jun. 30, 2020$ / sharesshares	Mar. 31, 2020shares	Dec. 31, 2019$ / sharesshares	Dec. 31, 2018shares
Class of Stock [Line Items]
Common shares, shares authorized (in shares)	74,666,115			74,666,115				61,057,864
Common shares, par value (in dollars per share) \| $ / shares	$ 0.0001			$ 0.0001	$ 0.0001			$ 0.0001
Common shares, shares issued (in shares)	4,595,168			2,765,097				8,396,425
Common shares, shares outstanding (in shares)	4,595,168		4,488,416	2,765,097	8,544,436		8,468,742	8,396,425	8,273,865
Class A common stock subject to possible redemption, issued (in shares)	41,587,368			41,587,368				32,653,742
Common stock subject to possible redemption	41,587,368			41,587,368	41,692,230			32,653,742
LifeSci Acquisition II Corp
Class of Stock [Line Items]
Common shares, shares authorized (in shares)	30,000,000	30,000,000				30,000,000
Common shares, par value (in dollars per share) \| $ / shares	$ 0.0001	$ 0.0001				$ 0.0001
Common shares, votes per share \| Vote	1	1
Common shares, shares issued (in shares)	2,002,260	2,002,260				2,156,250
Common shares, shares outstanding (in shares)	2,002,260	2,002,260				2,156,250
Common stock subject to possible redemption	8,009,041	8,009,041
Common stock subject to redemption \| LifeSci Acquisition II Corp
Class of Stock [Line Items]
Class A common stock subject to possible redemption, issued (in shares)		8,009,041				0
Common stock subject to possible redemption	8,009,041	8,009,041				0

STOCKHOLDERS' EQUITY - Warrants

STOCKHOLDERS' EQUITY - Warrants (Details) - LifeSci Acquisition II Corp	3 Months Ended	12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021
Class of Warrant or Right [Line Items]
Restrictions on transfer period of time after business combination completion		5 years
Private Placement Warrants
Class of Warrant or Right [Line Items]
Warrant exercise period condition one	1 year	1 year
Restrictions on transfer period of time after business combination completion	5 years

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - LifeSci Acquisition II Corp - USD ($)	Sep. 30, 2021	Jun. 30, 2021
Debt Securities, Held-to-maturity, Fair Value to Amortized Cost [Abstract]
Fair Value		$ 80,120,809
Assets:
Assets held in Trust Account	$ 80,121,806	80,120,809
Cash
Assets:
Assets held in Trust Account	$ 80,131,806	0
U.S. Treasury Securities
Assets:
Assets held in Trust Account		80,120,809
Mutual Fund
Assets:
Assets held in Trust Account		$ 80,120,809

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)	Oct. 06, 2021	Sep. 30, 2021	Dec. 31, 2020	Jun. 30, 2021
Subsequent Event [Line Items]
Number of shares redeemed		9,038,488
Aggregate amount of redeemed shares		$ 39,999,919
Amount paid from Trust account			$ 3,675,000
LifeSci Acquisition II Corp
Subsequent Event [Line Items]
Amount of remaining balance in Trust account		$ 80,121,806		$ 80,120,809
Merger agreement \| Subsequent events
Subsequent Event [Line Items]
Number of shares redeemed	2,299,493
Price per share	$ 10
Aggregate amount of redeemed shares	$ 23,003,944
Amount paid from Trust account	$ 23,003,944
Merger agreement \| Subsequent events \| LifeSci Acquisition II Corp
Subsequent Event [Line Items]
Number of shares redeemed	2,299,493
Price per share	$ 10
Aggregate amount of redeemed shares	$ 23,003,944
Amount paid from Trust account	23,003,944
Amount of remaining balance in Trust account	$ 57,100,000

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS	Jun. 30, 2020USD ($)
Current liabilities:
Common stock subject to possible redemption	$ 86,394,680
Stockholders' deficit:
Total Stockholders' (Deficit) Equity	(106,135,338)
LifeSci Acquisition II Corp
Current assets:
Cash and cash equivalents	25,000
Total Current Assets	25,000
Deferred offering costs	28,000
TOTAL ASSETS	53,000
Current liabilities:
Accounts payable and accrued expenses	1,000
Accrued offering costs	28,000
Total Liabilities	29,000
Commitments and contingencies (Note 14)
Stockholders' deficit:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued or outstanding
Common stock	216
Additional paid-in capital	24,784
Accumulated deficit	(1,000)
Total Stockholders' (Deficit) Equity	24,000
LIABILITIES, COMMON STOCK SUBJECT TO REDEMPTION AND STOCKHOLDERS' (DEFICIT) EQUITY	$ 53,000

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Nov. 24, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, shares outstanding	41,587,368
Common shares, par value, (per share)	$ 0.0001			$ 0.0001		$ 0.0001			$ 0.0001
Common shares, shares authorized (in shares)	74,666,115			74,666,115					61,057,864
Common shares, shares issued (in shares)	4,595,168			2,765,097					8,396,425
Common shares, shares outstanding (in shares)	4,595,168		4,488,416	2,765,097		8,544,436		8,468,742	8,396,425	8,273,865
Temporary equity, shares issued	41,587,368			41,587,368					32,653,742
Temporary equity, shares outstanding	41,587,368			41,587,368		41,692,230			32,653,742
LifeSci Acquisition II Corp
Preferred stock, par value, (per share)	$ 0.0001	$ 0.0001					$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000					1,000,000
Preferred stock, shares issued	0	0					0
Preferred stock, shares outstanding	0	0					0
Common shares, par value, (per share)	$ 0.0001	$ 0.0001					$ 0.0001
Common shares, shares authorized (in shares)	30,000,000	30,000,000					30,000,000
Common shares, shares issued (in shares)	2,002,260	2,002,260					2,156,250
Common shares, shares outstanding (in shares)	2,002,260	2,002,260					2,156,250
Temporary equity, shares outstanding	8,009,041	8,009,041
Over-allotment option \| LifeSci Acquisition II Corp
Purchase price, per unit	$ 10	$ 10			$ 10
Common stock subject to redemption \| LifeSci Acquisition II Corp
Temporary equity, shares issued		8,009,041					0
Temporary equity, shares outstanding	8,009,041	8,009,041					0
Purchase price, per unit		$ 10					$ 10

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended						6 Months Ended			9 Months Ended		12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Formation and operating costs													$ 56,167,682	$ 33,208,354
Loss from operations	$ (14,929,954)			$ (7,910,997)						$ (29,690,049)	$ (20,120,360)		(32,463,463)	(19,127,356)
Other income:
Interest income	151			1,554						1,424	76,019		77,229	625,608
Other income, net	238,083			227,167						457,531	770,412		789,379	658,580
Net loss	$ (14,691,871)	$ (7,715,120)	$ (6,825,527)	$ (7,683,830)	$ (5,916,947)	$ (5,749,171)		$ (1,000)		$ (29,232,518)	$ (19,349,948)		$ (31,674,084)	$ (18,468,776)
Weighted Average Number of Shares Outstanding, Basic	4,551,755			8,522,923				1,875,000		3,818,717	8,458,434		8,197,409	8,310,333
Weighted Average Number of Shares Outstanding, Diluted	4,551,755	3,956,455		8,522,923	8,442,703		3,446,123		8,425,655	3,818,717	8,458,434		8,197,409	8,310,604
Basic net loss per common share	$ (3.23)			$ (0.90)						$ (7.66)	$ (2.29)		$ (3.86)	$ (2.22)
Diluted net loss per common share	$ (3.23)	$ (1.95)		$ (0.90)	$ (0.70)		$ (4.22)		$ (1.38)	$ (7.66)	$ (2.29)		$ (3.86)	$ (2.22)
LifeSci Acquisition II Corp
Formation and operating costs	$ 830,627			$ 80				$ 1,000				$ 591,846
Loss from operations	(830,627)			(80)				(1,000)				(591,846)
Other income:
Interest income	997											30,397
Other income, net												30,397
Net loss	$ (829,630)			$ (80)				$ (1,000)				$ (561,449)
Weighted Average Number of Shares Outstanding, Basic	10,011,301			1,875,000								6,734,489
Weighted Average Number of Shares Outstanding, Diluted	10,011,301			1,875,000				1,875,000				6,734,489
Basic net loss per common share	$ (0.08)			$ 0				$ 0				$ (0.08)
Diluted net loss per common share	$ (0.08)			$ 0								$ (0.08)
Common Stock \| LifeSci Acquisition II Corp
Other income:
Weighted Average Number of Shares Outstanding, Basic								1,875,000				6,734,489
Weighted Average Number of Shares Outstanding, Diluted								1,875,000				6,734,489
Basic net loss per common share								$ 0				$ (0.08)
Diluted net loss per common share								$ 0				$ (0.08)

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Common StockLifeSci Acquisition II Corp	Common Stock	Additional Paid-in CapitalLifeSci Acquisition II Corp	Additional Paid-in Capital	Accumulated DeficitLifeSci Acquisition II Corp	Accumulated Deficit	LifeSci Acquisition II Corp	Total
Balance at the beginning at Dec. 31, 2018		$ 827		$ 941,902		$ (57,492,746)		$ (56,550,017)
Balance at the beginning (in shares) at Dec. 31, 2018		8,273,865
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Number of shares issued								122,560
Net loss						(18,468,776)		$ (18,468,776)
Balance at the end at Dec. 31, 2019		$ 839		1,374,319		(75,961,522)		(74,586,364)
Balance at the end (in shares) at Dec. 31, 2019		8,396,425
Balance at the beginning at Dec. 17, 2019	$ 0		$ 0		$ 0		$ 0
Balance at the beginning (in shares) at Dec. 17, 2019	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock to Sponsor	$ 216		24,784				25,000
Number of shares issued	2,156,250
Net loss					(1,000)		(1,000)	(1,000)
Balance at the end at Jun. 30, 2020	$ 216	$ 856	24,784	1,611,049	(1,000)	(106,135,338)	24,000	(106,135,338)
Balance at the end (in shares) at Jun. 30, 2020	2,156,250	2,765,097
Balance at the beginning at Dec. 31, 2019		$ 839		1,374,319		(75,961,522)		(74,586,364)
Balance at the beginning (in shares) at Dec. 31, 2019		8,396,425
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss						(5,749,171)		(5,749,171)
Balance at the beginning at Dec. 31, 2019		$ 839		1,374,319		(75,961,522)		$ (74,586,364)
Balance at the beginning (in shares) at Dec. 31, 2019		8,396,425
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Number of shares issued								148,011
Net loss								$ (19,349,948)
Balance at the end at Sep. 30, 2020	$ 216		24,784		(1,080)		23,920
Balance at the end (in shares) at Sep. 30, 2020	2,156,250
Balance at the beginning at Dec. 31, 2019		$ 839		1,374,319		(75,961,522)		$ (74,586,364)
Balance at the beginning (in shares) at Dec. 31, 2019		8,396,425
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Number of shares issued								164,886
Net loss						(31,674,084)		$ (31,674,084)
Balance at the end at Dec. 31, 2020								(106,135,338)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss						(5,916,947)		(5,916,947)
Balance at the end at Jun. 30, 2020	$ 216	$ 856	24,784	1,611,049	(1,000)	(106,135,338)	24,000	$ (106,135,338)
Balance at the end (in shares) at Jun. 30, 2020	2,156,250	2,765,097
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Number of shares issued								75,694
Net loss					(80)	(7,683,830)	(80)	$ (7,683,830)
Balance at the end at Sep. 30, 2020	$ 216		24,784		(1,080)		23,920
Balance at the end (in shares) at Sep. 30, 2020	2,156,250
Balance at the beginning at Jun. 30, 2020	$ 216	$ 856	24,784	1,611,049	(1,000)	(106,135,338)	24,000	(106,135,338)
Balance at the beginning (in shares) at Jun. 30, 2020	2,156,250	2,765,097
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of 3,146,454 Private Placement Warrants			2,831,809				2,831,809
Accretion of common stock subject to redemption to redemption value			(1,858,498)				(1,858,498)
Founder Shares Forfeited	$ (15)		15
Founder Shares Forfeited (in shares)	(153,990)
Net loss					(561,449)		(561,449)
Balance at the end at Jun. 30, 2021	$ 201	$ 1,028	998,110	3,663,679	(562,449)	(118,623,183)	435,862	(122,287,890)
Balance at the end (in shares) at Jun. 30, 2021	2,002,260	4,488,416
Balance at the beginning at Sep. 30, 2020	$ 216		24,784		(1,080)		23,920
Balance at the beginning (in shares) at Sep. 30, 2020	2,156,250
Balance at the end at Dec. 31, 2020								(106,135,338)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss						(6,825,527)		(6,825,527)
Balance at the end at Mar. 31, 2021		$ 907		2,168,412		(112,403,451)		(114,572,770)
Balance at the end (in shares) at Mar. 31, 2021		3,271,804
Balance at the beginning at Dec. 31, 2020								$ (106,135,338)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Number of shares issued								1,830,071
Net loss								$ (29,232,518)
Balance at the end at Sep. 30, 2021	$ 201	$ 1,039	998,110	4,769,114	(1,392,079)	(132,209,608)	(393,768)	(106,135,338)
Balance at the end (in shares) at Sep. 30, 2021	2,002,260	4,595,168
Balance at the beginning at Mar. 31, 2021		$ 907		2,168,412		(112,403,451)		(114,572,770)
Balance at the beginning (in shares) at Mar. 31, 2021		3,271,804
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss						(7,715,120)		(7,715,120)
Balance at the end at Jun. 30, 2021	$ 201	$ 1,028	998,110	3,663,679	(562,449)	(118,623,183)	435,862	$ (122,287,890)
Balance at the end (in shares) at Jun. 30, 2021	2,002,260	4,488,416
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Number of shares issued								106,752
Net loss					(829,630)	(14,691,871)	(829,630)	$ (14,691,871)
Balance at the end at Sep. 30, 2021	$ 201	$ 1,039	$ 998,110	$ 4,769,114	$ (1,392,079)	$ (132,209,608)	$ (393,768)	$ (106,135,338)
Balance at the end (in shares) at Sep. 30, 2021	2,002,260	4,595,168

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - shares	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020	Nov. 24, 2020
Number of warrants to purchase shares issued	6,439		6,439
Private Placement \| Private Placement Warrants \| LifeSci Acquisition II Corp
Number of warrants to purchase shares issued	3,146,454	3,146,454		3,146,454

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021
Cash Flows from Operating Activities:
Net loss				$ (29,232,518)	$ (19,349,948)
Adjustments to reconcile net loss to net cash used in operating activities:
Interest earned on marketable securities held in Trust Account	$ (151)	$ (1,554)		(1,424)	(76,019)
Changes in operating assets and liabilities:
Net cash used in operating activities				(14,660,144)	(16,863,907)
Cash Flows from Investing Activities:
Net cash used in investing activities				(12,071,736)	(4,183,465)
Cash Flows from Financing Activities:
Net cash provided by financing activities				1,245,152	40,040,045
Net Change in Cash				(25,486,728)	18,992,673
Cash - Beginning				33,483,090	28,808,017
Cash - Ending	7,996,362	47,800,690		7,996,362	47,800,690
LifeSci Acquisition II Corp
Cash Flows from Operating Activities:
Net loss	(829,630)	(80)	$ (1,000)			$ (561,449)
Adjustments to reconcile net loss to net cash used in operating activities:
Interest earned on marketable securities held in Trust Account	(997)					(30,397)
Changes in operating assets and liabilities:
Prepaid expenses	32,657	(25,000)				(121,157)
Accounts payable and accrued expenses	582,756		1,000			130,805
Net cash used in operating activities	(215,214)	(25,080)				(582,198)
Cash Flows from Investing Activities:
Investment of cash into Trust Account						(80,090,412)
Net cash used in investing activities						(80,090,412)
Cash Flows from Financing Activities:
Proceeds from issuance of common stock to Sponsor			25,000
Proceeds from sale of Units, net of underwriting discounts paid						78,488,602
Proceeds from sale of Private Placement Warrants						2,831,809
Proceeds from repayments of loan from related party		175,000				175,000
Repayment of promissory note - related party						(175,000)
Payment of offering costs		(66,195)				(256,690)
Net cash provided by financing activities		(108,805)	25,000			81,063,721
Net Change in Cash	(215,214)	83,725	391,111
Cash - Beginning	416,111	25,000				25,000
Cash - Ending	$ 200,897	$ 108,725	25,000	$ 200,897	$ 108,725	$ 416,111
Non-Cash Investing and Financing Activities:
Deferred offering costs included in accrued offering costs			$ 28,000

DESCRIPTION OF ORGANIZATION A_3

DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS	3 Months Ended	12 Months Ended
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS	Sep. 30, 2021	Jun. 30, 2021
LifeSci Acquisition II Corp
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS [TEXT BLOCK]	NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Science 37 Holdings, Inc. (formerly LifeSci Acquisition II Corp.) (the “Company”) was incorporated in Delaware on December 18, 2019. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business transaction with one or more businesses or entities (a “Business Combination”). The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of September 30, 2021, the Company had not commenced any operations. All activity through September 30, 2021 relates to the Company’s formation and the initial public offering (“Initial Public Offering”), which is described below, and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The registration statement for the Company’s Initial Public Offering was declared effective on November 20, 2020. On November 24, 2020 the Company consummated the Initial Public Offering of 8,009,041 shares of common stock (the “Public Shares”), which includes the partial exercise by the underwriter of its over-allotment option in the amount of 509,041 Public Shares, at $10.00 per Public Share, generating gross proceeds of $80,090,410 which is described in Note 4. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 3,146,454 warrants (the “Private Warrants”) at a price of $0.90 per Private Warrant in a private placement to LifeSci Holdings, LLC (the “Sponsor”), an entity affiliated LifeSci Capital LLC, generating gross proceeds of $2,831,809, which is described in Note 5. Transaction costs amounted to $1,858,498, consisting of $1,601,808 in cash underwriting fees and $256,690 of other offering costs. Following the closing of the Initial Public Offering on November 24, 2020, an amount of $ 80,090,410 On May 6, 2021, LSAQ entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among LSAQ, LifeSci Acquisition II Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of LSAQ (“Merger Sub”), and Science 37, Inc., a Delaware corporation (“Legacy Science 37”). Pursuant to the Merger Agreement, Merger Sub was merged with and into Legacy Science 37, with Legacy Science 37 surviving the merger as a wholly owned subsidiary of LSAQ (the “Business Combination” and, together with the other transactions contemplated by the Merger Agreement, the “Transactions”). On October 4, 2021, LSAQ held a special meeting of stockholders (the “Special Meeting”), at which the LSAQ stockholders considered and adopted, among other matters, a proposal to approve the Business Combination, including (a) adopting the Merger Agreement and (b) approving the other transactions and matters contemplated by the Merger Agreement and related agreements as described in the Proxy Statement/Prospectus. Pursuant to the terms and subject to the conditions set forth in the Merger Agreement, following the Special Meeting, on October 6, 2021, the Transactions were consummated. In connection with the Closing, the Company changed its name from LifeSci Acquisition II Corp. to Science 37 Holdings, Inc. Holders of 2,299,493 shares of LSAQ’s common stock sold in its initial public offering properly exercised their right to have such shares redeemed for a full pro rata portion of the trust account holding the proceeds from LSAQ’s initial public offering, calculated as of two business days prior to the consummation of the Business Combination, which was approximately $10.00 per share, or $23,003,944 in the aggregate. An aggregate of $23,003,944 was paid from the Company’s trust account to holders that properly exercised their right to have public shares redeemed, and the remaining balance immediately prior to the Closing of approximately $57.1 million remained in the trust account. The remaining amount in the trust account was used to fund the Business Combination. Preferred Stock . Immediately prior to the effective time of the Merger (the “Effective Time”), each issued and outstanding share of Legacy Science 37’s Series A, Series B, Series C, Series D and Series D-1 redeemable convertible preferred stock, par value $0.0001 per share (collectively, the “Science 37 Preferred Stock”), was converted into shares of the common stock, par value $0.0001 per share, of Science 37 (the “Science 37 common stock”) at the then-applicable conversion rate (the “Science 37 Preferred Stock Conversion”). Common Stock . At the Effective Time, following the Science 37 Preferred Stock Conversion, each share of Science 37 Common Stock (including shares of Science 37 Common Stock outstanding as a result of the Science 37 Preferred Stock Conversion, but excluding shares the holders of which perfect rights of appraisal under Delaware law) converted into the right to receive such number of shares of our common stock (“Common Stock”) equal to the Exchange Ratio (subject to rounding mechanisms as described in the Merger Agreement) and a number of Earn-Out Shares (as defined below). The Exchange Ratio is defined in the Merger Agreement to be the quotient of (i) 100,000,000 divided by (ii) the number of shares of Science 37’s Fully Diluted Capital Stock (as defined in the Merger Agreement). The Exchange Ratio was equal to approximately 1.815. Stock Options . At the Effective Time, each outstanding option to purchase shares of Science 37 Common Stock granted under the Science 37, Inc. 2015 Stock Plan (each, a “Science 37 Option”), whether or not then vested and exercisable, was converted automatically (and without any required action on the part of such holder of outstanding Science 37 Option) into an option to purchase a number of shares of Common Stock equal to the number of shares subject to such Science 37 Option immediately prior to the Effective Time multiplied by the Exchange Ratio (rounded down to the nearest whole share), with a per share exercise price equal to the exercise price per share of Science 37 Common Stock of such Science 37 Option immediately prior to the Effective Time divided by the Exchange Ratio (rounded up to the nearest whole cent). Earn-Out Shares . Following the Closing, former holders of shares of Science 37 Common Stock (including shares received as a result of the Science 37 Preferred Stock Conversion) and former holders of Science 37 Options are entitled to receive their respective pro rata shares of up to 12,500,000 additional shares of Common Stock (the “Earn-Out Shares”) if, within the three-year period beginning on the Closing Date, the closing share price of the Common Stock equals or exceeds either of two share price thresholds as set forth in the Merger Agreement over a period of at least 20 trading days within a 30-day trading period (each, a “Triggering Event”) and, in respect of a former holder of Science 37 Options, the holder continues to provide services to the Company or one of its subsidiaries at the time of such Triggering Event. If there is a change of control of the Company or its successor within such three-year period following the Closing that will result in the holders of Common Stock receiving a per share price equal to or in excess of any Triggering Event threshold(s), then immediately prior to such change of control, any Triggering Event that has not previously occurred shall be deemed to have occurred and the Company shall issue the Earn-Out Shares to the former holders of shares of Science 37 Common Stock and former holders of Science 37 Options in accordance with their respective pro rata shares. Pursuant to subscription agreements entered into in connection with the Merger Agreement (collectively, the “Subscription Agreements”), certain investors agreed to subscribe for an aggregate of 20,000,000 newly-issued shares of Common Stock at a purchase price of $10.00 per share for an aggregate purchase price of $200,000,000 (the “PIPE Investment”). At the Closing, the Company consummated the PIPE Investment. After giving effect to the Transactions, the redemption of public shares as described above, and the consummation of the PIPE Investment on October 6 th , 2021, there were 114,707,150 shares of Common Stock issued and outstanding . Liquidity and Capital Resources As of September 30, 2021, the Company had cash of $200,897 not held in the Trust Account and available for working capital purposes. The Company does not believe it will need to raise additional funds in order to meet the expenditures required for operating our business through the consummation of the business combination. Additionally, the Company notes that the consummation of the business combination on October 6 th , 2021, as mentioned above, brought in additional funds in the amount of $200,000,000 through the consummated PIPE Investment. As such, the Company notes that sufficient cash and capital is available to cover any expected costs or expenses incurred by the Company through the business combination date and through twelve months of the issuance of this report.	NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Science 37 Holdings, Inc. (Formerly LifeSci Acquisition II Corp.) (the “Company”) was incorporated in Delaware on December 18, 2019. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business transaction with one or more businesses or entities (a “Business Combination”). Although the Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends to focus on businesses operating in North America in the healthcare industry. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of June 30, 2021, the Company had not commenced any operations. All activity through June 30, 2021 relates to the Company’s formation and the initial public offering (“Initial Public Offering”), which is described below, and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The registration statement for the Company’s Initial Public Offering was declared effective on November 20, 2020. On November 24, 2020 the Company consummated the Initial Public Offering of 8,009,041 shares of common stock (the “Public Shares”), which includes the partial exercise by the underwriter of its over-allotment option in the amount of 509,041 Public Shares, at $10.00 per Public Share, generating gross proceeds of $80,090,412 which is described in Note 4. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 3,146,454 warrants (the “Private Warrants”) at a price of $0.90 per Private Warrant in a private placement to LifeSci Holdings, LLC (the “Sponsor”), an entity affiliated LifeSci Capital LLC, generating gross proceeds of $2,831,809, which is described in Note 5. Transaction costs amounted to $1,858,498, consisting of $1,601,808 in cash underwriting fees and $256,690 of other offering costs. Following the closing of the Initial Public Offering on November 24, 2020, an amount of $80,090,412 ($10.00 per Public Share) from the net proceeds of the sale of the Public Shares in the Initial Public Offering and the sale of the Private Warrants was placed in a trust account (the “Trust Account”), and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended, or the Investment Company Act, with a maturity of 183 days or less or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the funds in the Trust Account as described below. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Warrants, although substantially all of the net proceeds are intended to be applied toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the balance in the Trust Account (net of amounts previously released to the Company to pay its tax obligations and for working capital purposes, subject to an annual limit of $250,000) at the time of the signing an agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination. The Company will provide its stockholders with the opportunity to redeem all or a portion of their Public Shares sold in the Initial Public Offering upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then on deposit in the Trust Account (initially $10.00 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations or for working capital purposes). The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor and other initial stockholders (collectively, the “Initial Stockholders”) have agreed to (a) vote their Founder Shares (as defined in Note 6), and any Public Shares held by them in favor of a Business Combination and (b) not to convert any shares (including Founder Shares) in connection with a stockholder vote to approve a Business Combination or sell any such shares to the Company in a tender offer in connection with a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming their shares with respect to more than an aggregate of 20% of the Public Shares. The Company will have until November 24, 2022 to consummate a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than five business days thereafter, redeem 100% of the outstanding Public Shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (net of taxes payable), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Company’s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirements of applicable law. The proceeds deposited in the Trust Account could, however, become subject to claims of creditors. The Sponsor and Chardan Healthcare Investments LLC have agreed to (i) waive their redemption rights with respect to Founder Shares and any Public Shares they may acquire during or after the Initial Public Offering in connection with the consummation of a Business Combination, (ii) to waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if the Company fails to consummate a Business Combination within the Combination Period and (iii) not to propose an amendment to the Company’s Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the public stockholders an opportunity to redeem their Public Shares in conjunction with any such amendment. However, the Sponsor will be entitled to liquidating distributions with respect to any Public Shares acquired if the Company fails to consummate a Business Combination or liquidates within the Combination Period. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below $10.00 per share, except as to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Liquidity and Capital Resources As of June 30, 2021, the Company had cash of $416,111 not held in the Trust Account and available for working capital purposes. The Company does not believe it will need to raise additional funds in order to meet the expenditures required for operating our business. However, if the estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to our Business Combination. Moreover, the Company may need to obtain additional financing or draw on the Working Capital Loans (as defined below) either to complete a Business Combination or because it becomes obligated to redeem a significant number of the public shares upon consummation of our Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities laws, the Company would only complete such financing simultaneously with the completion of our Business Combination. If the Company is unable to complete the Business Combination because it does not have sufficient funds available, the Company will be forced to cease operations and liquidate the Trust Account. In addition, following the Business Combination, if cash on hand is insufficient, the Company may need to obtain additional financing in order to meet our obligations.

RESTATEMENT OF PREVIOUSLY ISSUE

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	3 Months Ended	12 Months Ended
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	Sep. 30, 2021	Jun. 30, 2021
LifeSci Acquisition II Corp
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	NOTE 2. REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS In connection with the preparation of the Company’s financial statements as of September 30, 2021, the Company concluded it should revise its financial statements to classify all Public Shares in temporary equity. In accordance with the SEC and its staff’s guidance on redeemable equity instruments, ASC 480, paragraph 10-S99, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. The Company previously determined the common stock subject to possible redemption to be equal to the redemption value of $10.00 per common stock while also taking into consideration a redemption cannot result in net tangible assets being less than $5,000,001. Previously, the Company did not consider redeemable shares classified as temporary equity as part of net tangible assets. Effective with these financial statements, the Company revised this interpretation to include temporary equity in net tangible assets. Accordingly, effective with this filing, the Company presents all redeemable common stock as temporary equity and recognizes accretion from the initial book value to redemption value at the time of its Initial Public Offering and in accordance with ASC 480. As a result, management has noted a reclassification adjustment related to temporary equity and permanent equity. This resulted in an adjustment to the initial carrying value of the common stock subject to possible redemption with the offset recorded to additional paid-in capital (to the extent available), accumulated deficit and common stock. The Company will present this revision in a prospective manner in all future filings. Under this approach, the previously issued Initial Public Offering Balance Sheet and Form 10-Q’s will not be amended, but historical amounts presented in the current and future filings will be recast to be consistent with the current presentation. In connection with the change in presentation for the common stock subject to redemption, the Company also revised its income (loss) per common share calculation to allocate net income (loss) pro rata to common stock. This presentation contemplates a Business Combination as the most likely outcome, in which case, both classes of common stock share pro rata in the income (loss) of the Company. There has been no change in the Company’s total assets, liabilities or operating results. The impact of the revision on the Company’s financial statements is reflected in the following table. As Previously Balance Sheet as of June 30, 2021 (audited) Reported Adjustment As Revised Common stock subject to possible redemption $ 75,526,270 $ 4,564,140 $ 80,090,410 Common stock $ 246 $ (45) $ 201 Additional paid-in capital $ 5,562,205 $ (4,564,095) $ 998,110 Accumulated deficit $ (562,449) $ — $ (562,449) Total Stockholders’ Equity (Deficit) $ 5,000,002 $ (4,564,140) $ 435,862	NOTE 2. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS In connection with the preparation of the Company’s financial statements, management identified errors made in its historical financial statements where, at the closing of the Company’s Initial Public Offering, the Company improperly classified its common stock subject to possible redemption. The Company previously determined the common stock subject to possible redemption to be equal to the redemption value, while also taking into consideration a redemption cannot result in net tangible assets being less than $5,000,001. Management determined that the Public Shares underlying the Units issued during the Initial Public Offering can be redeemed or become redeemable subject to the occurrence of future events considered outside the Company’s control. Therefore, management concluded that temporary equity should include all shares of common stock subject to possible redemption, resulting in the common stock subject to possible redemption being equal to their redemption value. As a result, management has noted a reclassification error related to temporary equity and permanent equity. This resulted in an adjustment to the initial carrying value of the common stock subject to possible redemption with the offset recorded to additional paid-in capital (to the extent available), accumulated deficit and common stock. In connection with the change in presentation for the common stock subject to possible redemption, the Company also restated its income (loss) per common share calculation to allocate net income (loss) evenly to all common stock. This presentation contemplates a Business Combination as the most likely outcome, in which case, all shares of common stock share pro rata in the income (loss) of the Company. There has been no change in the Company’s total assets, liabilities or operating results. As Previously Reported Adjustment As Restated Balance Sheet as of November 24, 2020 Common stock subject to possible redemption $ 76,087,640 $ 4,002,770 $ 80,090,410 Common stock $ 256 $ (40) $ 216 Additional paid-in capital $ 5,000,825 $ (4,002,730) $ 998,095 Accumulated deficit $ (1,080) $ — $ (1,080) Total Stockholders’ Equity $ 5,000,001 $ (4,002,770) $ 997,231 Number of shares of common stock subject to possible redemption 7,608,764 400,277 8,009,041 Balance Sheet as of December 31, 2020 (Unaudited) Common stock subject to possible redemption $ 76,007,090 $ 4,083,320 $ 80,090,410 Common stock $ 256 $ (40) $ 216 Additional paid-in capital $ 5,081,375 $ (4,083,280) $ 998,095 Accumulated deficit $ (81,623) $ — $ (81,623) Total Stockholders’ Equity $ 5,000,008 $ (4,083,320) $ 916,688 Number of shares of common stock subject to possible redemption 7,600,709 408,332 8,009,041 Balance Sheet as of March 31, 2021 (Unaudited) Common stock subject to possible redemption $ 75,901,950 $ 4,188,460 $ 80,090,410 Common stock $ 242 $ (41) $ 201 Additional paid-in capital $ 5,186,529 $ (4,188,419) $ 998,110 Accumulated deficit $ (186,762) $ — $ (186,762) Total Stockholders’ Equity $ 5,000,009 $ (4,188,460) $ 811,549 Number of shares of common stock subject to possible redemption 7,590,195 418,846 8,009,041 Balance Sheet as of June 30, 2021 Common stock subject to possible redemption $ 75,526,270 $ 4,564,140 $ 80,090,410 Common stock $ 246 $ (45) $ 201 Additional paid-in capital $ 5,562,205 $ (4,564,095) $ 998,110 Accumulated deficit $ (562,449) $ — $ (562,449) Total Stockholders’ Equity $ 5,000,002 $ (4,564,140) $ 435,862 Number of shares of common stock subject to possible redemption 7,552,627 456,414 8,009,041 Statement of Cash Flows for the six months ended December 31, 2020 (Unaudited) Initial classification of common stock subject to possible redemption $ 76,087,640 (76,087,640) $ — Change in value of Common Stock subject to possible redemption $ (80,550) $ 80,550 $ — Statement of Cash Flows for the nine months ended March 31, 2021 (Unaudited) Initial classification of common stock subject to possible redemption $ 76,087,640 (76,087,640) $ — Change in value of Common Stock subject to possible redemption $ (105,140) $ 105,140 $ — Statement of Cash Flows for the period ended June 30, 2021 (Unaudited) Initial classification of common stock subject to possible redemption $ 76,087,640 (76,087,640) $ — Change in value of Common Stock subject to possible redemption $ (375,680) $ 375,680 $ — Condensed Statement of Changes in Stockholders’ Equity for three months ended December 31, 2020 (Unaudited) Sale of 8,009,041 Units, net of underwriter discounts and offering expenses $ 78,231,912 $ (78,231,912) $ — Initial value of Common Stock subject to redemption $ 76,007,090 $ (76,007,090) $ — Accretion for Common Stock to redemption amount $ — $ (1,858,498) $ (1,858,498) Total Stockholders’ Equity $ 5,000,008 $ (4,083,320) $ 916,688 Condensed Statement of Changes in Stockholders’ Equity for three months ended March 31, 2021 (Unaudited) Change in value of Common Stock subject to redemption $ 105,140 $ (105,140) $ — Total Stockholders’ Equity $ 5,000,009 $ (4,188,460) $ 811,549 Condensed Statement of Changes in Stockholders’ Equity for three months ended June 30, 2021 (Unaudited) Change in value of Common Stock subject to redemption $ 375,680 $ (375,680) $ — Total Stockholders’ Equity $ 5,000,002 $ (4,564,140) $ 435,862 Statement of Operations for the three months ended December 31, 2020 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,875,000 (1,875,000) — Basic and diluted net loss per common stock $ (0.04) $ 0.04 $ — Basic and diluted weighted average shares outstanding, common stock — 5,112,023 5,112,023 Basic and diluted net loss (income) per share, common stock $ — $ (0.02) $ (0.02) Statement of Operations for the six months ended December 31, 2020 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,875,000 (1,875,000) — Basic and diluted net loss per common stock $ (0.04) $ 0.04 $ — Basic and diluted weighted average shares outstanding, common stock — 3,502,260 3,502,260 Basic and diluted net loss (income) per share, common stock $ — $ (0.02) $ (0.02) Statement of Operations for the three months ended March 31, 2021 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,990,948 (1,990,948) — Basic and diluted net loss per common stock $ (0.05) $ 0.05 $ — Basic and diluted weighted average shares outstanding, common stock — 10,011,301 10,011,301 Basic and diluted net loss (income) per share, common stock $ — $ (0.01) $ (0.01) Statement of Operations for the nine months ended March 31, 2021 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,913,085 (1,913,085) — Basic and diluted net loss per common stock $ (0.10) $ 0.10 $ — Basic and diluted weighted average shares outstanding, common stock — 5,646,205 5,646,205 Basic and diluted net loss (income) per share, common stock $ — $ (0.03) $ (0.03) Statement of Operations for the year ended June 30, 2021 Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,951,216 (1,951,216) — Basic and diluted net loss per common stock $ (0.29) $ 0.29 $ — Basic and diluted weighted average shares outstanding, common stock — 6,734,489 6,734,489 Basic and diluted net loss (income) per share, common stock $ — $ (0.08) $ (0.08)

SUMMARY OF SIGNIFICANT ACCOUN_7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2021	Jun. 30, 2021
LifeSci Acquisition II Corp
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s prospectus for its Initial Public Offering as filed with the SEC on November 23, 2020, the Company’s Current Reports on Form 8-K, as filed with the SEC on November 25, 2020, and December 1, 2020, as well as the Company’s Annual Report on Form 10-K, as amended and filed with the SEC on December 20, 2021. The interim results for the three months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending June 30, 2022 or for any future periods. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its majority owned subsidiary where the Company has the ability to exercise control. All significant intercompany balances and transactions have been eliminated in consolidation. Activities in relation to the noncontrolling interest are not considered to be significant and are, therefore, not presented in the accompanying unaudited condensed consolidated financial statements. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2021 and June 30, 2021. Common Stock Subject to Possible Redemption The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at September 30, 2021 and June 30, 2021, common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ equity (deficit) section of the Company’s unaudited condensed consolidated balance sheets. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable common stock resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit. At September 30, 2021 and June 30, 2021, the common stock reflected in the condensed consolidated balance sheets are reconciled in the following table: Gross proceeds $ 80,090,410 Less: Common stock issuance costs $ (1,858,498) Plus: Accretion of carrying value to redemption value $ 1,858,498 Common stock subject to possible redemption $ 80,090,410 Offering Costs Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs amounting to $1,858,498 were charged to temporary equity upon the completion of the Initial Public Offering. Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740 “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2021 and June 30, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may subject to potential examination by federal, state and city taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal, state and city tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company is subject to income tax examinations by major taxing authorities since inception. Net Loss Per Common Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Accretion associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 3,146,454 common stock in the aggregate. As of September 30, 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net loss per common stock is the same as basic net loss per common stock for the periods presented. Three Months Ended September 30, 2021 Basic and diluted net income (loss) per common stock Numerator: Allocation of net income (loss), as adjusted $ (829,630) Denominator: Basic and diluted 10,011,301 Basic and diluted $ (0.08) Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying unaudited condensed consolidated balance sheets, primarily due to their short-term nature. Warrant Classification The Company accounts for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815-40-15-7D under which the warrants do meet the criteria for equity treatment and must be recorded as equity. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. We are currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated financial statements.	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”). Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2021 and 2020. Common Stock Subject to Possible Redemption (Restated — see Note 2) The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2021, common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ equity section of the Company’s consolidated balance sheets. Under ASC 480-10-S99, the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid-in capital and accumulated deficit. At June 30, 2021, the common stock subject to possible redemption reflected in the balance sheet is reconciled in the following table: Gross proceeds $ 80,090,410 Less: Common stock issuance costs (1,858,498) Plus: Accretion of carrying value to redemption value 1,858,498 Common stock subject to possible redemption $ 80,090,410 Offering Costs Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs amounting to $1,858,498 were charged to stockholders’ equity upon the completion of the Initial Public Offering. Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740 “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the consolidated financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the consolidated financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2021 and 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may be subject to potential examination by federal, state and city taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal, state and city tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company is subject to income tax examinations by major taxing authorities since inception. Net Loss Per Common Share (Restated, see Note 2) The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. The Company applies the two-class method in calculating earnings per share. Accretion associated with the redeemable shares of Common Stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, as described in Note 4, since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 3,146,454 Common Stock in the aggregate. As of June 30, 2021, the Company did not have any other dilutive securities or other contracts that could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. As a result, diluted net loss per common share is the same as basic net loss per common share for the periods presented. The following table reflects the calculation of basic and diluted net loss per common share (in dollars, except per share amounts): For the Period from December 18, 2019 (Inception) Year Ended through June 30, June 30, 2021 2020 Basic and diluted net income (loss) per common stock Numerator: Allocation of net income (loss), as adjusted $ (561,449) $ (1,000) Denominator: Basic and diluted weighted average shares outstanding 6,734,489 1,875,000 Basic and diluted net income (loss) per common stock $ (0.08) $ (0.00) Note: As of June 30, 2021 and 2020, basic and diluted shares are the same as there are no non-redeemable securities that are dilutive to the Company’s stockholders. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximate the carrying amounts represented in the accompanying consolidated balance sheets, primarily due to their short-term nature. Warrant Classification The Company accounts for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815-40-15-7D under which the warrants do meet the criteria for equity treatment and must be recorded as equity. Recent Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, “Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”), to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. We are currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

PUBLIC OFFERING

PUBLIC OFFERING	3 Months Ended	12 Months Ended
PUBLIC OFFERING	Sep. 30, 2021	Jun. 30, 2021
LifeSci Acquisition II Corp
PUBLIC OFFERING	NOTE 4. INITIAL PUBLIC OFFERING Pursuant to the Initial Public Offering, the Company sold 8,009,041 Public Shares, which includes the partial exercise by the underwriters of their over-allotment option in the amount of 509,041 Public Shares, at a purchase price of $10.00 per Public Share.	NOTE 4. INITIAL PUBLIC OFFERING Pursuant to the Initial Public Offering, the Company sold 8,009,041 Public Shares, which includes the partial exercise by the underwriters of their over-allotment option in the amount of 509,041 Public Shares, at a purchase price of $10.00 per Public Share.

PRIVATE PLACEMENT_2

PRIVATE PLACEMENT	3 Months Ended	12 Months Ended
PRIVATE PLACEMENT	Sep. 30, 2021	Jun. 30, 2021
LifeSci Acquisition II Corp
PRIVATE PLACEMENT	NOTE 5. PRIVATE PLACEMENT Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 3,146,454 Private Warrants at a price of $0.90 per Private Warrant for an aggregate purchase price of $2,831,809. Each Private Warrant is exercisable to purchase one share of common stock at an exercise price of $11.50 per warrant. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Warrants.	NOTE 5. PRIVATE PLACEMENT Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 3,146,454 Private Warrants at a price of $0.90 per Private Warrant for an aggregate purchase price of $2,831,809. Each Private Warrant is exercisable to purchase one share of common stock at an exercise price of $11.50 per warrant. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Warrants.

RELATED PARTY TRANSACTIONS_2

RELATED PARTY TRANSACTIONS	3 Months Ended	9 Months Ended	12 Months Ended
RELATED PARTY TRANSACTIONS	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Related-Party Transactions		8. Related-Party Transactions In 2020, the Company subleased office space in Torrance, California to Good Dermatology, a professional medical corporation owned by the Founder and former CEO. Under the terms of the sublease, lease expenses incurred by the Company were 100% passed through to Good Dermatology. Total sublease income was $29,174 and $87,523 for the three and nine months ended September 30, 2020. The sublease was terminated as of November 30, 2020. 8. Related-Party Transactions (continued) For the three months ended September 30, 2021 and 2020, the Company had revenue of $2,756,011 and $3,146,148 , respectively, and for the nine months ended September 30, 2021 and 2020, the Company had revenue of $10,803,604 and $3,243,667 , respectively, and expenses of $128,084 and $0 , respectively, and as of September 30, 2021 and December 31, 2020, receivables of $2,244,157 and $6,927,470 , respectively, from Pharmaceutical Products Development, LLC, a shareholder who holds a minority interest in the Company and a seat on the Company’s Board of Directors. Pharmaceutical Products Development, LLC became a minority shareholder of the Company during the first quarter of 2019. For the three months ended September 30, 2021 and 2020, the Company had revenue of $269,547 and $108,280 , respectively, and for the nine months ended September 30, 2021 and 2020, the Company had revenue of $565,092 and $226,843 , respectively, and as of September 30, 2021 and December 31, 2020, receivables of $166,474 and $129,857 , respectively, from Novartis, who has a 50% ownership in dRX Capital AG, a shareholder who, until July 2021, had a minority interest in the Company and a seat on the Company’s Board of Directors. In July 2021, dRX Capital AG was dissolved and their interest in the Company was distributed to their owners. This dissolution and distribution did not cause any other shareholder of the Company to obtain a minority interest in the Company. For the three months ended September 30, 2021 and 2020, the Company had revenue of $9,875 and $0 , respectively, and for the nine months ended September 30, 2021 and 2020, the Company had revenue of $350,585 and $0 , respectively, and as of September 30, 2021 and December 31, 2020, receivables of $2,185 and $0 , respectively, from Allovir, who is an investee of a minority shareholder and Board of Directors seat holder of the Company. The minority shareholder became a shareholder of the Company in the third quarter of 2016.		13. Related-Party Transactions In 2020 and 2019, the Company subleased office space in Torrance, California to Good Dermatology, a professional medical corporation owned by the Founder and former CEO. Under the terms of the sublease, lease expenses incurred by the Company were 100% passed through to Good Dermatology. Total sublease income was $106,972 and $116,697 for the years ended December 31, 2020 and 2019, respectively. The sublease was terminated as of November 30, 2020. During the year ended December 31, 2019, the Company purchased clinical trial investigator services in an arm’s length transaction totaling $273,787 from Good Dermatology, a professional medical corporation owned by the Founder and former CEO. No services were purchased from Good Dermatology during the year ended December 31, 2020. During the year ended December 31, 2019, the Founder and former CEO had a personal loan from the Company in the amount of $300,000 which was paid off in its entirety, including accrued interest of $15,682 on June 26, 2019. There was a zero balance on the loan at December 31, 2019. For the years ended December 31, 2020 and 2019, the Company had revenue of $9,106,645 and $0, respectively, and as of December 31, 2020 and 2019, receivables of $6,927,470 and $0, respectively, from Pharmaceutical Products Development, LLC, a shareholder who holds a minority interest in the Company. Pharmaceutical Products Development, LLC became a minority shareholder of the Company during the first quarter of 2019. For the years ended December 31, 2020 and 2019, the Company had revenue of $351,034 and $451,558, respectively, and as of December 31, 2020 and 2019, receivables of $129,857 and $9,825, respectively, from Novartis, who has a 50% ownership in dRX Capital AG, a shareholder who has a minority interest in the Company. dRX Capital AG became a minority shareholder of the Company in the third quarter of 2015.
LifeSci Acquisition II Corp
Related-Party Transactions	NOTE 6. RELATED PARTY TRANSACTIONS Founder Shares On January 1, 2020, the Company issued an aggregate of 2,156,250 shares of common stock (the “Founder Shares”) to the Sponsor for an aggregate purchase price of $25,000. On September 30, 2020, LifeSci Holdings LLC transferred 215,625 Founder Shares to Chardan Healthcare Investments LLC, an investor in the Sponsor. The Founder Shares included an aggregate of up to 153,990 shares of common stock that remained subject to forfeiture by the Sponsor, following the underwriters’ election to partially exercise their over-allotment option so that the number of Founder Shares would collectively represent 20% of the Company’s issued and outstanding shares upon the completion of the Initial Public Offering. On January 8, 2021, the underwriters’ election to exercise their remaining over-allotment option expired unexercised, resulting in 127,260 shares no longer subject to forfeiture and the forfeiture of 153,990 shares. Accordingly, as of January 8, 2021, there were 2,002,260 Founder Shares issued and outstanding . The Sponsor and Chardan Healthcare Investments LLC have agreed that, subject to certain limited exceptions, 50% of the Founder Shares will not be transferred, assigned, sold or released from escrow until the earlier of (i) six months after the date of the consummation of a Business Combination or (ii) the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30- trading day period commencing after a Business Combination and the remaining 50% of the Founder Shares will not be transferred, assigned, sold or released from escrow until six months after the date of the consummation of a Business Combination, or earlier, in either case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the stockholders having the right to exchange their shares of common stock for cash, securities or other property. Administrative Support Agreement The Company entered into an agreement, commencing on November 20, 2020 through the earlier of the Company’s consummation of a Business Combination and its liquidation, to pay an affiliate of the Sponsor a total of $10,000 per month for office space, utilities and secretarial support. For the three months ended September 30, 2021 and 2020, the Company incurred $30,000 and $0, respectively, in fees for these services, of which $100,000 and $70,000 is included in accrued expenses in the accompanying unaudited condensed consolidated balance sheets at September 30, 2021 and June 30, 2021, respectively. Promissory Note — Related Party On June 19, 2020, the Company issued an unsecured promissory note to the Sponsor (the “Promissory Note”), pursuant to which the Company could borrow up to an aggregate principal amount of $175,000. The Promissory Note was non-interest bearing and payable within 15 days of the Sponsor providing the Company with written notice of demand. The outstanding balance under the Promissory Note of $175,000 was repaid at the closing of the Initial Public Offering on November 24, 2020. No future borrowings are permitted under this note. Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds from time to time or at any time, as may be required (“Working Capital Loans”). Each Working Capital Loan would be evidenced by a promissory note. The Working Capital Loans would be paid upon consummation of a Business Combination, without interest or, at the lender’s discretion, up to $500,000 of such Working Capital Loans may be converted into warrants of the post Business Combination entity at a price of $0.90 per warrant. In the event that a Business Combination does not close, the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The warrants would be identical to the Private Warrants. As of September 30, 2021 and June 30, 2020, the Company had no outstanding borrowings under the Working Capital Loans.		NOTE 6. RELATED PARTY TRANSACTIONS Founder Shares On January 1, 2020, the Company issued an aggregate of 2,156,250 shares of common stock (the "Founder Shares") to the Sponsor for an aggregate purchase price of $25,000. On September 30, 2020, LifeSci Holdings LLC transferred 215,625 Founder Shares to Chardan Healthcare Investments LLC, an investor in the Sponsor. The Founder Shares included an aggregate of up to 153,990 shares of common stock that remained subject to forfeiture by the Sponsor, following the underwriters’ election to partially exercise their over-allotment option so that the number of Founder Shares would collectively represent 20% of the Company’s issued and outstanding shares upon the completion of the Initial Public Offering. On January 8, 2021, the underwriters’ election to exercise their remaining over-allotment option expired unexercised, resulting in 127,260 shares no longer subject to forfeiture and the forfeiture of 153,990 shares. Accordingly, as of January 8, 2021 and June 30, 2021, there were 2,002,260 Founder Shares issued and outstanding. The Sponsor and Chardan Healthcare Investments LLC have agreed that, subject to certain limited exceptions, 50% of the Founder Shares will not be transferred, assigned, sold or released from escrow until the earlier of (i) six months after the date of the consummation of a Business Combination or (ii) the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30- trading day period commencing after a Business Combination and the remaining 50% of the Founder Shares will not be transferred, assigned, sold or released from escrow until six months after the date of the consummation of a Business Combination, or earlier, in either case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the stockholders having the right to exchange their shares of common stock for cash, securities or other property. Administrative Support Agreement The Company entered into an agreement, commencing on November 20, 2020 through the earlier of the Company’s consummation of a Business Combination and its liquidation, to pay an affiliate of the Sponsor a total of $10,000 per month for office space, utilities and secretarial support. For the year ended June 30, 2021, the Company incurred $70,000 in fees for these services, of which is included in accounts payable and accrued expenses in the accompanying consolidated balance sheets. For the year ended June 30, 2020 the Company did not incur any fees for these services. Promissory Note — Related Party On June 19, 2020, the Company issued an unsecured promissory note to the Sponsor (the “Promissory Note”), pursuant to which the Company could borrow up to an aggregate principal amount of $175,000. On July 9, 2020 the Company borrowed $175,000 from the Sponsor. The Promissory Note was non-interest bearing and payable within 15 days of the Sponsor providing the Company with written notice of demand. The outstanding balance under the Promissory Note of $175,000 was repaid at the closing of the Initial Public Offering on November 24, 2020. No future borrowings are permitted under this note. Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds from time to time or at any time, as may be required (“Working Capital Loans”). Each Working Capital Loan would be evidenced by a promissory note. The Working Capital Loans would be paid upon consummation of a Business Combination, without interest or, at the lender’s discretion, up to $500,000 of such Working Capital Loans may be converted into warrants of the post Business Combination entity at a price of $0.90 per warrant. In the event that a Business Combination does not close, the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The warrants would be identical to the Private Warrants. As of June 30, 2021 and 2020, the Company had no outstanding borrowings under the Working Capital Loans.

COMMITMENTS_2

COMMITMENTS	3 Months Ended	9 Months Ended	12 Months Ended
COMMITMENTS	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Commitments and Contingencies		9. Commitments and Contingencies Legal Proceedings During 2019 and 2020, the Company was in state court litigation in California. Noah Craft and Belinda Tan, former co-founders and former Chief Executive Officer and Chief Medical Officer, respectively, asserted derivative claims purportedly on behalf of the Company alleging that several of its current and former directors and investors committed various breaches of duty in connection with the termination of Craft and Tan’s employment. Craft and Tan also asserted direct tort claims arising from the same facts against the non-Company defendants. Moreover, Tan asserted a direct claim against the Company and certain current and former directors for gender discrimination. The Company disputed that it was liable, and that none of Craft and Tan’s claims had merit. Notwithstanding the Company’s stance, the litigation was settled in court in November 2020. As of September 30, 2021, all elements and payments associated with the settlement have been completed which included the following: 1) In June 2020, the Director Defendants paid $100,000 to the Company, which was used to offset the legal settlement in 3) below. 2) As part of the settlement, the Company paid $3,675,000 to Plaintiffs (“First Payment”) in December 2020. In return, the Plaintiffs conveyed all the Company shares and any other securities or interest in the Company shares. The Plaintiffs held the equivalent on an as converted basis of 5,901,076 common shares. 3) In December 2020, the Company accrued $1,225,000 for the legal settlement which was paid in June 2021 (“Second Payment”). 9. Commitments and Contingencies (continued) New Office Lease In March 2021, the Company entered into an operating lease agreement to lease office space in Culver City, CA commencing in July 2021 through October 2024 totaling $1,578,821 . Future minimum lease payments under non-cancellable leases as of September 30, 2021 were as follows: Operating Leases 2021 (remaining three months) $ 188,943 2022 1,286,301 2023 629,369 2024 599,327 2025 137,888 2026 11,517 Thereafter — Total future minimum lease payments $ 2,853,345 Less imputed interest (264,774) Total $ 2,588,571 Reported as of September 30, 2021: Other current liabilities $ 1,103,283 Operating lease liabilities 1,485,288 Total $ 2,588,571		14. Commitments and Contingencies Legal Proceedings During 2019 and 2020, the Company was in state court litigation in California. Noah Craft and Belinda Tan, former co-founders and former Chief Executive Officer and Chief Medical Officer, respectively, asserted derivative claims purportedly on behalf of the Company alleging that several of its current and former directors and investors committed various breaches of duty in connection with the termination of Craft and Tan’s employment. Craft and Tan also asserted direct tort claims arising from the same facts against the non-Company defendants. Moreover, Tan asserted a direct claim against the Company and certain current and former directors for gender discrimination. The Company disputed that it was liable, and that none of Craft and Tan’s claims had merit. On September 30, 2019, the Los Angeles County Superior Court stayed this litigation indefinitely after ruling that a contractual forum selection clause required Craft’s and Tan’s claims to be brought in Delaware. Craft and Tan have partially appealed that ruling to the California Court of Appeal. On February 26, 2020 agreement was reached on the terms of the pending litigation described above, and on June 30, 2020, the long form agreement was executed by all parties, and was settled in court in November 2020. The settlement agreement included the following elements: 1) Within five business days after a Final Dismissal occurred: a. The Director Defendants caused their insurers to pay $100,000 to Science 37. b. Science 37 paid $3,675,000 to Plaintiffs (“First Payment”). 2) Within five business days of the Plaintiffs’ receipt of the First Payment, the Plaintiffs conveyed all Science 37 shares and any other securities or interest in Science 37 shares. The Plaintiffs held the equivalent on an as converted basis of 5,901,076 common shares. 3) Good Dermatology, a company wholly owned by the Plaintiffs, was focused on providing dermatology care. Historically, Good Dermatology had sub-contracted employees from Science 37, and had allowed Science 37 the use of their medical offices to conduct clinical trials. In addition, Science 37 had advanced funds for rental payments and employee payroll, for the benefit of Good Dermatology. Good Dermatology delivered $600,000 to Science 37 to cover all outstanding obligations as of February 26, 2020: a. Within five business days after the Effective Date (June 30, 2020), Plaintiffs instructed Good Dermatology to pay Science 37 $400,000 for part of the payables due to Science 37 for rent, employee costs, etc. This amount was received in early July 2020. b. It was contemplated that Good Dermatology would dissolve or be wound down. Within five business days of such action, Science 37 is to pay the Plaintiffs either $1,225,000 or $ 1,025,000 (“Second Payment”). The amount paid was determined by whether Plaintiffs i) elected to pay $200,000 directly to Science 37 to satisfy the $600,000 outlined in 3) above and in which case, Science 37 would pay to the Plaintiffs $1,225,000 or ii) elected to pay $0 directly to Science 37 in which the Second Payment to the Plaintiffs would be $1,025,000 . Plaintiffs elected to pay $200,000 , resulting in Science 37 owing $1,225,000 . As of December 31, 2020, this payment is pending upon Good Dermatology’s dissolution. c. Additionally, prior to dissolution, Good Dermatology agreed to pay Science 37 all sums which accrued, arose or were incurred on Good Dermatology’s behalf by Science 37 from the time of February 26, 2020 through dissolution. 14. Commitments and Contingencies (continued) As of December 31, 2020, all payments were made by both parties with the exception of $1,225,000 owed by Science 37 to Plaintiffs in 3b above, the amount of which is recorded in accrued expenses on the balance sheet. The $1,225,000 was paid by Science 37 in June 2021.
LifeSci Acquisition II Corp
Commitments and Contingencies	NOTE 7. COMMITMENTS Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position and/or search for a target company, the specific impact is not readily determinable as of the date of the condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Registration and Stockholder Rights Pursuant to a registration rights agreement entered into on November 20, 2020, the holders of the Founder Shares and the Private Warrants and any shares that may be issued upon conversion of Working Capital Loans (and all underlying securities) will be entitled to registration and stockholder rights. The holders of a majority of these securities are entitled to make up to two demands that the Company register such securities. The holders of the majority of the Founders Warrants can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the Private Warrants can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. The Sponsor and its related persons may not, with respect to the Private Warrants purchased by it, (i) have more than one demand registration right at the Company’s expense, (ii) exercise their demand registration rights more than five (5) years from the effective date of the registration statement of the Initial Public Offering, and (iii) exercise their “piggy-back” registration rights more than seven (7) years from the effective date of the Initial Public Offering, as long as the Sponsor or any of its related persons are beneficial owners of Private Warrants. Underwriting Agreement The Company granted the underwriters a 45-day option from the date of the Initial Public Offering to purchase up to 1,125,000 additional Public Shares to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. As a result of the underwriter’s election to partially exercise the over-allotment option to purchase an additional 509,041 Public Shares, a total of 615,959 Public Shares remained available for purchase at a price of $10.00 per Public Share. On January 8, 2021, the underwriters’ election to exercise their remaining over-allotment option expired unexercised. The underwriters were paid cash underwriting discount of $0.20 per Public Share, or $1,601,808 in the aggregate. Business Combination Marketing Agreement The Company has engaged LifeSci Capital LLC and Ladenburg Thalmann & Co. Inc. (“Ladenburg Thalmann “) as advisors in connection with a Business Combination to assist the Company in holding meetings with its stockholders to discuss the potential Business Combination and the target business’ attributes, introduce the Company to potential investors that are interested in purchasing the Company’s securities in connection with a Business Combination, assist the Company in obtaining stockholder approval for the Business Combination and assist the Company with its press releases and public filings in connection with the Business Combination. The Company will pay LifeSci Capital LLC and Ladenburg Thalmann a cash fee for such services upon the consummation of a Business Combination in an amount equal to 3.5% of the gross proceeds of the Initial Public Offering, or $2,803,164, (exclusive of any applicable finders’ fees which might become payable) with 75% of such fee payable to LifeSci Capital LLC and 25% to Ladenburg Thalmann; provided that up to 33% of the fee may be allocated in the Company’s sole discretion to other third parties who are investment banks or financial advisory firms not participating in Initial Public Offering that assist the Company in identifying and consummating a Business Combination.		NOTE 7. COMMITMENTS Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position and/or search for a target company, the specific impact is not readily determinable as of the date of the consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Registration and Stockholder Rights Pursuant to a registration rights agreement entered into on November 20, 2020, the holders of the Founder Shares and the Private Warrants and any shares that may be issued upon conversion of Working Capital Loans (and all underlying securities) will be entitled to registration and stockholder rights. The holders of a majority of these securities are entitled to make up to two demands that the Company register such securities. The holders of the majority of the Founders Warrants can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the Private Warrants can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. The Sponsor and its related persons may not, with respect to the Private Warrants purchased by it, (i) have more than one demand registration right at the Company’s expense, (ii) exercise their demand registration rights more than five (5) years from the effective date of the registration statement of the Initial Public Offering, and (iii) exercise their “piggy-back” registration rights more than seven (7) years from the effective date of the Initial Public Offering, as long as the Sponsor or any of its related persons are beneficial owners of Private Warrants. Underwriting Agreement The Company granted the underwriters a 45-day option from the date of the Initial Public Offering to purchase up to 1,125,000 additional Public Shares to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. As a result of the underwriter’s election to partially exercise the over-allotment option to purchase an additional 509,041 Public Shares, a total of 615,959 Public Shares remained available for purchase at a price of $10.00 per Public Share. On January 8, 2021, the underwriters’ election to exercise their remaining over-allotment option expired unexercised. The underwriters were paid a cash underwriting discount of $0.20 per Public Share, or $1,601,808 in the aggregate. Business Combination Marketing Agreement The Company has engaged LifeSci Capital LLC and Ladenburg Thalmann & Co. Inc. (“Ladenburg Thalmann “) as advisors in connection with a Business Combination to assist the Company in holding meetings with its stockholders to discuss the potential Business Combination and the target business’ attributes, introduce the Company to potential investors that are interested in purchasing the Company’s securities in connection with a Business Combination, assist the Company in obtaining stockholder approval for the Business Combination and assist the Company with its press releases and public filings in connection with the Business Combination. The Company will pay LifeSci Capital LLC and Ladenburg Thalmann a cash fee for such services upon the consummation of a Business Combination in an amount equal to 3.5% of the gross proceeds of the Initial Public Offering, or $2,803,164, with 75% of such fee payable to LifeSci Capital LLC and 25% to Ladenburg Thalmann; provided that up to 33% of the fee may be allocated in the Company’s sole discretion to other third parties who are investment banks or financial advisory firms not participating in Initial Public Offering that assist the Company in identifying and consummating a Business Combination. Business Combination Agreement On May 6, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with LifeSci Acquisition II Merger Sub, Inc. (“Merger Sub”), and Science 37, Inc. (“Science 37”), pursuant to which the Merger Sub will merge with and into Science 37, with Science 37 surviving the merger as the Company’s wholly-owned subsidiary (the “Merger”). The Company’s board of directors has unanimously (i) approved and declared advisable the Merger Agreement, the Merger and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Merger Agreement and related matters by our stockholders. Immediately prior to the effective time of the Merger (the “Effective Time”) and subject to the consent of the holders of a majority of the then outstanding shares of Science 37’s Series A, Series, B, Series C, Series D and Series D-1 preferred stock, par value $0.0001 per share (collectively, the “Science 37 Preferred Stock”), voting together as a single class on an as-converted basis, each issued and outstanding share of Science 37 Preferred Stock will be converted into shares of the common stock, par value $0.0001 per share, of Science 37 (the “Science 37 Common Stock”) at the then-applicable conversion rates (the “Science 37 Preferred Stock Conversion”). At the Effective Time, each outstanding and unexercised warrant to purchase shares of Science 37 capital stock (“Science 37 Warrant”) that is outstanding and unexercised immediately prior to the Effective Time will be converted into a warrant exercisable to receive the Company’s common stock, in accordance with its terms. From and after the Effective Time: (i) each Science 37 Warrant assumed by the Company may be exercised solely for shares of the Company’s common stock; (ii) the number of shares of the Company’s common stock subject to each Science 37 Warrant assumed by the Company will be determined by multiplying (A) the number of shares of Science 37 Common Stock, or the number of shares of Science 37 Common Stock issuable upon exercise of the Science 37 Warrant that were subject to such Science 37 Warrant immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number up to the nearest whole number of shares of the Company’s common stock; (iii) the per share exercise price for the Company’s common stock issuable upon exercise of each Science 37 Warrant assumed by the Company will be determined by dividing the per share exercise price of Science 37 Common Stock subject to the Science 37 Warrant, as in effect immediately prior to the Effective Time, by the Exchange Ratio and rounding the resulting exercise price up to the nearest whole cent; and (iv) any restriction on any Science 37 Warrant assumed by the Company will continue in full force and effect and the terms and other provisions of such Science 37 Warrant will otherwise remain unchanged. The Exchange Ratio is defined in the Merger Agreement to be the quotient of (i) 100,000,000 divided by (ii) the number of shares of Science 37’s Fully Diluted Capital Stock (as defined in the Merger Agreement). At the Effective Time, following the Science 37 Preferred Stock Conversion, each share of Science 37 Common Stock (including shares of Science 37 Common Stock outstanding as a result of the Science 37 Preferred Stock Conversion, but excluding shares the holders of which perfect rights of appraisal under Delaware law) will be converted into the right to receive such number of shares of the Company’s common stock equal to the Exchange Ratio (subject to rounding mechanisms as described in the Merger Agreement) and a number of Earn-Out Shares (as defined below). At the Effective Time, each outstanding option to purchase shares of Science 37 Common Stock, whether or not then vested and exercisable, will be converted automatically (and without any required action on the part of such holder of outstanding option) into an option to purchase shares of the Company’s common stock equal to the number of shares subject to such option prior to the Effective Time multiplied by the Exchange Ratio, with the per share exercise price equal to the exercise price prior to the Effective Time divided by the Exchange Ratio. Following the closing of the Merger, former holders of shares of Science 37 Common Stock (including shares received as a result of the Science 37 Preferred Stock Conversion) and former holders of Science 37 stock options will be entitled to receive their pro rata share of up to 12,500,000 additional shares of the Company’s common stock (the “Earn-Out Shares”) if, within a three-year period following May 6, 2021, the signing date of the Merger Agreement, the closing share price of the Company’s common stock equals or exceeds any of two thresholds over any 20 trading days within a 30-day trading period (each, a “Triggering Event”) and, in respect of a former holder of Science 37 stock options, the holder continues to provide services to the Company or one of the subsidiaries at the time of such Triggering Event. In connection with the execution of the Merger Agreement, LSAQ entered into subscription agreements (collectively, the “Subscription Agreements”) with certain parties subscribing for shares of LSAQ Common Stock (the “Subscribers”) pursuant to which the Subscribers have agreed to purchase, and LSAQ has agreed to sell to the Subscribers, an aggregate of 20,000,000 shares of LSAQ Common Stock, for a purchase price of $10.00 per share and an aggregate purchase price of $200,000,000. The obligations to consummate the transactions contemplated by the Subscription Agreements are conditioned upon, among other things, customary closing conditions and the consummation of the transactions contemplated by the Merger Agreement. The Merger Agreement contains customary representations, warranties and covenants of the parties thereto. The consummation of the proposed Merger is subject to certain conditions as further described in the Merger Agreement.

STOCKHOLDERS EQUITY

STOCKHOLDERS EQUITY	3 Months Ended	9 Months Ended	12 Months Ended
STOCKHOLDERS EQUITY	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Shareholders' Deficit		6. Stockholders’ Deficit Par value for common shares is $0.0001 . The following is a summary of common share activity for the nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Common shares, beginning balance 4,488,416 8,468,742 2,765,097 8,396,425 Issuance of common shares 106,752 75,694 1,830,071 148,011 Common shares, ending balance 4,595,168 8,544,436 4,595,168 8,544,436 The Company has one common stock warrant outstanding with available shares to be issued of 6,439 and an exercise price of $1.61 per share as of September 30, 2021. This warrant was exercised on October 4, 2021.		11. Shareholders’ Deficit Science 37 was formed under Delaware law and is treated as a “C” corporation for U.S. tax purposes. Par value for common shares is $0.0001. The following is a summary of common share activity for the years ended December 31, 2020 and 2019: 2020 2019 Common stock shares, beginning balance 8,396,425 8,273,865 Issuance of common stock 164,886 122,560 Repurchase of common stock (5,796,214) — Common stock shares, ending balance 2,765,097 8,396,425 The Company has one common stock warrant outstanding with available shares to be issued of 6,439 and an exercise price of $1.61 per share as of December 31, 2020.
LifeSci Acquisition II Corp
Shareholders' Deficit	NOTE 8. STOCKHOLDERS’ EQUITY Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. At September 30, 2021 and June 30, 2021, there were no shares of preferred stock issued or outstanding. Common Stock — The Company is authorized to issue 30,000,000 shares of common stock with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share. At September 30, 2021 and June 30, 2021, there were 2,002,260 shares of non-redeemable common stock, excluding 8,009,041 shares of common stock subject to possible redemption which are presented as temporary equity. Warrants — The Private Warrants will become exercisable at any time commencing on the later of (1) one year after the closing of the Initial Public Offering or (2) the consummation of a Business Combination; provided that the Company has an effective and current registration statement covering the shares of common stock issuable upon the exercise of the Public Warrants and a current prospectus relating to such shares of common stock. The Private Warrants purchased by the Sponsor will be exercisable on a cashless basis and not be exercisable more than five years from the commencement of sales of the Initial Public Offering, in accordance with FINRA Rule 5110(g)(8)(A), as long as the Sponsor or any of its related persons beneficially own these Private Warrants.		NOTE 8. STOCKHOLDERS’ EQUITY Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. At June 30, 2021 and 2020, there were no shares of preferred stock issued or outstanding. Common Stock — The Company is authorized to issue 30,000,000 shares of common stock with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share. At June 30, 2021 and 2020, there were 2,002,260 and 2,156,250 shares of common stock issued and outstanding , excluding 8,009,041 and no shares of common stock subject to possible redemption, respectively. Warrants — The Private Warrants will become exercisable at any time commencing on the later of (1) one year after the closing of the Initial Public Offering or (2) the consummation of a Business Combination; provided that the Company has an effective and current registration statement covering the shares of common stock issuable upon the exercise of the Public Warrants and a current prospectus relating to such shares of common stock. The Private Warrants purchased by the Sponsor will be exercisable on a cashless basis and not be exercisable more than five years from the commencement of sales of the Initial Public Offering, in accordance with FINRA Rule 5110(g)(8)(A), as long as the Sponsor or any of its related persons beneficially own these Private Warrants.

INCOME TAX

INCOME TAX	9 Months Ended	12 Months Ended
INCOME TAX	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
INCOME TAX	11. Income Taxes The Company is treated as a “C” corporation for U.S. tax purposes. Adoption of Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (ASU 2019-12), which eliminates certain exceptions to the guidance in Income Taxes (Topic 740) related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted in an interim or annual period. Entities that elect to early adopt the amendments in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, entities that elect early adoption must adopt all the amendments in the same period. Entities will apply the guidance prospectively, except for certain amendments. The Company adopted ASU 2019-12 effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures. 11. Income Taxes (continued) The Company has incurred net operating losses since inception and is forecasting additional losses through December 31, 2021. Therefore, no U.S. Federal, state or foreign income taxes are expected for 2021 and no provision for such taxes has been recorded as of September 30, 2021. Due to the Company’s history of losses since inception, there is not enough evidence at this time to support the conclusion that the Company will generate future income of a sufficient amount and nature to utilize the benefits of the Company’s net deferred tax assets. Accordingly, as of September 30, 2021 and December 31, 2020, the Company provided a full valuation allowance against its net deferred tax assets since as of that time, the Company could not assert that it was more likely than not that these deferred tax assets would be realized.		17. Income Taxes For the years ended December 31, 2020 and 2019, the amount of loss before taxes was: 2020 2019 U.S. income (loss) before taxes $ (31,666,084) $ (18,468,776) Foreign income (loss) before taxes — — Total income (loss) before taxes $ (31,666,084) $ (18,468,776) Both current and deferred income tax (benefit) expense as of December 31, 2020 and 2019 were $0 and $0, respectively. 17. Income Taxes (continued) The Company has not recorded any provision for income taxes for the years ended December 31, 2020 and 2019, due to its history of operating losses. The effective tax rate for the year ended December 31, 2020, is different from the federal statutory rate primarily due to full valuation allowance against net deferred tax assets as a result of insufficient sources of income. The reconciliation of tax expense at the statutory federal tax rate versus the recorded income tax expense is as follows for the years ended December 31, 2020 and 2019: 2020 2019 Statutory U.S. federal rate $ (6,649,878) $ (3,878,443) State income tax net of federal benefit (1,141,758) (767,428) Permanent items 77,747 109,580 Other prior year adjustments (99,275) (1,339) Rate adjustment (12,921) 65,267 Valuation allowance 7,826,085 4,472,363 Total income tax expense (benefit) $ — $ — Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The principal components of the Company’s deferred tax assets for the years ended December 31, 2020 and 2019 consisted of the following: 2020 2019 Net operating loss carryforwards $ 24,923,945 $ 18,039,466 Amortizable assets 6,321 7,143 Equity compensation 50,118 77,916 Salaries and wages 1,048,104 151,442 Deferred rent — 133,387 Deferred revenue 861,120 544,415 Leasehold improvements 611,657 — Other 303,317 26,535 Total deferred tax assets 27,804,582 18,980,304 Less: valuation allowance (25,316,127) (17,490,042) Net deferred tax asset 2,488,455 1,490,262 Operating lease ROU (545,045) — Fixed assets (1,943,410) (1,490,262) Total deferred tax liabilities (2,488,455) (1,490,262) Net deferred tax assets (liabilities) $ — $ — The Company determines its valuation allowance on deferred tax assets by considering both positive and negative evidence in order to ascertain whether it is more likely than not that deferred tax assets will be realized. Realization of deferred tax assets is dependent upon the generation of future taxable income, if any, the timing and amount of which are uncertain. Due to the history of losses the Company has generated in the past, the Company believes that it is not more likely than not that all of the deferred taxes can be realized as of December 31, 2020 and 2019; accordingly, the Company has recorded a full valuation allowance on its net deferred tax assets. The valuation allowance increased $7,826,085 and $4,184,528 during the years ended December 31, 2020 and 2019, respectively. 17. Income Taxes (continued) At December 31, 2020, the Company has federal net operating loss carryforwards of approximately $103,569,264 and state net operating loss carryforwards of $56,390,660. As a result of Tax Cuts and Jobs Act, for U.S. income tax purposes, the net operating loss generated in tax years beginning before January 1, 2018 can be carried forward for 20 years, but net operating loss generated for tax years beginning after December 31, 2017 are carried forward indefinitely and are limited to 80% utilization against taxable income. Of the total federal net operating loss, $30,230,297 will begin to expire in 2034 and $73,338,967 will not expire but can only offset 80% of future taxable income in any given year. Of the total state NOL carryforwards, $247,181 can be carried forward indefinitely, with the remainder first beginning to expire in 2029. Pursuant to Code Sections 382 and 383, annual use of our net operating losses may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed a formal study in accordance with sections 382 and 383 to determine the limitations if a change in ownership has occurred or if there are any limitations on the utilization of net operating loss carryforwards. If net operating loss carryforwards are eliminated the related tax assets would be removed from the deferred tax assets schedule with a corresponding reduction in the valuation allowance. The Company files US. federal and various state and local income tax returns and is not under examination by any of the taxing authorities. Tax years 2017 and forward remain open for examination for federal tax purpose and tax years 2016 and forward remain open for examination for state tax purposes. Carryforward attributes that were generated in years where the statute of limitation is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authority. On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions are the extension of the carryback period of certain losses to five years and increasing the ability to deduct interest expense from 30 percent to 50 percent of modified taxable income. The CARES Act also provides for a credit against employee wages, the opportunity to defer payment of a portion of federal payroll taxes to December 2021 and December 2022 and enhanced small business loans to assist businesses impacted by the pandemic. The Company’s tax provision and financial position was not materially impacted by the CARES Act. On December 27, 2020, the United States enacted the Consolidated Appropriations Act which extended and modified many of the tax related provisions of the CARES Act. The Company’s tax provision and financial position was not materially impacted by the Consolidated Appropriations Act. On June 29, 2020, the state of California enacted Assembly Bill No. 85 (AB 85) suspending California net operating loss utilization and imposing a cap on the amount of business incentive tax credits companies can utilize, effective for tax years 2020, 2021 and 2022. There was no material impact from the provisions of AB 85 in 2020. 17. Income Taxes (continued) The following table summarizes the reconciliation of the unrecognized tax benefits activity during the year ended December 31, 2020: Unrecognized Tax Benefits – Beginning $ 239,927 Gross increases – tax positions in prior period — Gross decreases – tax positions in prior period — Gross increase – current-period tax positions — Gross decrease – current-period tax positions — Settlements — Lapse of statute of limitations — Unrecognized Tax Benefits – Ending $ 239,927 Due to the Company’s valuation allowance, none of the unrecognized tax benefits, if recognized, would affect the Company’s effective tax rate. The Company’s policy is to recognize interest expense and penalties related to income tax matters as tax expense. At December 31, 2020, there are no significant accruals for interest or penalties related to unrecognized tax benefits. The Company does not expect that there will be unrecognized tax benefits of a significant nature that will increase or decrease within 12 months of the reporting date.
LifeSci Acquisition II Corp
INCOME TAX		NOTE 9. INCOME TAX The Company did not have any significant deferred tax assets or liabilities as of June 30, 2021 and 2020. The Company’s net deferred tax assets are as follows: June 30, 2021 2020 Deferred tax asset Net operating loss carryforward $ 6,802 $ 210 Startup/Organization Expenses 111,312 — Total deferred tax asset 118,114 210 Valuation allowance (118,114) (210) Deferred tax asset, net of allowance $ — $ — The income tax provision consists of the following: June 30, 2021 2020 Federal Current $ — $ — Deferred (117,904) (210) State Current $ — $ — Deferred — — Change in valuation allowance 117,904 210 Income tax provision $ — $ — As of June 30, 2021 and 2020, the Company had $31,391 and $1,000 , respectively, of U.S. federal and state net operating loss carryovers available to offset future taxable income. In assessing the realization of the deferred tax assets, management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the year ended June 30, 2021 and for the period from December 18, 2019 (inception) through June 30, 2020, the change in the valuation allowance was $117,904 and $210 , respectively. A reconciliation of the federal income tax rate to the Company’s effective tax rate at June 30, 2021 and 2020 is as follows: June 30, 2021 2020 Statutory federal income tax rate 21.0 % 21.0 % State taxes, net of federal tax benefit 0.0 % 0.0 % Change in valuation allowance (21.0) % (21.0) % Income tax provision 0.0 % 0.0 % The Company files income tax returns in the U.S. federal jurisdiction in various state and local jurisdictions and is subject to examination by the various taxing authorities.

FAIR VALUE MEASUREMENTS_2

FAIR VALUE MEASUREMENTS	3 Months Ended	9 Months Ended	12 Months Ended
FAIR VALUE MEASUREMENTS	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021
Fair Value Measurements		3. Fair Value Measurements Fair value is the price that would be received to sell an asset or paid to transfer a liability between market participants in the principal market or the most advantageous market when no principal market exists. Market participants are assumed to be independent, knowledgeable, able, and willing to transact an exchange and not under duress. Considerable judgment may be required in interpreting market data used to develop the estimates of fair value. Accordingly, estimates of fair value are not necessarily indicative of the amounts that could be realized in a current or future market exchange. Fair values for substantially all the Company’s financial and non-financial instruments were measured using market, income, or cost approaches. The three levels of input are as follows: Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial instruments, including cash and cash equivalents, are recorded at cost, which approximates fair value. The Company does not have any assets or liabilities measured at Level 2 or Level 3.
LifeSci Acquisition II Corp
Fair Value Measurements	NOTE 9. FAIR VALUE MEASUREMENTS The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. The Company classifies its U.S. Treasury and equivalent securities as held-to-maturity in accordance with ASC Topic 320 “Investments — Debt and Equity Securities.” Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost on the accompanying balance sheets and adjusted for the amortization or accretion of premiums or discounts. The Company classifies its securities in the Trust Account that are invested in funds, such as Mutual Funds or Money Market Funds, that primarily invest in U.S. Treasury and equivalent securities as Trading Securities in accordance with ASC Topic 320 “Investments — Debt and Equity Securities. Trading Securities are recorded at fair market value on the accompanying consolidated balance sheets. At September 30, 2021, assets held in the Trust Account were comprised of $80,131,806 in cash. During the three months ended September 30, 2021, the Company did not withdraw any interest income from the Trust Account. At June 30, 2021, assets held in the Trust Account were comprised of $80,120,809 in a mutual fund that is invested primarily in U.S. Treasury Securities. Through June 30, 2021, the Company did not withdraw any of the interest earned on the Trust Account. The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at September 30, 2021 and June 30, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Trading Securities Level Fair Value June 30, 2021 Mutual Fund 1 80,120,809		NOTE 10. FAIR VALUE MEASUREMENTS The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on an assessment of the assumptions that market participants would use in pricing the asset or liability. The Company classifies its U.S. Treasury and equivalent securities as held-to-maturity in accordance with ASC Topic 320, “Investments — Debt and Equity Securities.” Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost on the accompanying consolidated balance sheets and adjusted for the amortization or accretion of premiums or discounts. The Company classifies its securities in the Trust Account that are invested in funds, such as Mutual Funds or Money Market Funds, that primarily invest in U.S. Treasury and equivalent securities as Trading Securities in accordance with ASC Topic 320, “Investments — Debt and Equity Securities.” Trading Securities are recorded at fair market value on the accompanying consolidated balance sheets. At June 30, 2021, assets held in the Trust Account were comprised of $0 in cash and $80,120,809 in a mutual fund that is invested primarily in U.S. Treasury Securities. Through June 30, 2021, the Company has not withdrawn any of the interest earned on the Trust Account. The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at June 30, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Trading Securities Level Fair Value June 30, 2021 Mutual Fund 1 $ 80,120,809

SUBSEQUENT EVENTS_2

SUBSEQUENT EVENTS	3 Months Ended	9 Months Ended	12 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Subsequent Events		12. Subsequent Events Merger with LSAQ On May 7, 2021, the Company announced a planned merger with LSAQ under a definitive business combination agreement. On October 6, 2021, the agreement was consummated, with the Company surviving the merger as Science 37 Holdings, Inc, now a public company. All outstanding common and preferred shares of legacy Science 37, Inc. converted into common shares of the surviving Science 37 Holdings, Inc. through application of an exchange ratio of approximately 1.815. In addition, awards under the Company's existing 2015 stock incentive plan continue under the same terms and conditions as were previously applicable to such awards, subject to the same exchange ratio for exercise price and number of options outstanding. Common shares and warrants held by former LSAQ shareholders were converted to 10,858,261 common shares of Science 37 Holdings, Inc. Science 37 Holdings, Inc. began trading on the Nasdaq stock exchange as SNCE effective October 7, 2021. The financial statements as of September 30, 2021, including share and per share amounts, do not include the effects of the merger. The table below shows, on a pro forma basis, the impact of the merger on certain condensed balance sheet items as of September 30, 2021: Balance Sheet Data: Actual Pro Forma Cash and cash equivalents $ 7,996,362 $ 242,991,191 Working capital (5,566,182) 228,647,166 Total assets 39,746,217 273,843,757 Redeemable convertible preferred stock 143,086,271 — Accumulated deficit (136,979,761) (136,979,761) Total stockholders’ equity (deficit) $ (132,209,608) $ 163,290,011 Share Data: Actual Pro Forma Redeemable convertible preferred stock outstanding 41,587,368 — Common stock outstanding 4,595,168 114,707,150 Going Concern From August 2021, the Company began to accelerate investments in hiring and in other critical areas, such as the technology platform, to facilitate the delivery of anticipated revenues, resulting from an increase in net bookings. Also, as several meaningful conditions of the contemplated transaction were met, the Company increased spend related to the requirements of being a publicly-traded company. The Company’s increased costs adversely affected the Company’s results of operations and liquidity and there was substantial doubt as to the Company’s ability to continue as a going concern at that time. On October 6, 2021, the definitive business combination agreement was consummated, with Science 37, Inc. surviving the merger as Science 37 Holdings, Inc., a now public company. All outstanding common and preferred shares of legacy Science 37, Inc. converted into common shares of the surviving Science 37 Holdings, Inc. through application of an exchange ratio of approximately 1.815. In addition, awards under the Company’s existing 2015 stock incentive plan continue under the same terms and conditions as were previously applicable to such awards, subject to the same exchange ratio for exercise price and number of options outstanding. Science 37 Holdings, Inc. began trading on the Nasdaq stock exchange as SNCE effective October 7, 2021. 12. Subsequent Events (continued) In conjunction with this merger, Science 37, Inc. received funds held in LSAQ's working capital and trust accounts together with $ 200 million in PIPE financing from institutional and strategic investors to further fund Science 37, Inc.’s decentralized trial technology platform and extend into new adjacencies. As a result of the Merger and inclusive of the PIPE financing, Science 37, Inc. received $ 234.2 million, net of fees and expenses paid in connection with the closing of the business combination. The transaction will be accounted for as a reverse capitalization in accordance with GAAP. Under the reverse capitalization model, the merger will be treated as Science 37, Inc. is issuing equity for the net assets of LSAQ, with no goodwill or intangible assets recorded, and LSAQ will be treated as the acquiree for financial reporting purposes. This is primarily because, subsequent to the merger, Science 37, Inc. shareholders have a majority of the voting power of the combined company. In addition, Science 37, Inc. comprises all of the ongoing operations, senior management, and a majority of the governing body of the combined company. As a result of the merger and related PIPE financing, the substantial doubt about the Company's ability to continue as a going concern has been alleviated. The Company has evaluated subsequent events through November 15, 2021, the date on which the accompanying condensed consolidated financial statements were issued, noting no additional items requiring disclosure.		18. Subsequent Events On March 25, 2021, the Company entered into an operating lease agreement for office space which will commence on July 1, 2021. The Company’s financial commitment for the office space is disclosed under Leases. On May 7, 2021, the Company announced a planned merger with LifeSci Acquisition II Corp (LSAQ) under a definitive business combination agreement. Going Concern From August 2021, the Company began to accelerate investments in hiring and in other critical areas, such as the technology platform, to facilitate the delivery of anticipated revenues, resulting from an increase in net bookings. Also, as several meaningful conditions of the contemplated transaction were met, the Company increased spend related to the requirements of being a publicly-traded company. The Company’s increased costs adversely affected the Company’s results of operations and liquidity and there was substantial doubt as to the Company’s ability to continue as a going concern at that time. On October 6, 2021, the definitive business combination agreement was consummated, with Science 37, Inc. surviving the merger as Science 37 Holdings, Inc., a now public company. All outstanding common and preferred shares of legacy Science 37, Inc. converted into common shares of the surviving Science 37 Holdings, Inc. through application of an exchange ratio of approximately 1.815. In addition, awards under the Company’s existing 2015 stock incentive plan continue under the same terms and conditions as were previously applicable to such awards, subject to the same exchange ratio for exercise price and number of options outstanding. Science 37 Holdings, Inc. began trading on the Nasdaq stock exchange as SNCE effective October 7, 2021. In conjunction with this merger, Science 37, Inc. received funds held in LSAQ’s working capital and trust accounts together with $200 million in PIPE financing from institutional and strategic investors to further fund Science 37, Inc.’s decentralized trial technology platform and extend into new adjacencies. As a result of the Merger and inclusive of the PIPE financing, Science 37, Inc. received $234.2 million, net of fees and expenses paid in connection with the closing of the business combination. The transaction will be accounted for as a reverse capitalization in accordance with GAAP. Under the reverse capitalization model, the merger will be treated as Science 37, Inc. is issuing equity for the net assets of LSAQ, with no goodwill or intangible assets recorded, and LSAQ will be treated as the acquiree for financial reporting purposes. This is primarily because, subsequent to the merger, Science 37, Inc. shareholders have a majority of the voting power of the combined company. In addition, Science 37, Inc. comprises all of the ongoing operations, senior management, and a majority of the governing body of the combined company. As a result of the merger and related PIPE financing, the substantial doubt about the Company’s ability to continue as a going concern has been alleviated. The Company has evaluated subsequent events through November 5, 2021, the date on which the accompanying consolidated financial statements were issued, noting no additional items requiring disclosure.
LifeSci Acquisition II Corp
Subsequent Events	NOTE 10. SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed consolidated financial statements were issued. Based upon this review, except as disclosed below , the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements. On October 4, 2021, LSAQ held a special meeting of stockholders (the “Special Meeting”), at which the LSAQ stockholders considered and adopted, among other matters, a proposal to approve the Business Combination, including (a) adopting the Merger Agreement and (b) approving the other transactions and matters contemplated by the Merger Agreement and related agreements as described in the Proxy Statement/Prospectus. Pursuant to the terms and subject to the conditions set forth in the Merger Agreement, following the Special Meeting, on October 6, 2021, the Transactions were consummated. In connection with the Closing, the Company changed its name from LifeSci Acquisition II Corp. to Science 37 Holdings, Inc. Holders of 2,299,493 shares of LSAQ’s common stock sold in its initial public offering (the “public shares”) exercised their right to have such shares redeemed for a full pro rata portion of the trust account holding the proceeds from LSAQ’s initial public offering, calculated as of two business days prior to the consummation of the Business Combination, which was approximately $10.00 per share, or $23,003,944 in the aggregate. As noted above, an aggregate of $23,003,944 was paid from the Company’s trust account to holders that properly exercised their right to have public shares redeemed, and the remaining balance immediately prior to the Closing of approximately $57.1 million remained in the trust account. The remaining amount in the trust account was used to fund the Business Combination (See Note 1).		NOTE 11. SUBSEQUENT EVENTS On October 4, 2021, the Company held a special meeting of stockholders (the “Special Meeting”), at which stockholders considered and adopted, among other matters, a proposal to approve the Business Combination, including (a) adopting the Merger Agreement and (b) approving the other transactions and matters contemplated by the Merger Agreement and related agreements as described in the Proxy Statement/Prospectus. Pursuant to the terms and subject to the conditions set forth in the Merger Agreement, following the Special Meeting, on October 6, 2021, the Transactions were consummated. In connection with the Closing, the Company changed its name from LifeSci Acquisition II Corp. to Science 37 Holdings, Inc. Holders of 2,299,493 shares of LSAQ’s common stock sold in its initial public offering exercised their right to have such shares redeemed for a full pro rata portion of the trust account holding the proceeds from LSAQ’s initial public offering, calculated as of two business days prior to the consummation of the Business Combination, which was approximately $10.00 per share, or $23,003,944 in the aggregate. An aggregate of $23,003,944 was paid from the Company’s trust account to holders that properly exercised their right to have public shares redeemed, and the remaining balance immediately prior to the Closing of approximately $57.1 million remained in the trust account. The remaining amount in the trust account was used to fund the Business Combination.

SUMMARY OF SIGNIFICANT ACCOUN_8

RESTATEMENT OF PREVIOUSLY ISS_2

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021
Summary of the impact of the revision on the financial statements		The financial statements as of September 30, 2021, including share and per share amounts, do not include the effects of the merger. The table below shows, on a pro forma basis, the impact of the merger on certain condensed balance sheet items as of September 30, 2021: Balance Sheet Data: Actual Pro Forma Cash and cash equivalents $ 7,996,362 $ 242,991,191 Working capital (5,566,182) 228,647,166 Total assets 39,746,217 273,843,757 Redeemable convertible preferred stock 143,086,271 — Accumulated deficit (136,979,761) (136,979,761) Total stockholders’ equity (deficit) $ (132,209,608) $ 163,290,011 Share Data: Actual Pro Forma Redeemable convertible preferred stock outstanding 41,587,368 — Common stock outstanding 4,595,168 114,707,150
LifeSci Acquisition II Corp
Summary of the impact of the revision on the financial statements	The impact of the revision on the Company’s financial statements is reflected in the following table. As Previously Balance Sheet as of June 30, 2021 (audited) Reported Adjustment As Revised Common stock subject to possible redemption $ 75,526,270 $ 4,564,140 $ 80,090,410 Common stock $ 246 $ (45) $ 201 Additional paid-in capital $ 5,562,205 $ (4,564,095) $ 998,110 Accumulated deficit $ (562,449) $ — $ (562,449) Total Stockholders’ Equity (Deficit) $ 5,000,002 $ (4,564,140) $ 435,862		As Previously Reported Adjustment As Restated Balance Sheet as of November 24, 2020 Common stock subject to possible redemption $ 76,087,640 $ 4,002,770 $ 80,090,410 Common stock $ 256 $ (40) $ 216 Additional paid-in capital $ 5,000,825 $ (4,002,730) $ 998,095 Accumulated deficit $ (1,080) $ — $ (1,080) Total Stockholders’ Equity $ 5,000,001 $ (4,002,770) $ 997,231 Number of shares of common stock subject to possible redemption 7,608,764 400,277 8,009,041 Balance Sheet as of December 31, 2020 (Unaudited) Common stock subject to possible redemption $ 76,007,090 $ 4,083,320 $ 80,090,410 Common stock $ 256 $ (40) $ 216 Additional paid-in capital $ 5,081,375 $ (4,083,280) $ 998,095 Accumulated deficit $ (81,623) $ — $ (81,623) Total Stockholders’ Equity $ 5,000,008 $ (4,083,320) $ 916,688 Number of shares of common stock subject to possible redemption 7,600,709 408,332 8,009,041 Balance Sheet as of March 31, 2021 (Unaudited) Common stock subject to possible redemption $ 75,901,950 $ 4,188,460 $ 80,090,410 Common stock $ 242 $ (41) $ 201 Additional paid-in capital $ 5,186,529 $ (4,188,419) $ 998,110 Accumulated deficit $ (186,762) $ — $ (186,762) Total Stockholders’ Equity $ 5,000,009 $ (4,188,460) $ 811,549 Number of shares of common stock subject to possible redemption 7,590,195 418,846 8,009,041 Balance Sheet as of June 30, 2021 Common stock subject to possible redemption $ 75,526,270 $ 4,564,140 $ 80,090,410 Common stock $ 246 $ (45) $ 201 Additional paid-in capital $ 5,562,205 $ (4,564,095) $ 998,110 Accumulated deficit $ (562,449) $ — $ (562,449) Total Stockholders’ Equity $ 5,000,002 $ (4,564,140) $ 435,862 Number of shares of common stock subject to possible redemption 7,552,627 456,414 8,009,041 Statement of Cash Flows for the six months ended December 31, 2020 (Unaudited) Initial classification of common stock subject to possible redemption $ 76,087,640 (76,087,640) $ — Change in value of Common Stock subject to possible redemption $ (80,550) $ 80,550 $ — Statement of Cash Flows for the nine months ended March 31, 2021 (Unaudited) Initial classification of common stock subject to possible redemption $ 76,087,640 (76,087,640) $ — Change in value of Common Stock subject to possible redemption $ (105,140) $ 105,140 $ — Statement of Cash Flows for the period ended June 30, 2021 (Unaudited) Initial classification of common stock subject to possible redemption $ 76,087,640 (76,087,640) $ — Change in value of Common Stock subject to possible redemption $ (375,680) $ 375,680 $ — Condensed Statement of Changes in Stockholders’ Equity for three months ended December 31, 2020 (Unaudited) Sale of 8,009,041 Units, net of underwriter discounts and offering expenses $ 78,231,912 $ (78,231,912) $ — Initial value of Common Stock subject to redemption $ 76,007,090 $ (76,007,090) $ — Accretion for Common Stock to redemption amount $ — $ (1,858,498) $ (1,858,498) Total Stockholders’ Equity $ 5,000,008 $ (4,083,320) $ 916,688 Condensed Statement of Changes in Stockholders’ Equity for three months ended March 31, 2021 (Unaudited) Change in value of Common Stock subject to redemption $ 105,140 $ (105,140) $ — Total Stockholders’ Equity $ 5,000,009 $ (4,188,460) $ 811,549 Condensed Statement of Changes in Stockholders’ Equity for three months ended June 30, 2021 (Unaudited) Change in value of Common Stock subject to redemption $ 375,680 $ (375,680) $ — Total Stockholders’ Equity $ 5,000,002 $ (4,564,140) $ 435,862 Statement of Operations for the three months ended December 31, 2020 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,875,000 (1,875,000) — Basic and diluted net loss per common stock $ (0.04) $ 0.04 $ — Basic and diluted weighted average shares outstanding, common stock — 5,112,023 5,112,023 Basic and diluted net loss (income) per share, common stock $ — $ (0.02) $ (0.02) Statement of Operations for the six months ended December 31, 2020 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,875,000 (1,875,000) — Basic and diluted net loss per common stock $ (0.04) $ 0.04 $ — Basic and diluted weighted average shares outstanding, common stock — 3,502,260 3,502,260 Basic and diluted net loss (income) per share, common stock $ — $ (0.02) $ (0.02) Statement of Operations for the three months ended March 31, 2021 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,990,948 (1,990,948) — Basic and diluted net loss per common stock $ (0.05) $ 0.05 $ — Basic and diluted weighted average shares outstanding, common stock — 10,011,301 10,011,301 Basic and diluted net loss (income) per share, common stock $ — $ (0.01) $ (0.01) Statement of Operations for the nine months ended March 31, 2021 (Unaudited) Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,913,085 (1,913,085) — Basic and diluted net loss per common stock $ (0.10) $ 0.10 $ — Basic and diluted weighted average shares outstanding, common stock — 5,646,205 5,646,205 Basic and diluted net loss (income) per share, common stock $ — $ (0.03) $ (0.03) Statement of Operations for the year ended June 30, 2021 Weighted average shares outstanding of redeemable common stock 8,009,041 (8,009,041) — Basic and diluted net loss per common stock $ — $ — $ — Weighted average shares outstanding of non-redeemable common stock 1,951,216 (1,951,216) — Basic and diluted net loss per common stock $ (0.29) $ 0.29 $ — Basic and diluted weighted average shares outstanding, common stock — 6,734,489 6,734,489 Basic and diluted net loss (income) per share, common stock $ — $ (0.08) $ (0.08)

SUMMARY OF SIGNIFICANT ACCOUN_9

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended	9 Months Ended	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Schedule of reconciliation of common stocks reflected in the condensed balance sheets				2020 2019 Preferred shares authorized Series A preferred 6,746,233 6,746,233 Series B preferred 7,588,369 7,588,369 Series C preferred 6,001,269 6,001,269 Series D preferred 12,317,871 17,596,960 Series D1 preferred 9,038,488 — Total preferred shares authorized 41,692,230 37,932,831 2020 2019 Preferred shares issued and outstanding Series A preferred 6,641,371 6,746,233 Series B preferred 7,588,369 7,588,369 Series C preferred 6,001,269 6,001,269 Series D preferred 12,317,871 12,317,871 Series D1 preferred 9,038,488 — Total preferred shares issued and outstanding 41,587,368 32,653,742
Schedule of basic and diluted net income (loss) per common stock		Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net Loss $ (14,691,871) $ (7,683,830) $ (29,232,518) $ (19,349,948) Denominator: Basic weighted average common shares outstanding 4,551,755 8,522,923 3,818,717 8,458,434 Earnings (loss) per share: Basic and diluted $ (3.23) $ (0.90) $ (7.66) $ (2.29)		2020 2019 Numerator: Net Loss $ (31,674,084) $ (18,468,776) Denominator: Basic weighted average common shares outstanding 8,197,409 8,310,333 Earnings (loss) per share: Basic and diluted $ (3.86) $ (2.22)
LifeSci Acquisition II Corp
Schedule of reconciliation of common stocks reflected in the condensed balance sheets	At September 30, 2021 and June 30, 2021, the common stock reflected in the condensed consolidated balance sheets are reconciled in the following table: Gross proceeds $ 80,090,410 Less: Common stock issuance costs $ (1,858,498) Plus: Accretion of carrying value to redemption value $ 1,858,498 Common stock subject to possible redemption $ 80,090,410		At June 30, 2021, the common stock subject to possible redemption reflected in the balance sheet is reconciled in the following table: Gross proceeds $ 80,090,410 Less: Common stock issuance costs (1,858,498) Plus: Accretion of carrying value to redemption value 1,858,498 Common stock subject to possible redemption $ 80,090,410
Schedule of basic and diluted net income (loss) per common stock	Three Months Ended September 30, 2021 Basic and diluted net income (loss) per common stock Numerator: Allocation of net income (loss), as adjusted $ (829,630) Denominator: Basic and diluted 10,011,301 Basic and diluted $ (0.08)		For the Period from December 18, 2019 (Inception) Year Ended through June 30, June 30, 2021 2020 Basic and diluted net income (loss) per common stock Numerator: Allocation of net income (loss), as adjusted $ (561,449) $ (1,000) Denominator: Basic and diluted weighted average shares outstanding 6,734,489 1,875,000 Basic and diluted net income (loss) per common stock $ (0.08) $ (0.00)

INCOME TAX (Tables)

INCOME TAX (Tables)	12 Months Ended
INCOME TAX (Tables)	Jun. 30, 2021	Dec. 31, 2020
Schedule of income tax provision		2020 2019 Statutory U.S. federal rate $ (6,649,878) $ (3,878,443) State income tax net of federal benefit (1,141,758) (767,428) Permanent items 77,747 109,580 Other prior year adjustments (99,275) (1,339) Rate adjustment (12,921) 65,267 Valuation allowance 7,826,085 4,472,363 Total income tax expense (benefit) $ — $ —
Summary of significant components of the Company's deferred tax assets		2020 2019 Net operating loss carryforwards $ 24,923,945 $ 18,039,466 Amortizable assets 6,321 7,143 Equity compensation 50,118 77,916 Salaries and wages 1,048,104 151,442 Deferred rent — 133,387 Deferred revenue 861,120 544,415 Leasehold improvements 611,657 — Other 303,317 26,535 Total deferred tax assets 27,804,582 18,980,304 Less: valuation allowance (25,316,127) (17,490,042) Net deferred tax asset 2,488,455 1,490,262 Operating lease ROU (545,045) — Fixed assets (1,943,410) (1,490,262) Total deferred tax liabilities (2,488,455) (1,490,262) Net deferred tax assets (liabilities) $ — $ —
LifeSci Acquisition II Corp
Schedule of income tax provision	June 30, 2021 2020 Federal Current $ — $ — Deferred (117,904) (210) State Current $ — $ — Deferred — — Change in valuation allowance 117,904 210 Income tax provision $ — $ —
Schedule of reconciliation of the total income tax provision tax rate to the statutory federal income tax rate	June 30, 2021 2020 Statutory federal income tax rate 21.0 % 21.0 % State taxes, net of federal tax benefit 0.0 % 0.0 % Change in valuation allowance (21.0) % (21.0) % Income tax provision 0.0 % 0.0 %
Summary of significant components of the Company's deferred tax assets	June 30, 2021 2020 Deferred tax asset Net operating loss carryforward $ 6,802 $ 210 Startup/Organization Expenses 111,312 — Total deferred tax asset 118,114 210 Valuation allowance (118,114) (210) Deferred tax asset, net of allowance $ — $ —

FAIR VALUE MEASUREMENTS (Tabl_2

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended	12 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Sep. 30, 2021	Jun. 30, 2021
LifeSci Acquisition II Corp
Schedule of Company's assets that are measured at fair value on a recurring basis	Trading Securities Level Fair Value June 30, 2021 Mutual Fund 1 80,120,809	Trading Securities Level Fair Value June 30, 2021 Mutual Fund 1 $ 80,120,809

DESCRIPTION OF ORGANIZATION A_4

DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)	Nov. 24, 2020USD ($)$ / sharesshares	Dec. 18, 2019	Sep. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)shares	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Sep. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2019USD ($)
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued \| shares			6,439	6,439			6,439
Cash held outside the Trust Account			$ 7,996,362	$ 32,478,948			$ 7,996,362		$ 27,787,314
Cash of not held in the trust account and available for working capital purposes							(5,566,182)
LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Sale of Units, net of underwriting discounts and offering expenses (in shares) \| shares				8,009,041
Proceeds from sale of Private Placement Warrants								$ 2,831,809
Transaction Costs	$ 1,858,498
Underwriting fees	1,601,808
Other offering costs	$ 256,690
Threshold minimum aggregate fair market value as a percentage of the assets held in the Trust Account								80.00%
Threshold percentage of outstanding voting securities of the target to be acquired by post-transaction company to complete business combination								50.00%
Cash held outside the Trust Account			200,897			$ 25,000	$ 200,897	$ 416,111
Cash of not held in the trust account and available for working capital purposes			$ 200,897					416,111
Aggregate purchase price						$ 25,000
Proceeds from Related Party Debt					$ 175,000			175,000
Condition for future business combination number of businesses minimum		1
Payments for investment of cash in Trust Account								80,090,412
Working capital subject to annual limit								250,000
Condition for future business combination threshold Net Tangible Assets								$ 5,000,001
Threshold percentage of Public Shares subject to redemption without the Company's prior written consent								20.00%
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)								100.00%
Threshold business days for redemption of public shares								5 days
Initial Public Offering \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Sale of Units, net of underwriting discounts and offering expenses (in shares) \| shares	8,009,041
Purchase price, per unit \| $ / shares	$ 10
Payments for investment of cash in Trust Account	$ 80,090,412
Private Placement \| Private Placement Warrants \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued \| shares	3,146,454		3,146,454				3,146,454	3,146,454
Price of warrant \| $ / shares	$ 0.90		$ 0.90				$ 0.90	$ 0.90
Proceeds from sale of Private Placement Warrants	$ 2,831,809		$ 2,831,809					$ 2,831,809
Over-allotment option \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Sale of Units, net of underwriting discounts and offering expenses (in shares) \| shares	509,041
Purchase price, per unit \| $ / shares	$ 10		$ 10				$ 10	$ 10
Proceeds from issuance initial public offering	$ 80,090,410

RESTATEMENT OF PREVIOUSLY ISS_3

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Details) - USD ($)	3 Months Ended						6 Months Ended				9 Months Ended			12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Nov. 24, 2020	Mar. 31, 2020	Dec. 17, 2019	Dec. 31, 2018
Balance Sheet
Common stock subject to possible redemption	$ 143,086,271			$ 143,086,271	$ 93,929,920	$ 86,394,680		$ 143,086,271	$ 86,394,680	$ 86,394,680	$ 143,086,271		$ 93,929,920		$ 143,086,271	$ 106,884,111		$ 80,397,819
Common stock	1,039			856				856			1,039				856	839
Additional paid-in capital	998,110			1,611,049				1,611,049			998,110				1,611,049	1,374,319
Accumulated deficit	(136,979,761)			(107,747,243)				(107,747,243)			(136,979,761)				(107,747,243)	(75,961,522)
Total Stockholders' Equity	$ (106,135,338)	$ (122,287,890)	$ (114,572,770)	$ (106,135,338)		(106,135,338)	$ (122,287,890)	$ (106,135,338)	(106,135,338)	(106,135,338)	$ (106,135,338)	$ (114,572,770)		$ (122,287,890)	$ (106,135,338)	$ (74,586,364)				$ (56,550,017)
Number of shares of common stock subject to possible redemption	41,587,368			41,587,368	41,692,230			41,587,368			41,587,368		41,692,230		41,587,368	32,653,742
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY
Total Stockholders' Equity	$ (106,135,338)	$ (122,287,890)	(114,572,770)	$ (106,135,338)		$ (106,135,338)	$ (122,287,890)	$ (106,135,338)	$ (106,135,338)	$ (106,135,338)	$ (106,135,338)	(114,572,770)		(122,287,890)	$ (106,135,338)	$ (74,586,364)				$ (56,550,017)
CONSOLIDATED STATEMENTS OF OPERATIONS
Weighted Average Number of Shares Outstanding, Basic	4,551,755				8,522,923				1,875,000		3,818,717		8,458,434		8,197,409	8,310,333
Weighted Average Number of Shares Outstanding, Diluted	4,551,755	3,956,455			8,522,923	8,442,703	3,446,123			8,425,655	3,818,717		8,458,434		8,197,409	8,310,604
Basic net loss per common stock	$ (3.23)				$ (0.90)						$ (7.66)		$ (2.29)		$ (3.86)	$ (2.22)
Diluted net loss per common stock	$ (3.23)	$ (1.95)			$ (0.90)	$ (0.70)	$ (4.22)			$ (1.38)	$ (7.66)		$ (2.29)		$ (3.86)	$ (2.22)
LifeSci Acquisition II Corp
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Minimum net tangible assets		$ 5,000,001					$ 5,000,001							5,000,001
Balance Sheet
Common stock subject to possible redemption	$ 80,090,410	80,090,410					80,090,410				$ 80,090,410			80,090,410
Common stock	201	201				$ 216	201		$ 216	$ 216	201			201
Additional paid-in capital	998,110	998,110				24,784	998,110		24,784	24,784	998,110			998,110
Accumulated deficit	(1,392,079)	(562,449)				(1,000)	(562,449)		(1,000)	(1,000)	(1,392,079)			(562,449)
Total Stockholders' Equity	$ (393,768)	$ 435,862			$ 23,920	24,000	$ 435,862		24,000	24,000	$ (393,768)		$ 23,920	$ 435,862					$ 0
Number of shares of common stock subject to possible redemption	8,009,041	8,009,041					8,009,041				8,009,041			8,009,041
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY
Sale of Units, net of underwriting discounts and offering expenses (in shares)				8,009,041
Accretion for Common Stock to redemption amount														$ (1,858,498)
Total Stockholders' Equity	$ (393,768)	$ 435,862			$ 23,920	$ 24,000	$ 435,862		$ 24,000	$ 24,000	$ (393,768)		$ 23,920	$ 435,862					$ 0
CONSOLIDATED STATEMENTS OF OPERATIONS
Weighted Average Number of Shares Outstanding, Basic	10,011,301				1,875,000									6,734,489
Weighted Average Number of Shares Outstanding, Diluted	10,011,301				1,875,000				1,875,000					6,734,489
Basic net loss per common stock	$ (0.08)				$ 0				$ 0					$ (0.08)
Diluted net loss per common stock	$ (0.08)				0									$ (0.08)
LifeSci Acquisition II Corp \| Restatement of redeemable common stock as temporary equity
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Redemption value per share					$ 10								$ 10
Minimum net tangible assets					$ 5,000,001								$ 5,000,001
Balance Sheet
Common stock subject to possible redemption		80,090,410	80,090,410	$ 80,090,410			80,090,410	80,090,410				80,090,410		$ 80,090,410	$ 80,090,410		$ 80,090,410
Common stock		201	201	216			201	216				201		201	216		216
Additional paid-in capital		998,110	998,110	998,095			998,110	998,095				998,110		998,110	998,095		998,095
Accumulated deficit		(562,449)	(186,762)	(81,623)			(562,449)	(81,623)				(186,762)		(562,449)	(81,623)		(1,080)
Total Stockholders' Equity		$ 435,862	$ 811,549	$ 916,688			$ 435,862	$ 916,688				$ 811,549		$ 435,862	$ 916,688		$ 997,231
Number of shares of common stock subject to possible redemption		8,009,041	8,009,041	8,009,041			8,009,041	8,009,041				8,009,041		8,009,041	8,009,041		8,009,041
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY
Accretion for Common Stock to redemption amount				$ (1,858,498)
Total Stockholders' Equity		$ 435,862	$ 811,549	$ 916,688			$ 435,862	$ 916,688				$ 811,549		$ 435,862	$ 916,688		$ 997,231
LifeSci Acquisition II Corp \| Common Stock
CONSOLIDATED STATEMENTS OF OPERATIONS
Weighted Average Number of Shares Outstanding, Basic									1,875,000					6,734,489
Weighted Average Number of Shares Outstanding, Diluted									1,875,000					6,734,489
Basic net loss per common stock									$ 0					$ (0.08)
Diluted net loss per common stock									$ 0					$ (0.08)
LifeSci Acquisition II Corp \| Common Stock \| Restatement of redeemable common stock as temporary equity
CONSOLIDATED STATEMENTS OF OPERATIONS
Weighted Average Number of Shares Outstanding, Basic			10,011,301	5,112,023								5,646,205		6,734,489
Weighted Average Number of Shares Outstanding, Diluted			10,011,301	5,112,023								5,646,205		6,734,489
Basic net loss per common stock			$ (0.01)	$ (0.02)								$ (0.03)		$ (0.08)
Diluted net loss per common stock			$ (0.01)	$ (0.02)								$ (0.03)		$ (0.08)
LifeSci Acquisition II Corp \| Common stock subject to redemption
Balance Sheet
Number of shares of common stock subject to possible redemption	8,009,041	8,009,041				0	8,009,041		0	0	8,009,041			8,009,041
LifeSci Acquisition II Corp \| Non-redeemable common stock \| Restatement of redeemable common stock as temporary equity
CONSOLIDATED STATEMENTS OF OPERATIONS
Weighted Average Number of Shares Outstanding, Basic								3,502,260
Weighted Average Number of Shares Outstanding, Diluted								3,502,260
Basic net loss per common stock								$ (0.02)
Diluted net loss per common stock								$ (0.02)
As Previously Reported \| LifeSci Acquisition II Corp
Balance Sheet
Common stock subject to possible redemption		$ 75,526,270					$ 75,526,270							$ 75,526,270
Common stock		246					246							246
Additional paid-in capital		5,562,205					5,562,205							5,562,205
Accumulated deficit		(562,449)					(562,449)							(562,449)
Total Stockholders' Equity		5,000,002					5,000,002							5,000,002
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY
Total Stockholders' Equity		5,000,002					5,000,002							5,000,002
As Previously Reported \| LifeSci Acquisition II Corp \| Restatement of redeemable common stock as temporary equity
Balance Sheet
Common stock subject to possible redemption		75,526,270	$ 75,901,950	$ 76,007,090			75,526,270	$ 76,007,090				$ 75,901,950		75,526,270	76,007,090		76,087,640
Common stock		246	242	256			246	256				242		246	256		256
Additional paid-in capital		5,562,205	5,186,529	5,081,375			5,562,205	5,081,375				5,186,529		5,562,205	5,081,375		5,000,825
Accumulated deficit		(562,449)	(186,762)	(81,623)			(562,449)	(81,623)				(186,762)		(562,449)	(81,623)		(1,080)
Total Stockholders' Equity		$ 5,000,002	$ 5,000,009	$ 5,000,008			$ 5,000,002	$ 5,000,008				$ 5,000,009		$ 5,000,002	$ 5,000,008		$ 5,000,001
Number of shares of common stock subject to possible redemption		7,552,627	7,590,195	7,600,709			7,552,627	7,600,709				7,590,195		7,552,627	7,600,709		7,608,764
CONSOLIDATED STATEMENTS OF CASH FLOWS
Initial classification of common stock subject to possible redemption		$ 76,087,640	$ 76,087,640	$ 76,007,090				$ 76,087,640
Change in value of common stock subject to possible redemption		375,680	105,140					(80,550)				$ (105,140)		$ (375,680)
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY
Sale of 8,009,041 Units, net of underwriting discounts and offering expenses				78,231,912
Initial value of Common Stock subject to redemption		76,087,640	76,087,640	76,007,090				76,087,640
Change in value of common stock subject to possible redemption		375,680	105,140					(80,550)				(105,140)		(375,680)
Total Stockholders' Equity		5,000,002	$ 5,000,009	$ 5,000,008			$ 5,000,002	$ 5,000,008				$ 5,000,009		$ 5,000,002	$ 5,000,008		$ 5,000,001
As Previously Reported \| LifeSci Acquisition II Corp \| Common stock subject to redemption \| Restatement of redeemable common stock as temporary equity
CONSOLIDATED STATEMENTS OF OPERATIONS
Weighted Average Number of Shares Outstanding, Basic			8,009,041	8,009,041				8,009,041				8,009,041		8,009,041
Weighted Average Number of Shares Outstanding, Diluted			8,009,041	8,009,041				8,009,041				8,009,041		8,009,041
As Previously Reported \| LifeSci Acquisition II Corp \| Non-redeemable common stock \| Restatement of redeemable common stock as temporary equity
CONSOLIDATED STATEMENTS OF OPERATIONS
Weighted Average Number of Shares Outstanding, Basic			1,990,948	1,875,000				1,875,000				1,913,085		1,951,216
Weighted Average Number of Shares Outstanding, Diluted			1,990,948	1,875,000				1,875,000				1,913,085		1,951,216
Basic net loss per common stock			$ (0.05)	$ (0.04)				$ (0.04)				$ (0.10)		$ (0.29)
Diluted net loss per common stock			$ (0.05)	$ (0.04)				$ (0.04)				$ (0.10)		$ (0.29)
Adjustment \| LifeSci Acquisition II Corp
Balance Sheet
Common stock subject to possible redemption		4,564,140					4,564,140							$ 4,564,140
Common stock		(45)					(45)							(45)
Additional paid-in capital		(4,564,095)					(4,564,095)							(4,564,095)
Total Stockholders' Equity		(4,564,140)					(4,564,140)							(4,564,140)
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY
Total Stockholders' Equity		(4,564,140)					(4,564,140)							(4,564,140)
Adjustment \| LifeSci Acquisition II Corp \| Restatement of redeemable common stock as temporary equity
Balance Sheet
Common stock subject to possible redemption		4,564,140	$ 4,188,460	$ 4,083,320			4,564,140	$ 4,083,320				$ 4,188,460		4,564,140	4,083,320		4,002,770
Common stock		(45)	(41)	(40)			(45)	(40)				(41)		(45)	(40)		(40)
Additional paid-in capital		(4,564,095)	(4,188,419)	(4,083,280)			(4,564,095)	(4,083,280)				(4,188,419)		(4,564,095)	(4,083,280)		(4,002,730)
Total Stockholders' Equity		$ (4,564,140)	$ (4,188,460)	$ (4,083,320)			$ (4,564,140)	$ (4,083,320)				$ (4,188,460)		$ (4,564,140)	$ (4,083,320)		$ (4,002,770)
Number of shares of common stock subject to possible redemption		456,414	418,846	408,332			456,414	408,332				418,846		456,414	408,332		400,277
CONSOLIDATED STATEMENTS OF CASH FLOWS
Initial classification of common stock subject to possible redemption		$ (76,087,640)	$ (76,087,640)	$ (76,007,090)				$ (76,087,640)
Change in value of common stock subject to possible redemption		(375,680)	(105,140)					80,550				$ 105,140		$ 375,680
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY
Sale of 8,009,041 Units, net of underwriting discounts and offering expenses				(78,231,912)
Initial value of Common Stock subject to redemption		(76,087,640)	(76,087,640)	(76,007,090)				(76,087,640)
Change in value of common stock subject to possible redemption		(375,680)	(105,140)					80,550				105,140		375,680
Accretion for Common Stock to redemption amount				(1,858,498)
Total Stockholders' Equity		$ (4,564,140)	$ (4,188,460)	$ (4,083,320)			$ (4,564,140)	$ (4,083,320)				$ (4,188,460)		$ (4,564,140)	$ (4,083,320)		$ (4,002,770)
Adjustment \| LifeSci Acquisition II Corp \| Common Stock \| Restatement of redeemable common stock as temporary equity
CONSOLIDATED STATEMENTS OF OPERATIONS
Weighted Average Number of Shares Outstanding, Basic			10,011,301	5,112,023				3,502,260				5,646,205		6,734,489
Weighted Average Number of Shares Outstanding, Diluted			10,011,301	5,112,023				3,502,260				5,646,205		6,734,489
Basic net loss per common stock			$ (0.01)	$ (0.02)				$ (0.02)				$ (0.03)		$ (0.08)
Diluted net loss per common stock			$ (0.01)	$ (0.02)				$ (0.02)				$ (0.03)		$ (0.08)
Adjustment \| LifeSci Acquisition II Corp \| Common stock subject to redemption \| Restatement of redeemable common stock as temporary equity
CONSOLIDATED STATEMENTS OF OPERATIONS
Weighted Average Number of Shares Outstanding, Basic			(8,009,041)	(8,009,041)				(8,009,041)				(8,009,041)		(8,009,041)
Weighted Average Number of Shares Outstanding, Diluted			(8,009,041)	(8,009,041)				(8,009,041)				(8,009,041)		(8,009,041)
Adjustment \| LifeSci Acquisition II Corp \| Non-redeemable common stock \| Restatement of redeemable common stock as temporary equity
CONSOLIDATED STATEMENTS OF OPERATIONS
Weighted Average Number of Shares Outstanding, Basic			(1,990,948)	(1,875,000)				(1,875,000)				(1,913,085)		(1,951,216)
Weighted Average Number of Shares Outstanding, Diluted			(1,990,948)	(1,875,000)				(1,875,000)				(1,913,085)		(1,951,216)
Basic net loss per common stock			$ 0.05	$ 0.04				$ 0.04				$ 0.10		$ 0.29
Diluted net loss per common stock			$ 0.05	$ 0.04				$ 0.04				$ 0.10		$ 0.29

SUMMARY OF SIGNIFICANT ACCOU_10

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Common Stock Subject to Possible Redemption (Details) - USD ($)	12 Months Ended	15 Months Ended
	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Common stock subject to possible redemption		$ 143,086,271	$ 143,086,271	$ 93,929,920	$ 86,394,680	$ 80,397,819	$ 106,884,111
LifeSci Acquisition II Corp
Gross proceeds	$ 80,090,410	80,090,410
Common stock issuance costs	(1,858,498)	1,858,498
Accretion of carrying value to redemption value	1,858,498	1,858,498
Common stock subject to possible redemption	$ 80,090,410	$ 80,090,410

SUMMARY OF SIGNIFICANT ACCOU_11

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020
Unrecognized tax benefits		$ 239,927					$ 239,927	$ 239,927
Anti-dilutive securities attributable to warrants (in shares)	50,445,978		40,345,124	50,195,421	48,113,121		43,058,865	35,919,104
Exercise price of warrant	$ 1.61	$ 1.61		$ 1.61			$ 1.61
Number of warrants to purchase shares issued	6,439	6,439		6,439			6,439
LifeSci Acquisition II Corp
Unrecognized tax benefits	$ 0			$ 0		$ 0			$ 0
Unrecognized tax benefits income tax penalties and accrued interest	$ 0			0		$ 0			$ 0
Anti-dilutive securities attributable to warrants (in shares)	50,445,978					3,146,454
Federal depository insurance coverage	$ 250,000			$ 250,000		$ 250,000
Units Issued During Period, Shares, New Issues		8,009,041
Offering Costs	$ 1,858,498					$ 1,858,498

SUMMARY OF SIGNIFICANT ACCOU_12

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Reconciliation of Net Loss per Common Share (Details) - USD ($)	3 Months Ended						6 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Allocation of net income (loss), as adjusted	$ (14,691,871)	$ (7,715,120)	$ (6,825,527)	$ (7,683,830)	$ (5,916,947)	$ (5,749,171)		$ (1,000)		$ (29,232,518)	$ (19,349,948)		$ (31,674,084)	$ (18,468,776)
Denominator:
Basic weighted average shares outstanding	4,551,755			8,522,923				1,875,000		3,818,717	8,458,434		8,197,409	8,310,333
Diluted weighted average shares outstanding	4,551,755	3,956,455		8,522,923	8,442,703		3,446,123		8,425,655	3,818,717	8,458,434		8,197,409	8,310,604
Basic net loss per common stock	$ (3.23)			$ (0.90)						$ (7.66)	$ (2.29)		$ (3.86)	$ (2.22)
Diluted net loss per common stock	$ (3.23)	$ (1.95)		$ (0.90)	$ (0.70)		$ (4.22)		$ (1.38)	$ (7.66)	$ (2.29)		$ (3.86)	$ (2.22)
LifeSci Acquisition II Corp
Numerator:
Allocation of net income (loss), as adjusted	$ (829,630)			$ (80)				$ (1,000)				$ (561,449)
Denominator:
Basic weighted average shares outstanding	10,011,301			1,875,000								6,734,489
Diluted weighted average shares outstanding	10,011,301			1,875,000				1,875,000				6,734,489
Basic net loss per common stock	$ (0.08)			$ 0				$ 0				$ (0.08)
Diluted net loss per common stock	$ (0.08)			$ 0								$ (0.08)

PUBLIC OFFERING (Details)

PUBLIC OFFERING (Details) - $ / shares	Nov. 24, 2020	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Subsidiary, Sale of Stock [Line Items]
Number of shares issued		106,752		75,694	1,830,071	148,011		164,886	122,560
Exercise price of warrant		$ 1.61	$ 1.61		$ 1.61			$ 1.61
LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Number of units sold			8,009,041
Initial Public Offering \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Number of units sold	8,009,041
Number of shares issued	8,009,041	1,125,000
Purchase price, per share	$ 10
Over-allotment option \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Number of units sold	509,041
Number of shares issued	509,041	509,041					509,041
Purchase price, per share	$ 10	$ 10			$ 10		$ 10

PRIVATE PLACEMENT (Details)_2

PRIVATE PLACEMENT (Details) - USD ($)	Nov. 24, 2020	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued		6,439		6,439
Exercise price of warrant		$ 1.61		$ 1.61
LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Aggregate purchase price			$ 2,831,809
Private Placement \| Private Placement Warrants \| LifeSci Acquisition II Corp
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued	3,146,454	3,146,454	3,146,454
Price of warrants	$ 0.90	$ 0.90	$ 0.90
Aggregate purchase price	$ 2,831,809	$ 2,831,809	$ 2,831,809
Number of shares per warrant		1	1
Exercise price of warrant		$ 11.50	$ 11.50

RELATED PARTY TRANSACTIONS - _2

RELATED PARTY TRANSACTIONS - Founder Shares (Details)	Jan. 08, 2021shares	Jan. 08, 2020shares	Jan. 01, 2020USD ($)D$ / sharesshares	Sep. 30, 2021shares	Sep. 30, 2020shares	Jun. 30, 2020USD ($)shares	Sep. 30, 2021shares	Sep. 30, 2020shares	Jun. 30, 2021shares	Dec. 31, 2020shares	Dec. 31, 2019shares	Mar. 31, 2021shares	Mar. 31, 2020shares	Dec. 31, 2018shares
Related Party Transaction [Line Items]
Number of shares issued				106,752	75,694		1,830,071	148,011		164,886	122,560
Common shares, shares issued (in shares)				4,595,168			4,595,168			2,765,097	8,396,425
Common shares, shares outstanding (in shares)				4,595,168	8,544,436		4,595,168	8,544,436		2,765,097	8,396,425	4,488,416	8,468,742	8,273,865
LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Aggregate purchase price \| $						$ 25,000
Restrictions on transfer period of time after business combination completion									5 years
Common shares, shares issued (in shares)				2,002,260		2,156,250	2,002,260		2,002,260
Common shares, shares outstanding (in shares)				2,002,260		2,156,250	2,002,260		2,002,260
Founder shares \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders			20.00%
Common shares, shares issued (in shares)	2,002,260	2,002,260							2,002,260
Common shares, shares outstanding (in shares)	2,002,260	2,002,260							2,002,260
Founder shares \| Sponsor \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Number of shares issued			2,156,250
Aggregate purchase price \| $			$ 25,000
Aggregate number of shares owned					215,625			215,625
Shares subject to forfeiture	153,990	153,990
Number of shares not subject to forfeiture	127,260	127,260
Maximum shares subject to forfeiture (in shares)			153,990
First Fifty Percent Of Shares \| Founder shares \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) \| $ / shares			$ 12.50
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination \| D			20
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination \| D			30
Threshold Period For Not To Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination			6 months
Threshold Period For Not To Transfer Assign Or Sell Any Shares Or Warrants Based On Date Of Consummation Of Business Combination Or Closing Price Of Shares Exceed Threshold Stock Price			50.00%
Remaining Fifty Percent Of Shares \| Founder shares \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Percentage of shares or warrants agreed not be transferred, assigned, sold or released from escrow			50.00%

RELATED PARTY TRANSACTIONS - _3

RELATED PARTY TRANSACTIONS - Additional Information (Details) - USD ($)	Nov. 24, 2020	Nov. 20, 2020	Jun. 19, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Jul. 09, 2020	Jun. 30, 2020
Related Party Transaction [Line Items]
Expenses incurred						$ 128,084	$ 0
LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Repayment of promissory note - related party								$ 175,000
Sponsor \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Maximum borrowing capacity of related party promissory note									$ 175,000
Administrative Support Agreement \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Expenses per month		$ 10,000
Expenses incurred				$ 30,000	$ 0			70,000
Promissory Note with Related Party \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Maximum borrowing capacity of related party promissory note			$ 175,000
Instrument term			15 days
Repayment of promissory note - related party	$ 175,000
Related Party Loans \| LifeSci Acquisition II Corp
Related Party Transaction [Line Items]
Outstanding balance of related party note				0		0		0		$ 0
Loan conversion agreement warrant				$ 500,000		$ 500,000		$ 500,000
Price of warrant				$ 0.90		$ 0.90		$ 0.90

COMMITMENTS (Details)_2

COMMITMENTS (Details)	Nov. 24, 2020$ / sharesshares	Sep. 30, 2021USD ($)item$ / sharesshares	Sep. 30, 2020$ / sharesshares	Sep. 30, 2021item$ / sharesshares	Sep. 30, 2020$ / sharesshares	Dec. 31, 2021item	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020$ / sharesshares	Dec. 31, 2019$ / sharesshares	Jun. 30, 2020$ / shares
Other Commitments [Line Items]
Common Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001			$ 0.0001	$ 0.0001
Number of shares issued \| shares		106,752	75,694	1,830,071	148,011			164,886	122,560
LifeSci Acquisition II Corp
Other Commitments [Line Items]
Maximum Number Of Demands For Registration Of Securities \| item		2		2		2
Threshold period to exercise registration rights		3 months				3 months
Maximum demand registration right at entity's expense \| item		1				1
Threshold period to exercise registration rights from the effective date of registration statement of Initial Public Offering		5 years				5 years
Threshold period to exercise "piggy-back" registration rights from the effective date of registration statement of Initial Public Offering		7 years				7 years
Underwriting cash discount per unit		$ 0.20					$ 0.20
Underwriter cash discount \| $		$ 1,601,808					$ 1,601,808
Preferred Stock, Par or Stated Value Per Share		$ 0.0001		$ 0.0001			$ 0.0001			$ 0.0001
Common Stock, Par or Stated Value Per Share		$ 0.0001		$ 0.0001			0.0001			$ 0.0001
Initial Public Offering \| LifeSci Acquisition II Corp
Other Commitments [Line Items]
Deferred Fee Per Unit							$ 1,125,000
Number of shares issued \| shares	8,009,041	1,125,000
Purchase price, per unit	$ 10
Over-allotment option \| LifeSci Acquisition II Corp
Other Commitments [Line Items]
Number of shares issued \| shares	509,041	509,041					509,041
Shares available for issue \| shares		615,959		615,959			615,959
Purchase price, per unit	$ 10	$ 10		$ 10			$ 10

COMMITMENTS - Business Combin_2

COMMITMENTS - Business Combination Marketing Agreement (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Other Commitments [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001
LifeSci Acquisition II Corp
Other Commitments [Line Items]
Preferred Stock, Par or Stated Value Per Share	0.0001	$ 0.0001			$ 0.0001
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001			$ 0.0001
Cash fee for services on gross proceeds of IPO	$ 2,803,164
Percentage of fees payable to service provider	75.00%
Percentage of fees that can be allocated to third party service provider	33.00%
Subscription agreement \| LifeSci Acquisition II Corp \| Common Stock
Other Commitments [Line Items]
Number of shares agreed to be issued		20,000,000
Price per share		$ 10
Aggregate purchase price		$ 200,000,000
Ladenburg Thalmann Member \| LifeSci Acquisition II Corp
Other Commitments [Line Items]
Percentage of fees payable to service provider		25.00%
Percentage of fees that can be allocated to third party service provider		33.00%
Lifesci Capital Llc Member \| LifeSci Acquisition II Corp
Other Commitments [Line Items]
Cash fee for services as percentage of gross proceeds of IPO		3.50%
Cash fee for services on gross proceeds of IPO		$ 2,803,164
Percentage of fees payable to service provider		75.00%
Science 37 Inc [Member] \| LifeSci Acquisition II Corp
Other Commitments [Line Items]
Preferred Stock, Par or Stated Value Per Share		$ 0.0001
Common Stock, Par or Stated Value Per Share		$ 0.0001
Quotient for determining exchange ratio		100,000,000
Percentage of fees payable to service provider	25.00%
Science 37 Inc [Member] \| Merger agreement \| LifeSci Acquisition II Corp \| Common Stock
Other Commitments [Line Items]
Authorized earnout shares (in shares)		12,500,000
Earnout period (in months)		3 years
Earnout shares, threshold trading days		20 days
Earnout shares, threshold trading period		30 days

STOCKHOLDERS EQUITY - Preferred

STOCKHOLDERS EQUITY - Preferred Stock Shares (Details) - $ / shares	Sep. 30, 2021	Jun. 30, 2021	Jun. 30, 2020
Preferred shares, shares outstanding	41,587,368
LifeSci Acquisition II Corp
Preferred shares, shares authorized	1,000,000	1,000,000	1,000,000
Preferred stock, par value, (per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred shares, shares issued	0	0	0
Preferred shares, shares outstanding	0	0	0

STOCKHOLDERS EQUITY - Common St

STOCKHOLDERS EQUITY - Common Stock Shares (Details)	Sep. 30, 2021Vote$ / sharesshares	Jun. 30, 2021Vote$ / sharesshares	Mar. 31, 2021shares	Dec. 31, 2020$ / sharesshares	Sep. 30, 2020$ / sharesshares	Jun. 30, 2020$ / sharesshares	Mar. 31, 2020shares	Dec. 31, 2019$ / sharesshares	Dec. 31, 2018shares
Class of Stock [Line Items]
Common shares, shares authorized (in shares)	74,666,115			74,666,115				61,057,864
Common shares, par value (in dollars per share) \| $ / shares	$ 0.0001			$ 0.0001	$ 0.0001			$ 0.0001
Common shares, shares issued (in shares)	4,595,168			2,765,097				8,396,425
Common shares, shares outstanding (in shares)	4,595,168		4,488,416	2,765,097	8,544,436		8,468,742	8,396,425	8,273,865
Preferred stock, issued	41,587,368			41,587,368				32,653,742
Common stock subject to possible redemption	41,587,368			41,587,368	41,692,230			32,653,742
LifeSci Acquisition II Corp
Class of Stock [Line Items]
Common shares, shares authorized (in shares)	30,000,000	30,000,000				30,000,000
Common shares, par value (in dollars per share) \| $ / shares	$ 0.0001	$ 0.0001				$ 0.0001
Common shares, votes per share \| Vote	1	1
Common shares, shares issued (in shares)	2,002,260	2,002,260				2,156,250
Common shares, shares outstanding (in shares)	2,002,260	2,002,260				2,156,250
Common stock subject to possible redemption	8,009,041	8,009,041
Common stock subject to redemption \| LifeSci Acquisition II Corp
Class of Stock [Line Items]
Preferred stock, issued		8,009,041				0
Common stock subject to possible redemption	8,009,041	8,009,041				0

STOCKHOLDERS EQUITY - Warrants

STOCKHOLDERS EQUITY - Warrants (Details) - LifeSci Acquisition II Corp	3 Months Ended	12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021
Class of Warrant or Right [Line Items]
Restrictions on transfer period of time after business combination completion		5 years
Private Placement Warrants
Class of Warrant or Right [Line Items]
Warrant exercise period condition one	1 year	1 year
Restrictions on transfer period of time after business combination completion	5 years

INCOME TAX - DEFERRED TAX (Deta

INCOME TAX - DEFERRED TAX (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating loss carryforward		$ 24,923,945		$ 18,039,466
Total deferred tax assets		27,804,582		18,980,304
Valuation allowance		(25,316,127)		(17,490,042)
Deferred tax assets, net of allowance		$ (2,488,455)		$ (1,490,262)
LifeSci Acquisition II Corp
Deferred tax assets:
Net operating loss carryforward	$ 6,802		$ 210
Startup/Organization Expenses	111,312
Total deferred tax assets	118,114		210
Valuation allowance	(118,114)		(210)
Operating Loss Carryforwards	$ 31,391		$ 1,000

INCOME TAX (Details)

INCOME TAX (Details) - USD ($)	7 Months Ended	12 Months Ended
INCOME TAX (Details) - USD ($)	Jun. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Federal
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount			$ (6,649,878)		$ (3,878,443)
State
Change in valuation allowance			$ 7,826,085		$ 4,472,363
LifeSci Acquisition II Corp
Federal
Deferred		$ (117,904)		$ (210)
State
Change in valuation allowance		$ 117,904		$ 210
Statutory federal income tax rate (in percent)	21.00%	21.00%
State taxes, net of federal tax benefit	0.00%	0.00%
Change in valuation allowance (in percent)	(21.00%)	(21.00%)
Income tax provision (in Percent)	(0.00%)	(0.00%)

FAIR VALUE MEASUREMENTS (Deta_2

FAIR VALUE MEASUREMENTS (Details) - LifeSci Acquisition II Corp - USD ($)	Sep. 30, 2021	Jun. 30, 2021
Debt Securities, Held-to-maturity, Fair Value to Amortized Cost [Abstract]
Fair Value		$ 80,120,809
Assets:
Assets held in Trust Account	$ 80,121,806	80,120,809
Cash
Assets:
Assets held in Trust Account	$ 80,131,806	0
U.S. Treasury Securities
Assets:
Assets held in Trust Account		$ 80,120,809

Subsequent Event (Details)

Subsequent Event (Details) - USD ($)	Oct. 06, 2021	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Subsequent Event [Line Items]
Shares sold		106,752	75,694		1,830,071	148,011		164,886	122,560
LifeSci Acquisition II Corp
Subsequent Event [Line Items]
Aggregate purchase price				$ 25,000
Payments for investment of cash in Trust Account							$ 80,090,412
Subsequent events \| LifeSci Acquisition II Corp
Subsequent Event [Line Items]
Shares sold	2,299,493
Redemption of shares calculated based on business days prior to consummation of business combination (in days)	2 days
Share price per share	$ 10
Aggregate purchase price	$ 23,003,944
Payment from trust account	23,003,944
Payments for investment of cash in Trust Account	$ 57,100,000

Condensed Consolidated Balanc_3

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 7,996,362			$ 32,478,948				$ 27,787,314
Restricted cash				1,004,142				720,703
Accounts receivable (including amounts with related parties)	6,998,708			11,200,252				3,339,897
Prepaid expenses and other current assets	4,226,079			1,364,162				1,137,739
Total Current Assets	19,221,149			46,047,504				32,985,653
Noncurrent restricted cash				0				300,000
Property and equipment, net	1,157,818			535,384				626,278
Operating lease right-of-use assets	2,362,445			2,210,253
Capitalized software, net	16,679,024			8,054,367				5,868,915
Other assets	325,782			183,718				546,874
TOTAL ASSETS	39,746,218			57,031,226				40,327,720
Current liabilities:
Accounts payable	7,488,575			4,401,874				423,414
Accrued expenses and other liabilities	10,727,474			8,762,839				1,686,142
Deferred revenue	6,571,281			5,136,457				3,561,778
Deferred rent								478,603
Total current liabilities	24,787,330			18,301,170				6,149,937
Long-term liabilities:
Long-term deferred revenue	1,055,624			427,667				1,370,834
Operating lease liabilities	1,485,288			1,127,837
Other long-term liabilities	1,541,313			223,619
Total Liabilities	28,869,555			20,080,293				8,029,973
Redeemable preferred stock:
Common stock subject to possible redemption	143,086,271			143,086,271	$ 93,929,920	$ 86,394,680	$ 80,397,819	106,884,111
Stockholders' deficit:
Common stock	1,039			856				839
Additional paid-in capital	998,110			1,611,049				1,374,319
Accumulated deficit	(136,979,761)			(107,747,243)				(75,961,522)
Total Stockholders' (Deficit) Equity	(106,135,338)	$ (122,287,890)	$ (114,572,770)	(106,135,338)		$ (106,135,338)		(74,586,364)	$ (56,550,017)
LIABILITIES, COMMON STOCK SUBJECT TO REDEMPTION AND STOCKHOLDERS' (DEFICIT) EQUITY	$ 39,746,218			$ 57,031,226				$ 40,327,720

Condensed Consolidated Balanc_4

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
CONSOLIDATED BALANCE SHEETS
Preferred stock, par value	$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares authorized	41,692,230		41,692,230			37,932,831
Preferred stock, issued	41,587,368		41,587,368			32,653,742
Preferred stock, outstanding	41,587,368		41,587,368	41,692,230		32,653,742
Common shares, par value, (per share)	$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001
Common shares, shares authorized	74,666,115		74,666,115			61,057,864
Common shares, shares issued	4,595,168		2,765,097			8,396,425
Common shares, shares outstanding	4,595,168	4,488,416	2,765,097	8,544,436	8,468,742	8,396,425	8,273,865

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues (including amounts with related parties)	$ 14,235,697	$ 6,583,413	$ 39,221,524	$ 12,541,208
Operating expenses:
Cost of revenues (including amounts with related parties)	10,318,268	7,050,897	26,245,932	10,929,068
Selling, general and administrative	16,931,866	6,301,712	37,477,055	17,870,603
Depreciation and amortization	1,915,517	1,141,801	5,188,586	3,162,424
Restructuring costs			771,942	699,473
Total operating expenses	29,165,651	14,494,410	68,911,573	32,661,568
Loss from operations	(14,929,954)	(7,910,997)	(29,690,049)	(20,120,360)
Other income:
Interest income	151	1,554	1,424	76,019
Sublease income (including amounts with related parties)	230,235	232,294	444,153	696,882
Other income	7,697	(6,681)	11,954	(2,489)
Other income, net	238,083	227,167	457,531	770,412
Net loss	$ (14,691,871)	$ (7,683,830)	$ (29,232,518)	$ (19,349,948)
Loss per share:
Basic net loss per common share	$ (3.23)	$ (0.90)	$ (7.66)	$ (2.29)
Diluted net loss per common share	$ (3.23)	$ (0.90)	$ (7.66)	$ (2.29)
Denominator:
Basic weighted average common shares outstanding	4,551,755	8,522,923	3,818,717	8,458,434
Diluted weighted average common shares outstanding	4,551,755	8,522,923	3,818,717	8,458,434

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit - USD ($)	Common Stock	Preferred StockRedeemable Convertible Preferred Stock.	Preferred Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at the beginning at Dec. 31, 2018			$ 72,155,654
Balance at the beginning (in shares) at Dec. 31, 2018			20,335,871
Increase (Decrease) in Temporary Equity [Roll Forward]
Preferred issuance, net of issuance costs			$ 34,728,457
Preferred issuance, net of issuance costs (in shares)			12,317,871
Balance at the end at Dec. 31, 2019	$ 839	$ 106,884,111	$ 106,884,111	$ 1,374,319	$ (75,961,522)	$ 106,884,111
Balance at the end (in shares) at Dec. 31, 2019	8,396,425	32,653,742	32,653,742			32,653,742
Balance at the beginning at Dec. 31, 2018	$ 827			941,902	(57,492,746)	$ (56,550,017)
Balance at the beginning (in shares) at Dec. 31, 2018	8,273,865
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				392,566		392,566
Proceeds from option exercises	$ 12			39,851		$ 39,863
Proceeds from option exercises (in shares)	122,560					122,560
Net loss					(18,468,776)	$ (18,468,776)
Balance at the end at Dec. 31, 2019	$ 839			1,374,319	(75,961,522)	(74,586,364)
Balance at the end (in shares) at Dec. 31, 2019	8,396,425
Balance at the end at Jun. 30, 2020	$ 846	$ 106,884,111	$ 143,086,271	1,343,750	(87,739,276)	86,394,680
Balance at the end (in shares) at Jun. 30, 2020	8,468,742	32,653,742
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss						(1,000)
Balance at the end at Jun. 30, 2020	$ 856			1,611,049	(106,135,338)	(106,135,338)
Balance at the end (in shares) at Jun. 30, 2020	2,765,097		41,587,368
Balance at the beginning at Dec. 31, 2019	$ 839	$ 106,884,111	$ 106,884,111	1,374,319	(75,961,522)	$ 106,884,111
Balance at the beginning (in shares) at Dec. 31, 2019	8,396,425	32,653,742	32,653,742			32,653,742
Balance at the end at Mar. 31, 2020	$ 841	$ 106,884,111		1,423,669	(81,822,329)	$ 80,397,819
Balance at the end (in shares) at Mar. 31, 2020	8,409,709	32,653,742
Balance at the beginning at Dec. 31, 2019	$ 839			1,374,319	(75,961,522)	(74,586,364)
Balance at the beginning (in shares) at Dec. 31, 2019	8,396,425
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				32,414		32,414
Proceeds from option exercises	$ 2			16,937		16,939
Proceeds from option exercises (in shares)	13,284
Net loss					(5,749,171)	(5,749,171)
Balance at the end (Impact of adoption of ASC 842) at Mar. 31, 2020					(111,637)	(111,637)
Balance at the beginning at Dec. 31, 2019	$ 839	$ 106,884,111	$ 106,884,111	1,374,319	(75,961,522)	$ 106,884,111
Balance at the beginning (in shares) at Dec. 31, 2019	8,396,425	32,653,742	32,653,742			32,653,742
Balance at the end at Sep. 30, 2020	$ 854	$ 146,807,916		1,492,332	(95,423,106)	$ 93,929,920
Balance at the end (in shares) at Sep. 30, 2020	8,544,436	41,692,230				41,692,230
Balance at the beginning at Dec. 31, 2019	$ 839			1,374,319	(75,961,522)	$ (74,586,364)
Balance at the beginning (in shares) at Dec. 31, 2019	8,396,425
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss						(19,349,948)
Balance at the beginning at Dec. 31, 2019	$ 839	$ 106,884,111	$ 106,884,111	1,374,319	(75,961,522)	$ 106,884,111
Balance at the beginning (in shares) at Dec. 31, 2019	8,396,425	32,653,742	32,653,742			32,653,742
Increase (Decrease) in Temporary Equity [Roll Forward]
Preferred issuance, net of issuance costs			$ 39,860,073
Preferred issuance, net of issuance costs (in shares)			9,038,488
Balance at the end at Dec. 31, 2020	$ 856	$ 143,086,271		1,611,049	(106,135,338)	$ 143,086,271
Balance at the end (in shares) at Dec. 31, 2020	2,765,097	41,587,368				41,587,368
Balance at the beginning at Dec. 31, 2019	$ 839			1,374,319	(75,961,522)	$ (74,586,364)
Balance at the beginning (in shares) at Dec. 31, 2019	8,396,425
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				122,032		122,032
Proceeds from option exercises	$ 17			131,785		$ 131,802
Proceeds from option exercises (in shares)	164,886					164,886
Net loss					(31,674,084)	$ (31,674,084)
Balance at the end (Impact of adoption of ASC 842) at Dec. 31, 2020					(111,637)	(111,637)
Balance at the end at Dec. 31, 2020						(106,135,338)
Balance at the beginning at Mar. 31, 2020	$ 841	$ 106,884,111		1,423,669	(81,822,329)	80,397,819
Balance at the beginning (in shares) at Mar. 31, 2020	8,409,709	32,653,742
Balance at the end at Jun. 30, 2020	$ 846	$ 106,884,111	$ 143,086,271	1,343,750	(87,739,276)	86,394,680
Balance at the end (in shares) at Jun. 30, 2020	8,468,742	32,653,742
Balance at the beginning (Impact of adoption of ASC 842) at Mar. 31, 2020					(111,637)	(111,637)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				(135,966)		(135,966)
Proceeds from option exercises	$ 5			56,047		56,052
Proceeds from option exercises (in shares)	59,033
Net loss					(5,916,947)	(5,916,947)
Balance at the end at Jun. 30, 2020	$ 856			1,611,049	(106,135,338)	(106,135,338)
Balance at the end (in shares) at Jun. 30, 2020	2,765,097		41,587,368
Increase (Decrease) in Temporary Equity [Roll Forward]
Preferred issuance, net of issuance costs		$ 39,923,805
Preferred issuance, net of issuance costs (in shares)		9,038,488
Balance at the end at Sep. 30, 2020	$ 854	$ 146,807,916		1,492,332	(95,423,106)	$ 93,929,920
Balance at the end (in shares) at Sep. 30, 2020	8,544,436	41,692,230				41,692,230
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				105,341		$ 105,341
Proceeds from option exercises	$ 8			43,241		43,249
Proceeds from option exercises (in shares)	75,694
Net loss					(7,683,830)	(7,683,830)
Balance at the beginning at Jun. 30, 2020	$ 846	$ 106,884,111	$ 143,086,271	1,343,750	(87,739,276)	86,394,680
Balance at the beginning (in shares) at Jun. 30, 2020	8,468,742	32,653,742
Balance at the end (in shares) at Jun. 30, 2021		41,587,368
Balance at the beginning at Jun. 30, 2020	$ 856			1,611,049	(106,135,338)	(106,135,338)
Balance at the beginning (in shares) at Jun. 30, 2020	2,765,097		41,587,368
Balance at the end at Jun. 30, 2021	$ 1,028	$ 143,086,271		3,663,679	(118,623,183)	(122,287,890)
Balance at the end (in shares) at Jun. 30, 2021	4,488,416
Balance at the beginning at Dec. 31, 2020	$ 856	$ 143,086,271		1,611,049	(106,135,338)	$ 143,086,271
Balance at the beginning (in shares) at Dec. 31, 2020	2,765,097	41,587,368				41,587,368
Balance at the end at Mar. 31, 2021		$ 143,086,271
Balance at the end (in shares) at Mar. 31, 2021		41,587,368
Balance at the beginning (Impact of adoption of ASC 842) at Dec. 31, 2020					(111,637)	$ (111,637)
Balance at the beginning at Dec. 31, 2020						(106,135,338)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				225,623	225,623
Proceeds from option exercises	$ 51			331,740	331,791
Proceeds from option exercises (in shares)	506,707
Net loss					(6,825,527)	(6,825,527)
Balance at the end at Mar. 31, 2021	$ 907			2,168,412	(112,403,451)	(114,572,770)
Balance at the end (in shares) at Mar. 31, 2021	3,271,804
Balance at the beginning at Dec. 31, 2020	$ 856	$ 143,086,271		1,611,049	(106,135,338)	$ 143,086,271
Balance at the beginning (in shares) at Dec. 31, 2020	2,765,097	41,587,368				41,587,368
Balance at the end at Sep. 30, 2021						$ 143,086,271
Balance at the end (in shares) at Sep. 30, 2021						41,587,368
Balance at the beginning (Impact of adoption of ASC 842) at Dec. 31, 2020					(111,637)	$ (111,637)
Balance at the beginning at Dec. 31, 2020						$ (106,135,338)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from option exercises (in shares)						1,830,071
Net loss						$ (29,232,518)
Balance at the end at Sep. 30, 2021	$ 1,039	$ 143,086,271		4,769,114	(132,209,608)	(106,135,338)
Balance at the end (in shares) at Sep. 30, 2021	4,595,168	41,587,368
Balance at the beginning at Mar. 31, 2021		$ 143,086,271
Balance at the beginning (in shares) at Mar. 31, 2021		41,587,368
Balance at the end (in shares) at Jun. 30, 2021		41,587,368
Balance at the beginning at Mar. 31, 2021	$ 907			2,168,412	(112,403,451)	(114,572,770)
Balance at the beginning (in shares) at Mar. 31, 2021	3,271,804
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				689,494	689,494
Proceeds from option exercises	$ 121			805,773	805,894
Proceeds from option exercises (in shares)	1,216,612
Net loss					(7,715,120)	(7,715,120)
Balance at the end at Jun. 30, 2021	$ 1,028	$ 143,086,271		3,663,679	(118,623,183)	(122,287,890)
Balance at the end (in shares) at Jun. 30, 2021	4,488,416
Balance at the end at Sep. 30, 2021						$ 143,086,271
Balance at the end (in shares) at Sep. 30, 2021						41,587,368
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				997,979	997,979
Proceeds from option exercises	$ 11			107,456	107,467
Proceeds from option exercises (in shares)	106,752
Net loss					(14,691,871)	$ (14,691,871)
Balance at the end at Sep. 30, 2021	$ 1,039	$ 143,086,271		$ 4,769,114	$ (132,209,608)	$ (106,135,338)
Balance at the end (in shares) at Sep. 30, 2021	4,595,168	41,587,368

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows	9 Months Ended
Condensed Consolidated Statements of Cash Flows	Sep. 30, 2020USD ($)
Operating activities
Net loss	$ (19,349,948)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,162,424
Amortization of operating ROU assets	1,400,294
Stock based compensation	1,789
Changes in assets and liabilities:
Accounts receivable (including amounts with related parties)	(3,265,235)
Prepaid expenses and other current assets	(1,265,844)
Other assets	363,156
Accounts payable	3,163,309
Accrued expenses and other current liabilities	3,158,333
Deferred revenue	(976,377)
Operating lease liabilities	(3,399,177)
Other long-term liabilities	143,369
Net cash used in operating activities	(16,863,907)
Investing activities
Capitalized software development costs	(3,938,788)
Purchases of fixed assets	(244,677)
Net cash used in investing activities	(4,183,465)
Financing activities
Proceeds From Series D-1 Financing, Net of Issuance Costs	39,923,805
Cash received from stock option exercises	116,240
Net cash provided by financing activities	40,040,045
Net Change in Cash	18,992,673
Cash - Beginning	28,808,017
Cash - Ending	47,800,690
Supplemental disclosures of non-cash activities
Net change in accounts payable and accrued expenses and other current liabilities related to capitalized software and fixed asset additions	$ (208,363)

Company Background and Basis of

Company Background and Basis of Presentation	9 Months Ended	12 Months Ended
Company Background and Basis of Presentation	Sep. 30, 2021	Dec. 31, 2020
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
Company Background and Basis of Presentation	1. Company Background and Basis of Presentation Organization Science 37, Inc. or “the Company”, a Delaware Corporation, was formed on September 8, 2014. Description of Business The Company is a leading provider of technology-based solutions that enable decentralized clinical trials on behalf of biopharmaceutical sponsors. The Company pioneered the decentralized clinical trial model and developed the industry’s first Decentralized Clinical Trial Operating System (DCT OS), combining its technology platform, which orchestrates workflows, supports evidence generation, and harmonizes data seamlessly, with its Specialized Network of patient communities, on-demand telemedicine investigators, flexible mobile nurses, scalable remote coordinators and robust connected technologies. By bringing research to patients and providers more directly, the Company’s operating system increases access and patient diversity, which can help speed the development of potentially life-saving drug treatments. On May 7, 2021, the Company announced a planned merger with LifeSci Acquisition II Corp (“LSAQ”) under a definitive business combination agreement. The merger was consummated on October 6, 2021, whereby LSAQ acquired 100% of the Company's issued and outstanding securities through a reverse merger of the Company with and into a wholly owned subsidiary of LSAQ, with the Company surviving the merger as Science 37 Holdings, Inc, now a public company. In conjunction with this merger, the Company received $200 million through a private investment in public entity (PIPE) offering from leading institutional and strategic investors to further fund the Company’s decentralized trial technology platform and extend into new adjacencies. Unaudited Interim Financial Information and Use of Estimates The Company prepared the accompanying unaudited condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all the information and notes required by GAAP for complete financial statements. The significant accounting policies followed by the Company for interim financial reporting are consistent with the accounting policies followed for annual financial reporting. The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. These estimates are based on historical experience and various other assumptions believed reasonable under the circumstances. The Company evaluates its estimates on an ongoing basis and makes changes to the estimates and related disclosures as experience develops or new information becomes known, including facts and circumstances related to the novel coronavirus disease pandemic. Actual results will most likely differ from those estimated. The Company’s most significant estimates and assumptions used in the preparation of the accompanying condensed consolidated financial statements relate to contract cost estimates in revenue recognition, capitalized software costs, and the valuation of the Company’s common stock. The condensed consolidated financial statements, in management’s opinion, include all adjustments of a normal recurring nature necessary for a fair presentation. The information included in this filing should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in this filing for the year ended December 31, 2020. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or any other future period. The consolidated balance sheet at December 31, 2020 is derived from the amounts in the audited balance sheet included in this filing for the year ended December 31, 2020. 1. Company Background and Basis of Presentation (continued) Liquidity The Company has continued to experience increased costs that adversely affect the Company's current results of operations and liquidity. The Company's condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements for the three and nine months ended September 30, 2021 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company's ability to continue as a going concern. As of September 30, 2021, the Company had $7,996,362 of unrestricted cash. On October 6, 2021, the definitive business combination agreement between the Company and LifeSci Acquisition II Corp (LSAQ) was consummated. LSAQ acquired 100% of the Company's issued and outstanding securities through a reverse merger of the Company with and into a wholly owned subsidiary of LSAQ, with the Company surviving the merger as Science 37 Holdings, Inc, now a public company. In conjunction with this merger, the Company received $200 million through a private investment in public entity (PIPE) offering from institutional and strategic investors to further fund the Company's decentralized trial technology platform and extend into new adjacencies. As a result of the merger and inclusive of the PIPE financing, the Company received $234.2 million, net of fees and expenses paid in connection with the closing of the business combination. The Company believes that its $8.0 million of cash as of September 30, 2021, in addition to the proceeds received from the merger with LSAQ and PIPE offering, are sufficient to fund planned operations for at least 12 months from the date these financial statements were available to be filed. Concentration Risks Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, deposits of up to $250,000 at Federal Deposit Insurance Corporation (FDIC) insured institutions are covered by FDIC insurance. At times, deposits at the Company’s financial institution may exceed federally insured limits. Management periodically assesses the financial condition of the institution and believes that any possible credit risk is minimal. The Company has not experienced any loss from such risk. COVID-19 Pandemic In March 2020 the World Health Organization declared the global novel coronavirus disease 2019 (COVID-19) outbreak a pandemic. The Company’s original sublease tenant in San Francisco was unable to fulfill its sublease obligations due to the pandemic’s impact on its business operations. The sublessee vacated the facility in February 2021 and a new sublessee was not secured until May 2021, at terms substantially similar to the original sublessee. For the nine months ended September 30, 2021 and 2020, the Company wrote-off $228,946 and $0 of sublease receivable against sublease income due to low probability of collection from the original sublessee. No other significant impacts to the Company’s operations due to the COVID-19 outbreak have occurred. 1. Company Background Basis of Presentation (continued) Capitalized Software The Company’s internal use proprietary software organizes workflows, captures real-time evidence, and harmonizes data during clinical trial support for its customers. Capitalized software is recorded at cost less accumulated amortization. The Company capitalizes software development cost related to the development of the Company’s proprietary platform in accordance with ASC 350 guidance. Internal and external costs incurred during the preliminary stage are expensed as incurred. Costs incurred during the application development stage are capitalized and consist of payroll labor and benefits to the extent of time spent directly on the project and external direct costs of materials and labor. Training and maintenance costs are expensed as incurred. The Company commences amortization once the respective assets are placed into service. The estimated useful life for capitalized software is 3 years . Assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the expected undiscounted future cash flow from the use of the asset and its eventual disposition is less than the carrying amount of the asset, an impairment loss is recognized and measured using the fair value of the related asset. No material impairments were recognized during the three and nine months ended September 30, 2021 and 2020. Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Segments Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined that its Senior Executive Committee, which includes the Chief Executive Officer, together with the Board of Directors is the CODM. The Company operates in a single operating segment as the CODM reviews financial information presented on a consolidated basis, at the Company level, for the purposes of making operating decisions, allocation of resources, and evaluating financial performance. As of and for the nine months ended September 30, 2021 and 2020, the Company did not have material revenue earned or assets located outside of the United States. Accounting Pronouncements Issued but Not Adopted as of September 30, 2021 In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by a reporting entity. The standard replaces the incurred loss impairment methodology in current GAAP with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company does not expect the adoption of the guidance to have a material effect on the Company’s consolidated financial statements. This is based on factors including the Company’s assessment of historical losses, customer’s creditworthiness, and the fact that the Company’s trade receivables are short term in duration. The Company expects to implement this new standard in January 2022.	1. Company Background and Basis of Presentation Organization Science 37 or the “Company”, a Delaware Corporation, was formed on September 8, 2014. Description of Business Science 37 is a leading provider of technology-based solutions that enable decentralized clinical trials (or direct-to patient virtual studies) on behalf of biopharmaceutical sponsors. Science 37 pioneered the decentralized clinical trial model and developed the industry’s first Decentralized Clinical Trial Operating System (DCT OS), combining its technology platform, which orchestrates workflows, supports evidence generation, and harmonizes data seamlessly, with its expansive network of patient communities, on-demand telemedicine investigators, flexible mobile nurses, scalable remote coordinators and robust connected technologies. By bringing research to patients and providers more directly, Science 37’s operating system increases access and patient diversity, which can help speed the development of potentially life-saving drug treatments. Liquidity The Company has continued to experience increased costs that adversely affect the Company’s current results of operations and liquidity. The Company’s consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements for the year ended December 31, 2020 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company's ability to continue as a going concern. The Company has evaluated principal conditions and events, considered in aggregate, that may raise substantial doubt about its ability to continue as a going concern within one year from the date that these financial statements were originally issued. As of December 31, 2020, the Company had $32,478,948 of unrestricted cash. On October 6, 2021, the definitive business combination agreement between the Company and LifeSci Acquisition II Corp (LSAQ) was consummated. LSAQ acquired 100% of the Company’s issued and outstanding securities through a reverse merger of the Company with and into a wholly owned subsidiary of LSAQ, with the Company surviving the merger as Science 37 Holdings, Inc, a now public company. In conjunction with this merger, the Company received $200 million through a private investment in public entity (PIPE) offering from institutional and strategic investors to further fund the Company’s decentralized trial technology platform and extend into new adjacencies. As a result of the merger and inclusive of the PIPE financing, the Company received $234.2 million, net of fees and expenses paid in connection with the closing of the business combination. The Company believes that its $32.5M of cash as of December 31, 2020, in addition to the proceeds received from the merger with LSAQ and PIPE offering, are sufficient to fund planned operations for at least 12 months from the date of issuance of these financial statements. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). 1. Company Background and Basis of Presentation (continued) Concentration Risks Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, deposits of up to $250,000 at Federal Deposit Insurance Corporation (FDIC) insured institutions are covered by FDIC insurance. At times, deposits at the Company’s financial institution may exceed federally insured limits. Management periodically assesses the financial condition of the institution and believes that any possible credit risk is minimal. The Company has not experienced any loss from such risk. COVID-19 Pandemic In March 2020 the World Health Organization declared the global novel coronavirus disease 2019 (COVID-19) outbreak a pandemic. The Company’s sublease tenant in San Francisco has been unable to fulfill its sublease obligations due to the pandemic’s impact on its business operations. The sublessee vacated the facility in February 2021. In 2020, the company wrote-off $312,940 of sublease receivable against sublease income due to low probability of collection. No other significant impacts to the Company’s operations due to the COVID-19 outbreak have occurred. The Company’s operations may be adversely affected in the near term as a result of COVID-19, and in the longer-term by the overall impact on the economy and disruptions to the Company’s existing business and partners, and the Company’s customer collection efforts. Additionally, there could be a near term impact on the Company’s employees as a result of COVID-19 and the related Federal, State, and local and UK governmental restrictions. However, the long- term impact is not fully known as the scale and severity of the outbreak continues to unfold. Since the second quarter of 2020, the Company has experienced overall top line growth due to the advantages the Company’s decentralized proprietary platform provides for healthcare companies and institutions in the clinical trial space. Due to these advantages, Management expects this growth to continue. On March 27, 2020, the U.S. enacted the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the U.S. economy and fund a nationwide effort to curtail the effect of COVID 19. While the CARES Act provides sweeping tax changes in response to the COVID 19 pandemic, some of the more significant provisions include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. Consistent with previous years, the Company expects to continue to generate net losses in the foreseeable future. The Company currently has significant federal and state deferred tax assets attributed to prior net operating losses. These deferred taxes are fully reserved. As the Company has never generated taxable income, the CARES Act feature allowing net operating losses originating in 2018, 2019 or 2020 to be carried back five years is not expected to have a significant impact. Management does not expect any other provisions of the CARES Act to have a material impact on the Company’s financial position, results of operations or cash flows during 2020.

Revenue

Revenue	9 Months Ended	12 Months Ended
Revenue	Sep. 30, 2021	Dec. 31, 2020
Revenue
Revenue	2. Revenue Revenues by Geography Substantially all of the Company’s revenue for the three and nine months ending September 30, 2021 and 2020 was derived from services performed within the United States. No other country represented more than 10% of total revenue for either period. Unsatisfied Performance Obligations As of September 30, 2021, the aggregate amount of transaction price allocated to the unsatisfied performance obligations was $118,892,662 . The Company expects to recognize this revenue over the remaining contract term of the individual projects, with contract terms generally ranging from one month to 6.4 years. The amount of unsatisfied performance obligations is lower than the potential contractual revenue since it excludes revenue that is constrained. Revenue amounts excluded due to constraints include those amounts under contracts that are wholly unperformed in which the customer has a unilateral right to cancel the arrangement, or that require the Company to undertake numerous activities to fulfill the performance obligations, including various activities that are outside of the Company’s control. Timing of Billing and Performance During the three and nine months ended September 30, 2021, the Company recognized approximately $3,151,080 and $3,962,270 of revenue that was included in the deferred revenue balance at the beginning of the period. During the three and nine months ended September 30, 2021, revenue recognized from performance obligations partially satisfied in previous periods was $3,170,297 and $6,322,520 . These cumulative catch-up adjustments primarily related to contract modifications executed in the current period, which resulted in changes to the transaction price resulting from change orders. Accounts Receivable, Unbilled Services, and Deferred Revenue Accounts receivable and unbilled services (including contract assets) consisted of the following: September 30, 2021 December 31, 2020 Accounts receivable $ 6,233,698 $ 8,688,441 Unbilled services $ 907,840 2,511,811 Total accounts receivable and unbilled services 7,141,538 11,200,252 Allowance for doubtful accounts (142,830) — Total accounts receivable and unbilled services, net $ 6,998,708 $ 11,200,252 As of September 30, 2021 and December 31, 2020, contract assets of $907,840 and $2,511,811 , respectively, were included in unbilled services. Deferred revenue consisted of the following: September 30, 2021 December 31, 2020 Deferred revenue $ 7,626,905 $ 5,564,124 The changes in the Company’s contract assets and deferred revenue resulted from the timing difference between the Company’s satisfaction of performance obligations under its contracts, achievement of billing milestones, and customer payments. 2. Revenue (continued) Concentration of Credit Risk Financial assets that subject the Company to credit risk primarily consist of cash and cash equivalents, accounts receivable and unbilled services. Based on the short-term nature and historical realization of the financial assets as well as the reputable credit ratings of the financial institutions holding the deposits, the Company believes it bears minimal credit risk. For the three months ended September 30, 2021 and 2020, four and three customers individually (totaling 58.7% and 64.9% , respectively) accounted for greater than 10% of revenue. For the nine months ended September 30, 2021 and 2020, three customers individually (totaling 57.7% and 55.2% , respectively) accounted for greater than 10% of revenue. As of September 30, 2021 and December 31, 2020, three and two customers individually (totaling 68.1% and 73.5% , respectively) accounted for greater than 10% of accounts receivable, net.	3. Revenue Revenues by Geography Substantially all of the Company’s revenue for the years ending December 31, 2020 and 2019 was derived from services performed within the United States. No other country represented more than 10% of total revenue for either year. Unsatisfied Performance Obligations As of December 31, 2020, the aggregate amount of transaction price allocated to the unsatisfied performance obligations with contract terms greater than one year was $52,415,469. The Company expects to recognize this revenue over the remaining contract term of the individual projects, with contract terms generally ranging from 1.5 to 7.1 years. The amount of unsatisfied performance obligations is lower than the potential contractual revenue since it excludes revenue that is constrained. Revenue amounts excluded due to constraints include those amounts under contracts that are wholly unperformed in which the customer has a unilateral right to cancel the arrangement, or that require the Company to undertake numerous activities to fulfill the performance obligations, including various activities that are outside of the Company’s control. Timing of Billing and Performance During the years ended December 31, 2020, and 2019, the Company recognized approximately $4,349,278 and $5,667,532 of revenue that was included in the deferred revenue balance at the beginning of the years, respectively. During the years ended December 31, 2020, and 2019 revenue recognized from performance obligations partially satisfied in previous periods was ($74,540) and $0, respectively. These cumulative catch-up adjustments primarily related to contract modification executed in the current period, which resulted in changes to the transaction price and changes in estimates such as estimated total costs. Accounts Receivable, Unbilled Services, and Deferred Revenue Accounts receivable and unbilled services (including contract assets) consisted of the following as of December 31: 2020 2019 Accounts receivable $ 8,688,441 $ 1,426,874 Unbilled services 2,511,811 1,913,023 Total accounts receivable and unbilled services $ 11,200,252 $ 3,339,897 As of December 31, 2020, and 2019, contract assets of $2,511,811 and $85,465, respectively, were included in unbilled services. 3. Revenue (continued) Deferred revenue consisted of the following as of December 31: 2020 2019 Deferred revenue $ 5,564,124 $ 4,932,612 Year over year changes in the Company’s accounts receivable, unbilled services, and deferred revenue resulted from 1) significant contract and revenue growth for the year ended December 31, 2020 as compared to the year ended December 31, 2019 and 2) the timing difference between the Company’s satisfaction of performance obligations under its contracts, achievement of billing milestones, and customer payments. Concentration of Credit Risk Financial assets that subject the Company to credit risk primarily consist of cash and cash equivalents, accounts receivable and unbilled services. Based on the short-term nature and historical realization of the financial assets as well as the reputable credit ratings of the financial institutions holding the deposits, the Company believes it bears minimal credit risk. As of December 31, 2020, and 2019, three customers and four customers individually (totaling 69.2% and 81.8%, respectively) accounted for greater than 10% of revenue and two customers and three customers individually (totaling 73.5% and 91.7%, respectively) accounted for greater than 10% of accounts receivable, net. Capitalized Commission Cost Capitalized commission costs are incremental costs incurred to obtain a contract. The Company incurs incremental costs to obtain contracts through payment of sales commissions on contracts signed. The Company capitalizes commission costs when incurred and amortizes to expense over the term of the related contract. Capitalized commission costs and related amortization consisted of the following as of December 31: 2020 2019 Capitalized commission cost, net $ 509,326 $ — 2020 2019 Amortization of capitalized commission cost $ (232,422) $ — $162,069 and $0 in contract costs were impaired related to canceled projects for the years ended December 31, 2020 and 2019, respectively.

Fair Value Measurements_2_3

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2021
FAIR VALUE MEASUREMENTS
Fair Value Measurements	3. Fair Value Measurements Fair value is the price that would be received to sell an asset or paid to transfer a liability between market participants in the principal market or the most advantageous market when no principal market exists. Market participants are assumed to be independent, knowledgeable, able, and willing to transact an exchange and not under duress. Considerable judgment may be required in interpreting market data used to develop the estimates of fair value. Accordingly, estimates of fair value are not necessarily indicative of the amounts that could be realized in a current or future market exchange. Fair values for substantially all the Company’s financial and non-financial instruments were measured using market, income, or cost approaches. The three levels of input are as follows: Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial instruments, including cash and cash equivalents, are recorded at cost, which approximates fair value. The Company does not have any assets or liabilities measured at Level 2 or Level 3.

Restructuring Costs

Restructuring Costs	9 Months Ended	12 Months Ended
Restructuring Costs	Sep. 30, 2021	Dec. 31, 2020
Restructuring Costs
Restructuring Costs	4. Restructuring Costs The Company carried out a reduction in force on February 28, 2020. Twenty employees were severed under a one-time restructuring arrangement at a total cost to the Company of $771,942 . As of December 31, 2020, there were no restructuring accruals remaining on the balance sheet as all severance was fully paid to severed employees during the year. There were no restructuring activities for the nine months ended September 30, 2021.	7. Restructuring Costs The Company carried out a reduction in force on February 28, 2020. Twenty employees were severed under a one-time restructuring arrangement at a total cost to the Company of $771,942. As of December 31, 2020, there were no restructuring accruals remaining on the balance sheet as all severance was fully paid to severed employees during the year.

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	9 Months Ended	12 Months Ended
Redeemable Convertible Preferred Stock	Sep. 30, 2021	Dec. 31, 2020
Redeemable Convertible Preferred Stock
Redeemable Convertible Preferred Stock	5. Preferred Stock Par value for each preferred stock share series is $0.0001 . Redeemable convertible preferred stock shares outstanding as of September 30, 2021 and 2020 was 41,587,368 and 41,692,230 , respectively. During the nine months ended September 30, 2020, 9,038,488 redeemable convertible preferred stock shares were issued through a series D-1 funding totaling $39,999,919 . No redeemable convertible preferred stock shares were repurchased during the nine months ended September 30, 2021. No redeemable convertible preferred stock shares were issued or repurchased during the nine months ended September 30, 2021.	10. Redeemable Preferred Stock Par value for redeemable preferred shares is $0.0001. The following is a summary of the Company’s authorized and outstanding redeemable preferred shares as of Dec 31, 2020 and 2019: 2020 2019 Preferred shares authorized Series A preferred 6,746,233 6,746,233 Series B preferred 7,588,369 7,588,369 Series C preferred 6,001,269 6,001,269 Series D preferred 12,317,871 17,596,960 Series D1 preferred 9,038,488 — Total preferred shares authorized 41,692,230 37,932,831 2020 2019 Preferred shares issued and outstanding Series A preferred 6,641,371 6,746,233 Series B preferred 7,588,369 7,588,369 Series C preferred 6,001,269 6,001,269 Series D preferred 12,317,871 12,317,871 Series D1 preferred 9,038,488 — Total preferred shares issued and outstanding 41,587,368 32,653,742 10. Redeemable Preferred Stock (continued) In the event of any liquidation, dissolution or winding-up of the Company, a sale of all or substantially all of the assets of the Company, a merger or consolidation of the Company with or into another entity (other than for solely reorganizational purposes) or a sale of a majority of the capital stock of the Company (each such event, a “Liquidation Event”), the holders of Series D Preferred Stock and Series D-1 Preferred Stock are entitled, on a pari passu basis, to receive prior to any distribution of any assets or funds of the Company to the holders of Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock or Common Stock, by reason of their ownership thereof, an amount per share equal to the applicable original issue price per share for such series of Preferred Stock, plus any declared but unpaid dividends. As of December 31, 2020 and 2019, there were no unpaid dividends. In the event of any Liquidation Event and after payment in full of the amounts owed to the holders of Series D Preferred Stock and Series D-1 Preferred Stock, by reason of their ownership thereof, the holders of Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock are entitled, on a pari passu basis, to receive prior to any distribution of any assets or funds of the Company to the holders of Common Stock, by reason of their ownership thereof, an amount per share equal to the applicable original issue price per share for such series of Preferred Stock, plus any declared but unpaid dividends. Notwithstanding the foregoing, a holder of shares of a series of Preferred Stock shall be deemed to have converted such holder’s shares of such series of Preferred Stock into shares of Common Stock immediately prior to the Liquidation Event if, as a result of an actual conversion of all shares of such series of Preferred Stock, such holder would receive, in the aggregate with respect to such shares, an amount greater than the amount distributable to such holder if such holder did not convert such series of Preferred Stock into shares of Common Stock. If any holder shall be deemed to have converted shares of Preferred Stock into Common Stock, then such holder is deemed to have waived the right to any distribution that would be made to holders of Preferred Stock that have not or have not been deemed to have converted into shares of Common Stock. The Preferred Stock is classified outside of shareholders’ equity in the mezzanine section of the balance sheet given that the preferred shareholders’ control the board.

Shareholders' Deficit

Shareholders' Deficit	9 Months Ended	12 Months Ended
Shareholders' Deficit	Sep. 30, 2021	Dec. 31, 2020
STOCKHOLDERS' EQUITY
Shareholders' Deficit	6. Stockholders’ Deficit Par value for common shares is $0.0001 . The following is a summary of common share activity for the nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Common shares, beginning balance 4,488,416 8,468,742 2,765,097 8,396,425 Issuance of common shares 106,752 75,694 1,830,071 148,011 Common shares, ending balance 4,595,168 8,544,436 4,595,168 8,544,436 The Company has one common stock warrant outstanding with available shares to be issued of 6,439 and an exercise price of $1.61 per share as of September 30, 2021. This warrant was exercised on October 4, 2021.	11. Shareholders’ Deficit Science 37 was formed under Delaware law and is treated as a “C” corporation for U.S. tax purposes. Par value for common shares is $0.0001. The following is a summary of common share activity for the years ended December 31, 2020 and 2019: 2020 2019 Common stock shares, beginning balance 8,396,425 8,273,865 Issuance of common stock 164,886 122,560 Repurchase of common stock (5,796,214) — Common stock shares, ending balance 2,765,097 8,396,425 The Company has one common stock warrant outstanding with available shares to be issued of 6,439 and an exercise price of $1.61 per share as of December 31, 2020.

Loss Per Share

Loss Per Share	9 Months Ended	12 Months Ended
Loss Per Share	Sep. 30, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Loss Per Share	7. Loss Per Share The following is a reconciliation of the numerators and denominators of the basic and diluted loss per share computations for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net Loss $ (14,691,871) $ (7,683,830) $ (29,232,518) $ (19,349,948) Denominator: Basic weighted average common shares outstanding 4,551,755 8,522,923 3,818,717 8,458,434 Earnings (loss) per share: Basic and diluted $ (3.23) $ (0.90) $ (7.66) $ (2.29) Potential common shares outstanding that are considered anti-dilutive are excluded from the computation of diluted earnings per share. As the Company has incurred losses from inception to date, due to its start-up nature, potential common shares are anti-dilutive due to this net loss. The number of potential shares outstanding that were anti-dilutive and therefore excluded from the computation of diluted earnings per share, weighted for the portion of the period they were outstanding, were as follows for the three and nine months ended September 30, 2021 and 2020, respectively. Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Preferred stock 41,587,368 32,653,742 41,587,368 41,692,230 Stock options outstanding 8,852,171 7,684,943 8,601,614 6,414,452 Warrants outstanding 6,439 6,439 6,439 6,439 Total 50,445,978 40,345,124 50,195,421 48,113,121	12. Loss Per Share The following is a reconciliation of the numerators and denominators of the basic loss per share computations for the years ended December 31, 2020 and 2019: 2020 2019 Numerator: Net Loss $ (31,674,084) $ (18,468,776) Denominator: Basic weighted average common shares outstanding 8,197,409 8,310,333 Earnings (loss) per share: Basic and diluted $ (3.86) $ (2.22) Potential common shares outstanding that are considered anti-dilutive are excluded from the computation of diluted earnings per share. As the Company has incurred losses inception to date, due to its start-up nature, potential common shares are anti-dilutive due to this net loss. The number of potential shares outstanding that were anti-dilutive and therefore excluded from the computation of diluted earnings per share, weighted for the portion of the period they were outstanding, were as follows for the years ended December 31, 2020 and 2019, respectively. 2020 2019 Preferred stock 36,338,255 30,610,834 Stock options outstanding 6,714,171 5,301,830 Warrants outstanding 6,439 6,439 Total 43,058,865 35,919,104

Related-Party Transactions

Related-Party Transactions	9 Months Ended	12 Months Ended
Related-Party Transactions	Sep. 30, 2021	Dec. 31, 2020
RELATED PARTY TRANSACTIONS
Related-Party Transactions	8. Related-Party Transactions In 2020, the Company subleased office space in Torrance, California to Good Dermatology, a professional medical corporation owned by the Founder and former CEO. Under the terms of the sublease, lease expenses incurred by the Company were 100% passed through to Good Dermatology. Total sublease income was $29,174 and $87,523 for the three and nine months ended September 30, 2020. The sublease was terminated as of November 30, 2020. 8. Related-Party Transactions (continued) For the three months ended September 30, 2021 and 2020, the Company had revenue of $2,756,011 and $3,146,148 , respectively, and for the nine months ended September 30, 2021 and 2020, the Company had revenue of $10,803,604 and $3,243,667 , respectively, and expenses of $128,084 and $0 , respectively, and as of September 30, 2021 and December 31, 2020, receivables of $2,244,157 and $6,927,470 , respectively, from Pharmaceutical Products Development, LLC, a shareholder who holds a minority interest in the Company and a seat on the Company’s Board of Directors. Pharmaceutical Products Development, LLC became a minority shareholder of the Company during the first quarter of 2019. For the three months ended September 30, 2021 and 2020, the Company had revenue of $269,547 and $108,280 , respectively, and for the nine months ended September 30, 2021 and 2020, the Company had revenue of $565,092 and $226,843 , respectively, and as of September 30, 2021 and December 31, 2020, receivables of $166,474 and $129,857 , respectively, from Novartis, who has a 50% ownership in dRX Capital AG, a shareholder who, until July 2021, had a minority interest in the Company and a seat on the Company’s Board of Directors. In July 2021, dRX Capital AG was dissolved and their interest in the Company was distributed to their owners. This dissolution and distribution did not cause any other shareholder of the Company to obtain a minority interest in the Company. For the three months ended September 30, 2021 and 2020, the Company had revenue of $9,875 and $0 , respectively, and for the nine months ended September 30, 2021 and 2020, the Company had revenue of $350,585 and $0 , respectively, and as of September 30, 2021 and December 31, 2020, receivables of $2,185 and $0 , respectively, from Allovir, who is an investee of a minority shareholder and Board of Directors seat holder of the Company. The minority shareholder became a shareholder of the Company in the third quarter of 2016.	13. Related-Party Transactions In 2020 and 2019, the Company subleased office space in Torrance, California to Good Dermatology, a professional medical corporation owned by the Founder and former CEO. Under the terms of the sublease, lease expenses incurred by the Company were 100% passed through to Good Dermatology. Total sublease income was $106,972 and $116,697 for the years ended December 31, 2020 and 2019, respectively. The sublease was terminated as of November 30, 2020. During the year ended December 31, 2019, the Company purchased clinical trial investigator services in an arm’s length transaction totaling $273,787 from Good Dermatology, a professional medical corporation owned by the Founder and former CEO. No services were purchased from Good Dermatology during the year ended December 31, 2020. During the year ended December 31, 2019, the Founder and former CEO had a personal loan from the Company in the amount of $300,000 which was paid off in its entirety, including accrued interest of $15,682 on June 26, 2019. There was a zero balance on the loan at December 31, 2019. For the years ended December 31, 2020 and 2019, the Company had revenue of $9,106,645 and $0, respectively, and as of December 31, 2020 and 2019, receivables of $6,927,470 and $0, respectively, from Pharmaceutical Products Development, LLC, a shareholder who holds a minority interest in the Company. Pharmaceutical Products Development, LLC became a minority shareholder of the Company during the first quarter of 2019. For the years ended December 31, 2020 and 2019, the Company had revenue of $351,034 and $451,558, respectively, and as of December 31, 2020 and 2019, receivables of $129,857 and $9,825, respectively, from Novartis, who has a 50% ownership in dRX Capital AG, a shareholder who has a minority interest in the Company. dRX Capital AG became a minority shareholder of the Company in the third quarter of 2015.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
Commitments and Contingencies	Sep. 30, 2021	Dec. 31, 2020
COMMITMENTS
Commitments and Contingencies	9. Commitments and Contingencies Legal Proceedings During 2019 and 2020, the Company was in state court litigation in California. Noah Craft and Belinda Tan, former co-founders and former Chief Executive Officer and Chief Medical Officer, respectively, asserted derivative claims purportedly on behalf of the Company alleging that several of its current and former directors and investors committed various breaches of duty in connection with the termination of Craft and Tan’s employment. Craft and Tan also asserted direct tort claims arising from the same facts against the non-Company defendants. Moreover, Tan asserted a direct claim against the Company and certain current and former directors for gender discrimination. The Company disputed that it was liable, and that none of Craft and Tan’s claims had merit. Notwithstanding the Company’s stance, the litigation was settled in court in November 2020. As of September 30, 2021, all elements and payments associated with the settlement have been completed which included the following: 1) In June 2020, the Director Defendants paid $100,000 to the Company, which was used to offset the legal settlement in 3) below. 2) As part of the settlement, the Company paid $3,675,000 to Plaintiffs (“First Payment”) in December 2020. In return, the Plaintiffs conveyed all the Company shares and any other securities or interest in the Company shares. The Plaintiffs held the equivalent on an as converted basis of 5,901,076 common shares. 3) In December 2020, the Company accrued $1,225,000 for the legal settlement which was paid in June 2021 (“Second Payment”). 9. Commitments and Contingencies (continued) New Office Lease In March 2021, the Company entered into an operating lease agreement to lease office space in Culver City, CA commencing in July 2021 through October 2024 totaling $1,578,821 . Future minimum lease payments under non-cancellable leases as of September 30, 2021 were as follows: Operating Leases 2021 (remaining three months) $ 188,943 2022 1,286,301 2023 629,369 2024 599,327 2025 137,888 2026 11,517 Thereafter — Total future minimum lease payments $ 2,853,345 Less imputed interest (264,774) Total $ 2,588,571 Reported as of September 30, 2021: Other current liabilities $ 1,103,283 Operating lease liabilities 1,485,288 Total $ 2,588,571	14. Commitments and Contingencies Legal Proceedings During 2019 and 2020, the Company was in state court litigation in California. Noah Craft and Belinda Tan, former co-founders and former Chief Executive Officer and Chief Medical Officer, respectively, asserted derivative claims purportedly on behalf of the Company alleging that several of its current and former directors and investors committed various breaches of duty in connection with the termination of Craft and Tan’s employment. Craft and Tan also asserted direct tort claims arising from the same facts against the non-Company defendants. Moreover, Tan asserted a direct claim against the Company and certain current and former directors for gender discrimination. The Company disputed that it was liable, and that none of Craft and Tan’s claims had merit. On September 30, 2019, the Los Angeles County Superior Court stayed this litigation indefinitely after ruling that a contractual forum selection clause required Craft’s and Tan’s claims to be brought in Delaware. Craft and Tan have partially appealed that ruling to the California Court of Appeal. On February 26, 2020 agreement was reached on the terms of the pending litigation described above, and on June 30, 2020, the long form agreement was executed by all parties, and was settled in court in November 2020. The settlement agreement included the following elements: 1) Within five business days after a Final Dismissal occurred: a. The Director Defendants caused their insurers to pay $100,000 to Science 37. b. Science 37 paid $3,675,000 to Plaintiffs (“First Payment”). 2) Within five business days of the Plaintiffs’ receipt of the First Payment, the Plaintiffs conveyed all Science 37 shares and any other securities or interest in Science 37 shares. The Plaintiffs held the equivalent on an as converted basis of 5,901,076 common shares. 3) Good Dermatology, a company wholly owned by the Plaintiffs, was focused on providing dermatology care. Historically, Good Dermatology had sub-contracted employees from Science 37, and had allowed Science 37 the use of their medical offices to conduct clinical trials. In addition, Science 37 had advanced funds for rental payments and employee payroll, for the benefit of Good Dermatology. Good Dermatology delivered $600,000 to Science 37 to cover all outstanding obligations as of February 26, 2020: a. Within five business days after the Effective Date (June 30, 2020), Plaintiffs instructed Good Dermatology to pay Science 37 $400,000 for part of the payables due to Science 37 for rent, employee costs, etc. This amount was received in early July 2020. b. It was contemplated that Good Dermatology would dissolve or be wound down. Within five business days of such action, Science 37 is to pay the Plaintiffs either $1,225,000 or $ 1,025,000 (“Second Payment”). The amount paid was determined by whether Plaintiffs i) elected to pay $200,000 directly to Science 37 to satisfy the $600,000 outlined in 3) above and in which case, Science 37 would pay to the Plaintiffs $1,225,000 or ii) elected to pay $0 directly to Science 37 in which the Second Payment to the Plaintiffs would be $1,025,000 . Plaintiffs elected to pay $200,000 , resulting in Science 37 owing $1,225,000 . As of December 31, 2020, this payment is pending upon Good Dermatology’s dissolution. c. Additionally, prior to dissolution, Good Dermatology agreed to pay Science 37 all sums which accrued, arose or were incurred on Good Dermatology’s behalf by Science 37 from the time of February 26, 2020 through dissolution. 14. Commitments and Contingencies (continued) As of December 31, 2020, all payments were made by both parties with the exception of $1,225,000 owed by Science 37 to Plaintiffs in 3b above, the amount of which is recorded in accrued expenses on the balance sheet. The $1,225,000 was paid by Science 37 in June 2021.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended	12 Months Ended
Stock-Based Compensation	Sep. 30, 2021	Dec. 31, 2020
Stock-Based Compensation
Stock-Based Compensation	10. Stock-Based Compensation The Company currently has one equity-based compensation plan, the 2015 Stock Option Plan (the 2015 Plan) from which stock-based compensation awards can be granted to employees, consultants, and non- executive directors. The 2015 Plan provides for awards in the form of service-based incentive stock options. A summary of stock option awards outstanding as of September 30, 2021 and changes during the nine months then ended is as follows: Weighted Average Number of Units Exercise Price Outstanding at January 1, 2021 7,478,736 $ 0.68 Granted 3,720,500 8.18 Exercised (1,830,071) 0.67 Forfeited (472,211) 1.19 Outstanding at September 30, 2021 8,896,954 $ 3.79 10. Stock-Based Compensation (continued) Stock-Based Compensation Valuation and Expense The Company accounts for stock options under the fair value method which requires the Company to estimate the grant-date fair value of its stock-based awards and amortize this value to compensation expense over the requisite service period. The Company uses the Black-Scholes-Merton model to estimate the value of such awards granted to its employees, consultants, and non-executive directors. Within this model, expected volatility is based upon the historical volatility of a peer group for a period equal to the expected term, as the Company does not have adequate history to calculate its own volatility. The Company believes the expected volatility will approximate the historical volatility of the peer group. The Company does not currently anticipate paying dividends. The expected term represents the period in which the grants are expected to be outstanding. The risk- free interest rate is based on the United States Treasury yield curve in effect at the time of the grant. Due to the absence of an active market for the Company’s common stock, the fair value of the Company’s common stock for purposes of determining the common stock price for stock option grants was determined by the Company’s Board of Directors. Stock-based compensation expense is recognized net of forfeitures such that expense is recognized only for those stock-based awards that are expected to vest. If forfeitures during the period are greater than expenses recognized, net stock-based compensation expense can be negative. Total stock-based compensation expense was classified in the statements of operations for the three and nine months ended September 30, 2021 and 2020 as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of revenues 129,464 4,381 346,516 (70,058) Selling, general and administrative 868,515 100,960 1,566,580 71,847 Total stock-based compensation expense 997,979 105,341 1,913,096 1,789	15. Stock-based Compensation Effective September 8, 2015, the Company established the 2015 Stock Option Plan (the 2015 Plan). The 2015 Plan authorizes the granting of options to purchase up to 11,708,001 shares of common stock to officers, employees and Board of Directors of the Company. As of December 31, 2020 and 2019, the 2015 Plan has issued 8,246,052 and 5,750,504 options to purchase shares of common stock of which 767,316 and 602,430 have been exercised and 7,478,736 and 5,148,074 remain outstanding. Granted options typically vest at 25% per year and become exercisable after one year of service after the date of issuance, with equal and successive vesting for the next 36 Due to the absence of an active market for the Company’s common stock, the fair value of the Company’s common stock for purposes of determining the common stock price for stock option grants was determined by the Company’s Board of Directors, the members of which have extensive business, financial and investment experience. The Company’s Board of Directors sets the exercise price of stock options at least equal to the fair value of the Company’s common stock on the date of grant. The Company’s Board of Directors exercised judgment while considering numerous objective and subjective factors in order to determine the fair market value on each date of grant in accordance with the guidance in the American Institute of Certified Public Accountants Technical Practice Aid entitled, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, or the AICPA Practice Aid, including the receipt of a valuation prepared by an independent third party with extensive experience valuing common stock of privately held companies. The exercise price of the unit is determined by the Board but shall not be less than 100% of the fair market value on the date of grant. For purposes of this limitation, the shares of common stock underlying any awards that are forfeited, canceled, withheld upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of common units, or otherwise terminated other than by exercise will be added back to the shares of common stock available for issuance under the 2015 Plan. The units available for issuance under the 2015 Plan may be authorized but may be unissued common units or common units reacquired by the Company. No award may be granted under the plan upon the earlier of the tenth anniversary of the date the plan is adopted by the Board, the date on which all units available for issuance under the plan shall have been issued as vested units, or the termination of all outstanding awards under the plan in connection with a change in control. 15. Stock-based Compensation (continued) The following table summarizes the stock option activity for the years ended December 31, 2020 and 2019: Weighted Average Weighted Remaining Aggregate Number of Average Contractual Intrinsic Units Exercise Price Term (Years) Value Outstanding as of January 1, 2019 4,823,893 $ 1.20 8.71 Granted 1,654,000 0.82 — Exercised (122,560) 0.33 — Forfeited (1,207,259) 1.33 — Outstanding as of January 1, 2020 5,148,074 $ 1.10 8.22 Granted 4,704,932 0.52 — Exercised (164,886) (0.80) — Forfeited (2,209,384) (1.26) — Outstanding at December 31, 2020 7,478,736 $ 0.68 8.35 $ 6,058,137 Exercisable at December 31, 2020 3,142,881 $ 0.81 7.30 $ 2,173,188 The total intrinsic value of options exercised was approximately $115,201 and $55,056 in 2020 and 2019, respectively. The Company recognized stock-based compensation expense of $122,032 and $392,566 during the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020 and 2019, total unrecognized compensation cost related to unvested stock options was approximately $1,046,844 and $1,142,965, respectively, which is expected to be recognized over a weighted average period of 2.87 and 2.51 years, based on the original date of service of each specific grant holder. Total stock-based compensation expense was classified in the statements of operations for the years ended December 31, 2020 and 2019 as follows: 2020 2019 Cost of revenues $ (64,919) $ 65,096 Selling, general and administrative 186,950 327,470 Total stock-based compensation expense $ 122,032 $ 392,566 The Company received cash of approximately $131,802 and $39,863 in 2020 and 2019, respectively, from options exercised. Other information about the Company’s stock options for the years ending December 31, 2020 and 2019 was as follows: 2020 2019 Total grant date fair value of stock options vested $ 533,089 $ 643,425 15. Stock-based Compensation (continued) The following table summarizes the assumptions used in valuing the stock options for the year ended December 31, 2020 and 2019: 2020 2019 Expected term 6.25 years 2.25 years – 6.25 years Weighted-average grant date fair value per stock option granted $ 0.23 $ 0.28 Risk-free interest rate 0.4% – 1.4% 1.1% – 3.0% Expected volatility 43.5% – 46.4% 32.3% – 37.9% Dividend yield 0% 0% The expected term of the stock options represents the average period the stock options are expected to remain outstanding. The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Therefore, the expected term of options granted is derived from the average midpoint between the weighted-average vesting and the contractual term, also known as the simplified method. The risk-free interest rate was the rate at the date of grant for a zero-coupon U.S. Treasury bond with a term that approximated the expected term of the stock option. As the Company does not have sufficient historical data to calculate the historical volatility of its stock, the expected volatility is derived from the historical volatilities of a selected peer group for a period that is equal to the expected term. The Company does not have a history of paying regular dividends and does not expect to pay regular cash dividends for the foreseeable future.

Income Taxes

Income Taxes	9 Months Ended	12 Months Ended
Income Taxes	Sep. 30, 2021	Dec. 31, 2020
Income Taxes
Income Taxes	11. Income Taxes The Company is treated as a “C” corporation for U.S. tax purposes. Adoption of Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (ASU 2019-12), which eliminates certain exceptions to the guidance in Income Taxes (Topic 740) related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted in an interim or annual period. Entities that elect to early adopt the amendments in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, entities that elect early adoption must adopt all the amendments in the same period. Entities will apply the guidance prospectively, except for certain amendments. The Company adopted ASU 2019-12 effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures. 11. Income Taxes (continued) The Company has incurred net operating losses since inception and is forecasting additional losses through December 31, 2021. Therefore, no U.S. Federal, state or foreign income taxes are expected for 2021 and no provision for such taxes has been recorded as of September 30, 2021. Due to the Company’s history of losses since inception, there is not enough evidence at this time to support the conclusion that the Company will generate future income of a sufficient amount and nature to utilize the benefits of the Company’s net deferred tax assets. Accordingly, as of September 30, 2021 and December 31, 2020, the Company provided a full valuation allowance against its net deferred tax assets since as of that time, the Company could not assert that it was more likely than not that these deferred tax assets would be realized.	17. Income Taxes For the years ended December 31, 2020 and 2019, the amount of loss before taxes was: 2020 2019 U.S. income (loss) before taxes $ (31,666,084) $ (18,468,776) Foreign income (loss) before taxes — — Total income (loss) before taxes $ (31,666,084) $ (18,468,776) Both current and deferred income tax (benefit) expense as of December 31, 2020 and 2019 were $0 and $0, respectively. 17. Income Taxes (continued) The Company has not recorded any provision for income taxes for the years ended December 31, 2020 and 2019, due to its history of operating losses. The effective tax rate for the year ended December 31, 2020, is different from the federal statutory rate primarily due to full valuation allowance against net deferred tax assets as a result of insufficient sources of income. The reconciliation of tax expense at the statutory federal tax rate versus the recorded income tax expense is as follows for the years ended December 31, 2020 and 2019: 2020 2019 Statutory U.S. federal rate $ (6,649,878) $ (3,878,443) State income tax net of federal benefit (1,141,758) (767,428) Permanent items 77,747 109,580 Other prior year adjustments (99,275) (1,339) Rate adjustment (12,921) 65,267 Valuation allowance 7,826,085 4,472,363 Total income tax expense (benefit) $ — $ — Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The principal components of the Company’s deferred tax assets for the years ended December 31, 2020 and 2019 consisted of the following: 2020 2019 Net operating loss carryforwards $ 24,923,945 $ 18,039,466 Amortizable assets 6,321 7,143 Equity compensation 50,118 77,916 Salaries and wages 1,048,104 151,442 Deferred rent — 133,387 Deferred revenue 861,120 544,415 Leasehold improvements 611,657 — Other 303,317 26,535 Total deferred tax assets 27,804,582 18,980,304 Less: valuation allowance (25,316,127) (17,490,042) Net deferred tax asset 2,488,455 1,490,262 Operating lease ROU (545,045) — Fixed assets (1,943,410) (1,490,262) Total deferred tax liabilities (2,488,455) (1,490,262) Net deferred tax assets (liabilities) $ — $ — The Company determines its valuation allowance on deferred tax assets by considering both positive and negative evidence in order to ascertain whether it is more likely than not that deferred tax assets will be realized. Realization of deferred tax assets is dependent upon the generation of future taxable income, if any, the timing and amount of which are uncertain. Due to the history of losses the Company has generated in the past, the Company believes that it is not more likely than not that all of the deferred taxes can be realized as of December 31, 2020 and 2019; accordingly, the Company has recorded a full valuation allowance on its net deferred tax assets. The valuation allowance increased $7,826,085 and $4,184,528 during the years ended December 31, 2020 and 2019, respectively. 17. Income Taxes (continued) At December 31, 2020, the Company has federal net operating loss carryforwards of approximately $103,569,264 and state net operating loss carryforwards of $56,390,660. As a result of Tax Cuts and Jobs Act, for U.S. income tax purposes, the net operating loss generated in tax years beginning before January 1, 2018 can be carried forward for 20 years, but net operating loss generated for tax years beginning after December 31, 2017 are carried forward indefinitely and are limited to 80% utilization against taxable income. Of the total federal net operating loss, $30,230,297 will begin to expire in 2034 and $73,338,967 will not expire but can only offset 80% of future taxable income in any given year. Of the total state NOL carryforwards, $247,181 can be carried forward indefinitely, with the remainder first beginning to expire in 2029. Pursuant to Code Sections 382 and 383, annual use of our net operating losses may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed a formal study in accordance with sections 382 and 383 to determine the limitations if a change in ownership has occurred or if there are any limitations on the utilization of net operating loss carryforwards. If net operating loss carryforwards are eliminated the related tax assets would be removed from the deferred tax assets schedule with a corresponding reduction in the valuation allowance. The Company files US. federal and various state and local income tax returns and is not under examination by any of the taxing authorities. Tax years 2017 and forward remain open for examination for federal tax purpose and tax years 2016 and forward remain open for examination for state tax purposes. Carryforward attributes that were generated in years where the statute of limitation is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authority. On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions are the extension of the carryback period of certain losses to five years and increasing the ability to deduct interest expense from 30 percent to 50 percent of modified taxable income. The CARES Act also provides for a credit against employee wages, the opportunity to defer payment of a portion of federal payroll taxes to December 2021 and December 2022 and enhanced small business loans to assist businesses impacted by the pandemic. The Company’s tax provision and financial position was not materially impacted by the CARES Act. On December 27, 2020, the United States enacted the Consolidated Appropriations Act which extended and modified many of the tax related provisions of the CARES Act. The Company’s tax provision and financial position was not materially impacted by the Consolidated Appropriations Act. On June 29, 2020, the state of California enacted Assembly Bill No. 85 (AB 85) suspending California net operating loss utilization and imposing a cap on the amount of business incentive tax credits companies can utilize, effective for tax years 2020, 2021 and 2022. There was no material impact from the provisions of AB 85 in 2020. 17. Income Taxes (continued) The following table summarizes the reconciliation of the unrecognized tax benefits activity during the year ended December 31, 2020: Unrecognized Tax Benefits – Beginning $ 239,927 Gross increases – tax positions in prior period — Gross decreases – tax positions in prior period — Gross increase – current-period tax positions — Gross decrease – current-period tax positions — Settlements — Lapse of statute of limitations — Unrecognized Tax Benefits – Ending $ 239,927 Due to the Company’s valuation allowance, none of the unrecognized tax benefits, if recognized, would affect the Company’s effective tax rate. The Company’s policy is to recognize interest expense and penalties related to income tax matters as tax expense. At December 31, 2020, there are no significant accruals for interest or penalties related to unrecognized tax benefits. The Company does not expect that there will be unrecognized tax benefits of a significant nature that will increase or decrease within 12 months of the reporting date.

Subsequent Events_2_3

Subsequent Events	9 Months Ended	12 Months Ended
Subsequent Events	Sep. 30, 2021	Dec. 31, 2020
SUBSEQUENT EVENTS
Subsequent Events	12. Subsequent Events Merger with LSAQ On May 7, 2021, the Company announced a planned merger with LSAQ under a definitive business combination agreement. On October 6, 2021, the agreement was consummated, with the Company surviving the merger as Science 37 Holdings, Inc, now a public company. All outstanding common and preferred shares of legacy Science 37, Inc. converted into common shares of the surviving Science 37 Holdings, Inc. through application of an exchange ratio of approximately 1.815. In addition, awards under the Company's existing 2015 stock incentive plan continue under the same terms and conditions as were previously applicable to such awards, subject to the same exchange ratio for exercise price and number of options outstanding. Common shares and warrants held by former LSAQ shareholders were converted to 10,858,261 common shares of Science 37 Holdings, Inc. Science 37 Holdings, Inc. began trading on the Nasdaq stock exchange as SNCE effective October 7, 2021. The financial statements as of September 30, 2021, including share and per share amounts, do not include the effects of the merger. The table below shows, on a pro forma basis, the impact of the merger on certain condensed balance sheet items as of September 30, 2021: Balance Sheet Data: Actual Pro Forma Cash and cash equivalents $ 7,996,362 $ 242,991,191 Working capital (5,566,182) 228,647,166 Total assets 39,746,217 273,843,757 Redeemable convertible preferred stock 143,086,271 — Accumulated deficit (136,979,761) (136,979,761) Total stockholders’ equity (deficit) $ (132,209,608) $ 163,290,011 Share Data: Actual Pro Forma Redeemable convertible preferred stock outstanding 41,587,368 — Common stock outstanding 4,595,168 114,707,150 Going Concern From August 2021, the Company began to accelerate investments in hiring and in other critical areas, such as the technology platform, to facilitate the delivery of anticipated revenues, resulting from an increase in net bookings. Also, as several meaningful conditions of the contemplated transaction were met, the Company increased spend related to the requirements of being a publicly-traded company. The Company’s increased costs adversely affected the Company’s results of operations and liquidity and there was substantial doubt as to the Company’s ability to continue as a going concern at that time. On October 6, 2021, the definitive business combination agreement was consummated, with Science 37, Inc. surviving the merger as Science 37 Holdings, Inc., a now public company. All outstanding common and preferred shares of legacy Science 37, Inc. converted into common shares of the surviving Science 37 Holdings, Inc. through application of an exchange ratio of approximately 1.815. In addition, awards under the Company’s existing 2015 stock incentive plan continue under the same terms and conditions as were previously applicable to such awards, subject to the same exchange ratio for exercise price and number of options outstanding. Science 37 Holdings, Inc. began trading on the Nasdaq stock exchange as SNCE effective October 7, 2021. 12. Subsequent Events (continued) In conjunction with this merger, Science 37, Inc. received funds held in LSAQ's working capital and trust accounts together with $ 200 million in PIPE financing from institutional and strategic investors to further fund Science 37, Inc.’s decentralized trial technology platform and extend into new adjacencies. As a result of the Merger and inclusive of the PIPE financing, Science 37, Inc. received $ 234.2 million, net of fees and expenses paid in connection with the closing of the business combination. The transaction will be accounted for as a reverse capitalization in accordance with GAAP. Under the reverse capitalization model, the merger will be treated as Science 37, Inc. is issuing equity for the net assets of LSAQ, with no goodwill or intangible assets recorded, and LSAQ will be treated as the acquiree for financial reporting purposes. This is primarily because, subsequent to the merger, Science 37, Inc. shareholders have a majority of the voting power of the combined company. In addition, Science 37, Inc. comprises all of the ongoing operations, senior management, and a majority of the governing body of the combined company. As a result of the merger and related PIPE financing, the substantial doubt about the Company's ability to continue as a going concern has been alleviated. The Company has evaluated subsequent events through November 15, 2021, the date on which the accompanying condensed consolidated financial statements were issued, noting no additional items requiring disclosure.	18. Subsequent Events On March 25, 2021, the Company entered into an operating lease agreement for office space which will commence on July 1, 2021. The Company’s financial commitment for the office space is disclosed under Leases. On May 7, 2021, the Company announced a planned merger with LifeSci Acquisition II Corp (LSAQ) under a definitive business combination agreement. Going Concern From August 2021, the Company began to accelerate investments in hiring and in other critical areas, such as the technology platform, to facilitate the delivery of anticipated revenues, resulting from an increase in net bookings. Also, as several meaningful conditions of the contemplated transaction were met, the Company increased spend related to the requirements of being a publicly-traded company. The Company’s increased costs adversely affected the Company’s results of operations and liquidity and there was substantial doubt as to the Company’s ability to continue as a going concern at that time. On October 6, 2021, the definitive business combination agreement was consummated, with Science 37, Inc. surviving the merger as Science 37 Holdings, Inc., a now public company. All outstanding common and preferred shares of legacy Science 37, Inc. converted into common shares of the surviving Science 37 Holdings, Inc. through application of an exchange ratio of approximately 1.815. In addition, awards under the Company’s existing 2015 stock incentive plan continue under the same terms and conditions as were previously applicable to such awards, subject to the same exchange ratio for exercise price and number of options outstanding. Science 37 Holdings, Inc. began trading on the Nasdaq stock exchange as SNCE effective October 7, 2021. In conjunction with this merger, Science 37, Inc. received funds held in LSAQ’s working capital and trust accounts together with $200 million in PIPE financing from institutional and strategic investors to further fund Science 37, Inc.’s decentralized trial technology platform and extend into new adjacencies. As a result of the Merger and inclusive of the PIPE financing, Science 37, Inc. received $234.2 million, net of fees and expenses paid in connection with the closing of the business combination. The transaction will be accounted for as a reverse capitalization in accordance with GAAP. Under the reverse capitalization model, the merger will be treated as Science 37, Inc. is issuing equity for the net assets of LSAQ, with no goodwill or intangible assets recorded, and LSAQ will be treated as the acquiree for financial reporting purposes. This is primarily because, subsequent to the merger, Science 37, Inc. shareholders have a majority of the voting power of the combined company. In addition, Science 37, Inc. comprises all of the ongoing operations, senior management, and a majority of the governing body of the combined company. As a result of the merger and related PIPE financing, the substantial doubt about the Company’s ability to continue as a going concern has been alleviated. The Company has evaluated subsequent events through November 5, 2021, the date on which the accompanying consolidated financial statements were issued, noting no additional items requiring disclosure.

Company Background and Basis _2

Company Background and Basis of Presentation (Policies)	9 Months Ended	12 Months Ended
Company Background and Basis of Presentation (Policies)	Sep. 30, 2021	Dec. 31, 2020
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
Description of Business	Description of Business The Company is a leading provider of technology-based solutions that enable decentralized clinical trials on behalf of biopharmaceutical sponsors. The Company pioneered the decentralized clinical trial model and developed the industry’s first Decentralized Clinical Trial Operating System (DCT OS), combining its technology platform, which orchestrates workflows, supports evidence generation, and harmonizes data seamlessly, with its Specialized Network of patient communities, on-demand telemedicine investigators, flexible mobile nurses, scalable remote coordinators and robust connected technologies. By bringing research to patients and providers more directly, the Company’s operating system increases access and patient diversity, which can help speed the development of potentially life-saving drug treatments. On May 7, 2021, the Company announced a planned merger with LifeSci Acquisition II Corp (“LSAQ”) under a definitive business combination agreement. The merger was consummated on October 6, 2021, whereby LSAQ acquired 100% of the Company's issued and outstanding securities through a reverse merger of the Company with and into a wholly owned subsidiary of LSAQ, with the Company surviving the merger as Science 37 Holdings, Inc, now a public company. In conjunction with this merger, the Company received $200 million through a private investment in public entity (PIPE) offering from leading institutional and strategic investors to further fund the Company’s decentralized trial technology platform and extend into new adjacencies.
Unaudited Interim Financial Information and Use of Estimates	Unaudited Interim Financial Information and Use of Estimates The Company prepared the accompanying unaudited condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all the information and notes required by GAAP for complete financial statements. The significant accounting policies followed by the Company for interim financial reporting are consistent with the accounting policies followed for annual financial reporting. The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. These estimates are based on historical experience and various other assumptions believed reasonable under the circumstances. The Company evaluates its estimates on an ongoing basis and makes changes to the estimates and related disclosures as experience develops or new information becomes known, including facts and circumstances related to the novel coronavirus disease pandemic. Actual results will most likely differ from those estimated. The Company’s most significant estimates and assumptions used in the preparation of the accompanying condensed consolidated financial statements relate to contract cost estimates in revenue recognition, capitalized software costs, and the valuation of the Company’s common stock. The condensed consolidated financial statements, in management’s opinion, include all adjustments of a normal recurring nature necessary for a fair presentation. The information included in this filing should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in this filing for the year ended December 31, 2020. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or any other future period. The consolidated balance sheet at December 31, 2020 is derived from the amounts in the audited balance sheet included in this filing for the year ended December 31, 2020. 1. Company Background and Basis of Presentation (continued)
Liquidity	Liquidity The Company has continued to experience increased costs that adversely affect the Company's current results of operations and liquidity. The Company's condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements for the three and nine months ended September 30, 2021 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company's ability to continue as a going concern. As of September 30, 2021, the Company had $7,996,362 of unrestricted cash. On October 6, 2021, the definitive business combination agreement between the Company and LifeSci Acquisition II Corp (LSAQ) was consummated. LSAQ acquired 100% of the Company's issued and outstanding securities through a reverse merger of the Company with and into a wholly owned subsidiary of LSAQ, with the Company surviving the merger as Science 37 Holdings, Inc, now a public company. In conjunction with this merger, the Company received $200 million through a private investment in public entity (PIPE) offering from institutional and strategic investors to further fund the Company's decentralized trial technology platform and extend into new adjacencies. As a result of the merger and inclusive of the PIPE financing, the Company received $234.2 million, net of fees and expenses paid in connection with the closing of the business combination. The Company believes that its $8.0 million of cash as of September 30, 2021, in addition to the proceeds received from the merger with LSAQ and PIPE offering, are sufficient to fund planned operations for at least 12 months from the date these financial statements were available to be filed.
Concentration Risks	Concentration Risks Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, deposits of up to $250,000 at Federal Deposit Insurance Corporation (FDIC) insured institutions are covered by FDIC insurance. At times, deposits at the Company’s financial institution may exceed federally insured limits. Management periodically assesses the financial condition of the institution and believes that any possible credit risk is minimal. The Company has not experienced any loss from such risk.
COVID 19 Pandemic	COVID-19 Pandemic In March 2020 the World Health Organization declared the global novel coronavirus disease 2019 (COVID-19) outbreak a pandemic. The Company’s original sublease tenant in San Francisco was unable to fulfill its sublease obligations due to the pandemic’s impact on its business operations. The sublessee vacated the facility in February 2021 and a new sublessee was not secured until May 2021, at terms substantially similar to the original sublessee. For the nine months ended September 30, 2021 and 2020, the Company wrote-off $228,946 and $0 of sublease receivable against sublease income due to low probability of collection from the original sublessee. No other significant impacts to the Company’s operations due to the COVID-19 outbreak have occurred. 1. Company Background Basis of Presentation (continued)
Capitalized Software	Capitalized Software The Company’s internal use proprietary software organizes workflows, captures real-time evidence, and harmonizes data during clinical trial support for its customers. Capitalized software is recorded at cost less accumulated amortization. The Company capitalizes software development cost related to the development of the Company’s proprietary platform in accordance with ASC 350 guidance. Internal and external costs incurred during the preliminary stage are expensed as incurred. Costs incurred during the application development stage are capitalized and consist of payroll labor and benefits to the extent of time spent directly on the project and external direct costs of materials and labor. Training and maintenance costs are expensed as incurred. The Company commences amortization once the respective assets are placed into service. The estimated useful life for capitalized software is 3 years . Assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the expected undiscounted future cash flow from the use of the asset and its eventual disposition is less than the carrying amount of the asset, an impairment loss is recognized and measured using the fair value of the related asset. No material impairments were recognized during the three and nine months ended September 30, 2021 and 2020.	Capitalized Costs The Company capitalizes certain costs associated with commissions paid to its employees because these costs are incurred in obtaining contracts that have a term greater than one year and are expected to be recovered. Capitalized costs are included in prepaid expenses and other current assets and other assets in the accompanying balance sheet and are amortized to selling, general and administrative expense on the statement of operations. The Company amortizes these costs in a manner that is consistent with the pattern of revenue recognition described above. The Company expenses costs to obtain contracts that have a term of one year or less when incurred.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.	Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.
Segments	Segments Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined that its Senior Executive Committee, which includes the Chief Executive Officer, together with the Board of Directors is the CODM. The Company operates in a single operating segment as the CODM reviews financial information presented on a consolidated basis, at the Company level, for the purposes of making operating decisions, allocation of resources, and evaluating financial performance. As of and for the nine months ended September 30, 2021 and 2020, the Company did not have material revenue earned or assets located outside of the United States.	Segments Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined that its Senior Executive Committee, which includes the Chief Executive Officer, together with the Board of Directors is the CODM. The Company operates in a single operating segment as the CODM reviews financial information presented on a consolidated basis, at the Company level, for the purposes of making operating decisions, allocation of resources, and evaluating financial performance. As of and for the years ended December 31, 2020 and 2019, the Company did not have material revenue earned or assets located outside of the United States.
Accounting Pronouncements Issued but Not Adopted	Accounting Pronouncements Issued but Not Adopted as of September 30, 2021 In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by a reporting entity. The standard replaces the incurred loss impairment methodology in current GAAP with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company does not expect the adoption of the guidance to have a material effect on the Company’s consolidated financial statements. This is based on factors including the Company’s assessment of historical losses, customer’s creditworthiness, and the fact that the Company’s trade receivables are short term in duration. The Company expects to implement this new standard in January 2022.	2. Summary of Significant Accounting Policies (continued) Accounting Pronouncements Issued but Not Adopted as of December 31, 2020 In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by a reporting entity. The standard replaces the incurred loss impairment methodology in current GAAP with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company does not expect the adoption of the guidance to have a material effect on the Company’s consolidated financial statements. This is based on factors including the Company’s assessment of historical losses, customers’ creditworthiness, and the fact that the Company’s trade receivables are short term in duration. The Company expects to implement this new standard in January 2022.

Revenue (Tables)

Revenue (Tables)	9 Months Ended	12 Months Ended
Revenue (Tables)	Sep. 30, 2021	Dec. 31, 2020
Revenue
Summary of accounts receivable and unbilled services (including contract assets)	September 30, 2021 December 31, 2020 Accounts receivable $ 6,233,698 $ 8,688,441 Unbilled services $ 907,840 2,511,811 Total accounts receivable and unbilled services 7,141,538 11,200,252 Allowance for doubtful accounts (142,830) — Total accounts receivable and unbilled services, net $ 6,998,708 $ 11,200,252	2020 2019 Accounts receivable $ 8,688,441 $ 1,426,874 Unbilled services 2,511,811 1,913,023 Total accounts receivable and unbilled services $ 11,200,252 $ 3,339,897
Summary of deferred revenue	September 30, 2021 December 31, 2020 Deferred revenue $ 7,626,905 $ 5,564,124	2020 2019 Deferred revenue $ 5,564,124 $ 4,932,612
Summary of capitalized commission costs and related amortization		2020 2019 Capitalized commission cost, net $ 509,326 $ — 2020 2019 Amortization of capitalized commission cost $ (232,422) $ —

Shareholders' Deficit (Tables)

Shareholders' Deficit (Tables)	9 Months Ended	12 Months Ended
Shareholders' Deficit (Tables)	Sep. 30, 2021	Dec. 31, 2020
STOCKHOLDERS' EQUITY
Summary of common share activity	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Common shares, beginning balance 4,488,416 8,468,742 2,765,097 8,396,425 Issuance of common shares 106,752 75,694 1,830,071 148,011 Common shares, ending balance 4,595,168 8,544,436 4,595,168 8,544,436	2020 2019 Common stock shares, beginning balance 8,396,425 8,273,865 Issuance of common stock 164,886 122,560 Repurchase of common stock (5,796,214) — Common stock shares, ending balance 2,765,097 8,396,425

Loss Per Share (Tables)

Loss Per Share (Tables)	9 Months Ended	12 Months Ended
Loss Per Share (Tables)	Sep. 30, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Scheduel of reconciliation of the numerators and denominators of the basic loss per share	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net Loss $ (14,691,871) $ (7,683,830) $ (29,232,518) $ (19,349,948) Denominator: Basic weighted average common shares outstanding 4,551,755 8,522,923 3,818,717 8,458,434 Earnings (loss) per share: Basic and diluted $ (3.23) $ (0.90) $ (7.66) $ (2.29)	2020 2019 Numerator: Net Loss $ (31,674,084) $ (18,468,776) Denominator: Basic weighted average common shares outstanding 8,197,409 8,310,333 Earnings (loss) per share: Basic and diluted $ (3.86) $ (2.22)
Schedule of number of potential shares outstanding that were anti-dilutive and therefore excluded from the computation of diluted earnings per share, weighted for the portion of the period they were outstanding	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Preferred stock 41,587,368 32,653,742 41,587,368 41,692,230 Stock options outstanding 8,852,171 7,684,943 8,601,614 6,414,452 Warrants outstanding 6,439 6,439 6,439 6,439 Total 50,445,978 40,345,124 50,195,421 48,113,121	2020 2019 Preferred stock 36,338,255 30,610,834 Stock options outstanding 6,714,171 5,301,830 Warrants outstanding 6,439 6,439 Total 43,058,865 35,919,104

Disclosure - Commitments and Co

Disclosure - Commitments and Contingencies (Tables)	9 Months Ended	12 Months Ended
Disclosure - Commitments and Contingencies (Tables)	Sep. 30, 2021	Dec. 31, 2020
COMMITMENTS
Schedule of future minimum lease payments under non-cancellable leases	Future minimum lease payments under non-cancellable leases as of September 30, 2021 were as follows: Operating Leases 2021 (remaining three months) $ 188,943 2022 1,286,301 2023 629,369 2024 599,327 2025 137,888 2026 11,517 Thereafter — Total future minimum lease payments $ 2,853,345 Less imputed interest (264,774) Total $ 2,588,571 Reported as of September 30, 2021: Other current liabilities $ 1,103,283 Operating lease liabilities 1,485,288 Total $ 2,588,571	Future minimum lease payments under non-cancellable leases as of December 31, 2020 were as follows: Operating Leases 2021 $ 1,462,045 2022 801,800 2023 130,332 2024 134,054 2025 137,888 Thereafter 11,518 Total future minimum lease payments 2,677,637 Less imputed interest (197,263) Total $ 2,480,374 Reported as of December 31, 2020: Accrued expenses and other liabilities $ 1,352,537 Operating lease liabilities 1,127,837 Total $ 2,480,374 Future minimum lease payments under non-cancellable leases as of December 31, 2019 were as follows: 2020 $ 2,325,562 2021 1,360,130 2022 752,532 2023 124,068 2024 127,790 Thereafter 142,618 Total $ 4,832,700

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended	12 Months Ended
Stock-Based Compensation (Tables)	Sep. 30, 2021	Dec. 31, 2020
Stock-Based Compensation
Schedule of stock option activity	A summary of stock option awards outstanding as of September 30, 2021 and changes during the nine months then ended is as follows: Weighted Average Number of Units Exercise Price Outstanding at January 1, 2021 7,478,736 $ 0.68 Granted 3,720,500 8.18 Exercised (1,830,071) 0.67 Forfeited (472,211) 1.19 Outstanding at September 30, 2021 8,896,954 $ 3.79	Weighted Average Weighted Remaining Aggregate Number of Average Contractual Intrinsic Units Exercise Price Term (Years) Value Outstanding as of January 1, 2019 4,823,893 $ 1.20 8.71 Granted 1,654,000 0.82 — Exercised (122,560) 0.33 — Forfeited (1,207,259) 1.33 — Outstanding as of January 1, 2020 5,148,074 $ 1.10 8.22 Granted 4,704,932 0.52 — Exercised (164,886) (0.80) — Forfeited (2,209,384) (1.26) — Outstanding at December 31, 2020 7,478,736 $ 0.68 8.35 $ 6,058,137 Exercisable at December 31, 2020 3,142,881 $ 0.81 7.30 $ 2,173,188
Schedule of stock based compensation expense	Total stock-based compensation expense was classified in the statements of operations for the three and nine months ended September 30, 2021 and 2020 as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of revenues 129,464 4,381 346,516 (70,058) Selling, general and administrative 868,515 100,960 1,566,580 71,847 Total stock-based compensation expense 997,979 105,341 1,913,096 1,789	2020 2019 Cost of revenues $ (64,919) $ 65,096 Selling, general and administrative 186,950 327,470 Total stock-based compensation expense $ 122,032 $ 392,566
Schedule of stock options vested		2020 2019 Total grant date fair value of stock options vested $ 533,089 $ 643,425
Schedule of assumptions of valuing the stock options		2020 2019 Expected term 6.25 years 2.25 years – 6.25 years Weighted-average grant date fair value per stock option granted $ 0.23 $ 0.28 Risk-free interest rate 0.4% – 1.4% 1.1% – 3.0% Expected volatility 43.5% – 46.4% 32.3% – 37.9% Dividend yield 0% 0%

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2020
Income Taxes
Schedule of income (loss) before taxes	2020 2019 U.S. income (loss) before taxes $ (31,666,084) $ (18,468,776) Foreign income (loss) before taxes — — Total income (loss) before taxes $ (31,666,084) $ (18,468,776)
Schedule of components of income tax expense	2020 2019 Statutory U.S. federal rate $ (6,649,878) $ (3,878,443) State income tax net of federal benefit (1,141,758) (767,428) Permanent items 77,747 109,580 Other prior year adjustments (99,275) (1,339) Rate adjustment (12,921) 65,267 Valuation allowance 7,826,085 4,472,363 Total income tax expense (benefit) $ — $ —
Summary of components of deferred tax assets and liabilities	2020 2019 Net operating loss carryforwards $ 24,923,945 $ 18,039,466 Amortizable assets 6,321 7,143 Equity compensation 50,118 77,916 Salaries and wages 1,048,104 151,442 Deferred rent — 133,387 Deferred revenue 861,120 544,415 Leasehold improvements 611,657 — Other 303,317 26,535 Total deferred tax assets 27,804,582 18,980,304 Less: valuation allowance (25,316,127) (17,490,042) Net deferred tax asset 2,488,455 1,490,262 Operating lease ROU (545,045) — Fixed assets (1,943,410) (1,490,262) Total deferred tax liabilities (2,488,455) (1,490,262) Net deferred tax assets (liabilities) $ — $ —
Schedule of unrecognized tax benefits	Unrecognized Tax Benefits – Beginning $ 239,927 Gross increases – tax positions in prior period — Gross decreases – tax positions in prior period — Gross increase – current-period tax positions — Gross decrease – current-period tax positions — Settlements — Lapse of statute of limitations — Unrecognized Tax Benefits – Ending $ 239,927

Disclosure - Subsequent Events

Disclosure - Subsequent Events (Tables)	9 Months Ended
Disclosure - Subsequent Events (Tables)	Sep. 30, 2021
SUBSEQUENT EVENTS
Pro Forma Financial Statements	The financial statements as of September 30, 2021, including share and per share amounts, do not include the effects of the merger. The table below shows, on a pro forma basis, the impact of the merger on certain condensed balance sheet items as of September 30, 2021: Balance Sheet Data: Actual Pro Forma Cash and cash equivalents $ 7,996,362 $ 242,991,191 Working capital (5,566,182) 228,647,166 Total assets 39,746,217 273,843,757 Redeemable convertible preferred stock 143,086,271 — Accumulated deficit (136,979,761) (136,979,761) Total stockholders’ equity (deficit) $ (132,209,608) $ 163,290,011 Share Data: Actual Pro Forma Redeemable convertible preferred stock outstanding 41,587,368 — Common stock outstanding 4,595,168 114,707,150

Company Background and Basis _3

Company Background and Basis of Presentation (Details) - USD ($)	Oct. 06, 2021	May 07, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Write off of Sublease Receivable			$ 228,946	$ 0	$ 312,940
Amount of federal deposit insurance corporation			250,000		250,000
Cash and cash equivalents			$ 7,996,362		$ 32,478,948	$ 27,787,314
Estimated useful life for capitalized software			3 years		3 years
Subsequent events
Business Acquisition [Line Items]
PIPE financing loans	$ 200,000,000
PIPE financing net of fees and expenses	$ 234,200,000
Percentage of acquired issued and outstanding	100.00%
Business combination agreement
Business Acquisition [Line Items]
Amount Received in PIPE Financing From Leading Institutional and Strategic Investors		$ 200,000,000

Revenue - Unsatisfied Performan

Revenue - Unsatisfied Performance Obligations (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price allocated to the unsatisfied performance obligations	$ 118,892,662	$ 52,415,469
Minimum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract term	1 month	1 year 6 months
Maximum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract term	6 years 4 months 24 days	7 years 1 month 6 days

Revenue - Timing of Billing and

Revenue - Timing of Billing and Performance (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue
Revenue recognized that was included in the deferred revenue balance	$ 3,151,080	$ 3,962,270	$ 4,349,278	$ 5,667,532
Revenue recognized from performance obligations partially satisfied in previous periods	$ 3,170,297	$ 6,322,520	$ (74,540)	$ 0

Revenue - Accounts Receivable,

Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts receivable and unbilled services (including contract assets)
Accounts receivable	$ 6,233,698	$ 8,688,441	$ 1,426,874
Unbilled services	907,840	2,511,811	1,913,023
Total accounts receivable and unbilled services	7,141,538	11,200,252
Allowance for doubtful accounts	(142,830)	0	0
Total accounts receivable and unbilled services, net	6,998,708	11,200,252	3,339,897
Contract assets	907,840	2,511,811	85,465
Deferred revenue	$ 6,571,281	$ 5,136,457	$ 3,561,778

Revenue - Concentration of Cred

Revenue - Concentration of Credit Risk (Details) - customer	3 Months Ended		9 Months Ended		12 Months Ended
Revenue - Concentration of Credit Risk (Details) - customer	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Customer concentration
Concentration Risk [Line Items]
Concentration Risk Threshold Percentage	10.00%		10.00%
Credit concentration
Concentration Risk [Line Items]
Concentration Risk Threshold Percentage			10.00%
Revenues \| Customer concentration
Concentration Risk [Line Items]
Number of customers	4	3	3		3	4
Concentration Risk Threshold Percentage	58.70%	64.90%	57.70%	55.20%
Accounts receivable, net \| Credit concentration
Concentration Risk [Line Items]
Number of customers			3		2	3
Concentration Risk Threshold Percentage			68.10%		73.50%

Revenue - Capitalized Commissio

Revenue - Capitalized Commission Cost (Details) - USD ($)	12 Months Ended
Revenue - Capitalized Commission Cost (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Revenue
Capitalized commission cost, net	$ 509,326
Amortization of capitalized commission cost	232,422
Impairment of contract costs related to canceled projects	$ 162,069	$ 0

Restructuring Costs (Details)

Restructuring Costs (Details)	6 Months Ended	9 Months Ended		12 Months Ended
Restructuring Costs (Details)	Jun. 30, 2021employee	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)employee
Restructuring Costs
Number of employees severed \| employee	20			20
Restructuring costs		$ 771,942	$ 699,473	$ 771,942
Restructuring accruals		$ 0		$ 0

Redeemable Preferred Stock (Det

Redeemable Preferred Stock (Details) - USD ($)	9 Months Ended	12 Months Ended
Redeemable Preferred Stock (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2020
Temporary Equity [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	41,692,230	41,692,230	37,932,831
Preferred stock, issued	41,587,368	41,587,368	32,653,742
Preferred stock, outstanding	41,587,368	41,587,368	32,653,742	41,692,230
Unpaid dividends		$ 0	$ 0
Redeemable shares	9,038,488
Redeemable shares, Value	$ 39,999,919
Preferred stock
Temporary Equity [Line Items]
Preferred stock, issued	0
Series A preferred
Temporary Equity [Line Items]
Preferred stock, shares authorized		6,746,233	6,746,233
Preferred stock, issued		6,641,371	6,746,233
Preferred stock, outstanding		6,641,371	6,746,233
Series B preferred
Temporary Equity [Line Items]
Preferred stock, shares authorized		7,588,369	7,588,369
Preferred stock, issued		7,588,369	7,588,369
Preferred stock, outstanding		7,588,369	7,588,369
Series C preferred
Temporary Equity [Line Items]
Preferred stock, shares authorized		6,001,269	6,001,269
Preferred stock, issued		6,001,269	6,001,269
Preferred stock, outstanding		6,001,269	6,001,269
Series D preferred
Temporary Equity [Line Items]
Preferred stock, shares authorized		12,317,871	17,596,960
Preferred stock, issued		12,317,871	12,317,871
Preferred stock, outstanding		12,317,871	12,317,871
Series D-1 preferred
Temporary Equity [Line Items]
Preferred stock, shares authorized		9,038,488
Preferred stock, issued		9,038,488
Preferred stock, outstanding		9,038,488

Shareholders' Deficit (Details)

Shareholders' Deficit (Details) - $ / shares	3 Months Ended		9 Months Ended		12 Months Ended
Shareholders' Deficit (Details) - $ / shares	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
STOCKHOLDERS' EQUITY
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common stock shares, beginning balance			2,765,097	8,396,425	8,396,425	8,273,865
Issuance of common stock (in shares)	106,752	75,694	1,830,071	148,011	164,886	122,560
Repurchase of common stock					5,796,214
Common stock shares, ending balance	4,595,168	8,544,436	4,595,168	8,544,436	2,765,097	8,396,425
Number of warrants outstanding	1		1		1
Sale of Private Placement Warrants (in shares)	6,439		6,439		6,439
Exercise price of warrants	$ 1.61		$ 1.61		$ 1.61

Loss Per Share (Details)

Loss Per Share (Details) - USD ($)	3 Months Ended				6 Months Ended			9 Months Ended		12 Months Ended
Loss Per Share (Details) - USD ($)	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Net Loss	$ (14,691,871)		$ (7,683,830)					$ (29,232,518)	$ (19,349,948)	$ (31,674,084)	$ (18,468,776)
Denominator:
Basic weighted average common shares outstanding	4,551,755		8,522,923			1,875,000		3,818,717	8,458,434	8,197,409	8,310,333
Diluted weighted average common shares outstanding	4,551,755	3,956,455	8,522,923	8,442,703	3,446,123		8,425,655	3,818,717	8,458,434	8,197,409	8,310,604
Earnings (loss) per share:
Basic (in dollars per share)	$ (3.23)		$ (0.90)					$ (7.66)	$ (2.29)	$ (3.86)	$ (2.22)
Diluted (in dollars per share)	$ (3.23)	$ (1.95)	$ (0.90)	$ (0.70)	$ (4.22)		$ (1.38)	$ (7.66)	$ (2.29)	$ (3.86)	$ (2.22)

Loss Per Share - number of pote

Loss Per Share - number of potential shares outstanding that were anti-dilutive and therefore excluded from the computation of diluted earnings per share, weighted for the portion of the period they were outstanding (Details) - shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	50,445,978	40,345,124	50,195,421	48,113,121	43,058,865	35,919,104
Preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	41,587,368	32,653,742	41,587,368	41,692,230	36,338,255	30,610,834
Stock options outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	8,852,171	7,684,943	8,601,614	6,414,452	6,714,171	5,301,830
Redeemable warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,439	6,439	6,439	6,439	6,439	6,439

Related-Party Transactions (Det

Related-Party Transactions (Details) - USD ($)	Jun. 26, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Total sublease income		$ 230,235	$ 232,294	$ 444,153	$ 696,882	$ 714,254
Revenue from related party		9,875	0	350,585	0
Receivables from related party		2,185		2,185		0
Related party expenses				128,084	0
dRX Capital AG
Related Party Transaction [Line Items]
Revenue from related party		269,547	108,280	565,092	$ 226,843	351,034	$ 451,558
Receivables from related party		166,474		166,474		$ 129,857
Percentage of ownership in related party						50.00%
Good Dermatology
Related Party Transaction [Line Items]
Percentage of lease expenses incurred by entity passed through related party					100.00%	100.00%	100.00%
Total sublease income			29,174		$ 87,523	$ 106,972	$ 116,697
Purchase of clinical trial investigator services						0	273,787
Founder and former CEO
Related Party Transaction [Line Items]
Proceeds from repayments of loan from related party							300,000
Proceeds from repayments of accrued interest on loan from related party	$ 15,682
Pharmaceutical Products Development, LLC, a shareholder
Related Party Transaction [Line Items]
Revenue from related party		2,756,011	$ 3,146,148	10,803,604	$ 3,243,667	9,106,645	0
Receivables from related party		$ 2,244,157		$ 2,244,157		6,927,470	0
Novartis \| dRX Capital AG
Related Party Transaction [Line Items]
Receivables from related party						$ 129,857	$ 9,825
Percentage of ownership in related party		50.00%		50.00%

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Feb. 26, 2020	Nov. 30, 2020	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Dec. 31, 2020	Mar. 31, 2021	Dec. 31, 2019
Commitments And Contingencies [Line Items]
Amount of payments to Director Defendants causing insurers				$ 100,000
Payments to be made to Plaintiffs						$ 1,225,000
Total minimum lease payments					$ 2,853,345	2,677,637	$ 1,578,821	$ 4,832,700
Amount accrued						$ 1,225,000
Good Dermatology
Commitments And Contingencies [Line Items]
Amount owed to cover all outstanding obligations	$ 600,000
Within five business days after Final Dismissal occurred
Commitments And Contingencies [Line Items]
Amount of payments to Director Defendants causing insurers		$ 100,000
Payments to Plaintiffs					$ 3,675,000
Within five business days of the Plaintiffs' receipt of the First Payment
Commitments And Contingencies [Line Items]
Payments to Plaintiffs		$ 3,675,000
Number of common shares equivalent to which Plaintiffs held amount		5,901,076			5,901,076
Within five business days after the Effective Date \| Good Dermatology
Commitments And Contingencies [Line Items]
Amount received for rent and employee costs from plantiff			$ 400,000
Within five business days of wound down \| Good Dermatology
Commitments And Contingencies [Line Items]
Payments to be made to Plaintiffs	1,225,000
Amount owed to cover all outstanding obligations	600,000
If plantiff elected to pay $200,000 directly to Science 37
Commitments And Contingencies [Line Items]
Payments to be made to Plaintiffs	1,225,000
Condition of amount elected to pay directly	200,000
If plantiff elected to pay $0 directly to Science 37
Commitments And Contingencies [Line Items]
Payments to be made to Plaintiffs	1,025,000
Condition of amount elected to pay directly	$ 0

Commitments and Contingencies -

Commitments and Contingencies - Operating Leases (Details) - USD ($)	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Future minimum lease payments under non-cancellable leases
2021	$ 188,943		$ 1,462,045	$ 2,325,562
2022	1,286,301		801,800	1,360,130
2023	629,369		130,332	752,532
2024	599,327		134,054	124,068
2025	137,888		137,888	127,790
2026	11,517
Thereafter			11,518	142,618
Total	2,853,345	$ 1,578,821	2,677,637	$ 4,832,700
Less imputed interest	(264,774)		(197,263)
Accrued expenses and other liabilities	1,103,283		1,352,537
Operating lease liabilities	1,485,288		1,127,837
Total	$ 2,588,571		$ 2,480,374

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock option activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of units outstanding at beginning	7,478,736	5,148,074	4,823,893
Number of units Granted	3,720,500	4,704,932	1,654,000
Number of units Exercised	(1,830,071)	(164,886)	(122,560)
Number of units Forfeited	(472,211)	(2,209,384)	(1,207,259)
Number of units outstanding at ending	8,896,954	7,478,736	5,148,074
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price at beginning	$ 0.68	$ 1.10	$ 1.20
Weighted Average Exercise Price Granted	8.18	0.52	0.82
Weighted Average Exercise Price Exercised	0.67	0.80	0.33
Weighted Average Exercise Price Forfeited	1.19	1.26	1.33
Weighted Average Exercise Price at End	$ 3.79	$ 0.68	$ 1.10

Stock-Based Compensation - Clas

Stock-Based Compensation - Classification of stock-based compensation expense (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 997,979	$ 105,341	$ 1,913,096	$ 1,789	$ 122,032	$ 392,566
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	129,464	4,381	346,516	(70,058)	(64,919)	65,096
Selling, general and administrative costs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 868,515	$ 100,960	$ 1,566,580	$ 71,847	$ 186,950	$ 327,470

Subsequent Events (Details)_2

Subsequent Events (Details) - USD ($)	9 Months Ended
Subsequent Events (Details) - USD ($)	Sep. 30, 2021	Oct. 06, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Balance Sheet Data:
Cash and cash equivalents	$ 7,996,362				$ 32,478,948				$ 27,787,314
Working Capital	(5,566,182)
TOTAL ASSETS	39,746,218				57,031,226				40,327,720
Redeemable convertible preferred stock	143,086,271				143,086,271	$ 93,929,920	$ 86,394,680	$ 80,397,819	106,884,111
Accumulated deficit	(136,979,761)				(107,747,243)				(75,961,522)
Total Stockholders' (Deficit) Equity	$ (106,135,338)		$ (122,287,890)	$ (114,572,770)	$ (106,135,338)		$ (106,135,338)		$ (74,586,364)	$ (56,550,017)
Preferred Stock, Shares Outstanding	41,587,368
Common shares, shares outstanding (in shares)	4,595,168			4,488,416	2,765,097	8,544,436		8,468,742	8,396,425	8,273,865
Pro Forma
Balance Sheet Data:
Cash and cash equivalents	$ 242,991,191
Working Capital	228,647,166
TOTAL ASSETS	273,843,757
Accumulated deficit	(136,979,761)
Total Stockholders' (Deficit) Equity	$ 163,290,011
Common shares, shares outstanding (in shares)	114,707,150
Subsequent events
Subsequent Event [Line Items]
PIPE financing net of fees and expenses		$ 234,200,000
PIPE financing loans		$ 200,000,000

Consolidated Balance Sheets_2

Consolidated Balance Sheets	Dec. 31, 2019USD ($)
Current assets:
Cash and cash equivalents	$ 27,787,314
Restricted cash	720,703
Accounts receivable (including amounts with related parties)	3,339,897
Prepaid expenses and other current assets	1,137,739
Total Current Assets	32,985,653
Noncurrent restricted cash	300,000
Property and equipment, net	626,278
Capitalized software, net	5,868,915
Other assets	546,874
TOTAL ASSETS	40,327,720
Current liabilities:
Accounts payable	423,414
Accrued expenses and other liabilities	1,686,142
Deferred revenue	3,561,778
Deferred rent	478,603
Total current liabilities	6,149,937
Long-term liabilities:
Long-term deferred revenue	1,370,834
Long-term deferred rent	509,202
Total Liabilities	8,029,973
Redeemable preferred stock:
Common stock subject to possible redemption, 8,009,041 and shares at $10.00 per share as of September 30, 2021 and June 30, 2021	106,884,111
Stockholders' deficit:
Common stock, $0.0001 par value; 30,000,000 shares authorized; 2,002,260 shares issued and outstanding at September 30, 2021 and June 30, 2021, excluding 8,009,041 shares of common stock subject to possible redemption	839
Additional paid-in capital	1,374,319
Accumulated deficit	(75,961,522)
Total Stockholders' (Deficit) Equity	(74,586,364)
LIABILITIES, COMMON STOCK SUBJECT TO REDEMPTION AND STOCKHOLDERS' (DEFICIT) EQUITY	$ 40,327,720

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
CONSOLIDATED BALANCE SHEETS
Preferred stock, par value	$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares authorized	41,692,230		41,692,230			37,932,831
Preferred stock, issued	41,587,368		41,587,368			32,653,742
Preferred stock, outstanding	41,587,368		41,587,368	41,692,230		32,653,742
Common shares, par value, (per share)	$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001
Common shares, shares authorized	74,666,115		74,666,115			61,057,864
Common shares, shares issued	4,595,168		2,765,097			8,396,425
Common shares, shares outstanding	4,595,168	4,488,416	2,765,097	8,544,436	8,468,742	8,396,425	8,273,865

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues (including amounts with related parties)	$ 23,704,219	$ 14,080,998
Operating expenses:
Cost of revenues (including amounts with related parties)	22,597,361	7,852,390
Selling, general and administrative	28,351,709	22,012,162
Depreciation and amortization	4,446,670	3,343,802
Restructuring costs	771,942
Total operating expenses	56,167,682	33,208,354
Loss from operations	(32,463,463)	(19,127,356)
Other income:
Interest income	77,229	625,608
Sublease income (including amounts with related parties)	709,283
Other income	2,867	32,972
Other income, net	789,379	658,580
Net loss and other comprehensive loss	$ (31,674,084)	$ (18,468,776)
Loss per share:
Basic net loss per common share	$ (3.86)	$ (2.22)
Diluted net loss per common share	$ (3.86)	$ (2.22)
Denominator:
Basic weighted average common shares outstanding	8,197,409	8,310,333
Diluted weighted average common shares outstanding	8,197,409	8,310,604

Consolidated Statements of Pref

Consolidated Statements of Preferred Stock and Stockholders' Deficit - USD ($)	Common Stock	Preferred StockRedeemable Convertible Preferred Stock.	Preferred Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at the beginning at Dec. 31, 2018			$ 72,155,654
Balance at the beginning (in shares) at Dec. 31, 2018			20,335,871
Increase (Decrease) in Temporary Equity [Roll Forward]
Preferred issuance, net of issuance costs			$ 34,728,457
Preferred issuance, net of issuance costs (in shares)			12,317,871
Balance at the end at Dec. 31, 2019	$ 839	$ 106,884,111	$ 106,884,111	$ 1,374,319	$ (75,961,522)	$ 106,884,111
Balance at the end (in shares) at Dec. 31, 2019	8,396,425	32,653,742	32,653,742			32,653,742
Balance at the beginning at Dec. 31, 2018	$ 827			941,902	(57,492,746)	$ (56,550,017)
Balance at the beginning (in shares) at Dec. 31, 2018	8,273,865
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				392,566		392,566
Proceeds from option exercises	$ 12			39,851		$ 39,863
Proceeds from option exercises (in shares)	122,560					122,560
Net loss						$ (18,468,776)
Balance at the end at Dec. 31, 2019	$ 839			1,374,319	(75,961,522)	(74,586,364)
Balance at the end (in shares) at Dec. 31, 2019	8,396,425
Balance at the end at Mar. 31, 2020	$ 841	$ 106,884,111		1,423,669	(81,822,329)	80,397,819
Balance at the end (in shares) at Mar. 31, 2020	8,409,709	32,653,742
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				32,414		32,414
Proceeds from option exercises	$ 2			16,937		16,939
Proceeds from option exercises (in shares)	13,284
Balance at the beginning at Dec. 31, 2019	$ 839	$ 106,884,111	$ 106,884,111	1,374,319	(75,961,522)	$ 106,884,111
Balance at the beginning (in shares) at Dec. 31, 2019	8,396,425	32,653,742	32,653,742			32,653,742
Increase (Decrease) in Temporary Equity [Roll Forward]
Preferred issuance, net of issuance costs			$ 39,860,073
Preferred issuance, net of issuance costs (in shares)			9,038,488
Treasury stock			$ (3,657,913)
Treasury stock (in shares)			(104,862)
Balance at the end at Dec. 31, 2020	$ 856	$ 143,086,271		1,611,049	(106,135,338)	$ 143,086,271
Balance at the end (in shares) at Dec. 31, 2020	2,765,097	41,587,368				41,587,368
Balance at the beginning at Dec. 31, 2019	$ 839			1,374,319	(75,961,522)	$ (74,586,364)
Balance at the beginning (in shares) at Dec. 31, 2019	8,396,425
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				122,032		122,032
Proceeds from option exercises	$ 17			131,785		$ 131,802
Proceeds from option exercises (in shares)	164,886					164,886
Treasury stock				(17,087)		$ (17,087)
Treasury stock (in shares)	(5,796,214)
Net loss						(31,674,084)
Balance at the end at Dec. 31, 2020						(106,135,338)
Balance at the beginning at Mar. 31, 2020	$ 841	$ 106,884,111		1,423,669	(81,822,329)	80,397,819
Balance at the beginning (in shares) at Mar. 31, 2020	8,409,709	32,653,742
Balance at the end at Jun. 30, 2020	$ 846	$ 106,884,111	$ 143,086,271	1,343,750	(87,739,276)	86,394,680
Balance at the end (in shares) at Jun. 30, 2020	8,468,742	32,653,742
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				(135,966)		(135,966)
Proceeds from option exercises	$ 5			56,047		56,052
Proceeds from option exercises (in shares)	59,033
Balance at the end at Jun. 30, 2020	$ 856			1,611,049	(106,135,338)	(106,135,338)
Balance at the end (in shares) at Jun. 30, 2020	2,765,097		41,587,368
Increase (Decrease) in Temporary Equity [Roll Forward]
Preferred issuance, net of issuance costs		$ 39,923,805
Preferred issuance, net of issuance costs (in shares)		9,038,488
Balance at the end at Sep. 30, 2020	$ 854	$ 146,807,916		1,492,332	(95,423,106)	$ 93,929,920
Balance at the end (in shares) at Sep. 30, 2020	8,544,436	41,692,230				41,692,230
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				105,341		$ 105,341
Proceeds from option exercises	$ 8			43,241		43,249
Proceeds from option exercises (in shares)	75,694
Balance at the beginning at Dec. 31, 2020	$ 856	$ 143,086,271		1,611,049	(106,135,338)	$ 143,086,271
Balance at the beginning (in shares) at Dec. 31, 2020	2,765,097	41,587,368				41,587,368
Balance at the end at Mar. 31, 2021		$ 143,086,271
Balance at the end (in shares) at Mar. 31, 2021		41,587,368
Balance at the beginning at Dec. 31, 2020						$ (106,135,338)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				225,623	225,623
Proceeds from option exercises	$ 51			331,740	331,791
Proceeds from option exercises (in shares)	506,707
Balance at the end at Mar. 31, 2021	$ 907			2,168,412	(112,403,451)	(114,572,770)
Balance at the end (in shares) at Mar. 31, 2021	3,271,804
Balance at the beginning at Dec. 31, 2020	$ 856	$ 143,086,271		1,611,049	(106,135,338)	$ 143,086,271
Balance at the beginning (in shares) at Dec. 31, 2020	2,765,097	41,587,368				41,587,368
Balance at the end at Sep. 30, 2021						$ 143,086,271
Balance at the end (in shares) at Sep. 30, 2021						41,587,368
Balance at the beginning at Dec. 31, 2020						$ (106,135,338)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from option exercises (in shares)						1,830,071
Balance at the end at Sep. 30, 2021	$ 1,039	$ 143,086,271		4,769,114	(132,209,608)	$ (106,135,338)
Balance at the end (in shares) at Sep. 30, 2021	4,595,168	41,587,368
Balance at the beginning at Mar. 31, 2021		$ 143,086,271
Balance at the beginning (in shares) at Mar. 31, 2021		41,587,368
Balance at the end (in shares) at Jun. 30, 2021		41,587,368
Balance at the beginning at Mar. 31, 2021	$ 907			2,168,412	(112,403,451)	(114,572,770)
Balance at the beginning (in shares) at Mar. 31, 2021	3,271,804
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				689,494	689,494
Proceeds from option exercises	$ 121			805,773	805,894
Proceeds from option exercises (in shares)	1,216,612
Balance at the end at Jun. 30, 2021	$ 1,028	$ 143,086,271		3,663,679	(118,623,183)	(122,287,890)
Balance at the end (in shares) at Jun. 30, 2021	4,488,416
Balance at the end at Sep. 30, 2021						$ 143,086,271
Balance at the end (in shares) at Sep. 30, 2021						41,587,368
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense				997,979	997,979
Proceeds from option exercises	$ 11			107,456	107,467
Proceeds from option exercises (in shares)	106,752
Balance at the end at Sep. 30, 2021	$ 1,039	$ 143,086,271		$ 4,769,114	$ (132,209,608)	$ (106,135,338)
Balance at the end (in shares) at Sep. 30, 2021	4,595,168	41,587,368

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Operating activities
Net loss	$ (31,674,084)	$ (18,468,776)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,446,670	3,343,802
Amortization of operating ROU assets	1,885,456
Stock based compensation	122,032	392,566
Changes in assets and liabilities:
Accounts receivable (including amounts with related parties)	(7,860,356)	1,933,814
Prepaid expenses and other current assets	(226,423)	(255,325)
Other assets	363,156	(142,251)
Accounts payable	3,832,398	(443,221)
Accrued expenses and other current liabilities	6,782,108	735,379
Deferred revenue	631,513	(2,889,187)
Operating lease liabilities	(3,607,302)
Deferred rent		194,852
Other long-term liabilities	(170,677)
Net cash used in operating activities	(25,475,509)	(15,598,347)
Investing activities
Capitalized software development costs	(5,814,284)	(4,429,289)
Purchases of fixed assets	(352,009)	(16,664)
Proceeds from receipt of related party advances		454,200
Net cash used in investing activities	(6,166,293)	(3,991,753)
Financing activities
Proceeds from Series D-1 financing, net of issuance costs	39,860,073	34,728,457
Repurchase of common stock	(3,675,000)
Cash received from stock option exercises	131,802	39,863
Net cash provided by financing activities	(36,316,875)	(34,768,320)
Net Change in Cash	4,675,073	15,178,220
Cash - Beginning	28,808,017	13,629,797
Cash - Ending	33,483,090	$ 28,808,017
Supplemental disclosures of non-cash activities
Net change in accounts payable and accrued expenses and other current liabilities related to capitalized software and fixed asset additions	$ 374,935

Company Background and Basis _4

Company Background and Basis of Presentation	9 Months Ended	12 Months Ended
Company Background and Basis of Presentation	Sep. 30, 2021	Dec. 31, 2020
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
Company Background and Basis of Presentation	1. Company Background and Basis of Presentation Organization Science 37, Inc. or “the Company”, a Delaware Corporation, was formed on September 8, 2014. Description of Business The Company is a leading provider of technology-based solutions that enable decentralized clinical trials on behalf of biopharmaceutical sponsors. The Company pioneered the decentralized clinical trial model and developed the industry’s first Decentralized Clinical Trial Operating System (DCT OS), combining its technology platform, which orchestrates workflows, supports evidence generation, and harmonizes data seamlessly, with its Specialized Network of patient communities, on-demand telemedicine investigators, flexible mobile nurses, scalable remote coordinators and robust connected technologies. By bringing research to patients and providers more directly, the Company’s operating system increases access and patient diversity, which can help speed the development of potentially life-saving drug treatments. On May 7, 2021, the Company announced a planned merger with LifeSci Acquisition II Corp (“LSAQ”) under a definitive business combination agreement. The merger was consummated on October 6, 2021, whereby LSAQ acquired 100% of the Company's issued and outstanding securities through a reverse merger of the Company with and into a wholly owned subsidiary of LSAQ, with the Company surviving the merger as Science 37 Holdings, Inc, now a public company. In conjunction with this merger, the Company received $200 million through a private investment in public entity (PIPE) offering from leading institutional and strategic investors to further fund the Company’s decentralized trial technology platform and extend into new adjacencies. Unaudited Interim Financial Information and Use of Estimates The Company prepared the accompanying unaudited condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all the information and notes required by GAAP for complete financial statements. The significant accounting policies followed by the Company for interim financial reporting are consistent with the accounting policies followed for annual financial reporting. The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. These estimates are based on historical experience and various other assumptions believed reasonable under the circumstances. The Company evaluates its estimates on an ongoing basis and makes changes to the estimates and related disclosures as experience develops or new information becomes known, including facts and circumstances related to the novel coronavirus disease pandemic. Actual results will most likely differ from those estimated. The Company’s most significant estimates and assumptions used in the preparation of the accompanying condensed consolidated financial statements relate to contract cost estimates in revenue recognition, capitalized software costs, and the valuation of the Company’s common stock. The condensed consolidated financial statements, in management’s opinion, include all adjustments of a normal recurring nature necessary for a fair presentation. The information included in this filing should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in this filing for the year ended December 31, 2020. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or any other future period. The consolidated balance sheet at December 31, 2020 is derived from the amounts in the audited balance sheet included in this filing for the year ended December 31, 2020. 1. Company Background and Basis of Presentation (continued) Liquidity The Company has continued to experience increased costs that adversely affect the Company's current results of operations and liquidity. The Company's condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements for the three and nine months ended September 30, 2021 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company's ability to continue as a going concern. As of September 30, 2021, the Company had $7,996,362 of unrestricted cash. On October 6, 2021, the definitive business combination agreement between the Company and LifeSci Acquisition II Corp (LSAQ) was consummated. LSAQ acquired 100% of the Company's issued and outstanding securities through a reverse merger of the Company with and into a wholly owned subsidiary of LSAQ, with the Company surviving the merger as Science 37 Holdings, Inc, now a public company. In conjunction with this merger, the Company received $200 million through a private investment in public entity (PIPE) offering from institutional and strategic investors to further fund the Company's decentralized trial technology platform and extend into new adjacencies. As a result of the merger and inclusive of the PIPE financing, the Company received $234.2 million, net of fees and expenses paid in connection with the closing of the business combination. The Company believes that its $8.0 million of cash as of September 30, 2021, in addition to the proceeds received from the merger with LSAQ and PIPE offering, are sufficient to fund planned operations for at least 12 months from the date these financial statements were available to be filed. Concentration Risks Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, deposits of up to $250,000 at Federal Deposit Insurance Corporation (FDIC) insured institutions are covered by FDIC insurance. At times, deposits at the Company’s financial institution may exceed federally insured limits. Management periodically assesses the financial condition of the institution and believes that any possible credit risk is minimal. The Company has not experienced any loss from such risk. COVID-19 Pandemic In March 2020 the World Health Organization declared the global novel coronavirus disease 2019 (COVID-19) outbreak a pandemic. The Company’s original sublease tenant in San Francisco was unable to fulfill its sublease obligations due to the pandemic’s impact on its business operations. The sublessee vacated the facility in February 2021 and a new sublessee was not secured until May 2021, at terms substantially similar to the original sublessee. For the nine months ended September 30, 2021 and 2020, the Company wrote-off $228,946 and $0 of sublease receivable against sublease income due to low probability of collection from the original sublessee. No other significant impacts to the Company’s operations due to the COVID-19 outbreak have occurred. 1. Company Background Basis of Presentation (continued) Capitalized Software The Company’s internal use proprietary software organizes workflows, captures real-time evidence, and harmonizes data during clinical trial support for its customers. Capitalized software is recorded at cost less accumulated amortization. The Company capitalizes software development cost related to the development of the Company’s proprietary platform in accordance with ASC 350 guidance. Internal and external costs incurred during the preliminary stage are expensed as incurred. Costs incurred during the application development stage are capitalized and consist of payroll labor and benefits to the extent of time spent directly on the project and external direct costs of materials and labor. Training and maintenance costs are expensed as incurred. The Company commences amortization once the respective assets are placed into service. The estimated useful life for capitalized software is 3 years . Assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the expected undiscounted future cash flow from the use of the asset and its eventual disposition is less than the carrying amount of the asset, an impairment loss is recognized and measured using the fair value of the related asset. No material impairments were recognized during the three and nine months ended September 30, 2021 and 2020. Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Segments Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined that its Senior Executive Committee, which includes the Chief Executive Officer, together with the Board of Directors is the CODM. The Company operates in a single operating segment as the CODM reviews financial information presented on a consolidated basis, at the Company level, for the purposes of making operating decisions, allocation of resources, and evaluating financial performance. As of and for the nine months ended September 30, 2021 and 2020, the Company did not have material revenue earned or assets located outside of the United States. Accounting Pronouncements Issued but Not Adopted as of September 30, 2021 In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by a reporting entity. The standard replaces the incurred loss impairment methodology in current GAAP with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company does not expect the adoption of the guidance to have a material effect on the Company’s consolidated financial statements. This is based on factors including the Company’s assessment of historical losses, customer’s creditworthiness, and the fact that the Company’s trade receivables are short term in duration. The Company expects to implement this new standard in January 2022.	1. Company Background and Basis of Presentation Organization Science 37 or the “Company”, a Delaware Corporation, was formed on September 8, 2014. Description of Business Science 37 is a leading provider of technology-based solutions that enable decentralized clinical trials (or direct-to patient virtual studies) on behalf of biopharmaceutical sponsors. Science 37 pioneered the decentralized clinical trial model and developed the industry’s first Decentralized Clinical Trial Operating System (DCT OS), combining its technology platform, which orchestrates workflows, supports evidence generation, and harmonizes data seamlessly, with its expansive network of patient communities, on-demand telemedicine investigators, flexible mobile nurses, scalable remote coordinators and robust connected technologies. By bringing research to patients and providers more directly, Science 37’s operating system increases access and patient diversity, which can help speed the development of potentially life-saving drug treatments. Liquidity The Company has continued to experience increased costs that adversely affect the Company’s current results of operations and liquidity. The Company’s consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements for the year ended December 31, 2020 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company's ability to continue as a going concern. The Company has evaluated principal conditions and events, considered in aggregate, that may raise substantial doubt about its ability to continue as a going concern within one year from the date that these financial statements were originally issued. As of December 31, 2020, the Company had $32,478,948 of unrestricted cash. On October 6, 2021, the definitive business combination agreement between the Company and LifeSci Acquisition II Corp (LSAQ) was consummated. LSAQ acquired 100% of the Company’s issued and outstanding securities through a reverse merger of the Company with and into a wholly owned subsidiary of LSAQ, with the Company surviving the merger as Science 37 Holdings, Inc, a now public company. In conjunction with this merger, the Company received $200 million through a private investment in public entity (PIPE) offering from institutional and strategic investors to further fund the Company’s decentralized trial technology platform and extend into new adjacencies. As a result of the merger and inclusive of the PIPE financing, the Company received $234.2 million, net of fees and expenses paid in connection with the closing of the business combination. The Company believes that its $32.5M of cash as of December 31, 2020, in addition to the proceeds received from the merger with LSAQ and PIPE offering, are sufficient to fund planned operations for at least 12 months from the date of issuance of these financial statements. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). 1. Company Background and Basis of Presentation (continued) Concentration Risks Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, deposits of up to $250,000 at Federal Deposit Insurance Corporation (FDIC) insured institutions are covered by FDIC insurance. At times, deposits at the Company’s financial institution may exceed federally insured limits. Management periodically assesses the financial condition of the institution and believes that any possible credit risk is minimal. The Company has not experienced any loss from such risk. COVID-19 Pandemic In March 2020 the World Health Organization declared the global novel coronavirus disease 2019 (COVID-19) outbreak a pandemic. The Company’s sublease tenant in San Francisco has been unable to fulfill its sublease obligations due to the pandemic’s impact on its business operations. The sublessee vacated the facility in February 2021. In 2020, the company wrote-off $312,940 of sublease receivable against sublease income due to low probability of collection. No other significant impacts to the Company’s operations due to the COVID-19 outbreak have occurred. The Company’s operations may be adversely affected in the near term as a result of COVID-19, and in the longer-term by the overall impact on the economy and disruptions to the Company’s existing business and partners, and the Company’s customer collection efforts. Additionally, there could be a near term impact on the Company’s employees as a result of COVID-19 and the related Federal, State, and local and UK governmental restrictions. However, the long- term impact is not fully known as the scale and severity of the outbreak continues to unfold. Since the second quarter of 2020, the Company has experienced overall top line growth due to the advantages the Company’s decentralized proprietary platform provides for healthcare companies and institutions in the clinical trial space. Due to these advantages, Management expects this growth to continue. On March 27, 2020, the U.S. enacted the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the U.S. economy and fund a nationwide effort to curtail the effect of COVID 19. While the CARES Act provides sweeping tax changes in response to the COVID 19 pandemic, some of the more significant provisions include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. Consistent with previous years, the Company expects to continue to generate net losses in the foreseeable future. The Company currently has significant federal and state deferred tax assets attributed to prior net operating losses. These deferred taxes are fully reserved. As the Company has never generated taxable income, the CARES Act feature allowing net operating losses originating in 2018, 2019 or 2020 to be carried back five years is not expected to have a significant impact. Management does not expect any other provisions of the CARES Act to have a material impact on the Company’s financial position, results of operations or cash flows during 2020.

Summary of Significant Accou_13

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. These estimates are based on historical experience and various other assumptions believed reasonable under the circumstances. The Company evaluates its estimates on an ongoing basis and makes changes to the estimates and related disclosures as experience develops or new information becomes known, including facts and circumstances related to the novel coronavirus disease pandemic. Actual results may differ from those estimated. The Company’s most significant estimates and assumptions used in the preparation of the accompanying consolidated financial statements relate to contract cost estimates in revenue recognition, capitalized software costs, and the valuation of the Company’s common stock. 2. Summary of Significant Accounting Policies (continued) Foreign Currency The Company has one bank account with a de minimis balance denominated in Swiss Francs and, therefore, has minimal foreign currency exposure. Revenue Recognition The Company derives its revenues primarily from two sources: (i) contractual arrangements to enable and enhance clinical trials through technology and/or services, and (ii) licensing of its proprietary hosted technology platform to a variety of life science institutions. Revenues are recognized when control of these services is transferred to our customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. The Company determines revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when, or as, we satisfy a performance obligation A performance obligation is a promise (or a combination of promises) in a contract to transfer distinct goods or services to a customer and is the unit of accounting under ASC 606 for purposes of revenue recognition. A contract’s transaction price is allocated to each separate performance obligation based on the standalone selling price and is recognized as revenue, when, or as, the performance obligation is satisfied. All of the Company’s contracts have a single performance obligation because the promise to transfer individual services is not separately identifiable from other promises in the contracts, and therefore, is not distinct. The majority of the Company’s revenue arrangements are service contracts that range in duration from a few months to several years. Substantially all of the Company’s performance obligations, and associated revenue, are transferred to the customer over time. The performance obligation is satisfied over time and the Company generally recognizes revenue based on a cost-based input method, due to costs being incurred consistently throughout the life of the contract, as there is no single output measure that would fairly depict the transfer of control over the life of the performance obligation. Progress on the performance obligation is measured by the proportion of actual costs incurred to the total costs expected to complete the contract. Costs included in the measure of progress include direct labor and third-party costs (such as payments to investigators and other pass-through expenses for the Company’s clinical monitors). This cost-to-cost input method of revenue recognition requires the Company to make estimates of costs to complete its projects on an ongoing basis. Contract estimates are based on various assumptions to project future outcomes of events that often span several years and require significant judgment. These estimates are reviewed periodically, and any adjustments are recognized on a cumulative catch-up basis in the period they become known. 2. Summary of Significant Accounting Policies (continued) The Company generally receives compensation based on measuring progress toward completion using anticipated project budgets and direct labor and prices for each service offering. The Company is also reimbursed for certain third party pass-through and out-of-pocket costs. The pass-through costs are included in total operating expenses. The pass-through costs are also recognized as revenue on a gross basis as the Company is the principal in the relationship (i.e., the Company is primarily responsible for the services provided by third parties, and significantly integrates the services of third parties with its own services in delivering a combined output to the customer). In addition, in certain instances, a customer contract may include forms of variable consideration such as incentive fees, volume rebates or other provisions that can increase or decrease the transaction price. This variable consideration is generally awarded upon achievement of certain performance metrics, program milestones or cost targets. For the purpose of revenue recognition, variable consideration is assessed on a contract-by-contract basis and the amount included in the transaction price is estimated based on the Company’s anticipated performance and consideration of all information that is reasonably available. Variable consideration is recognized as revenue if and when it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved in the future. The Company has one performance-based contract, which is unique in that the Company’s obligation to the customer is solely for the recruitment of successfully processed patients or “completers”. The successful recruitment of completers constitutes a single performance obligation to our customer. Completer revenue is recognized at a point in time, as completers are processed. For contracts where the Company licenses its proprietary hosted software independently, value transfers to the customer over time as the customer has access to the system once it is live and continues to benefit over the life of the arrangement. Revenue is recorded straight line over the term of the hosting and maintenance period as there is no better measure of the transfer of value for these services. Most of the Company’s contracts can be terminated by the customer without cause with a 30-day notice. In the event of termination, the Company’s contracts generally provide that the customer pay the Company for: (i) fees earned through the termination date; (ii) fees and expenses for winding down the project, which include both fees incurred and actual expenses; (iii) non-cancellable expenditures; and (iv) in some cases, a fee to cover a portion of the remaining professional fees on the project. Changes in the scope of work are common, especially under long-term contracts, and generally result in a change in the total contract transaction price. If the customer does not agree to a contract modification, the Company could bear the risk of cost overruns. Most of the Company’s contract modifications are for services that are not distinct from the services under the existing contract due to the significant integration service provided in the context of the contract and therefore result in a cumulative catch-up adjustment to revenue at the date of contract modification. Capitalized Costs The Company capitalizes certain costs associated with commissions paid to its employees because these costs are incurred in obtaining contracts that have a term greater than one year and are expected to be recovered. Capitalized costs are included in prepaid expenses and other current assets and other assets in the accompanying balance sheet and are amortized to selling, general and administrative expense on the statement of operations. The Company amortizes these costs in a manner that is consistent with the pattern of revenue recognition described above. The Company expenses costs to obtain contracts that have a term of one year or less when incurred. Cost of Revenues Cost of revenues includes the cost to conduct trials remotely and make available the Company’s technology solutions to its customers. Cost of revenues includes direct labor salaries, direct labor stock- based compensation, and third-party costs (such as payments to investigators, marketing costs, and other pass through expenses) for the Company’s clinical trial revenue. Clinical trial marketing costs totaled $6,814,902 and $762,740 for the year ended December 31, 2020 and 2019, respectively. 2. Summary of Significant Accounting Policies (continued) Selling, General and Administrative Costs Selling, general and administrative costs are summarized as follows for the years ended December 31, 2020 and 2019: 2020 2019 Compensation and benefits $ 16,696,017 $ 13,094,579 Rent expense and other facilities costs 7,132,472 5,801,044 Professional fees and consultants 3,211,270 2,789,069 Legal settlement 1,125,000 — Stock based compensation 186,950 327,470 Total $ 28,351,709 $ 22,012,162 Restructuring Restructuring costs consist of one-time employee termination benefits. The Company accounts for restructuring costs in accordance with ASC Topic 420, Exit or Disposal Cost Obligations. This guidance requires that liabilities related to one-time employee termination benefits be measured and recognized at the date the entity notifies employees of termination, unless employees are required to render services beyond a minimum retention period, in which case the liability is recognized ratably over the future service period. Restructuring liabilities are included in accrued expenses. Cash and Cash Equivalents The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents, which consist of cash on deposit with banks are stated at cost, which approximates fair value. Restricted Cash Restricted cash consists of funds held as security related to the Company’s credit instrument held as collateral on the Company’s operating lease. The funds become no longer restricted at certain intervals in accordance with the related lease agreement. Restricted cash is classified as a current or long-term asset based on the timing and nature of when and how the cash is expected to be used or when the restrictions are expected to lapse. As of December 31, 2020, and 2019, restricted cash balances were $1,004,142 and $1,020,703 Accounts Receivable, Unbilled Services, and Deferred Revenue The Company establishes prerequisites for billings based on contractual terms, including payment schedules and the completion of milestones. In general, the Company’s intention in its invoicing and related payment terms is to maintain cash neutrality over the life of the contract. Generally, the payment terms are 30 to 90 days. Upfront payments, when they occur, are intended to cover certain expenses the Company incurs at the beginning of the contract. Neither the Company nor its customers view such upfront payments and contracted payment schedules as a means of financing. Unbilled services represent revenue earned and recognized for services performed for which amounts have not yet been billed to the customer in accordance with contractual terms. Contractual provisions and payment schedules may or may not correspond to the timing of the performance of services under the contract. Unbilled services include contract assets, under which the right to bill the customer is subject to factors other than the passage of time, such as the satisfaction of milestones. Accounts receivable and unbilled services are recorded, net, on the balance sheet. 2. Summary of Significant Accounting Policies (continued) Deferred revenue is a contract liability that consists of customer payments received in advance of performance and billings that exceed revenue recognized. The Company reduces deferred revenue and recognizes revenue as the related performance obligations for services are performed. Deferred revenue is classified as a current liability on the balance sheet when the Company expects to recognize the associated revenue in less than one year, and a long-term liability when the company expects to recognize the associated revenue in excess of one year. Allowance for Doubtful Accounts The Company maintains a credit approval process and makes judgments to assess its customers’ ability to pay for contracted services. Generally, the Company can limit credit exposure by discontinuing services in the event of non-payment. The Company monitors its customers’ credit worthiness and applies judgment in establishing a provision for estimated credit losses based on historical experience, the aging of receivables, and customer-specific circumstances. The Company continuously monitors collections and payments from its customers and writes off uncollectible invoices once appropriate collection efforts have been exhausted. The allowance for doubtful accounts is included in accounts receivable on the consolidated balance sheet. As of December 31, 2020 and 2019, no allowances were necessary. Long-Lived Assets Property and equipment are recorded at cost less accumulated depreciation. Maintenance and repairs are expensed as incurred. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method. The estimated useful lives of depreciable assets are as follows: Furniture and fixtures 5 years Computer equipment 3 years Drug storage equipment 5 years Leasehold improvements 4 – 5 years Depreciation of leasehold improvements is computed using the straight-line method over the shorter of the remaining lease term or the estimated useful lives of the improvements. Upon the sale or retirement of property or equipment, the cost and related accumulated depreciation or amortization are removed from the Company’s consolidated financial statements with the resulting gain or loss reflected in the Company’s results of operations. The Company’s internal use proprietary hosted software organizes workflows, captures real-time evidence, and harmonizes data during clinical trial support or enhancement for its customers. Capitalized software is recorded at cost less accumulated amortization. The Company capitalizes software development cost related to the development of the Company’s proprietary platform in accordance with ASC 350 guidance. Internal and external costs incurred during the preliminary stage are expensed as incurred. Costs incurred during the development stage are capitalized and consist of payroll labor and benefits to the extent of time spent directly on the project and external direct costs of materials and labor. Training and maintenance costs are expensed as incurred. The Company commences amortization once the respective assets are placed into service. The estimated useful life for capitalized software is 3 years. Assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the expected undiscounted future cash flow from the use of the asset and its eventual disposition is less than the carrying amount of the asset, an impairment loss is recognized and measured using the fair value of the related asset. No material impairments were recognized during the years ended 2020 or 2019. 2. Summary of Significant Accounting Policies (continued) Leases On January 1, 2020, the Company adopted ASC 842 under the revised modified retrospective approach which recognizes the impact of initially applying the new leases standard as a cumulative effect adjustment to accumulated deficit as of the adoption date. Under this election, the provisions of prior GAAP (ASC 840) apply to the accounting and disclosure for leases in the comparative periods of the entity’s financial statements. The Company also elected the package of practical expedients permitted under the ASC 842 transition guidance. Under this election, the Company need not reassess (i) the historical lease classification, (ii) whether any expired or existing contract is or contains a lease, or (iii) the initial direct costs for any existing leases. The Company determines if an arrangement is a lease at inception of the contract. A contract contains a lease if the Company controls the use of an identified asset. Control exists if the Company can direct the use of and obtain substantially all the economic benefit of the asset. Operating lease right-of-use (ROU) assets and liabilities are recorded on our balance sheet and are measured based on the present value of the future minimum lease payments over the lease term at commencement date. The Company’s uses its incremental borrowing rate at lease commencement in determining the present value of future payments. In addition, the operating lease ROU asset includes any prepaid lease payments and initial direct costs and excludes lease incentives. If the Company has an option to extend, or terminate, a lease and is reasonably certain to exercise that option, the extension or termination is included in the lease term used to measure the ROU asset and lease liability. Lease expense for minimum lease payments is recognized on a straight-line basis over the term of the lease. The Company has elected to account for lease components and non-lease components in a contract as a single lease component. For short-term leases (those with a term of one year or less), the Company has elected not to recognize ROU assets and lease liabilities. Lease payments on short-term leases are recognized as lease expense on a straight-line basis over the term of the lease. Deferred Rent Under prior GAAP (ASC 840), rent expense on facility leases, including free rent and scheduled rent increases, is recorded on a straight-line basis over the term of the lease for the year ending December 31, 2019. The difference between the straight-line rent expense and the amount payable under the lease is included in deferred rent on the accompanying 2019 balance sheet. Lease incentives were recorded and amortized as a reduction of rent expense on a straight-line basis over the term of the lease. Stock-Based Compensation The Company measures stock-based compensation cost based on the fair value of the award at the grant date, and recognizes it as expense, net of actual forfeitures as they occur, over the requisite service period of the employee. The Company accounts for stock options under the fair value method and uses the Black-Scholes- Merton model to estimate the value of such awards granted to its employees, consultants, and non-executive directors. Within this model, expected volatility is based upon the historical volatility of a peer group for a period equal to the expected term, as the Company does not have adequate history to calculate its own volatility. The Company believes the expected volatility will approximate the historical volatility of the peer group. The Company does not currently anticipate paying dividends. The expected term represents the period in which the grants are expected to be outstanding. The risk- free interest rate is based on the United States Treasury yield curve in effect at the time of the grant. 2. Summary of Significant Accounting Policies (continued) Assets Measured at Fair Value Fair value is the price that would be received to sell an asset or paid to transfer a liability between market participants in the principal market or the most advantageous market when no principal market exists. Market participants are assumed to be independent, knowledgeable, able, and willing to transact an exchange and not under duress. Considerable judgment may be required in interpreting market data used to develop the estimates of fair value. Accordingly, estimates of fair value are not necessarily indicative of the amounts that could be realized in a current or future market exchange. Fair values for substantially all of the Company’s financial and nonfinancial instruments were measured using market, income, or cost approaches. The three levels of input are as follows: Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial instruments, including cash and cash equivalents, are recorded at cost, which approximates fair value. The Company does not have any assets or liabilities measured at Level 2 or Level 3. Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records valuation allowances to reduce deferred tax assets to the amount the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not upheld on examination by the taxing authorities based solely upon the technical merits of the positions. The Company recognizes interest and penalties, if any, related to unrecognized income tax uncertainties in income tax expense. Contingencies The Company is party to legal proceedings incidental to its business. The Company records accruals for claims, suits, investigations, and proceedings when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company reviews these contingencies regularly and records or adjusts accruals related to such matters to reflect the impact and status of any settlements, rulings, advice of counsel or other information pertinent to a particular matter. Gain contingencies are not recognized. Legal fees are expenses as incurred. Since these matters are inherently unpredictable, assessing contingencies is highly subjective and requires judgments about future events. Although the Company believes it has substantial defenses in these matters, the amount of losses incurred as a result of actual outcomes may differ significantly from the Company’s estimates. 2. Summary of Significant Accounting Policies (continued) Treasury Stock The Company records treasury stock purchases under the cost method. Upon reissuance of treasury stock, amounts in excess of the acquisition cost are credited to additional paid in capital. If the Company reissues treasury stock at an amount below its acquisition cost and additional paid in capital associated with prior treasury stock transactions is insufficient to cover the difference between the acquisition cost and the reissue price, this shortfall is recorded in accumulated deficit. Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Segments Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined that its Senior Executive Committee, which includes the Chief Executive Officer, together with the Board of Directors is the CODM. The Company operates in a single operating segment as the CODM reviews financial information presented on a consolidated basis, at the Company level, for the purposes of making operating decisions, allocation of resources, and evaluating financial performance. As of and for the years ended December 31, 2020 and 2019, the Company did not have material revenue earned or assets located outside of the United States. Accounting Pronouncements Adopted as of December 31, 2020 In February 2016, the FASB issued new accounting guidance that requires lessees to recognize leases greater than 12 months in duration on their balance sheet as a right-of-use asset and a lease liability, as well as the disclosure of key information about leasing arrangements. The income statement will reflect lease expense for operating leases, and amortization and interest expense for financing leases. The Company adopted this new accounting guidance on January 1, 2020 and elected the practical expedients that retained the lease classification, initial direct costs, and determination of whether contracts are or contain a lease, for any leases that existed prior to adoption of the new guidance. The Company also elected the transition method which allows for disclosures to be updated prospectively and prior periods to be presented in accordance with previous GAAP. The adoption of this standard had a material impact on the Company’s balance sheet but did not have a material impact on the Company’s results of operations or cash flows. 2. Summary of Significant Accounting Policies (continued) Accounting Pronouncements Issued but Not Adopted as of December 31, 2020 In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by a reporting entity. The standard replaces the incurred loss impairment methodology in current GAAP with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company does not expect the adoption of the guidance to have a material effect on the Company’s consolidated financial statements. This is based on factors including the Company’s assessment of historical losses, customers’ creditworthiness, and the fact that the Company’s trade receivables are short term in duration. The Company expects to implement this new standard in January 2022.

Revenue_2

Revenue	9 Months Ended	12 Months Ended
Revenue	Sep. 30, 2021	Dec. 31, 2020
Revenue
Revenue	2. Revenue Revenues by Geography Substantially all of the Company’s revenue for the three and nine months ending September 30, 2021 and 2020 was derived from services performed within the United States. No other country represented more than 10% of total revenue for either period. Unsatisfied Performance Obligations As of September 30, 2021, the aggregate amount of transaction price allocated to the unsatisfied performance obligations was $118,892,662 . The Company expects to recognize this revenue over the remaining contract term of the individual projects, with contract terms generally ranging from one month to 6.4 years. The amount of unsatisfied performance obligations is lower than the potential contractual revenue since it excludes revenue that is constrained. Revenue amounts excluded due to constraints include those amounts under contracts that are wholly unperformed in which the customer has a unilateral right to cancel the arrangement, or that require the Company to undertake numerous activities to fulfill the performance obligations, including various activities that are outside of the Company’s control. Timing of Billing and Performance During the three and nine months ended September 30, 2021, the Company recognized approximately $3,151,080 and $3,962,270 of revenue that was included in the deferred revenue balance at the beginning of the period. During the three and nine months ended September 30, 2021, revenue recognized from performance obligations partially satisfied in previous periods was $3,170,297 and $6,322,520 . These cumulative catch-up adjustments primarily related to contract modifications executed in the current period, which resulted in changes to the transaction price resulting from change orders. Accounts Receivable, Unbilled Services, and Deferred Revenue Accounts receivable and unbilled services (including contract assets) consisted of the following: September 30, 2021 December 31, 2020 Accounts receivable $ 6,233,698 $ 8,688,441 Unbilled services $ 907,840 2,511,811 Total accounts receivable and unbilled services 7,141,538 11,200,252 Allowance for doubtful accounts (142,830) — Total accounts receivable and unbilled services, net $ 6,998,708 $ 11,200,252 As of September 30, 2021 and December 31, 2020, contract assets of $907,840 and $2,511,811 , respectively, were included in unbilled services. Deferred revenue consisted of the following: September 30, 2021 December 31, 2020 Deferred revenue $ 7,626,905 $ 5,564,124 The changes in the Company’s contract assets and deferred revenue resulted from the timing difference between the Company’s satisfaction of performance obligations under its contracts, achievement of billing milestones, and customer payments. 2. Revenue (continued) Concentration of Credit Risk Financial assets that subject the Company to credit risk primarily consist of cash and cash equivalents, accounts receivable and unbilled services. Based on the short-term nature and historical realization of the financial assets as well as the reputable credit ratings of the financial institutions holding the deposits, the Company believes it bears minimal credit risk. For the three months ended September 30, 2021 and 2020, four and three customers individually (totaling 58.7% and 64.9% , respectively) accounted for greater than 10% of revenue. For the nine months ended September 30, 2021 and 2020, three customers individually (totaling 57.7% and 55.2% , respectively) accounted for greater than 10% of revenue. As of September 30, 2021 and December 31, 2020, three and two customers individually (totaling 68.1% and 73.5% , respectively) accounted for greater than 10% of accounts receivable, net.	3. Revenue Revenues by Geography Substantially all of the Company’s revenue for the years ending December 31, 2020 and 2019 was derived from services performed within the United States. No other country represented more than 10% of total revenue for either year. Unsatisfied Performance Obligations As of December 31, 2020, the aggregate amount of transaction price allocated to the unsatisfied performance obligations with contract terms greater than one year was $52,415,469. The Company expects to recognize this revenue over the remaining contract term of the individual projects, with contract terms generally ranging from 1.5 to 7.1 years. The amount of unsatisfied performance obligations is lower than the potential contractual revenue since it excludes revenue that is constrained. Revenue amounts excluded due to constraints include those amounts under contracts that are wholly unperformed in which the customer has a unilateral right to cancel the arrangement, or that require the Company to undertake numerous activities to fulfill the performance obligations, including various activities that are outside of the Company’s control. Timing of Billing and Performance During the years ended December 31, 2020, and 2019, the Company recognized approximately $4,349,278 and $5,667,532 of revenue that was included in the deferred revenue balance at the beginning of the years, respectively. During the years ended December 31, 2020, and 2019 revenue recognized from performance obligations partially satisfied in previous periods was ($74,540) and $0, respectively. These cumulative catch-up adjustments primarily related to contract modification executed in the current period, which resulted in changes to the transaction price and changes in estimates such as estimated total costs. Accounts Receivable, Unbilled Services, and Deferred Revenue Accounts receivable and unbilled services (including contract assets) consisted of the following as of December 31: 2020 2019 Accounts receivable $ 8,688,441 $ 1,426,874 Unbilled services 2,511,811 1,913,023 Total accounts receivable and unbilled services $ 11,200,252 $ 3,339,897 As of December 31, 2020, and 2019, contract assets of $2,511,811 and $85,465, respectively, were included in unbilled services. 3. Revenue (continued) Deferred revenue consisted of the following as of December 31: 2020 2019 Deferred revenue $ 5,564,124 $ 4,932,612 Year over year changes in the Company’s accounts receivable, unbilled services, and deferred revenue resulted from 1) significant contract and revenue growth for the year ended December 31, 2020 as compared to the year ended December 31, 2019 and 2) the timing difference between the Company’s satisfaction of performance obligations under its contracts, achievement of billing milestones, and customer payments. Concentration of Credit Risk Financial assets that subject the Company to credit risk primarily consist of cash and cash equivalents, accounts receivable and unbilled services. Based on the short-term nature and historical realization of the financial assets as well as the reputable credit ratings of the financial institutions holding the deposits, the Company believes it bears minimal credit risk. As of December 31, 2020, and 2019, three customers and four customers individually (totaling 69.2% and 81.8%, respectively) accounted for greater than 10% of revenue and two customers and three customers individually (totaling 73.5% and 91.7%, respectively) accounted for greater than 10% of accounts receivable, net. Capitalized Commission Cost Capitalized commission costs are incremental costs incurred to obtain a contract. The Company incurs incremental costs to obtain contracts through payment of sales commissions on contracts signed. The Company capitalizes commission costs when incurred and amortizes to expense over the term of the related contract. Capitalized commission costs and related amortization consisted of the following as of December 31: 2020 2019 Capitalized commission cost, net $ 509,326 $ — 2020 2019 Amortization of capitalized commission cost $ (232,422) $ — $162,069 and $0 in contract costs were impaired related to canceled projects for the years ended December 31, 2020 and 2019, respectively.

Property and Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2020
Property and Equipment
Property and Equipment	4. Property and Equipment Property and equipment are summarized as follows at December 31, 2020 and 2019: 2020 2019 Furniture and fixtures $ 298,877 $ 298,877 Drug storage equipment 115,054 115,054 Computer equipment 475,798 111,574 Leasehold improvements 1,239,147 1,252,885 2,128,876 1,778,390 Less accumulated depreciation (1,593,492) (1,152,112) Property and equipment, net $ 535,384 $ 626,278 Depreciation on property and equipment was $449,815 and $424,796 for the years ended December 31, 2020 and 2019, respectively.

Capitalized Software

Capitalized Software	12 Months Ended
Capitalized Software	Dec. 31, 2020
Capitalized Software
Capitalized Software	5. Capitalized Software For the years ended December 31, 2020 and 2019 the Company capitalized $6,177,005 and $4,429,289, and recognized amortization expense of $3,991,553 and $2,919,006, respectively. Estimated amortization expense for the years ending December 31, 2021 through December 31, 2023 is as follows: Amortization Expense Year: 2021 $ 4,195,131 2022 2,804,127 2023 1,055,109 Estimated amortization expense can be affected by various factors, including new software releases, acquisitions or divestitures of software and/or impairments. The following represents capitalized software balances as of December 31, 2020 and 2019: 2020 2019 Gross Accumulated Net Gross Accumulated Net Amount Amortization Amount Amount Amortization Amount Capitalized software $ 18,638,249 $ (10,583,882) $ 8,054,367 $ 12,461,245 $ (6,592,330) $ 5,868,915

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2020
Leases
Leases	6. Leases The Company has operating leases for office facilities. These operating leases expire at various dates through 2026 with options to renew at the Company’s discretion. The Company does not currently plan to exercise renewal options. The components of lease expense for the year ended December 31, 2020 were as follows: Classification 2020 Operating fixed lease cost Selling, general and administrative expenses $ 2,126,662 Operating variable lease cost Selling, general and administrative expenses 238,205 Total lease cost $ 2,364,867 Under ASC 840, the Company recorded rent expense of $2,005,583 for the year ended December 31, 2019. Lease expense for the years ended December 31, 2020 and 2019 contains $359,776 and $79,360, respectively, of expense related to short-term leases. Variable lease expense for both years includes excess common area maintenance, electricity, and taxes. Other information related to leases was as follows: 2020 Supplemental cash flow Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 2,495,972 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 4,095,709 Weighted average remaining lease term (years): Operating leases 2.24 Weight average discount rate: Operating leases 6.50 % Future minimum lease payments under non-cancellable leases as of December 31, 2020 were as follows: Operating Leases 2021 $ 1,462,045 2022 801,800 2023 130,332 2024 134,054 2025 137,888 Thereafter 11,518 Total future minimum lease payments 2,677,637 Less imputed interest (197,263) Total $ 2,480,374 Reported as of December 31, 2020: Accrued expenses and other liabilities $ 1,352,537 Operating lease liabilities 1,127,837 Total $ 2,480,374 6. Leases (continued) As discussed in Note 2, the Company elected the modified retrospective approach. The modified retrospective approach recognizes the effects of initially applying the new leases standard as a cumulative effect adjustment to accumulated deficit as of the adoption date. Under this election, the provisions of ASC 840 apply to the accounting and disclosures for lease arrangements in the comparative periods in an entity’s financial statements. Therefore, included below is the prior period information as reported under ASC 840. Future minimum lease payments under non-cancellable leases as of December 31, 2019 were as follows: 2020 $ 2,325,562 2021 1,360,130 2022 752,532 2023 124,068 2024 127,790 Thereafter 142,618 Total $ 4,832,700 In March 2021, the Company entered into an operating lease agreement to lease office space commencing in July 2021 through October 2024 totaling $1,578,821. The Company subleases two of its office facilities to third parties under the same terms and conditions as the original lease agreements and has elected the practical expedient to combine lease and non-lease components as a single lease component under ASC 842 guidance. In 2020, the Company wrote-off sublease receivables totaling $312,940 against sublease income due to the Subtenants inability to pay. Sublease income for the year ended December 31, 2020 was as follows: 2020 Sublease income Fixed $ 709,283 Variable 4,971 Total sublease income $ 714,254 The undiscounted cash flows for contractual subleases as of December 31, 2020 were as follows: 2021 $ 666,740 2022 823,900 2023 130,332 2024 134,054 2025 137,888 Thereafter 11,517 Total $ 1,904,431

Restructuring Costs_2

Restructuring Costs	9 Months Ended	12 Months Ended
Restructuring Costs	Sep. 30, 2021	Dec. 31, 2020
Restructuring Costs
Restructuring Costs	4. Restructuring Costs The Company carried out a reduction in force on February 28, 2020. Twenty employees were severed under a one-time restructuring arrangement at a total cost to the Company of $771,942 . As of December 31, 2020, there were no restructuring accruals remaining on the balance sheet as all severance was fully paid to severed employees during the year. There were no restructuring activities for the nine months ended September 30, 2021.	7. Restructuring Costs The Company carried out a reduction in force on February 28, 2020. Twenty employees were severed under a one-time restructuring arrangement at a total cost to the Company of $771,942. As of December 31, 2020, there were no restructuring accruals remaining on the balance sheet as all severance was fully paid to severed employees during the year.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
Prepaid Expenses and Other Current Assets	Dec. 31, 2020
Prepaid Expenses and Other Current Assets
Prepaid Expenses and Other Current Assets	8. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following as of December 31, 2020 and 2019: 2020 2019 Prepaid expenses $ 543,148 $ 551,689 Good Dermatology receivable — 448,098 Leased facility security deposit 231,901 — Capitalized commission cost, net 509,326 — Other 79,787 137,952 Total prepaid expenses and other current assets $ 1,364,162 $ 1,137,739

Accrued Expenses

Accrued Expenses	12 Months Ended
Accrued Expenses	Dec. 31, 2020
Accrued Expenses
Accrued Expenses	9. Accrued Expenses Accrued expenses consist of the following as of December 31, 2020 and 2019: 2020 2019 Professional fees $ 1,623,286 $ 375,902 Compensation, including bonuses, fringe benefits, and payroll taxes 4,364,645 1,310,240 Current portion of operating lease liabilities 1,352,537 — Commissions payable 197,371 — Legal settlement 1,225,000 — Total accrued expenses $ 8,762,839 $ 1,686,142

Redeemable Preferred Stock

Redeemable Preferred Stock	9 Months Ended	12 Months Ended
Redeemable Preferred Stock	Sep. 30, 2021	Dec. 31, 2020
Redeemable Convertible Preferred Stock
Redeemable Preferred Stock	5. Preferred Stock Par value for each preferred stock share series is $0.0001 . Redeemable convertible preferred stock shares outstanding as of September 30, 2021 and 2020 was 41,587,368 and 41,692,230 , respectively. During the nine months ended September 30, 2020, 9,038,488 redeemable convertible preferred stock shares were issued through a series D-1 funding totaling $39,999,919 . No redeemable convertible preferred stock shares were repurchased during the nine months ended September 30, 2021. No redeemable convertible preferred stock shares were issued or repurchased during the nine months ended September 30, 2021.	10. Redeemable Preferred Stock Par value for redeemable preferred shares is $0.0001. The following is a summary of the Company’s authorized and outstanding redeemable preferred shares as of Dec 31, 2020 and 2019: 2020 2019 Preferred shares authorized Series A preferred 6,746,233 6,746,233 Series B preferred 7,588,369 7,588,369 Series C preferred 6,001,269 6,001,269 Series D preferred 12,317,871 17,596,960 Series D1 preferred 9,038,488 — Total preferred shares authorized 41,692,230 37,932,831 2020 2019 Preferred shares issued and outstanding Series A preferred 6,641,371 6,746,233 Series B preferred 7,588,369 7,588,369 Series C preferred 6,001,269 6,001,269 Series D preferred 12,317,871 12,317,871 Series D1 preferred 9,038,488 — Total preferred shares issued and outstanding 41,587,368 32,653,742 10. Redeemable Preferred Stock (continued) In the event of any liquidation, dissolution or winding-up of the Company, a sale of all or substantially all of the assets of the Company, a merger or consolidation of the Company with or into another entity (other than for solely reorganizational purposes) or a sale of a majority of the capital stock of the Company (each such event, a “Liquidation Event”), the holders of Series D Preferred Stock and Series D-1 Preferred Stock are entitled, on a pari passu basis, to receive prior to any distribution of any assets or funds of the Company to the holders of Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock or Common Stock, by reason of their ownership thereof, an amount per share equal to the applicable original issue price per share for such series of Preferred Stock, plus any declared but unpaid dividends. As of December 31, 2020 and 2019, there were no unpaid dividends. In the event of any Liquidation Event and after payment in full of the amounts owed to the holders of Series D Preferred Stock and Series D-1 Preferred Stock, by reason of their ownership thereof, the holders of Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock are entitled, on a pari passu basis, to receive prior to any distribution of any assets or funds of the Company to the holders of Common Stock, by reason of their ownership thereof, an amount per share equal to the applicable original issue price per share for such series of Preferred Stock, plus any declared but unpaid dividends. Notwithstanding the foregoing, a holder of shares of a series of Preferred Stock shall be deemed to have converted such holder’s shares of such series of Preferred Stock into shares of Common Stock immediately prior to the Liquidation Event if, as a result of an actual conversion of all shares of such series of Preferred Stock, such holder would receive, in the aggregate with respect to such shares, an amount greater than the amount distributable to such holder if such holder did not convert such series of Preferred Stock into shares of Common Stock. If any holder shall be deemed to have converted shares of Preferred Stock into Common Stock, then such holder is deemed to have waived the right to any distribution that would be made to holders of Preferred Stock that have not or have not been deemed to have converted into shares of Common Stock. The Preferred Stock is classified outside of shareholders’ equity in the mezzanine section of the balance sheet given that the preferred shareholders’ control the board.

Shareholders' Deficit_2

Shareholders' Deficit	9 Months Ended	12 Months Ended
Shareholders' Deficit	Sep. 30, 2021	Dec. 31, 2020
STOCKHOLDERS' EQUITY
Shareholders' Deficit	6. Stockholders’ Deficit Par value for common shares is $0.0001 . The following is a summary of common share activity for the nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Common shares, beginning balance 4,488,416 8,468,742 2,765,097 8,396,425 Issuance of common shares 106,752 75,694 1,830,071 148,011 Common shares, ending balance 4,595,168 8,544,436 4,595,168 8,544,436 The Company has one common stock warrant outstanding with available shares to be issued of 6,439 and an exercise price of $1.61 per share as of September 30, 2021. This warrant was exercised on October 4, 2021.	11. Shareholders’ Deficit Science 37 was formed under Delaware law and is treated as a “C” corporation for U.S. tax purposes. Par value for common shares is $0.0001. The following is a summary of common share activity for the years ended December 31, 2020 and 2019: 2020 2019 Common stock shares, beginning balance 8,396,425 8,273,865 Issuance of common stock 164,886 122,560 Repurchase of common stock (5,796,214) — Common stock shares, ending balance 2,765,097 8,396,425 The Company has one common stock warrant outstanding with available shares to be issued of 6,439 and an exercise price of $1.61 per share as of December 31, 2020.

Loss Per Share_2

Loss Per Share	9 Months Ended	12 Months Ended
Loss Per Share	Sep. 30, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Loss Per Share	7. Loss Per Share The following is a reconciliation of the numerators and denominators of the basic and diluted loss per share computations for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net Loss $ (14,691,871) $ (7,683,830) $ (29,232,518) $ (19,349,948) Denominator: Basic weighted average common shares outstanding 4,551,755 8,522,923 3,818,717 8,458,434 Earnings (loss) per share: Basic and diluted $ (3.23) $ (0.90) $ (7.66) $ (2.29) Potential common shares outstanding that are considered anti-dilutive are excluded from the computation of diluted earnings per share. As the Company has incurred losses from inception to date, due to its start-up nature, potential common shares are anti-dilutive due to this net loss. The number of potential shares outstanding that were anti-dilutive and therefore excluded from the computation of diluted earnings per share, weighted for the portion of the period they were outstanding, were as follows for the three and nine months ended September 30, 2021 and 2020, respectively. Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Preferred stock 41,587,368 32,653,742 41,587,368 41,692,230 Stock options outstanding 8,852,171 7,684,943 8,601,614 6,414,452 Warrants outstanding 6,439 6,439 6,439 6,439 Total 50,445,978 40,345,124 50,195,421 48,113,121	12. Loss Per Share The following is a reconciliation of the numerators and denominators of the basic loss per share computations for the years ended December 31, 2020 and 2019: 2020 2019 Numerator: Net Loss $ (31,674,084) $ (18,468,776) Denominator: Basic weighted average common shares outstanding 8,197,409 8,310,333 Earnings (loss) per share: Basic and diluted $ (3.86) $ (2.22) Potential common shares outstanding that are considered anti-dilutive are excluded from the computation of diluted earnings per share. As the Company has incurred losses inception to date, due to its start-up nature, potential common shares are anti-dilutive due to this net loss. The number of potential shares outstanding that were anti-dilutive and therefore excluded from the computation of diluted earnings per share, weighted for the portion of the period they were outstanding, were as follows for the years ended December 31, 2020 and 2019, respectively. 2020 2019 Preferred stock 36,338,255 30,610,834 Stock options outstanding 6,714,171 5,301,830 Warrants outstanding 6,439 6,439 Total 43,058,865 35,919,104

Related-Party Transactions_2

Related-Party Transactions	9 Months Ended	12 Months Ended
Related-Party Transactions	Sep. 30, 2021	Dec. 31, 2020
RELATED PARTY TRANSACTIONS
Related-Party Transactions	8. Related-Party Transactions In 2020, the Company subleased office space in Torrance, California to Good Dermatology, a professional medical corporation owned by the Founder and former CEO. Under the terms of the sublease, lease expenses incurred by the Company were 100% passed through to Good Dermatology. Total sublease income was $29,174 and $87,523 for the three and nine months ended September 30, 2020. The sublease was terminated as of November 30, 2020. 8. Related-Party Transactions (continued) For the three months ended September 30, 2021 and 2020, the Company had revenue of $2,756,011 and $3,146,148 , respectively, and for the nine months ended September 30, 2021 and 2020, the Company had revenue of $10,803,604 and $3,243,667 , respectively, and expenses of $128,084 and $0 , respectively, and as of September 30, 2021 and December 31, 2020, receivables of $2,244,157 and $6,927,470 , respectively, from Pharmaceutical Products Development, LLC, a shareholder who holds a minority interest in the Company and a seat on the Company’s Board of Directors. Pharmaceutical Products Development, LLC became a minority shareholder of the Company during the first quarter of 2019. For the three months ended September 30, 2021 and 2020, the Company had revenue of $269,547 and $108,280 , respectively, and for the nine months ended September 30, 2021 and 2020, the Company had revenue of $565,092 and $226,843 , respectively, and as of September 30, 2021 and December 31, 2020, receivables of $166,474 and $129,857 , respectively, from Novartis, who has a 50% ownership in dRX Capital AG, a shareholder who, until July 2021, had a minority interest in the Company and a seat on the Company’s Board of Directors. In July 2021, dRX Capital AG was dissolved and their interest in the Company was distributed to their owners. This dissolution and distribution did not cause any other shareholder of the Company to obtain a minority interest in the Company. For the three months ended September 30, 2021 and 2020, the Company had revenue of $9,875 and $0 , respectively, and for the nine months ended September 30, 2021 and 2020, the Company had revenue of $350,585 and $0 , respectively, and as of September 30, 2021 and December 31, 2020, receivables of $2,185 and $0 , respectively, from Allovir, who is an investee of a minority shareholder and Board of Directors seat holder of the Company. The minority shareholder became a shareholder of the Company in the third quarter of 2016.	13. Related-Party Transactions In 2020 and 2019, the Company subleased office space in Torrance, California to Good Dermatology, a professional medical corporation owned by the Founder and former CEO. Under the terms of the sublease, lease expenses incurred by the Company were 100% passed through to Good Dermatology. Total sublease income was $106,972 and $116,697 for the years ended December 31, 2020 and 2019, respectively. The sublease was terminated as of November 30, 2020. During the year ended December 31, 2019, the Company purchased clinical trial investigator services in an arm’s length transaction totaling $273,787 from Good Dermatology, a professional medical corporation owned by the Founder and former CEO. No services were purchased from Good Dermatology during the year ended December 31, 2020. During the year ended December 31, 2019, the Founder and former CEO had a personal loan from the Company in the amount of $300,000 which was paid off in its entirety, including accrued interest of $15,682 on June 26, 2019. There was a zero balance on the loan at December 31, 2019. For the years ended December 31, 2020 and 2019, the Company had revenue of $9,106,645 and $0, respectively, and as of December 31, 2020 and 2019, receivables of $6,927,470 and $0, respectively, from Pharmaceutical Products Development, LLC, a shareholder who holds a minority interest in the Company. Pharmaceutical Products Development, LLC became a minority shareholder of the Company during the first quarter of 2019. For the years ended December 31, 2020 and 2019, the Company had revenue of $351,034 and $451,558, respectively, and as of December 31, 2020 and 2019, receivables of $129,857 and $9,825, respectively, from Novartis, who has a 50% ownership in dRX Capital AG, a shareholder who has a minority interest in the Company. dRX Capital AG became a minority shareholder of the Company in the third quarter of 2015.

Commitments and Contingencies L

Commitments and Contingencies Legal Proceedings	9 Months Ended	12 Months Ended
Commitments and Contingencies Legal Proceedings	Sep. 30, 2021	Dec. 31, 2020
COMMITMENTS
Commitments and Contingencies	9. Commitments and Contingencies Legal Proceedings During 2019 and 2020, the Company was in state court litigation in California. Noah Craft and Belinda Tan, former co-founders and former Chief Executive Officer and Chief Medical Officer, respectively, asserted derivative claims purportedly on behalf of the Company alleging that several of its current and former directors and investors committed various breaches of duty in connection with the termination of Craft and Tan’s employment. Craft and Tan also asserted direct tort claims arising from the same facts against the non-Company defendants. Moreover, Tan asserted a direct claim against the Company and certain current and former directors for gender discrimination. The Company disputed that it was liable, and that none of Craft and Tan’s claims had merit. Notwithstanding the Company’s stance, the litigation was settled in court in November 2020. As of September 30, 2021, all elements and payments associated with the settlement have been completed which included the following: 1) In June 2020, the Director Defendants paid $100,000 to the Company, which was used to offset the legal settlement in 3) below. 2) As part of the settlement, the Company paid $3,675,000 to Plaintiffs (“First Payment”) in December 2020. In return, the Plaintiffs conveyed all the Company shares and any other securities or interest in the Company shares. The Plaintiffs held the equivalent on an as converted basis of 5,901,076 common shares. 3) In December 2020, the Company accrued $1,225,000 for the legal settlement which was paid in June 2021 (“Second Payment”). 9. Commitments and Contingencies (continued) New Office Lease In March 2021, the Company entered into an operating lease agreement to lease office space in Culver City, CA commencing in July 2021 through October 2024 totaling $1,578,821 . Future minimum lease payments under non-cancellable leases as of September 30, 2021 were as follows: Operating Leases 2021 (remaining three months) $ 188,943 2022 1,286,301 2023 629,369 2024 599,327 2025 137,888 2026 11,517 Thereafter — Total future minimum lease payments $ 2,853,345 Less imputed interest (264,774) Total $ 2,588,571 Reported as of September 30, 2021: Other current liabilities $ 1,103,283 Operating lease liabilities 1,485,288 Total $ 2,588,571	14. Commitments and Contingencies Legal Proceedings During 2019 and 2020, the Company was in state court litigation in California. Noah Craft and Belinda Tan, former co-founders and former Chief Executive Officer and Chief Medical Officer, respectively, asserted derivative claims purportedly on behalf of the Company alleging that several of its current and former directors and investors committed various breaches of duty in connection with the termination of Craft and Tan’s employment. Craft and Tan also asserted direct tort claims arising from the same facts against the non-Company defendants. Moreover, Tan asserted a direct claim against the Company and certain current and former directors for gender discrimination. The Company disputed that it was liable, and that none of Craft and Tan’s claims had merit. On September 30, 2019, the Los Angeles County Superior Court stayed this litigation indefinitely after ruling that a contractual forum selection clause required Craft’s and Tan’s claims to be brought in Delaware. Craft and Tan have partially appealed that ruling to the California Court of Appeal. On February 26, 2020 agreement was reached on the terms of the pending litigation described above, and on June 30, 2020, the long form agreement was executed by all parties, and was settled in court in November 2020. The settlement agreement included the following elements: 1) Within five business days after a Final Dismissal occurred: a. The Director Defendants caused their insurers to pay $100,000 to Science 37. b. Science 37 paid $3,675,000 to Plaintiffs (“First Payment”). 2) Within five business days of the Plaintiffs’ receipt of the First Payment, the Plaintiffs conveyed all Science 37 shares and any other securities or interest in Science 37 shares. The Plaintiffs held the equivalent on an as converted basis of 5,901,076 common shares. 3) Good Dermatology, a company wholly owned by the Plaintiffs, was focused on providing dermatology care. Historically, Good Dermatology had sub-contracted employees from Science 37, and had allowed Science 37 the use of their medical offices to conduct clinical trials. In addition, Science 37 had advanced funds for rental payments and employee payroll, for the benefit of Good Dermatology. Good Dermatology delivered $600,000 to Science 37 to cover all outstanding obligations as of February 26, 2020: a. Within five business days after the Effective Date (June 30, 2020), Plaintiffs instructed Good Dermatology to pay Science 37 $400,000 for part of the payables due to Science 37 for rent, employee costs, etc. This amount was received in early July 2020. b. It was contemplated that Good Dermatology would dissolve or be wound down. Within five business days of such action, Science 37 is to pay the Plaintiffs either $1,225,000 or $ 1,025,000 (“Second Payment”). The amount paid was determined by whether Plaintiffs i) elected to pay $200,000 directly to Science 37 to satisfy the $600,000 outlined in 3) above and in which case, Science 37 would pay to the Plaintiffs $1,225,000 or ii) elected to pay $0 directly to Science 37 in which the Second Payment to the Plaintiffs would be $1,025,000 . Plaintiffs elected to pay $200,000 , resulting in Science 37 owing $1,225,000 . As of December 31, 2020, this payment is pending upon Good Dermatology’s dissolution. c. Additionally, prior to dissolution, Good Dermatology agreed to pay Science 37 all sums which accrued, arose or were incurred on Good Dermatology’s behalf by Science 37 from the time of February 26, 2020 through dissolution. 14. Commitments and Contingencies (continued) As of December 31, 2020, all payments were made by both parties with the exception of $1,225,000 owed by Science 37 to Plaintiffs in 3b above, the amount of which is recorded in accrued expenses on the balance sheet. The $1,225,000 was paid by Science 37 in June 2021.

Stock-based Compensation_2

Stock-based Compensation	9 Months Ended	12 Months Ended
Stock-based Compensation	Sep. 30, 2021	Dec. 31, 2020
Stock-Based Compensation
Stock-based Compensation	10. Stock-Based Compensation The Company currently has one equity-based compensation plan, the 2015 Stock Option Plan (the 2015 Plan) from which stock-based compensation awards can be granted to employees, consultants, and non- executive directors. The 2015 Plan provides for awards in the form of service-based incentive stock options. A summary of stock option awards outstanding as of September 30, 2021 and changes during the nine months then ended is as follows: Weighted Average Number of Units Exercise Price Outstanding at January 1, 2021 7,478,736 $ 0.68 Granted 3,720,500 8.18 Exercised (1,830,071) 0.67 Forfeited (472,211) 1.19 Outstanding at September 30, 2021 8,896,954 $ 3.79 10. Stock-Based Compensation (continued) Stock-Based Compensation Valuation and Expense The Company accounts for stock options under the fair value method which requires the Company to estimate the grant-date fair value of its stock-based awards and amortize this value to compensation expense over the requisite service period. The Company uses the Black-Scholes-Merton model to estimate the value of such awards granted to its employees, consultants, and non-executive directors. Within this model, expected volatility is based upon the historical volatility of a peer group for a period equal to the expected term, as the Company does not have adequate history to calculate its own volatility. The Company believes the expected volatility will approximate the historical volatility of the peer group. The Company does not currently anticipate paying dividends. The expected term represents the period in which the grants are expected to be outstanding. The risk- free interest rate is based on the United States Treasury yield curve in effect at the time of the grant. Due to the absence of an active market for the Company’s common stock, the fair value of the Company’s common stock for purposes of determining the common stock price for stock option grants was determined by the Company’s Board of Directors. Stock-based compensation expense is recognized net of forfeitures such that expense is recognized only for those stock-based awards that are expected to vest. If forfeitures during the period are greater than expenses recognized, net stock-based compensation expense can be negative. Total stock-based compensation expense was classified in the statements of operations for the three and nine months ended September 30, 2021 and 2020 as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of revenues 129,464 4,381 346,516 (70,058) Selling, general and administrative 868,515 100,960 1,566,580 71,847 Total stock-based compensation expense 997,979 105,341 1,913,096 1,789	15. Stock-based Compensation Effective September 8, 2015, the Company established the 2015 Stock Option Plan (the 2015 Plan). The 2015 Plan authorizes the granting of options to purchase up to 11,708,001 shares of common stock to officers, employees and Board of Directors of the Company. As of December 31, 2020 and 2019, the 2015 Plan has issued 8,246,052 and 5,750,504 options to purchase shares of common stock of which 767,316 and 602,430 have been exercised and 7,478,736 and 5,148,074 remain outstanding. Granted options typically vest at 25% per year and become exercisable after one year of service after the date of issuance, with equal and successive vesting for the next 36 Due to the absence of an active market for the Company’s common stock, the fair value of the Company’s common stock for purposes of determining the common stock price for stock option grants was determined by the Company’s Board of Directors, the members of which have extensive business, financial and investment experience. The Company’s Board of Directors sets the exercise price of stock options at least equal to the fair value of the Company’s common stock on the date of grant. The Company’s Board of Directors exercised judgment while considering numerous objective and subjective factors in order to determine the fair market value on each date of grant in accordance with the guidance in the American Institute of Certified Public Accountants Technical Practice Aid entitled, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, or the AICPA Practice Aid, including the receipt of a valuation prepared by an independent third party with extensive experience valuing common stock of privately held companies. The exercise price of the unit is determined by the Board but shall not be less than 100% of the fair market value on the date of grant. For purposes of this limitation, the shares of common stock underlying any awards that are forfeited, canceled, withheld upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of common units, or otherwise terminated other than by exercise will be added back to the shares of common stock available for issuance under the 2015 Plan. The units available for issuance under the 2015 Plan may be authorized but may be unissued common units or common units reacquired by the Company. No award may be granted under the plan upon the earlier of the tenth anniversary of the date the plan is adopted by the Board, the date on which all units available for issuance under the plan shall have been issued as vested units, or the termination of all outstanding awards under the plan in connection with a change in control. 15. Stock-based Compensation (continued) The following table summarizes the stock option activity for the years ended December 31, 2020 and 2019: Weighted Average Weighted Remaining Aggregate Number of Average Contractual Intrinsic Units Exercise Price Term (Years) Value Outstanding as of January 1, 2019 4,823,893 $ 1.20 8.71 Granted 1,654,000 0.82 — Exercised (122,560) 0.33 — Forfeited (1,207,259) 1.33 — Outstanding as of January 1, 2020 5,148,074 $ 1.10 8.22 Granted 4,704,932 0.52 — Exercised (164,886) (0.80) — Forfeited (2,209,384) (1.26) — Outstanding at December 31, 2020 7,478,736 $ 0.68 8.35 $ 6,058,137 Exercisable at December 31, 2020 3,142,881 $ 0.81 7.30 $ 2,173,188 The total intrinsic value of options exercised was approximately $115,201 and $55,056 in 2020 and 2019, respectively. The Company recognized stock-based compensation expense of $122,032 and $392,566 during the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020 and 2019, total unrecognized compensation cost related to unvested stock options was approximately $1,046,844 and $1,142,965, respectively, which is expected to be recognized over a weighted average period of 2.87 and 2.51 years, based on the original date of service of each specific grant holder. Total stock-based compensation expense was classified in the statements of operations for the years ended December 31, 2020 and 2019 as follows: 2020 2019 Cost of revenues $ (64,919) $ 65,096 Selling, general and administrative 186,950 327,470 Total stock-based compensation expense $ 122,032 $ 392,566 The Company received cash of approximately $131,802 and $39,863 in 2020 and 2019, respectively, from options exercised. Other information about the Company’s stock options for the years ending December 31, 2020 and 2019 was as follows: 2020 2019 Total grant date fair value of stock options vested $ 533,089 $ 643,425 15. Stock-based Compensation (continued) The following table summarizes the assumptions used in valuing the stock options for the year ended December 31, 2020 and 2019: 2020 2019 Expected term 6.25 years 2.25 years – 6.25 years Weighted-average grant date fair value per stock option granted $ 0.23 $ 0.28 Risk-free interest rate 0.4% – 1.4% 1.1% – 3.0% Expected volatility 43.5% – 46.4% 32.3% – 37.9% Dividend yield 0% 0% The expected term of the stock options represents the average period the stock options are expected to remain outstanding. The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Therefore, the expected term of options granted is derived from the average midpoint between the weighted-average vesting and the contractual term, also known as the simplified method. The risk-free interest rate was the rate at the date of grant for a zero-coupon U.S. Treasury bond with a term that approximated the expected term of the stock option. As the Company does not have sufficient historical data to calculate the historical volatility of its stock, the expected volatility is derived from the historical volatilities of a selected peer group for a period that is equal to the expected term. The Company does not have a history of paying regular dividends and does not expect to pay regular cash dividends for the foreseeable future.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2020
Employee Benefit Plan
Employee Benefit Plan	16. Employee Benefit Plan The Company sponsors a defined contribution plan, the Science 37, Inc. Profit Sharing Plan (the “401(k) Plan”) which is a tax-qualified retirement and savings plan covering all full-time employees of the Company, subject to certain eligibility requirements. The Company matches employees’ contributions at 50% up to a maximum of the first 6% of an employee’s eligible compensation. For the years ended December 31, 2020 and 2019, the Company made matching contributions of $456,589 and $400,238, respectively. The Company’s contributions associated with its defined contribution retirement plan are recorded in cost of revenues and selling, general and administrative expenses on the accompanying statements of operations.

Income Taxes_2

Income Taxes	9 Months Ended	12 Months Ended
Income Taxes	Sep. 30, 2021	Dec. 31, 2020
Income Taxes
Income Taxes	11. Income Taxes The Company is treated as a “C” corporation for U.S. tax purposes. Adoption of Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (ASU 2019-12), which eliminates certain exceptions to the guidance in Income Taxes (Topic 740) related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted in an interim or annual period. Entities that elect to early adopt the amendments in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, entities that elect early adoption must adopt all the amendments in the same period. Entities will apply the guidance prospectively, except for certain amendments. The Company adopted ASU 2019-12 effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures. 11. Income Taxes (continued) The Company has incurred net operating losses since inception and is forecasting additional losses through December 31, 2021. Therefore, no U.S. Federal, state or foreign income taxes are expected for 2021 and no provision for such taxes has been recorded as of September 30, 2021. Due to the Company’s history of losses since inception, there is not enough evidence at this time to support the conclusion that the Company will generate future income of a sufficient amount and nature to utilize the benefits of the Company’s net deferred tax assets. Accordingly, as of September 30, 2021 and December 31, 2020, the Company provided a full valuation allowance against its net deferred tax assets since as of that time, the Company could not assert that it was more likely than not that these deferred tax assets would be realized.	17. Income Taxes For the years ended December 31, 2020 and 2019, the amount of loss before taxes was: 2020 2019 U.S. income (loss) before taxes $ (31,666,084) $ (18,468,776) Foreign income (loss) before taxes — — Total income (loss) before taxes $ (31,666,084) $ (18,468,776) Both current and deferred income tax (benefit) expense as of December 31, 2020 and 2019 were $0 and $0, respectively. 17. Income Taxes (continued) The Company has not recorded any provision for income taxes for the years ended December 31, 2020 and 2019, due to its history of operating losses. The effective tax rate for the year ended December 31, 2020, is different from the federal statutory rate primarily due to full valuation allowance against net deferred tax assets as a result of insufficient sources of income. The reconciliation of tax expense at the statutory federal tax rate versus the recorded income tax expense is as follows for the years ended December 31, 2020 and 2019: 2020 2019 Statutory U.S. federal rate $ (6,649,878) $ (3,878,443) State income tax net of federal benefit (1,141,758) (767,428) Permanent items 77,747 109,580 Other prior year adjustments (99,275) (1,339) Rate adjustment (12,921) 65,267 Valuation allowance 7,826,085 4,472,363 Total income tax expense (benefit) $ — $ — Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The principal components of the Company’s deferred tax assets for the years ended December 31, 2020 and 2019 consisted of the following: 2020 2019 Net operating loss carryforwards $ 24,923,945 $ 18,039,466 Amortizable assets 6,321 7,143 Equity compensation 50,118 77,916 Salaries and wages 1,048,104 151,442 Deferred rent — 133,387 Deferred revenue 861,120 544,415 Leasehold improvements 611,657 — Other 303,317 26,535 Total deferred tax assets 27,804,582 18,980,304 Less: valuation allowance (25,316,127) (17,490,042) Net deferred tax asset 2,488,455 1,490,262 Operating lease ROU (545,045) — Fixed assets (1,943,410) (1,490,262) Total deferred tax liabilities (2,488,455) (1,490,262) Net deferred tax assets (liabilities) $ — $ — The Company determines its valuation allowance on deferred tax assets by considering both positive and negative evidence in order to ascertain whether it is more likely than not that deferred tax assets will be realized. Realization of deferred tax assets is dependent upon the generation of future taxable income, if any, the timing and amount of which are uncertain. Due to the history of losses the Company has generated in the past, the Company believes that it is not more likely than not that all of the deferred taxes can be realized as of December 31, 2020 and 2019; accordingly, the Company has recorded a full valuation allowance on its net deferred tax assets. The valuation allowance increased $7,826,085 and $4,184,528 during the years ended December 31, 2020 and 2019, respectively. 17. Income Taxes (continued) At December 31, 2020, the Company has federal net operating loss carryforwards of approximately $103,569,264 and state net operating loss carryforwards of $56,390,660. As a result of Tax Cuts and Jobs Act, for U.S. income tax purposes, the net operating loss generated in tax years beginning before January 1, 2018 can be carried forward for 20 years, but net operating loss generated for tax years beginning after December 31, 2017 are carried forward indefinitely and are limited to 80% utilization against taxable income. Of the total federal net operating loss, $30,230,297 will begin to expire in 2034 and $73,338,967 will not expire but can only offset 80% of future taxable income in any given year. Of the total state NOL carryforwards, $247,181 can be carried forward indefinitely, with the remainder first beginning to expire in 2029. Pursuant to Code Sections 382 and 383, annual use of our net operating losses may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed a formal study in accordance with sections 382 and 383 to determine the limitations if a change in ownership has occurred or if there are any limitations on the utilization of net operating loss carryforwards. If net operating loss carryforwards are eliminated the related tax assets would be removed from the deferred tax assets schedule with a corresponding reduction in the valuation allowance. The Company files US. federal and various state and local income tax returns and is not under examination by any of the taxing authorities. Tax years 2017 and forward remain open for examination for federal tax purpose and tax years 2016 and forward remain open for examination for state tax purposes. Carryforward attributes that were generated in years where the statute of limitation is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authority. On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions are the extension of the carryback period of certain losses to five years and increasing the ability to deduct interest expense from 30 percent to 50 percent of modified taxable income. The CARES Act also provides for a credit against employee wages, the opportunity to defer payment of a portion of federal payroll taxes to December 2021 and December 2022 and enhanced small business loans to assist businesses impacted by the pandemic. The Company’s tax provision and financial position was not materially impacted by the CARES Act. On December 27, 2020, the United States enacted the Consolidated Appropriations Act which extended and modified many of the tax related provisions of the CARES Act. The Company’s tax provision and financial position was not materially impacted by the Consolidated Appropriations Act. On June 29, 2020, the state of California enacted Assembly Bill No. 85 (AB 85) suspending California net operating loss utilization and imposing a cap on the amount of business incentive tax credits companies can utilize, effective for tax years 2020, 2021 and 2022. There was no material impact from the provisions of AB 85 in 2020. 17. Income Taxes (continued) The following table summarizes the reconciliation of the unrecognized tax benefits activity during the year ended December 31, 2020: Unrecognized Tax Benefits – Beginning $ 239,927 Gross increases – tax positions in prior period — Gross decreases – tax positions in prior period — Gross increase – current-period tax positions — Gross decrease – current-period tax positions — Settlements — Lapse of statute of limitations — Unrecognized Tax Benefits – Ending $ 239,927 Due to the Company’s valuation allowance, none of the unrecognized tax benefits, if recognized, would affect the Company’s effective tax rate. The Company’s policy is to recognize interest expense and penalties related to income tax matters as tax expense. At December 31, 2020, there are no significant accruals for interest or penalties related to unrecognized tax benefits. The Company does not expect that there will be unrecognized tax benefits of a significant nature that will increase or decrease within 12 months of the reporting date.

Subsequent Events_2_3_4

Subsequent Events	9 Months Ended	12 Months Ended
Subsequent Events	Sep. 30, 2021	Dec. 31, 2020
SUBSEQUENT EVENTS
Subsequent Events	12. Subsequent Events Merger with LSAQ On May 7, 2021, the Company announced a planned merger with LSAQ under a definitive business combination agreement. On October 6, 2021, the agreement was consummated, with the Company surviving the merger as Science 37 Holdings, Inc, now a public company. All outstanding common and preferred shares of legacy Science 37, Inc. converted into common shares of the surviving Science 37 Holdings, Inc. through application of an exchange ratio of approximately 1.815. In addition, awards under the Company's existing 2015 stock incentive plan continue under the same terms and conditions as were previously applicable to such awards, subject to the same exchange ratio for exercise price and number of options outstanding. Common shares and warrants held by former LSAQ shareholders were converted to 10,858,261 common shares of Science 37 Holdings, Inc. Science 37 Holdings, Inc. began trading on the Nasdaq stock exchange as SNCE effective October 7, 2021. The financial statements as of September 30, 2021, including share and per share amounts, do not include the effects of the merger. The table below shows, on a pro forma basis, the impact of the merger on certain condensed balance sheet items as of September 30, 2021: Balance Sheet Data: Actual Pro Forma Cash and cash equivalents $ 7,996,362 $ 242,991,191 Working capital (5,566,182) 228,647,166 Total assets 39,746,217 273,843,757 Redeemable convertible preferred stock 143,086,271 — Accumulated deficit (136,979,761) (136,979,761) Total stockholders’ equity (deficit) $ (132,209,608) $ 163,290,011 Share Data: Actual Pro Forma Redeemable convertible preferred stock outstanding 41,587,368 — Common stock outstanding 4,595,168 114,707,150 Going Concern From August 2021, the Company began to accelerate investments in hiring and in other critical areas, such as the technology platform, to facilitate the delivery of anticipated revenues, resulting from an increase in net bookings. Also, as several meaningful conditions of the contemplated transaction were met, the Company increased spend related to the requirements of being a publicly-traded company. The Company’s increased costs adversely affected the Company’s results of operations and liquidity and there was substantial doubt as to the Company’s ability to continue as a going concern at that time. On October 6, 2021, the definitive business combination agreement was consummated, with Science 37, Inc. surviving the merger as Science 37 Holdings, Inc., a now public company. All outstanding common and preferred shares of legacy Science 37, Inc. converted into common shares of the surviving Science 37 Holdings, Inc. through application of an exchange ratio of approximately 1.815. In addition, awards under the Company’s existing 2015 stock incentive plan continue under the same terms and conditions as were previously applicable to such awards, subject to the same exchange ratio for exercise price and number of options outstanding. Science 37 Holdings, Inc. began trading on the Nasdaq stock exchange as SNCE effective October 7, 2021. 12. Subsequent Events (continued) In conjunction with this merger, Science 37, Inc. received funds held in LSAQ's working capital and trust accounts together with $ 200 million in PIPE financing from institutional and strategic investors to further fund Science 37, Inc.’s decentralized trial technology platform and extend into new adjacencies. As a result of the Merger and inclusive of the PIPE financing, Science 37, Inc. received $ 234.2 million, net of fees and expenses paid in connection with the closing of the business combination. The transaction will be accounted for as a reverse capitalization in accordance with GAAP. Under the reverse capitalization model, the merger will be treated as Science 37, Inc. is issuing equity for the net assets of LSAQ, with no goodwill or intangible assets recorded, and LSAQ will be treated as the acquiree for financial reporting purposes. This is primarily because, subsequent to the merger, Science 37, Inc. shareholders have a majority of the voting power of the combined company. In addition, Science 37, Inc. comprises all of the ongoing operations, senior management, and a majority of the governing body of the combined company. As a result of the merger and related PIPE financing, the substantial doubt about the Company's ability to continue as a going concern has been alleviated. The Company has evaluated subsequent events through November 15, 2021, the date on which the accompanying condensed consolidated financial statements were issued, noting no additional items requiring disclosure.	18. Subsequent Events On March 25, 2021, the Company entered into an operating lease agreement for office space which will commence on July 1, 2021. The Company’s financial commitment for the office space is disclosed under Leases. On May 7, 2021, the Company announced a planned merger with LifeSci Acquisition II Corp (LSAQ) under a definitive business combination agreement. Going Concern From August 2021, the Company began to accelerate investments in hiring and in other critical areas, such as the technology platform, to facilitate the delivery of anticipated revenues, resulting from an increase in net bookings. Also, as several meaningful conditions of the contemplated transaction were met, the Company increased spend related to the requirements of being a publicly-traded company. The Company’s increased costs adversely affected the Company’s results of operations and liquidity and there was substantial doubt as to the Company’s ability to continue as a going concern at that time. On October 6, 2021, the definitive business combination agreement was consummated, with Science 37, Inc. surviving the merger as Science 37 Holdings, Inc., a now public company. All outstanding common and preferred shares of legacy Science 37, Inc. converted into common shares of the surviving Science 37 Holdings, Inc. through application of an exchange ratio of approximately 1.815. In addition, awards under the Company’s existing 2015 stock incentive plan continue under the same terms and conditions as were previously applicable to such awards, subject to the same exchange ratio for exercise price and number of options outstanding. Science 37 Holdings, Inc. began trading on the Nasdaq stock exchange as SNCE effective October 7, 2021. In conjunction with this merger, Science 37, Inc. received funds held in LSAQ’s working capital and trust accounts together with $200 million in PIPE financing from institutional and strategic investors to further fund Science 37, Inc.’s decentralized trial technology platform and extend into new adjacencies. As a result of the Merger and inclusive of the PIPE financing, Science 37, Inc. received $234.2 million, net of fees and expenses paid in connection with the closing of the business combination. The transaction will be accounted for as a reverse capitalization in accordance with GAAP. Under the reverse capitalization model, the merger will be treated as Science 37, Inc. is issuing equity for the net assets of LSAQ, with no goodwill or intangible assets recorded, and LSAQ will be treated as the acquiree for financial reporting purposes. This is primarily because, subsequent to the merger, Science 37, Inc. shareholders have a majority of the voting power of the combined company. In addition, Science 37, Inc. comprises all of the ongoing operations, senior management, and a majority of the governing body of the combined company. As a result of the merger and related PIPE financing, the substantial doubt about the Company’s ability to continue as a going concern has been alleviated. The Company has evaluated subsequent events through November 5, 2021, the date on which the accompanying consolidated financial statements were issued, noting no additional items requiring disclosure.

Summary of Significant Accou_14

Summary of Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2021	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates		Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. These estimates are based on historical experience and various other assumptions believed reasonable under the circumstances. The Company evaluates its estimates on an ongoing basis and makes changes to the estimates and related disclosures as experience develops or new information becomes known, including facts and circumstances related to the novel coronavirus disease pandemic. Actual results may differ from those estimated. The Company’s most significant estimates and assumptions used in the preparation of the accompanying consolidated financial statements relate to contract cost estimates in revenue recognition, capitalized software costs, and the valuation of the Company’s common stock.
Foreign Currency		2. Summary of Significant Accounting Policies (continued) Foreign Currency The Company has one bank account with a de minimis balance denominated in Swiss Francs and, therefore, has minimal foreign currency exposure.
Revenue Recognition		Revenue Recognition The Company derives its revenues primarily from two sources: (i) contractual arrangements to enable and enhance clinical trials through technology and/or services, and (ii) licensing of its proprietary hosted technology platform to a variety of life science institutions. Revenues are recognized when control of these services is transferred to our customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. The Company determines revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when, or as, we satisfy a performance obligation A performance obligation is a promise (or a combination of promises) in a contract to transfer distinct goods or services to a customer and is the unit of accounting under ASC 606 for purposes of revenue recognition. A contract’s transaction price is allocated to each separate performance obligation based on the standalone selling price and is recognized as revenue, when, or as, the performance obligation is satisfied. All of the Company’s contracts have a single performance obligation because the promise to transfer individual services is not separately identifiable from other promises in the contracts, and therefore, is not distinct. The majority of the Company’s revenue arrangements are service contracts that range in duration from a few months to several years. Substantially all of the Company’s performance obligations, and associated revenue, are transferred to the customer over time. The performance obligation is satisfied over time and the Company generally recognizes revenue based on a cost-based input method, due to costs being incurred consistently throughout the life of the contract, as there is no single output measure that would fairly depict the transfer of control over the life of the performance obligation. Progress on the performance obligation is measured by the proportion of actual costs incurred to the total costs expected to complete the contract. Costs included in the measure of progress include direct labor and third-party costs (such as payments to investigators and other pass-through expenses for the Company’s clinical monitors). This cost-to-cost input method of revenue recognition requires the Company to make estimates of costs to complete its projects on an ongoing basis. Contract estimates are based on various assumptions to project future outcomes of events that often span several years and require significant judgment. These estimates are reviewed periodically, and any adjustments are recognized on a cumulative catch-up basis in the period they become known. 2. Summary of Significant Accounting Policies (continued) The Company generally receives compensation based on measuring progress toward completion using anticipated project budgets and direct labor and prices for each service offering. The Company is also reimbursed for certain third party pass-through and out-of-pocket costs. The pass-through costs are included in total operating expenses. The pass-through costs are also recognized as revenue on a gross basis as the Company is the principal in the relationship (i.e., the Company is primarily responsible for the services provided by third parties, and significantly integrates the services of third parties with its own services in delivering a combined output to the customer). In addition, in certain instances, a customer contract may include forms of variable consideration such as incentive fees, volume rebates or other provisions that can increase or decrease the transaction price. This variable consideration is generally awarded upon achievement of certain performance metrics, program milestones or cost targets. For the purpose of revenue recognition, variable consideration is assessed on a contract-by-contract basis and the amount included in the transaction price is estimated based on the Company’s anticipated performance and consideration of all information that is reasonably available. Variable consideration is recognized as revenue if and when it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved in the future. The Company has one performance-based contract, which is unique in that the Company’s obligation to the customer is solely for the recruitment of successfully processed patients or “completers”. The successful recruitment of completers constitutes a single performance obligation to our customer. Completer revenue is recognized at a point in time, as completers are processed. For contracts where the Company licenses its proprietary hosted software independently, value transfers to the customer over time as the customer has access to the system once it is live and continues to benefit over the life of the arrangement. Revenue is recorded straight line over the term of the hosting and maintenance period as there is no better measure of the transfer of value for these services. Most of the Company’s contracts can be terminated by the customer without cause with a 30-day notice. In the event of termination, the Company’s contracts generally provide that the customer pay the Company for: (i) fees earned through the termination date; (ii) fees and expenses for winding down the project, which include both fees incurred and actual expenses; (iii) non-cancellable expenditures; and (iv) in some cases, a fee to cover a portion of the remaining professional fees on the project. Changes in the scope of work are common, especially under long-term contracts, and generally result in a change in the total contract transaction price. If the customer does not agree to a contract modification, the Company could bear the risk of cost overruns. Most of the Company’s contract modifications are for services that are not distinct from the services under the existing contract due to the significant integration service provided in the context of the contract and therefore result in a cumulative catch-up adjustment to revenue at the date of contract modification.
Capitalized Costs	Capitalized Software The Company’s internal use proprietary software organizes workflows, captures real-time evidence, and harmonizes data during clinical trial support for its customers. Capitalized software is recorded at cost less accumulated amortization. The Company capitalizes software development cost related to the development of the Company’s proprietary platform in accordance with ASC 350 guidance. Internal and external costs incurred during the preliminary stage are expensed as incurred. Costs incurred during the application development stage are capitalized and consist of payroll labor and benefits to the extent of time spent directly on the project and external direct costs of materials and labor. Training and maintenance costs are expensed as incurred. The Company commences amortization once the respective assets are placed into service. The estimated useful life for capitalized software is 3 years . Assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the expected undiscounted future cash flow from the use of the asset and its eventual disposition is less than the carrying amount of the asset, an impairment loss is recognized and measured using the fair value of the related asset. No material impairments were recognized during the three and nine months ended September 30, 2021 and 2020.	Capitalized Costs The Company capitalizes certain costs associated with commissions paid to its employees because these costs are incurred in obtaining contracts that have a term greater than one year and are expected to be recovered. Capitalized costs are included in prepaid expenses and other current assets and other assets in the accompanying balance sheet and are amortized to selling, general and administrative expense on the statement of operations. The Company amortizes these costs in a manner that is consistent with the pattern of revenue recognition described above. The Company expenses costs to obtain contracts that have a term of one year or less when incurred.
Cost of Revenues		Cost of Revenues Cost of revenues includes the cost to conduct trials remotely and make available the Company’s technology solutions to its customers. Cost of revenues includes direct labor salaries, direct labor stock- based compensation, and third-party costs (such as payments to investigators, marketing costs, and other pass through expenses) for the Company’s clinical trial revenue. Clinical trial marketing costs totaled $6,814,902 and $762,740 for the year ended December 31, 2020 and 2019, respectively.
Selling, General and Administrative Costs		2. Summary of Significant Accounting Policies (continued) Selling, General and Administrative Costs Selling, general and administrative costs are summarized as follows for the years ended December 31, 2020 and 2019: 2020 2019 Compensation and benefits $ 16,696,017 $ 13,094,579 Rent expense and other facilities costs 7,132,472 5,801,044 Professional fees and consultants 3,211,270 2,789,069 Legal settlement 1,125,000 — Stock based compensation 186,950 327,470 Total $ 28,351,709 $ 22,012,162
Restructuring		Restructuring Restructuring costs consist of one-time employee termination benefits. The Company accounts for restructuring costs in accordance with ASC Topic 420, Exit or Disposal Cost Obligations. This guidance requires that liabilities related to one-time employee termination benefits be measured and recognized at the date the entity notifies employees of termination, unless employees are required to render services beyond a minimum retention period, in which case the liability is recognized ratably over the future service period. Restructuring liabilities are included in accrued expenses.
Cash and Cash Equivalents		Cash and Cash Equivalents The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents, which consist of cash on deposit with banks are stated at cost, which approximates fair value.
Restricted Cash		Restricted Cash Restricted cash consists of funds held as security related to the Company’s credit instrument held as collateral on the Company’s operating lease. The funds become no longer restricted at certain intervals in accordance with the related lease agreement. Restricted cash is classified as a current or long-term asset based on the timing and nature of when and how the cash is expected to be used or when the restrictions are expected to lapse. As of December 31, 2020, and 2019, restricted cash balances were $1,004,142 and $1,020,703
Accounts Receivable, Unbilled Services, and Deferred Revenue		Accounts Receivable, Unbilled Services, and Deferred Revenue The Company establishes prerequisites for billings based on contractual terms, including payment schedules and the completion of milestones. In general, the Company’s intention in its invoicing and related payment terms is to maintain cash neutrality over the life of the contract. Generally, the payment terms are 30 to 90 days. Upfront payments, when they occur, are intended to cover certain expenses the Company incurs at the beginning of the contract. Neither the Company nor its customers view such upfront payments and contracted payment schedules as a means of financing. Unbilled services represent revenue earned and recognized for services performed for which amounts have not yet been billed to the customer in accordance with contractual terms. Contractual provisions and payment schedules may or may not correspond to the timing of the performance of services under the contract. Unbilled services include contract assets, under which the right to bill the customer is subject to factors other than the passage of time, such as the satisfaction of milestones. Accounts receivable and unbilled services are recorded, net, on the balance sheet. 2. Summary of Significant Accounting Policies (continued) Deferred revenue is a contract liability that consists of customer payments received in advance of performance and billings that exceed revenue recognized. The Company reduces deferred revenue and recognizes revenue as the related performance obligations for services are performed. Deferred revenue is classified as a current liability on the balance sheet when the Company expects to recognize the associated revenue in less than one year, and a long-term liability when the company expects to recognize the associated revenue in excess of one year.
Allowance for Doubtful Accounts		Allowance for Doubtful Accounts The Company maintains a credit approval process and makes judgments to assess its customers’ ability to pay for contracted services. Generally, the Company can limit credit exposure by discontinuing services in the event of non-payment. The Company monitors its customers’ credit worthiness and applies judgment in establishing a provision for estimated credit losses based on historical experience, the aging of receivables, and customer-specific circumstances. The Company continuously monitors collections and payments from its customers and writes off uncollectible invoices once appropriate collection efforts have been exhausted. The allowance for doubtful accounts is included in accounts receivable on the consolidated balance sheet. As of December 31, 2020 and 2019, no allowances were necessary.
Long-Lived Assets		Long-Lived Assets Property and equipment are recorded at cost less accumulated depreciation. Maintenance and repairs are expensed as incurred. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method. The estimated useful lives of depreciable assets are as follows: Furniture and fixtures 5 years Computer equipment 3 years Drug storage equipment 5 years Leasehold improvements 4 – 5 years Depreciation of leasehold improvements is computed using the straight-line method over the shorter of the remaining lease term or the estimated useful lives of the improvements. Upon the sale or retirement of property or equipment, the cost and related accumulated depreciation or amortization are removed from the Company’s consolidated financial statements with the resulting gain or loss reflected in the Company’s results of operations. The Company’s internal use proprietary hosted software organizes workflows, captures real-time evidence, and harmonizes data during clinical trial support or enhancement for its customers. Capitalized software is recorded at cost less accumulated amortization. The Company capitalizes software development cost related to the development of the Company’s proprietary platform in accordance with ASC 350 guidance. Internal and external costs incurred during the preliminary stage are expensed as incurred. Costs incurred during the development stage are capitalized and consist of payroll labor and benefits to the extent of time spent directly on the project and external direct costs of materials and labor. Training and maintenance costs are expensed as incurred. The Company commences amortization once the respective assets are placed into service. The estimated useful life for capitalized software is 3 years. Assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the expected undiscounted future cash flow from the use of the asset and its eventual disposition is less than the carrying amount of the asset, an impairment loss is recognized and measured using the fair value of the related asset. No material impairments were recognized during the years ended 2020 or 2019.
Leases		2. Summary of Significant Accounting Policies (continued) Leases On January 1, 2020, the Company adopted ASC 842 under the revised modified retrospective approach which recognizes the impact of initially applying the new leases standard as a cumulative effect adjustment to accumulated deficit as of the adoption date. Under this election, the provisions of prior GAAP (ASC 840) apply to the accounting and disclosure for leases in the comparative periods of the entity’s financial statements. The Company also elected the package of practical expedients permitted under the ASC 842 transition guidance. Under this election, the Company need not reassess (i) the historical lease classification, (ii) whether any expired or existing contract is or contains a lease, or (iii) the initial direct costs for any existing leases. The Company determines if an arrangement is a lease at inception of the contract. A contract contains a lease if the Company controls the use of an identified asset. Control exists if the Company can direct the use of and obtain substantially all the economic benefit of the asset. Operating lease right-of-use (ROU) assets and liabilities are recorded on our balance sheet and are measured based on the present value of the future minimum lease payments over the lease term at commencement date. The Company’s uses its incremental borrowing rate at lease commencement in determining the present value of future payments. In addition, the operating lease ROU asset includes any prepaid lease payments and initial direct costs and excludes lease incentives. If the Company has an option to extend, or terminate, a lease and is reasonably certain to exercise that option, the extension or termination is included in the lease term used to measure the ROU asset and lease liability. Lease expense for minimum lease payments is recognized on a straight-line basis over the term of the lease. The Company has elected to account for lease components and non-lease components in a contract as a single lease component. For short-term leases (those with a term of one year or less), the Company has elected not to recognize ROU assets and lease liabilities. Lease payments on short-term leases are recognized as lease expense on a straight-line basis over the term of the lease.
Deferred Rent		Deferred Rent Under prior GAAP (ASC 840), rent expense on facility leases, including free rent and scheduled rent increases, is recorded on a straight-line basis over the term of the lease for the year ending December 31, 2019. The difference between the straight-line rent expense and the amount payable under the lease is included in deferred rent on the accompanying 2019 balance sheet. Lease incentives were recorded and amortized as a reduction of rent expense on a straight-line basis over the term of the lease.
Stock-Based Compensation		Stock-Based Compensation The Company measures stock-based compensation cost based on the fair value of the award at the grant date, and recognizes it as expense, net of actual forfeitures as they occur, over the requisite service period of the employee. The Company accounts for stock options under the fair value method and uses the Black-Scholes- Merton model to estimate the value of such awards granted to its employees, consultants, and non-executive directors. Within this model, expected volatility is based upon the historical volatility of a peer group for a period equal to the expected term, as the Company does not have adequate history to calculate its own volatility. The Company believes the expected volatility will approximate the historical volatility of the peer group. The Company does not currently anticipate paying dividends. The expected term represents the period in which the grants are expected to be outstanding. The risk- free interest rate is based on the United States Treasury yield curve in effect at the time of the grant.
Assets Measured at Fair Value		2. Summary of Significant Accounting Policies (continued) Assets Measured at Fair Value Fair value is the price that would be received to sell an asset or paid to transfer a liability between market participants in the principal market or the most advantageous market when no principal market exists. Market participants are assumed to be independent, knowledgeable, able, and willing to transact an exchange and not under duress. Considerable judgment may be required in interpreting market data used to develop the estimates of fair value. Accordingly, estimates of fair value are not necessarily indicative of the amounts that could be realized in a current or future market exchange. Fair values for substantially all of the Company’s financial and nonfinancial instruments were measured using market, income, or cost approaches. The three levels of input are as follows: Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial instruments, including cash and cash equivalents, are recorded at cost, which approximates fair value. The Company does not have any assets or liabilities measured at Level 2 or Level 3.
Income Taxes		Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records valuation allowances to reduce deferred tax assets to the amount the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not upheld on examination by the taxing authorities based solely upon the technical merits of the positions. The Company recognizes interest and penalties, if any, related to unrecognized income tax uncertainties in income tax expense.
Contingencies		Contingencies The Company is party to legal proceedings incidental to its business. The Company records accruals for claims, suits, investigations, and proceedings when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company reviews these contingencies regularly and records or adjusts accruals related to such matters to reflect the impact and status of any settlements, rulings, advice of counsel or other information pertinent to a particular matter. Gain contingencies are not recognized. Legal fees are expenses as incurred. Since these matters are inherently unpredictable, assessing contingencies is highly subjective and requires judgments about future events. Although the Company believes it has substantial defenses in these matters, the amount of losses incurred as a result of actual outcomes may differ significantly from the Company’s estimates.
Treasury Stock		2. Summary of Significant Accounting Policies (continued) Treasury Stock The Company records treasury stock purchases under the cost method. Upon reissuance of treasury stock, amounts in excess of the acquisition cost are credited to additional paid in capital. If the Company reissues treasury stock at an amount below its acquisition cost and additional paid in capital associated with prior treasury stock transactions is insufficient to cover the difference between the acquisition cost and the reissue price, this shortfall is recorded in accumulated deficit.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.	Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.
Segments	Segments Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined that its Senior Executive Committee, which includes the Chief Executive Officer, together with the Board of Directors is the CODM. The Company operates in a single operating segment as the CODM reviews financial information presented on a consolidated basis, at the Company level, for the purposes of making operating decisions, allocation of resources, and evaluating financial performance. As of and for the nine months ended September 30, 2021 and 2020, the Company did not have material revenue earned or assets located outside of the United States.	Segments Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined that its Senior Executive Committee, which includes the Chief Executive Officer, together with the Board of Directors is the CODM. The Company operates in a single operating segment as the CODM reviews financial information presented on a consolidated basis, at the Company level, for the purposes of making operating decisions, allocation of resources, and evaluating financial performance. As of and for the years ended December 31, 2020 and 2019, the Company did not have material revenue earned or assets located outside of the United States.
Accounting Pronouncements Adopted		Accounting Pronouncements Adopted as of December 31, 2020 In February 2016, the FASB issued new accounting guidance that requires lessees to recognize leases greater than 12 months in duration on their balance sheet as a right-of-use asset and a lease liability, as well as the disclosure of key information about leasing arrangements. The income statement will reflect lease expense for operating leases, and amortization and interest expense for financing leases. The Company adopted this new accounting guidance on January 1, 2020 and elected the practical expedients that retained the lease classification, initial direct costs, and determination of whether contracts are or contain a lease, for any leases that existed prior to adoption of the new guidance. The Company also elected the transition method which allows for disclosures to be updated prospectively and prior periods to be presented in accordance with previous GAAP. The adoption of this standard had a material impact on the Company’s balance sheet but did not have a material impact on the Company’s results of operations or cash flows.
Accounting Pronouncements Issued but Not Adopted	Accounting Pronouncements Issued but Not Adopted as of September 30, 2021 In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by a reporting entity. The standard replaces the incurred loss impairment methodology in current GAAP with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company does not expect the adoption of the guidance to have a material effect on the Company’s consolidated financial statements. This is based on factors including the Company’s assessment of historical losses, customer’s creditworthiness, and the fact that the Company’s trade receivables are short term in duration. The Company expects to implement this new standard in January 2022.	2. Summary of Significant Accounting Policies (continued) Accounting Pronouncements Issued but Not Adopted as of December 31, 2020 In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by a reporting entity. The standard replaces the incurred loss impairment methodology in current GAAP with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company does not expect the adoption of the guidance to have a material effect on the Company’s consolidated financial statements. This is based on factors including the Company’s assessment of historical losses, customers’ creditworthiness, and the fact that the Company’s trade receivables are short term in duration. The Company expects to implement this new standard in January 2022.

Summary of Significant Accou_15

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Summary of selling, general and administrative costs	2020 2019 Compensation and benefits $ 16,696,017 $ 13,094,579 Rent expense and other facilities costs 7,132,472 5,801,044 Professional fees and consultants 3,211,270 2,789,069 Legal settlement 1,125,000 — Stock based compensation 186,950 327,470 Total $ 28,351,709 $ 22,012,162
Schedule of estimated useful lives of depreciable assets	Furniture and fixtures 5 years Computer equipment 3 years Drug storage equipment 5 years Leasehold improvements 4 – 5 years

Revenue (Tables)_2

Revenue (Tables)	9 Months Ended	12 Months Ended
Revenue (Tables)	Sep. 30, 2021	Dec. 31, 2020
Revenue
Summary of accounts receivable and unbilled services (including contract assets)	September 30, 2021 December 31, 2020 Accounts receivable $ 6,233,698 $ 8,688,441 Unbilled services $ 907,840 2,511,811 Total accounts receivable and unbilled services 7,141,538 11,200,252 Allowance for doubtful accounts (142,830) — Total accounts receivable and unbilled services, net $ 6,998,708 $ 11,200,252	2020 2019 Accounts receivable $ 8,688,441 $ 1,426,874 Unbilled services 2,511,811 1,913,023 Total accounts receivable and unbilled services $ 11,200,252 $ 3,339,897
Summary of deferred revenue	September 30, 2021 December 31, 2020 Deferred revenue $ 7,626,905 $ 5,564,124	2020 2019 Deferred revenue $ 5,564,124 $ 4,932,612
Summary of capitalized commission costs and related amortization		2020 2019 Capitalized commission cost, net $ 509,326 $ — 2020 2019 Amortization of capitalized commission cost $ (232,422) $ —

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2020
Property and Equipment
Summary of property and equipment	2020 2019 Furniture and fixtures $ 298,877 $ 298,877 Drug storage equipment 115,054 115,054 Computer equipment 475,798 111,574 Leasehold improvements 1,239,147 1,252,885 2,128,876 1,778,390 Less accumulated depreciation (1,593,492) (1,152,112) Property and equipment, net $ 535,384 $ 626,278

Capitalized Software (Tables)

Capitalized Software (Tables)	12 Months Ended
Capitalized Software (Tables)	Dec. 31, 2020
Capitalized Software
Schedule of estimated amortization expense	Estimated amortization expense for the years ending December 31, 2021 through December 31, 2023 is as follows: Amortization Expense Year: 2021 $ 4,195,131 2022 2,804,127 2023 1,055,109
Schedule of capitalized software balances	2020 2019 Gross Accumulated Net Gross Accumulated Net Amount Amortization Amount Amount Amortization Amount Capitalized software $ 18,638,249 $ (10,583,882) $ 8,054,367 $ 12,461,245 $ (6,592,330) $ 5,868,915

Leases (Tables)

Leases (Tables)	9 Months Ended	12 Months Ended
Leases (Tables)	Sep. 30, 2021	Dec. 31, 2020
Leases
Schedule of components of lease expense		The components of lease expense for the year ended December 31, 2020 were as follows: Classification 2020 Operating fixed lease cost Selling, general and administrative expenses $ 2,126,662 Operating variable lease cost Selling, general and administrative expenses 238,205 Total lease cost $ 2,364,867
Schedule of supplemental cash flow		2020 Supplemental cash flow Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 2,495,972 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 4,095,709 Weighted average remaining lease term (years): Operating leases 2.24 Weight average discount rate: Operating leases 6.50 %
Schedule of future minimum lease payments under non-cancellable leases	Future minimum lease payments under non-cancellable leases as of September 30, 2021 were as follows: Operating Leases 2021 (remaining three months) $ 188,943 2022 1,286,301 2023 629,369 2024 599,327 2025 137,888 2026 11,517 Thereafter — Total future minimum lease payments $ 2,853,345 Less imputed interest (264,774) Total $ 2,588,571 Reported as of September 30, 2021: Other current liabilities $ 1,103,283 Operating lease liabilities 1,485,288 Total $ 2,588,571	Future minimum lease payments under non-cancellable leases as of December 31, 2020 were as follows: Operating Leases 2021 $ 1,462,045 2022 801,800 2023 130,332 2024 134,054 2025 137,888 Thereafter 11,518 Total future minimum lease payments 2,677,637 Less imputed interest (197,263) Total $ 2,480,374 Reported as of December 31, 2020: Accrued expenses and other liabilities $ 1,352,537 Operating lease liabilities 1,127,837 Total $ 2,480,374 Future minimum lease payments under non-cancellable leases as of December 31, 2019 were as follows: 2020 $ 2,325,562 2021 1,360,130 2022 752,532 2023 124,068 2024 127,790 Thereafter 142,618 Total $ 4,832,700
Schedule of sublease income		Sublease income for the year ended December 31, 2020 was as follows: 2020 Sublease income Fixed $ 709,283 Variable 4,971 Total sublease income $ 714,254
Schedule of he undiscounted cash flows for contractual subleases		The undiscounted cash flows for contractual subleases as of December 31, 2020 were as follows: 2021 $ 666,740 2022 823,900 2023 130,332 2024 134,054 2025 137,888 Thereafter 11,517 Total $ 1,904,431

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
Prepaid Expenses and Other Current Assets (Tables)	Dec. 31, 2020
Prepaid Expenses and Other Current Assets
Schedule of prepaid expenses and other current assets	2020 2019 Prepaid expenses $ 543,148 $ 551,689 Good Dermatology receivable — 448,098 Leased facility security deposit 231,901 — Capitalized commission cost, net 509,326 — Other 79,787 137,952 Total prepaid expenses and other current assets $ 1,364,162 $ 1,137,739

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
Accrued Expenses (Tables)	Dec. 31, 2020
Accrued Expenses
Schedule of accrued expenses	2020 2019 Professional fees $ 1,623,286 $ 375,902 Compensation, including bonuses, fringe benefits, and payroll taxes 4,364,645 1,310,240 Current portion of operating lease liabilities 1,352,537 — Commissions payable 197,371 — Legal settlement 1,225,000 — Total accrued expenses $ 8,762,839 $ 1,686,142

Redeemable Preferred Stock (Tab

Redeemable Preferred Stock (Tables)	12 Months Ended
Redeemable Preferred Stock (Tables)	Dec. 31, 2020
Redeemable Convertible Preferred Stock
Schedule of Company authorized and outstanding redeemable preferred shares	2020 2019 Preferred shares authorized Series A preferred 6,746,233 6,746,233 Series B preferred 7,588,369 7,588,369 Series C preferred 6,001,269 6,001,269 Series D preferred 12,317,871 17,596,960 Series D1 preferred 9,038,488 — Total preferred shares authorized 41,692,230 37,932,831 2020 2019 Preferred shares issued and outstanding Series A preferred 6,641,371 6,746,233 Series B preferred 7,588,369 7,588,369 Series C preferred 6,001,269 6,001,269 Series D preferred 12,317,871 12,317,871 Series D1 preferred 9,038,488 — Total preferred shares issued and outstanding 41,587,368 32,653,742

Shareholders' Deficit (Tables_2

Shareholders' Deficit (Tables)	9 Months Ended	12 Months Ended
Shareholders' Deficit (Tables)	Sep. 30, 2021	Dec. 31, 2020
STOCKHOLDERS' EQUITY
Summary of common share activity	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Common shares, beginning balance 4,488,416 8,468,742 2,765,097 8,396,425 Issuance of common shares 106,752 75,694 1,830,071 148,011 Common shares, ending balance 4,595,168 8,544,436 4,595,168 8,544,436	2020 2019 Common stock shares, beginning balance 8,396,425 8,273,865 Issuance of common stock 164,886 122,560 Repurchase of common stock (5,796,214) — Common stock shares, ending balance 2,765,097 8,396,425

Loss Per Share (Tables)_2

Loss Per Share (Tables)	9 Months Ended	12 Months Ended
Loss Per Share (Tables)	Sep. 30, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Scheduel of reconciliation of the numerators and denominators of the basic loss per share	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net Loss $ (14,691,871) $ (7,683,830) $ (29,232,518) $ (19,349,948) Denominator: Basic weighted average common shares outstanding 4,551,755 8,522,923 3,818,717 8,458,434 Earnings (loss) per share: Basic and diluted $ (3.23) $ (0.90) $ (7.66) $ (2.29)	2020 2019 Numerator: Net Loss $ (31,674,084) $ (18,468,776) Denominator: Basic weighted average common shares outstanding 8,197,409 8,310,333 Earnings (loss) per share: Basic and diluted $ (3.86) $ (2.22)
Schedule of number of potential shares outstanding that were anti-dilutive and therefore excluded from the computation of diluted earnings per share, weighted for the portion of the period they were outstanding	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Preferred stock 41,587,368 32,653,742 41,587,368 41,692,230 Stock options outstanding 8,852,171 7,684,943 8,601,614 6,414,452 Warrants outstanding 6,439 6,439 6,439 6,439 Total 50,445,978 40,345,124 50,195,421 48,113,121	2020 2019 Preferred stock 36,338,255 30,610,834 Stock options outstanding 6,714,171 5,301,830 Warrants outstanding 6,439 6,439 Total 43,058,865 35,919,104

Stock-based Compensation (Tab_2

Stock-based Compensation (Tables)	9 Months Ended	12 Months Ended
Stock-based Compensation (Tables)	Sep. 30, 2021	Dec. 31, 2020
Stock-Based Compensation
Schedule of stock option activity	A summary of stock option awards outstanding as of September 30, 2021 and changes during the nine months then ended is as follows: Weighted Average Number of Units Exercise Price Outstanding at January 1, 2021 7,478,736 $ 0.68 Granted 3,720,500 8.18 Exercised (1,830,071) 0.67 Forfeited (472,211) 1.19 Outstanding at September 30, 2021 8,896,954 $ 3.79	Weighted Average Weighted Remaining Aggregate Number of Average Contractual Intrinsic Units Exercise Price Term (Years) Value Outstanding as of January 1, 2019 4,823,893 $ 1.20 8.71 Granted 1,654,000 0.82 — Exercised (122,560) 0.33 — Forfeited (1,207,259) 1.33 — Outstanding as of January 1, 2020 5,148,074 $ 1.10 8.22 Granted 4,704,932 0.52 — Exercised (164,886) (0.80) — Forfeited (2,209,384) (1.26) — Outstanding at December 31, 2020 7,478,736 $ 0.68 8.35 $ 6,058,137 Exercisable at December 31, 2020 3,142,881 $ 0.81 7.30 $ 2,173,188
Schedule of stock based compensation expense	Total stock-based compensation expense was classified in the statements of operations for the three and nine months ended September 30, 2021 and 2020 as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of revenues 129,464 4,381 346,516 (70,058) Selling, general and administrative 868,515 100,960 1,566,580 71,847 Total stock-based compensation expense 997,979 105,341 1,913,096 1,789	2020 2019 Cost of revenues $ (64,919) $ 65,096 Selling, general and administrative 186,950 327,470 Total stock-based compensation expense $ 122,032 $ 392,566
Schedule of stock options vested		2020 2019 Total grant date fair value of stock options vested $ 533,089 $ 643,425
Schedule of assumptions of valuing the stock options		2020 2019 Expected term 6.25 years 2.25 years – 6.25 years Weighted-average grant date fair value per stock option granted $ 0.23 $ 0.28 Risk-free interest rate 0.4% – 1.4% 1.1% – 3.0% Expected volatility 43.5% – 46.4% 32.3% – 37.9% Dividend yield 0% 0%

Income Taxes (Tables)_2

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2020
Income Taxes
Schedule of income (loss) before taxes	2020 2019 U.S. income (loss) before taxes $ (31,666,084) $ (18,468,776) Foreign income (loss) before taxes — — Total income (loss) before taxes $ (31,666,084) $ (18,468,776)
Schedule of components of income tax expense	2020 2019 Statutory U.S. federal rate $ (6,649,878) $ (3,878,443) State income tax net of federal benefit (1,141,758) (767,428) Permanent items 77,747 109,580 Other prior year adjustments (99,275) (1,339) Rate adjustment (12,921) 65,267 Valuation allowance 7,826,085 4,472,363 Total income tax expense (benefit) $ — $ —
Summary of components of deferred tax assets and liabilities	2020 2019 Net operating loss carryforwards $ 24,923,945 $ 18,039,466 Amortizable assets 6,321 7,143 Equity compensation 50,118 77,916 Salaries and wages 1,048,104 151,442 Deferred rent — 133,387 Deferred revenue 861,120 544,415 Leasehold improvements 611,657 — Other 303,317 26,535 Total deferred tax assets 27,804,582 18,980,304 Less: valuation allowance (25,316,127) (17,490,042) Net deferred tax asset 2,488,455 1,490,262 Operating lease ROU (545,045) — Fixed assets (1,943,410) (1,490,262) Total deferred tax liabilities (2,488,455) (1,490,262) Net deferred tax assets (liabilities) $ — $ —
Schedule of unrecognized tax benefits	Unrecognized Tax Benefits – Beginning $ 239,927 Gross increases – tax positions in prior period — Gross decreases – tax positions in prior period — Gross increase – current-period tax positions — Gross decrease – current-period tax positions — Settlements — Lapse of statute of limitations — Unrecognized Tax Benefits – Ending $ 239,927

Company Background and Basis _5

Company Background and Basis of Presentation (Details) - USD ($)	Oct. 06, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Amount of federal deposit insurance corporation		$ 250,000		$ 250,000
Write off of sublease receivable		228,946	$ 0	312,940
Cash and cash equivalents		$ 7,996,362		$ 32,478,948	$ 27,787,314
Subsequent events
Business Acquisition [Line Items]
Percentage of acquired issued and outstanding	100.00%
PIPE financing loans	$ 200,000,000
PIPE financing net of fees and expenses	$ 234,200,000

Summary of Significant Accou_16

Summary of Significant Accounting Policies - Cost of Revenues (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cost of Revenues
Clinical trial marketing costs	$ 6,814,902	$ 762,740

Summary of Significant Accou_17

Summary of Significant Accounting Policies - Selling, general and administrative costs (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Accounting Policy [Line Items]
Rent expense and other facilities costs						$ 2,005,583
Stock based compensation	$ 997,979	$ 105,341	$ 1,913,096	$ 1,789	$ 122,032	392,566
Total	16,931,866	6,301,712	37,477,055	17,870,603	28,351,709	22,012,162
Selling, general and administrative costs
Accounting Policy [Line Items]
Compensation and benefits					16,696,017	13,094,579
Rent expense and other facilities costs					7,132,472	5,801,044
Professional fees and consultants					3,211,270	2,789,069
Legal settlement					1,125,000
Stock based compensation	$ 868,515	$ 100,960	$ 1,566,580	$ 71,847	186,950	327,470
Total					$ 28,351,709	$ 22,012,162

Summary of Significant Accou_18

Summary of Significant Accounting Policies - Restricted cash (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Restricted cash balances	$ 1,004,142	$ 720,703
Restricted cash balances, long term	$ 0	$ 300,000

Summary of Significant Accou_19

Summary of Significant Accounting Policies - Accounts Receivable, Unbilled Services, and Deferred Revenue and Allowance for Doubtful Accounts (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2021	Dec. 31, 2019
Accounting Policy [Line Items]
Allowances for doubtful accounts	$ 0	$ 142,830	$ 0
Minimum
Accounting Policy [Line Items]
Payment terms	30 days
Maximum
Accounting Policy [Line Items]
Payment terms	90 days

Summary of Significant Accou_20

Summary of Significant Accounting Policies - Long-Lived Assets (Details)	12 Months Ended
	Dec. 31, 2020
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Computer equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Drug storage equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Leasehold improvements \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	4 years
Leasehold improvements \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years

Summary of Significant Accou_21

Summary of Significant Accounting Policies - Additional information (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Estimated useful life for capitalized software	3 years	3 years

Revenue - Unsatisfied Perform_2

Revenue - Unsatisfied Performance Obligations (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price allocated to the unsatisfied performance obligations	$ 118,892,662	$ 52,415,469
Minimum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract term	1 month	1 year 6 months
Maximum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract term	6 years 4 months 24 days	7 years 1 month 6 days

Revenue - Timing of Billing a_2

Revenue - Timing of Billing and Performance (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue
Revenue recognized that was included in the deferred revenue balance	$ 3,151,080	$ 3,962,270	$ 4,349,278	$ 5,667,532
Revenue recognized from performance obligations partially satisfied in previous periods	$ 3,170,297	$ 6,322,520	$ (74,540)	$ 0

Revenue - Accounts Receivable_2

Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts receivable and unbilled services (including contract assets)
Accounts receivable	$ 6,233,698	$ 8,688,441	$ 1,426,874
Unbilled services	907,840	2,511,811	1,913,023
Total accounts receivable and unbilled services, net	6,998,708	11,200,252	3,339,897
Contract assets	907,840	2,511,811	85,465
Deferred revenue	$ 6,571,281	$ 5,136,457	$ 3,561,778

Revenue - Concentration of Cr_2

Revenue - Concentration of Credit Risk (Details) - customer	3 Months Ended		9 Months Ended	12 Months Ended
Revenue - Concentration of Credit Risk (Details) - customer	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues \| Customer concentration
Concentration Risk [Line Items]
Number of customers	4	3	3	3	4
Revenues \| Three Customers [Member] \| Customer concentration
Concentration Risk [Line Items]
Concentration risk percentage				69.20%
Revenues \| Four Customers [Member] \| Customer concentration
Concentration Risk [Line Items]
Concentration risk percentage					81.80%
Accounts receivable, net \| Credit concentration
Concentration Risk [Line Items]
Number of customers			3	2	3
Accounts receivable, net \| Two Customers [Member] \| Credit concentration
Concentration Risk [Line Items]
Concentration risk percentage				73.50%
Accounts receivable, net \| Three Customers [Member] \| Credit concentration
Concentration Risk [Line Items]
Concentration risk percentage					91.70%

Revenue - Capitalized Commiss_2

Revenue - Capitalized Commission Cost (Details) - USD ($)	12 Months Ended
Revenue - Capitalized Commission Cost (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Revenue
Capitalized commission cost, net	$ 509,326
Amortization of capitalized commission cost	232,422
Impairment of contract costs related to canceled projects	$ 162,069	$ 0

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
Property and Equipment (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2021
Property, Plant and Equipment [Line Items]
Total	$ 2,128,876	$ 1,778,390
Less accumulated depreciation	(1,593,492)	(1,152,112)
Property and equipment, net	535,384	626,278	$ 1,157,818
Depreciation on property and equipment	449,815	424,796
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total	298,877	298,877
Drug storage equipment
Property, Plant and Equipment [Line Items]
Total	115,054	115,054
Computer equipment
Property, Plant and Equipment [Line Items]
Total	475,798	111,574
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total	$ 1,239,147	$ 1,252,885

Capitalized Software (Details)

Capitalized Software (Details) - USD ($)	12 Months Ended
Capitalized Software (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Capitalized Software
Amount of capitalized software	$ 6,177,005	$ 4,429,289
Amortization expense	$ 3,991,553	$ 2,919,006

Capitalized Software - Estimate

Capitalized Software - Estimated amortization expense (Details)	Dec. 31, 2020USD ($)
Estimated amortization expense
2021	$ 4,195,131
2022	2,804,127
2023	$ 1,055,109

Capitalized Software - Capitali

Capitalized Software - Capitalized software balances (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Capitalized software
Gross Amount		$ 18,638,249	$ 12,461,245
Accumulated Amortization		(10,583,882)	(6,592,330)
Net Amount	$ 16,679,024	$ 8,054,367	$ 5,868,915

Leases (Details)

Leases (Details) - USD ($)	12 Months Ended
Leases (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Components of lease expense
Operating fixed lease cost	$ 2,126,662
Operating variable lease cost	238,205
Total lease cost	2,364,867
Rent expense		$ 2,005,583
Expense related to short-term leases	$ 359,776	$ 79,360

Leases - Other information rela

Leases - Other information related to leases (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases		$ 2,495,972
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$ 1,305,448	$ 4,095,709
Weighted average remaining lease term (years):
Operating leases		2 years 2 months 26 days
Weight average discount rate:
Operating leases		6.50%

Leases - Future minimum lease p

Leases - Future minimum lease payments (Details) - USD ($)	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Future minimum lease payments under non-cancellable leases
2021	$ 188,943		$ 1,462,045	$ 2,325,562
2022	1,286,301		801,800	1,360,130
2023	629,369		130,332	752,532
2024	599,327		134,054	124,068
2025	137,888		137,888	127,790
Thereafter			11,518	142,618
Total	2,853,345	$ 1,578,821	2,677,637	$ 4,832,700
Less imputed interest	264,774		197,263
Total	2,588,571		2,480,374
Reported as of December 31, 2020:
Accrued expenses and other liabilities	1,103,283		1,352,537
Operating lease liabilities	1,485,288		1,127,837
Total	$ 2,588,571		$ 2,480,374

Leases - Future minimum lease_2

Leases - Future minimum lease payments under non-cancellable (Details) - USD ($)	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2020	$ 188,943		$ 1,462,045	$ 2,325,562
2021	1,286,301		801,800	1,360,130
2022	629,369		130,332	752,532
2023	599,327		134,054	124,068
2024	137,888		137,888	127,790
Thereafter			11,518	142,618
Total	$ 2,853,345	$ 1,578,821	$ 2,677,637	$ 4,832,700

Leases - Additional Information

Leases - Additional Information 1 (Details)	1 Months Ended	9 Months Ended		12 Months Ended
Leases - Additional Information 1 (Details)	Mar. 31, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)facility
Leases
Amount of lease not yet commenced	$ 1,578,821
Number of facilities subleased \| facility				2
Write off of sublease receivable		$ 228,946	$ 0	$ 312,940

Leases - Sublease income (Detai

Leases - Sublease income (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Leases - Sublease income (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Sublease income
Fixed					$ 709,283
Variable					4,971
Total sublease income	$ 230,235	$ 232,294	$ 444,153	$ 696,882	$ 714,254

Leases - Undiscounted cash flow

Leases - Undiscounted cash flows (Details)	Dec. 31, 2020USD ($)
Undiscounted cash flows for contractual subleases
2021	$ 666,740
2022	823,900
2023	130,332
2024	134,054
2025	137,888
Thereafter	11,517
Total	$ 1,904,431

Restructuring Costs (Details)_2

Restructuring Costs (Details)	6 Months Ended	9 Months Ended		12 Months Ended
Restructuring Costs (Details)	Jun. 30, 2021employee	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)employee
Restructuring Costs
Number of employees severed \| employee	20			20
Restructuring costs		$ 771,942	$ 699,473	$ 771,942
Restructuring accruals		$ 0		$ 0

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Prepaid Expenses and Other Current Assets
Prepaid expenses		$ 543,148	$ 551,689
Good Dermatology receivable			448,098
Leased facility security deposit		231,901
Capitalized commission cost, net		509,326
Other		79,787	137,952
Total prepaid expenses and other current assets	$ 4,226,079	$ 1,364,162	$ 1,137,739

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Accrued Expenses
Professional fees		$ 1,623,286	$ 375,902
Compensation, including bonuses, fringe benefits, and payroll taxes		4,364,645	1,310,240
Current portion of operating lease liabilities	$ 1,103,283	1,352,537
Commissions payable		197,371
Legal settlement		1,225,000
Total accrued expenses	$ 10,727,474	$ 8,762,839	$ 1,686,142

Redeemable Preferred Stock (D_2

Redeemable Preferred Stock (Details) - USD ($)	12 Months Ended
Redeemable Preferred Stock (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2021	Sep. 30, 2020
Temporary Equity [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	41,692,230	37,932,831	41,692,230
Preferred stock, issued	41,587,368	32,653,742	41,587,368
Preferred stock, outstanding	41,587,368	32,653,742	41,587,368	41,692,230
Unpaid dividends	$ 0	$ 0
Series A preferred
Temporary Equity [Line Items]
Preferred stock, shares authorized	6,746,233	6,746,233
Preferred stock, issued	6,641,371	6,746,233
Preferred stock, outstanding	6,641,371	6,746,233
Series B preferred
Temporary Equity [Line Items]
Preferred stock, shares authorized	7,588,369	7,588,369
Preferred stock, issued	7,588,369	7,588,369
Preferred stock, outstanding	7,588,369	7,588,369
Series C preferred
Temporary Equity [Line Items]
Preferred stock, shares authorized	6,001,269	6,001,269
Preferred stock, issued	6,001,269	6,001,269
Preferred stock, outstanding	6,001,269	6,001,269
Series D preferred
Temporary Equity [Line Items]
Preferred stock, shares authorized	12,317,871	17,596,960
Preferred stock, issued	12,317,871	12,317,871
Preferred stock, outstanding	12,317,871	12,317,871
Series D-1 preferred
Temporary Equity [Line Items]
Preferred stock, shares authorized	9,038,488
Preferred stock, issued	9,038,488
Preferred stock, outstanding	9,038,488

Shareholders' Deficit (Detail_2

Shareholders' Deficit (Details) - $ / shares	3 Months Ended		9 Months Ended		12 Months Ended
Shareholders' Deficit (Details) - $ / shares	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
STOCKHOLDERS' EQUITY
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common stock shares, beginning balance			2,765,097	8,396,425	8,396,425	8,273,865
Issuance of common stock (in shares)	106,752	75,694	1,830,071	148,011	164,886	122,560
Repurchase of common stock					5,796,214
Common stock shares, ending balance	4,595,168	8,544,436	4,595,168	8,544,436	2,765,097	8,396,425
Number of warrants outstanding	1		1		1
Sale of Private Placement Warrants (in shares)	6,439		6,439		6,439
Exercise price of warrants	$ 1.61		$ 1.61		$ 1.61

Loss Per Share (Details)_2

Loss Per Share (Details) - USD ($)	3 Months Ended				6 Months Ended			9 Months Ended		12 Months Ended
Loss Per Share (Details) - USD ($)	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Net Loss	$ (14,691,871)		$ (7,683,830)					$ (29,232,518)	$ (19,349,948)	$ (31,674,084)	$ (18,468,776)
Denominator:
Basic weighted average common shares outstanding	4,551,755		8,522,923			1,875,000		3,818,717	8,458,434	8,197,409	8,310,333
Diluted weighted average common shares outstanding	4,551,755	3,956,455	8,522,923	8,442,703	3,446,123		8,425,655	3,818,717	8,458,434	8,197,409	8,310,604
Earnings (loss) per share:
Basic (in dollars per share)	$ (3.23)		$ (0.90)					$ (7.66)	$ (2.29)	$ (3.86)	$ (2.22)
Diluted (in dollars per share)	$ (3.23)	$ (1.95)	$ (0.90)	$ (0.70)	$ (4.22)		$ (1.38)	$ (7.66)	$ (2.29)	$ (3.86)	$ (2.22)

Loss Per Share - Schedule of co

Loss Per Share - Schedule of computation of diluted earnings per share, weighted for the portion of the period they were outstanding (Details) - shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	50,445,978	40,345,124	50,195,421	48,113,121	43,058,865	35,919,104
Preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	41,587,368	32,653,742	41,587,368	41,692,230	36,338,255	30,610,834
Stock options outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	8,852,171	7,684,943	8,601,614	6,414,452	6,714,171	5,301,830
Redeemable warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,439	6,439	6,439	6,439	6,439	6,439

Related-Party Transactions (D_2

Related-Party Transactions (Details) - USD ($)	Jun. 26, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Total sublease income		$ 230,235	$ 232,294	$ 444,153	$ 696,882	$ 714,254
Revenue from related party		9,875	0	350,585	0
Receivables from related party		2,185		2,185		0
dRX Capital AG
Related Party Transaction [Line Items]
Revenue from related party		269,547	108,280	565,092	$ 226,843	351,034	$ 451,558
Receivables from related party		166,474		166,474		$ 129,857
Percentage of ownership in related party						50.00%
Good Dermatology
Related Party Transaction [Line Items]
Percentage of lease expenses incurred by entity passed through related party					100.00%	100.00%	100.00%
Total sublease income			29,174		$ 87,523	$ 106,972	$ 116,697
Purchase of clinical trial investigator services						0	273,787
Founder and former CEO
Related Party Transaction [Line Items]
Proceeds from repayments of loan from related party							300,000
Proceeds from repayments of accrued interest on loan from related party	$ 15,682
Pharmaceutical Products Development, LLC, a shareholder
Related Party Transaction [Line Items]
Revenue from related party		2,756,011	$ 3,146,148	10,803,604	$ 3,243,667	9,106,645	0
Receivables from related party		$ 2,244,157		$ 2,244,157		6,927,470	0
Novartis \| dRX Capital AG
Related Party Transaction [Line Items]
Receivables from related party						$ 129,857	$ 9,825
Percentage of ownership in related party		50.00%		50.00%

Commitments and Contingencies_2

Commitments and Contingencies Legal Proceedings (Details) - USD ($)	Feb. 26, 2020	Jun. 30, 2021	Nov. 30, 2020	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Dec. 31, 2020
Commitments And Contingencies [Line Items]
Amount of payments to Director Defendants causing insurers					$ 100,000
Payments to be made to Plaintiffs							$ 1,225,000
Amount accrued							$ 1,225,000
Good Dermatology
Commitments And Contingencies [Line Items]
Amount owed to cover all outstanding obligations	$ 600,000
Within five business days after Final Dismissal occurred
Commitments And Contingencies [Line Items]
Amount of payments to Director Defendants causing insurers			$ 100,000
Payments to Plaintiffs						$ 3,675,000
Within five business days of the Plaintiffs' receipt of the First Payment
Commitments And Contingencies [Line Items]
Payments to Plaintiffs			$ 3,675,000
Number of common shares equivalent to which Plaintiffs held amount			5,901,076			5,901,076
Within five business days after the Effective Date \| Good Dermatology
Commitments And Contingencies [Line Items]
Amount received for rent and employee costs from plantiff				$ 400,000
Within five business days of wound down \| Good Dermatology
Commitments And Contingencies [Line Items]
Payments to be made to Plaintiffs	1,225,000
Amount owed to cover all outstanding obligations	600,000
Within five business days of wound down \| Good Dermatology \| Maximum
Commitments And Contingencies [Line Items]
Payments to be made to Plaintiffs	1,225,000
Within five business days of wound down \| Good Dermatology \| Minimum
Commitments And Contingencies [Line Items]
Payments to be made to Plaintiffs	1,025,000
If plantiff elected to pay $200,000 directly to Science 37
Commitments And Contingencies [Line Items]
Payments to be made to Plaintiffs	1,225,000
Condition of amount elected to pay directly	200,000
If plantiff elected to pay $0 directly to Science 37
Commitments And Contingencies [Line Items]
Payments to be made to Plaintiffs	1,025,000
Condition of amount elected to pay directly	$ 0
Forecast Member
Commitments And Contingencies [Line Items]
Payments to Plaintiffs		$ 1,225,000

Stock-based Compensation (Detai

Stock-based Compensation (Details) - shares	9 Months Ended	12 Months Ended
Stock-based Compensation (Details) - shares	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted	3,720,500	4,704,932	1,654,000
Number of units Exercised	1,830,071	164,886	122,560
Common stock outstanding	8,896,954	7,478,736	5,148,074	4,823,893
Minimum percentage of fair market value		100.00%
After one year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting of shares (In percentage)		25.00%
More than one year and with in 36 months
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting of shares (In percentage)		75.00%
2015 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued		8,246,052	5,750,504
Number of units Exercised		767,316	602,430
Common stock outstanding		7,478,736	5,148,074
2015 Stock Option Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted		11,708,001

Stock-based Compensation - St_2

Stock-based Compensation - Stock option activity (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of units outstanding at beginning			7,478,736	5,148,074	5,148,074	4,823,893
Number of units Granted			3,720,500		4,704,932	1,654,000
Number of units Exercised			1,830,071		164,886	122,560
Number of units Forfeited			472,211		2,209,384	1,207,259
Number of units outstanding at ending	8,896,954		8,896,954		7,478,736	5,148,074	4,823,893
Number of units Exercisable					3,142,881
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price at beginning			$ 0.68	$ 1.10	$ 1.10	$ 1.20
Weighted Average Exercise Price Granted			8.18		0.52	0.82
Weighted Average Exercise Price Exercised			0.67		0.80	0.33
Weighted Average Exercise Price Forfeited			1.19		1.26	1.33
Weighted Average Exercise Price at End	$ 3.79		$ 3.79		0.68	$ 1.10	$ 1.20
Weighted Average Exercisable					$ 0.81
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Contractual Term outstanding					8 years 4 months 6 days	8 years 2 months 19 days	8 years 8 months 15 days
Weighted Average Remaining Contractual Term exercisable					7 years 3 months 18 days
Average Intrinsic value Outstanding					$ 6,058,137
Average Intrinsic value Exercisable					2,173,188
Intrinsic value of options exercised					115,201	$ 55,056
Stock based compensation	$ 997,979	$ 105,341	$ 1,913,096	$ 1,789	122,032	392,566
Unrecognized compensation cost related to unvested stock options					$ 1,046,844	$ 1,142,965
Weighted average period					2 years 10 months 13 days	2 years 6 months 3 days

Stock-based Compensation - Cl_2

Stock-based Compensation - Classification of stock-based compensation expense (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 997,979	$ 105,341	$ 1,913,096	$ 1,789	$ 122,032	$ 392,566
Cash received from exercise of options			1,245,152	116,240	131,802	39,863
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	129,464	4,381	346,516	(70,058)	(64,919)	65,096
Selling, general and administrative costs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 868,515	$ 100,960	$ 1,566,580	$ 71,847	$ 186,950	$ 327,470

Stock-based Compensation - Fair

Stock-based Compensation - Fair value of stock options vested (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stock-Based Compensation
Total grant date fair value of stock options vested	$ 533,089	$ 643,425

Stock-based Compensation - Assu

Stock-based Compensation - Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years 3 months
Weighted-average grant date fair value per stock option granted	$ 0.23	$ 0.28
Dividend yield	0.00%	0.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		6 years 3 months
Risk-free interest rate	1.40%	3.00%
Expected volatility	46.40%	37.90%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		2 years 3 months
Risk-free interest rate	0.40%	1.10%
Expected volatility	43.50%	32.30%

Employee Benefit Plan (Details)

Employee Benefit Plan (Details) - USD ($)	12 Months Ended
Employee Benefit Plan (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Employee Benefit Plan
Matching contribution of employer with employee (in Percentage)	50.00%
Maximum annual contribution of employee	6.00%
Matching contributions of employer with employee	$ 456,589	$ 400,238

Income Taxes - Amount of loss b

Income Taxes - Amount of loss before taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Taxes
U.S. income (loss) before taxes	$ (31,666,084)	$ (18,468,776)
Loss before income taxes	(31,674,084)	(18,468,776)
Current income tax expense	0	0
Deferred income tax (benefit) expense	$ 0	$ 0

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of tax expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Taxes
Statutory U.S. federal rate	$ (6,649,878)	$ (3,878,443)
State income tax net of federal benefit	(1,141,758)	(767,428)
Permanent items	77,747	109,580
Other prior year adjustments	(99,275)	(1,339)
Rate adjustment	(12,921)	65,267
Valuation allowance	$ 7,826,085	$ 4,472,363

Income Taxes - Deferred tax (De

Income Taxes - Deferred tax (Details) - USD ($)	12 Months Ended
Income Taxes - Deferred tax (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 24,923,945	$ 18,039,466
Amortizable assets	6,321	7,143
Equity compensation	50,118	77,916
Salaries and wages	1,048,104	151,442
Deferred rent		133,387
Deferred revenue	861,120	544,415
Leasehold improvements	611,657
Other	303,317	26,535
Total deferred tax assets	27,804,582	18,980,304
Less: valuation allowance	25,316,127	17,490,042
Net deferred tax asset	2,488,455	1,490,262
Operating lease ROU	(545,045)
Fixed assets	(1,943,410)	(1,490,262)
Total deferred tax liabilities	2,488,455	1,490,262
Changes in valuation allowance	$ 7,826,085	$ 4,184,528
Carry forward loss utilization against taxable income (in percentage)	80.00%
Cumulative change in ownership net operating loss limitation	50.00%
Cumulative Change In Ownership Net Operating Loss Limitation Period	3 years
Tax Cuts And Jobs Act Of 2017 Measurement Period Adjustment Operating Loss Carry Forward Period	20 years
Extension of Carryback Period	5 years
Maximum
Operating Loss Carryforwards [Line Items]
Deduction of interest expense ( In Percentage)	50.00%
Minimum
Operating Loss Carryforwards [Line Items]
Deduction of interest expense ( In Percentage)	30.00%
State
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 56,390,660
Deferred tax assets net operating loss carry forward subject to expire	247,181
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	103,569,264
Deferred tax assets net operating loss subject to expire	30,230,297
Deferred Tax Assets Net Operating Loss Not Subject To Expire	$ 73,338,967

Subsequent Events (Details)_2_3

Subsequent Events (Details) - Subsequent events $ in Millions	Oct. 06, 2021USD ($)
Subsequent Event [Line Items]
PIPE financing loans	$ 200
PIPE financing net of fees and expenses	$ 234.2